{"5bc13185f8fc98b99cd1fb22078afeda41eb1e7e": [["IntroductionThe SARS-CoV (severe acute respiratory syndromeassociated coronavirus) has been generally accepted as the major pathogen of SARS, which has cost thousands of lives globally a few months ago (1 , 2 ) .", [["SARS-CoV", "DISEASE", 16, 24], ["respiratory syndromeassociated coronavirus", "DISEASE", 39, 81], ["SARS", "DISEASE", 136, 140], ["SARS-CoV", "ORGANISM", 16, 24], ["SARS-CoV (severe acute respiratory syndromeassociated coronavirus", "SPECIES", 16, 81], ["The SARS-CoV (severe acute respiratory syndromeassociated coronavirus", "PROBLEM", 12, 81], ["SARS", "PROBLEM", 136, 140], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["respiratory syndromeassociated coronavirus", "OBSERVATION", 39, 81]]], ["This coronavirus has been classified as a new member of Genus Coronavirus in Family Coronaviridae and Order Nidovirales (3 ) .IntroductionSerologically, the seventeen species coronavirus have been classified into three groups.", [["coronavirus", "DISEASE", 5, 16], ["coronavirus", "ORGANISM", 5, 16], ["Genus Coronavirus", "ORGANISM", 56, 73], ["coronavirus", "ORGANISM", 175, 186], ["the seventeen species coronavirus", "PROBLEM", 153, 186], ["Genus Coronavirus", "OBSERVATION", 56, 73]]], ["Groups I and II contain mammalian viruses, while Group III contains only avian viruses.", [["mammalian viruses", "ORGANISM", 24, 41], ["avian viruses", "ORGANISM", 73, 86], ["mammalian viruses", "PROBLEM", 24, 41], ["mammalian viruses", "OBSERVATION", 24, 41], ["avian viruses", "OBSERVATION", 73, 86]]], ["Within each group, the viruses are further subclassified into distinct species by the host range, antigenic relationship, and genomic organization.", [["the viruses", "PROBLEM", 19, 30], ["viruses", "OBSERVATION", 23, 30], ["distinct", "OBSERVATION_MODIFIER", 62, 70], ["species", "OBSERVATION", 71, 78], ["host range", "OBSERVATION_MODIFIER", 86, 96], ["genomic organization", "OBSERVATION", 126, 146]]], ["Genomic analyses have revealed that the SARS-CoV has typical features of coronavirus, but it represents a novel virus that is phylogenetically distinct from any other member in the three known * These authors contributed equally to this work. # Corresponding authors.", [["SARS", "DISEASE", 40, 44], ["coronavirus", "DISEASE", 73, 84], ["SARS-CoV", "ORGANISM", 40, 48], ["coronavirus", "ORGANISM", 73, 84], ["SARS-CoV", "SPECIES", 40, 48], ["Genomic analyses", "TEST", 0, 16], ["the SARS-CoV", "PROBLEM", 36, 48], ["coronavirus", "PROBLEM", 73, 84], ["a novel virus", "PROBLEM", 104, 117], ["coronavirus", "OBSERVATION", 73, 84], ["virus", "OBSERVATION", 112, 117]]], ["E-mail: junyu@genomics.org.cn; yanghm@genomics.org.cn groups.IntroductionIt has been suggested that the SARS-CoV is more closely related to the cow coronavirus and MHV (Murine Hepatitis Virus) by comparing a conserved 215-a.a. (amino acid) segment of the polymerase protein (4 ) .", [["SARS", "DISEASE", 104, 108], ["Murine Hepatitis Virus", "DISEASE", 169, 191], ["amino acid", "CHEMICAL", 228, 238], ["amino acid", "CHEMICAL", 228, 238], ["SARS-CoV", "ORGANISM", 104, 112], ["cow coronavirus", "ORGANISM", 144, 159], ["MHV", "ORGANISM", 164, 167], ["Murine Hepatitis Virus", "ORGANISM", 169, 191], ["amino acid", "AMINO_ACID", 228, 238], ["215-a.a. (amino acid) segment", "PROTEIN", 218, 247], ["polymerase protein", "PROTEIN", 255, 273], ["cow", "SPECIES", 144, 147], ["coronavirus", "SPECIES", 148, 159], ["Murine Hepatitis Virus", "SPECIES", 169, 191], ["SARS-CoV", "SPECIES", 104, 112], ["cow coronavirus", "SPECIES", 144, 159], ["MHV", "SPECIES", 164, 167], ["Murine Hepatitis Virus", "SPECIES", 169, 191], ["yanghm@genomics.org.cn groups", "PROBLEM", 31, 60], ["the SARS-CoV", "PROBLEM", 100, 112], ["the cow coronavirus", "PROBLEM", 140, 159], ["MHV (Murine Hepatitis Virus", "PROBLEM", 164, 191], ["the polymerase protein", "TEST", 251, 273], ["coronavirus", "OBSERVATION", 148, 159]]], ["However, the strength of the association is reduced if the entire genome is taken into consideration.", [["reduced", "OBSERVATION_MODIFIER", 44, 51]]], ["In this paper, we present the phylogenetic comparison between SARS-CoV and other viruses, and the analysis of the mutation sites of 42 SARS-CoV isolates, as well as the possible recombination and horizontal transfer.Results and DiscussionComparison of the GC content and genome size distribution with other viruses Genome sizes of viruses range from a few hundred base pairs to a few hundred thousand base pairs (Figure 1 ).", [["SARS-CoV", "DISEASE", 62, 70], ["SARS", "DISEASE", 135, 139], ["SARS-CoV", "ORGANISM", 62, 70], ["SARS-CoV", "ORGANISM", 135, 143], ["SARS-CoV", "SPECIES", 62, 70], ["SARS-CoV", "SPECIES", 135, 143], ["SARS", "TEST", 62, 66], ["the analysis", "TEST", 94, 106], ["the mutation sites", "TEST", 110, 128], ["CoV isolates", "TEST", 140, 152], ["the GC content", "TEST", 252, 266], ["size", "OBSERVATION_MODIFIER", 278, 282], ["sizes", "OBSERVATION_MODIFIER", 322, 327], ["viruses range", "OBSERVATION", 331, 344]]], ["According to their genome sizes, the 2,498 virus isolates can be classified as three groups.", [["the 2,498 virus isolates", "PROBLEM", 33, 57], ["sizes", "OBSERVATION_MODIFIER", 26, 31]]], ["The first group, also the smallest group corresponding to the low part of the figure, represents the viroids.", [["smallest", "OBSERVATION_MODIFIER", 26, 34], ["low part", "OBSERVATION_MODIFIER", 62, 70], ["viroids", "OBSERVATION", 101, 108]]], ["The range of genome sizes of this group is between 120 bp (Avocado sunblotch viroid; NCBI accession number: AF404074) and 374 bp (Citrus exocortis viroids, NCBI accession number: N30870).", [["Citrus exocortis", "SPECIES", 130, 146], ["Avocado sunblotch viroid", "SPECIES", 59, 83], ["Citrus exocortis viroids", "SPECIES", 130, 154], ["bp", "TEST", 55, 57], ["bp (Citrus exocortis viroids", "TREATMENT", 126, 154], ["range", "OBSERVATION_MODIFIER", 4, 9], ["sizes", "OBSERVATION_MODIFIER", 20, 25]]], ["The range of the GC content is between 35.5% (Avocado sunblotch viroid; genome size: 248 bp; NCBI accession number: AF404068) and 61.1% (Grapevine yellow speckle viroid 1; genome size: 365 bp; NCBI accession number: AF462165).", [["Avocado sunblotch viroid", "SPECIES", 46, 70], ["Grapevine yellow speckle viroid 1", "SPECIES", 137, 170], ["the GC content", "TEST", 13, 27], ["Avocado", "TEST", 46, 53], ["genome size", "TEST", 72, 83], ["bp", "TEST", 89, 91], ["Grapevine yellow speckle viroid", "TEST", 137, 168], ["genome size", "TEST", 172, 183], ["bp", "TEST", 189, 191], ["range", "OBSERVATION_MODIFIER", 4, 9], ["GC content", "OBSERVATION", 17, 27]]], ["Here, the two isolates of AF404068 and AF404074 demonstrate the sequence diversity of viroid genomes.", [["AF404068", "CHEMICAL", 26, 34], ["AF404074", "CHEMICAL", 39, 47], ["AF404074", "SIMPLE_CHEMICAL", 39, 47], ["viroid genomes", "DNA", 86, 100], ["viroid genomes", "PROBLEM", 86, 100], ["viroid genomes", "OBSERVATION", 86, 100]]], ["Although they are only different isolates of Avocado sunblotch viroid, the difference of their genome sizes is still great.", [["Avocado sunblotch viroid", "ORGANISM", 45, 69], ["Avocado sunblotch viroid", "SPECIES", 45, 69], ["Avocado sunblotch viroid", "SPECIES", 45, 69], ["Avocado sunblotch viroid", "TREATMENT", 45, 69], ["Avocado sunblotch viroid", "OBSERVATION", 45, 69], ["difference", "OBSERVATION_MODIFIER", 75, 85], ["genome", "OBSERVATION_MODIFIER", 95, 101], ["sizes", "OBSERVATION_MODIFIER", 102, 107], ["great", "OBSERVATION_MODIFIER", 117, 122]]], ["The third group, also the largest group corresponding to the middle part of the figure, is the most complicated one that includes all other kinds of viruses.", [["viruses", "PROBLEM", 149, 156], ["largest", "OBSERVATION_MODIFIER", 26, 33], ["middle", "ANATOMY_MODIFIER", 61, 67], ["figure", "OBSERVATION", 80, 86], ["most complicated", "OBSERVATION_MODIFIER", 95, 111], ["viruses", "OBSERVATION", 149, 156]]], ["The SARS-CoV belongs to this group.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["SARS-CoV", "SPECIES", 4, 12]]], ["From the figure, it is easy to see that the GC content and genome size of the SARS-CoV are normal.Sequence comparison with other virusesWe performed a genomic sequence comparison between Isolate BJ01 of SARS-CoV and other viruses.", [["SARS", "DISEASE", 78, 82], ["SARS-CoV", "DISEASE", 203, 211], ["SARS-CoV", "ORGANISM", 78, 86], ["SARS-CoV", "ORGANISM", 203, 211], ["SARS-CoV", "SPECIES", 78, 86], ["Isolate BJ01", "SPECIES", 187, 199], ["SARS-CoV", "SPECIES", 203, 211], ["the GC content", "TEST", 40, 54], ["Sequence comparison", "TEST", 98, 117], ["a genomic sequence comparison", "TEST", 149, 178], ["SARS", "PROBLEM", 203, 207], ["other viruses", "PROBLEM", 216, 229], ["size", "OBSERVATION_MODIFIER", 66, 70], ["CoV", "ANATOMY", 83, 86], ["normal", "OBSERVATION", 91, 97]]], ["As a contrast, we divided the viruses into coronaviruses and non-coronaviruses.", [["coronaviruses", "ORGANISM", 43, 56], ["non-coronaviruses", "CANCER", 61, 78], ["coronaviruses", "PROBLEM", 43, 56]]], ["BLASTN (default parameters) was used to compare the SARS-CoV genomic sequence with the dataset of non-coronaviruses, and sequences more than 20 nt in length and identity greater than 70% were extracted to create the conservative map ( Figure 2 ).", [["non-coronaviruses", "CANCER", 98, 115], ["SARS-CoV genomic sequence", "DNA", 52, 77], ["non-coronaviruses", "DNA", 98, 115], ["SARS-CoV", "SPECIES", 52, 60], ["BLASTN (default parameters", "TEST", 0, 26], ["the SARS", "TEST", 48, 56]]], ["The coronaviruses are phylogenetically close to the SARS-CoV.", [["SARS", "DISEASE", 52, 56], ["coronaviruses", "ORGANISM", 4, 17], ["SARS-CoV", "ORGANISM", 52, 60], ["SARS-CoV", "SPECIES", 52, 60], ["The coronaviruses", "PROBLEM", 0, 17], ["coronaviruses", "OBSERVATION", 4, 17]]], ["To demonstrate their respective similar regions to the SARS-CoV, we mapped the comparison results to BJ01 sequence to see the distribution.", [["SARS", "DISEASE", 55, 59], ["SARS-CoV", "DNA", 55, 63], ["BJ01 sequence", "DNA", 101, 114], ["SARS-CoV", "SPECIES", 55, 63]]], ["As shown in Figure 3 , the SARS-CoV genomic fragments are plotted along the horizontal axis in the order they appeared in the genome, and other coronaviruses are placed vertically.", [["coronaviruses", "ORGANISM", 144, 157], ["SARS-CoV genomic fragments", "DNA", 27, 53], ["SARS-CoV", "SPECIES", 27, 35], ["the SARS-CoV genomic fragments", "PROBLEM", 23, 53], ["CoV", "OBSERVATION_MODIFIER", 32, 35], ["genomic fragments", "OBSERVATION", 36, 53], ["horizontal axis", "OBSERVATION_MODIFIER", 76, 91], ["genome", "ANATOMY", 126, 132], ["coronaviruses", "OBSERVATION", 144, 157]]], ["The darkness of a pixel corresponds to the strength of the match between a SARS-CoV fragment and a coronavirus genome, and the width of the rectangle corresponds to the length of the matched sequence.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV fragment", "DNA", 75, 92], ["coronavirus genome", "DNA", 99, 117], ["SARS-CoV", "SPECIES", 75, 83], ["The darkness of a pixel", "PROBLEM", 0, 23], ["a SARS-CoV fragment", "PROBLEM", 73, 92], ["a coronavirus genome", "PROBLEM", 97, 117], ["darkness", "OBSERVATION_MODIFIER", 4, 12], ["strength", "OBSERVATION_MODIFIER", 43, 51], ["SARS", "OBSERVATION", 75, 79], ["CoV fragment", "OBSERVATION", 80, 92], ["coronavirus genome", "OBSERVATION", 99, 117], ["width", "OBSERVATION_MODIFIER", 127, 132], ["rectangle", "OBSERVATION_MODIFIER", 140, 149], ["length", "OBSERVATION_MODIFIER", 169, 175]]], ["The length of the longest matched segment is 138 nt (Codons 14,914-15,051) with the identity of about 81.16% (112/138).", [["Codons", "TEST", 53, 59], ["the identity", "TEST", 80, 92], ["length", "OBSERVATION_MODIFIER", 4, 10], ["segment", "ANATOMY_MODIFIER", 34, 41]]], ["This segment lies in the gene coding region of the R (replicase) protein of SARS-CoV.Motif frequency profile comparison with other virusesWe computed the average absolute distance of the motif frequency profile (MFP) between BJ01 and other viruses.", [["SARS", "DISEASE", 76, 80], ["R", "GENE_OR_GENE_PRODUCT", 51, 52], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["R (replicase) protein", "PROTEIN", 51, 72], ["SARS-CoV", "SPECIES", 76, 84], ["Motif frequency profile", "TEST", 85, 108], ["the motif frequency profile", "TEST", 183, 210], ["R", "ANATOMY_MODIFIER", 51, 52], ["viruses", "OBSERVATION", 240, 247]]], ["The analysis results with the motif length from 2 to 8 nt all demonstrate that the SARS-CoV is most adjacent to coronaviruses.", [["SARS", "DISEASE", 83, 87], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 83, 91], ["coronaviruses", "ORGANISM", 112, 125], ["SARS-CoV", "SPECIES", 83, 91], ["The analysis", "TEST", 0, 12], ["the motif length", "TEST", 26, 42], ["the SARS-CoV", "PROBLEM", 79, 91], ["coronaviruses", "PROBLEM", 112, 125], ["SARS", "OBSERVATION", 83, 87], ["coronaviruses", "OBSERVATION", 112, 125]]], ["Here we only show the comparison result with coronaviruses since the distances with non-coronavirus are very large.", [["coronaviruses", "ORGANISM", 45, 58], ["coronaviruses", "PROBLEM", 45, 58], ["coronaviruses", "OBSERVATION", 45, 58], ["very", "OBSERVATION_MODIFIER", 104, 108], ["large", "OBSERVATION", 109, 114]]], ["To present the similarity of the MFP between the SARS-CoV and other coronaviruses more clearly, we use the chaos game representation (CGR) to demonstrate the results.", [["SARS", "DISEASE", 49, 53], ["coronaviruses", "ORGANISM", 68, 81], ["SARS-CoV", "SPECIES", 49, 57], ["the SARS-CoV and other coronaviruses", "PROBLEM", 45, 81]]], ["Only one isolate is selected to represent its species because the MFP of different isolates within the same species is very similar.", [["MFP", "GENE_OR_GENE_PRODUCT", 66, 69], ["its species", "PROBLEM", 42, 53], ["different isolates", "PROBLEM", 73, 91], ["very", "OBSERVATION_MODIFIER", 119, 123], ["similar", "OBSERVATION_MODIFIER", 124, 131]]], ["To find whether there is a relationship between the viruses and their hosts, we also demonstrate the MFP of Homo Sapiens (host of the SARS-CoV) and Mus Musculus (host of the MHV).", [["Homo Sapiens", "ORGANISM", 108, 120], ["SARS-CoV", "ORGANISM", 134, 142], ["Mus Musculus", "ORGANISM", 148, 160], ["MHV", "ORGANISM", 174, 177], ["Homo Sapiens", "SPECIES", 108, 120], ["Mus Musculus", "SPECIES", 148, 160], ["Homo Sapiens", "SPECIES", 108, 120], ["SARS-CoV", "SPECIES", 134, 142], ["Mus Musculus", "SPECIES", 148, 160], ["MHV", "SPECIES", 174, 177], ["Homo Sapiens", "PROBLEM", 108, 120], ["the SARS", "TEST", 130, 138], ["viruses", "OBSERVATION", 52, 59], ["Homo Sapiens", "OBSERVATION", 108, 120], ["Mus Musculus", "ANATOMY", 148, 160]]], ["Figure 4 presents the dinucleotide frequency profile.", [["dinucleotide", "CHEMICAL", 22, 34], ["dinucleotide", "CHEMICAL", 22, 34], ["the dinucleotide frequency profile", "PROBLEM", 18, 52]]], ["It is obvious that the frequency of dinucletide TT is rich in all the eight organisms.", [["dinucletide", "CHEMICAL", 36, 47], ["dinucletide TT", "SIMPLE_CHEMICAL", 36, 50], ["dinucletide TT", "PROBLEM", 36, 50]]], ["BJ01, MHV and PEDV (Porcine Epidemic Diarrhea Virus) have another similar characteristic of the high frequency of TG.", [["Epidemic Diarrhea", "DISEASE", 28, 45], ["TG", "DISEASE", 114, 116], ["BJ01", "GENE_OR_GENE_PRODUCT", 0, 4], ["MHV", "ORGANISM", 6, 9], ["PEDV", "ORGANISM", 14, 18], ["Porcine Epidemic Diarrhea Virus", "ORGANISM", 20, 51], ["TG", "SIMPLE_CHEMICAL", 114, 116], ["Porcine", "SPECIES", 20, 27], ["BJ01", "SPECIES", 0, 4], ["MHV", "SPECIES", 6, 9], ["PEDV", "SPECIES", 14, 18], ["Porcine Epidemic Diarrhea Virus", "SPECIES", 20, 51], ["BJ01", "TREATMENT", 0, 4], ["MHV", "TREATMENT", 6, 9], ["PEDV (Porcine Epidemic Diarrhea Virus", "TREATMENT", 14, 51], ["MHV", "ANATOMY", 6, 9]]], ["The obvious difference between BJ01 and other coronaviruses is that the AA frequency of BJ01 is higher.", [["AA", "CHEMICAL", 72, 74], ["BJ01", "CHEMICAL", 88, 92], ["BJ01", "CANCER", 31, 35], ["coronaviruses", "ORGANISM", 46, 59], ["The obvious difference between BJ01 and other coronaviruses", "PROBLEM", 0, 59], ["BJ01", "TEST", 88, 92], ["obvious", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["higher", "OBSERVATION_MODIFIER", 96, 102]]], ["This AA-rich characteristic is the same to Homo Sapiens, so probably in SARS-CoV it is influenced by its host\u2212Homo Sapiens.", [["AA", "CHEMICAL", 5, 7], ["SARS", "DISEASE", 72, 76], ["SARS-CoV", "ORGANISM", 72, 80], ["Homo Sapiens", "SPECIES", 43, 55], ["SARS-CoV", "SPECIES", 72, 80], ["Homo Sapiens", "SPECIES", 110, 122], ["SARS", "PROBLEM", 72, 76], ["Sapiens", "OBSERVATION", 115, 122]]], ["The result that the MFPs of Homo Sapiens and mouse are very similar to each other is in accordance with the phylogenetic analysis.", [["MFPs", "GENE_OR_GENE_PRODUCT", 20, 24], ["Homo Sapiens", "ORGANISM", 28, 40], ["mouse", "ORGANISM", 45, 50], ["mouse", "SPECIES", 45, 50], ["Homo Sapiens", "SPECIES", 28, 40], ["mouse", "SPECIES", 45, 50], ["the phylogenetic analysis", "TEST", 104, 129]]], ["The lower frequency of CG in all the images could be easily explained by the reason that there is a relatively high chance of a methyl-C mutation into a T. Theoretically, the C-T methyl mutation should induce the frequency increase of TG, while the result shows that the frequency of TG is not high in about six organisms out of the eight.", [["methyl-C", "CHEMICAL", 128, 136], ["C-T methyl", "CHEMICAL", 175, 185], ["TG", "DISEASE", 235, 237], ["TG", "DISEASE", 284, 286], ["methyl-C", "CHEMICAL", 128, 136], ["methyl", "CHEMICAL", 179, 185], ["methyl-C", "SIMPLE_CHEMICAL", 128, 136], ["C-T methyl", "GENE_OR_GENE_PRODUCT", 175, 185], ["TG", "SIMPLE_CHEMICAL", 235, 237], ["TG", "SIMPLE_CHEMICAL", 284, 286], ["TG", "PROTEIN", 235, 237], ["TG", "PROTEIN", 284, 286], ["a methyl-C mutation", "TREATMENT", 126, 145], ["the C-T methyl mutation", "TREATMENT", 171, 194], ["TG", "TEST", 235, 237], ["TG", "TEST", 284, 286], ["lower", "OBSERVATION_MODIFIER", 4, 9]]], ["So there should be some other mechanisms that lead to the decrease of TG in these organisms.Motif frequency profile comparison with other virusesTo see what contributes to the high content of TT, we also did the MFP analysis with the motif length from 3 to 8 nt.", [["TG", "DISEASE", 70, 72], ["TG", "SIMPLE_CHEMICAL", 70, 72], ["TG", "PROTEIN", 70, 72], ["some other mechanisms", "PROBLEM", 19, 40], ["the decrease of TG in these organisms", "PROBLEM", 54, 91], ["Motif frequency profile", "TEST", 92, 115], ["the MFP analysis", "TEST", 208, 224], ["the motif length", "TEST", 230, 246], ["decrease", "OBSERVATION_MODIFIER", 58, 66]]], ["We found out that at motif length 4, almost all the tetranucleotide of coronaviruses with the highest frequency are TGTT except those in SARS-CoV ( Figure 5 ).", [["SARS", "DISEASE", 137, 141], ["coronaviruses", "ORGANISM", 71, 84], ["SARS-CoV", "ORGANISM", 137, 145], ["SARS-CoV", "SPECIES", 137, 145], ["coronaviruses", "PROBLEM", 71, 84]]], ["The richest tetranucleotide of the SARS-CoV is TGCT, while TGTT is the second.", [["SARS", "DISEASE", 35, 39], ["TGCT", "DISEASE", 47, 51], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 35, 43], ["TGCT", "CANCER", 47, 51], ["TGTT", "DNA", 59, 63], ["SARS-CoV", "SPECIES", 35, 43], ["TGCT", "PROBLEM", 47, 51], ["TGCT", "OBSERVATION", 47, 51]]], ["This fact demonstrates that the SARS-CoV is phylogenetically far from other coronaviruses, and this conclusion is the same as the serological analysis result.", [["SARS", "DISEASE", 32, 36], ["SARS-CoV", "ORGANISM", 32, 40], ["coronaviruses", "ORGANISM", 76, 89], ["SARS-CoV", "SPECIES", 32, 40], ["the SARS-CoV", "PROBLEM", 28, 40], ["other coronaviruses", "PROBLEM", 70, 89], ["the serological analysis", "TEST", 126, 150], ["SARS", "OBSERVATION", 32, 36]]], ["To see whether this characteristic is unique to coronaviruses, we searched 2,497 virus genomes, and found only two viruses, Beet soil-borne mosaic virus (genome size: 4,616 bp; NCBI accession number: AF061869) and Soil-borne cereal mosaic virus (genome size: 3,683 bp; NCBI accession number: AJ132577), have this characteristic.", [["cereal mosaic virus", "DISEASE", 225, 244], ["Beet soil-borne mosaic virus", "ORGANISM", 124, 152], ["cereal mosaic virus", "ORGANISM", 225, 244], ["mosaic virus", "SPECIES", 140, 152], ["cereal mosaic virus", "SPECIES", 225, 244], ["Beet soil-borne mosaic virus", "SPECIES", 124, 152], ["Soil-borne cereal mosaic virus", "SPECIES", 214, 244], ["coronaviruses", "PROBLEM", 48, 61], ["two viruses", "PROBLEM", 111, 122], ["Beet soil", "TEST", 124, 133], ["borne mosaic virus", "PROBLEM", 134, 152], ["genome size", "TEST", 154, 165], ["bp", "TEST", 173, 175], ["Soil", "TEST", 214, 218], ["genome size", "TEST", 246, 257], ["bp", "TEST", 265, 267], ["viruses", "OBSERVATION", 115, 122], ["mosaic virus", "OBSERVATION", 232, 244]]], ["Both these two exceptions are ssRNA positively stranded viruses and belong to two different subspecies: Furovirus and Benyvirus.", [["ssRNA positively stranded viruses", "PROBLEM", 30, 63], ["Furovirus and Benyvirus", "PROBLEM", 104, 127], ["two", "OBSERVATION_MODIFIER", 11, 14], ["ssRNA", "OBSERVATION", 30, 35], ["positively", "OBSERVATION_MODIFIER", 36, 46], ["stranded viruses", "OBSERVATION", 47, 63]]], ["We computed the TGTT content of coronavirus genomes and the result is shown in Table 1 .", [["coronavirus", "ORGANISM", 32, 43], ["TGTT", "DNA", 16, 20], ["coronavirus genomes", "DNA", 32, 51], ["coronavirus genomes", "PROBLEM", 32, 51], ["coronavirus genomes", "OBSERVATION", 32, 51]]], ["As a comparison, the contents of other viruses have also been computed, but the results are not listed here.", [["other viruses", "PROBLEM", 33, 46], ["viruses", "OBSERVATION", 39, 46]]], ["The lowest content is 0.13% appeared in TT-like mini virus (NCBI accession number: AF291073), and the highest content is 7.33% in HCoV-229.", [["HCoV-229", "CHEMICAL", 130, 138], ["TT-like mini virus", "ORGANISM", 40, 58], ["HCoV-229", "SIMPLE_CHEMICAL", 130, 138], ["HCoV-229", "SPECIES", 130, 138], ["The lowest content", "TEST", 0, 18], ["TT", "TEST", 40, 42], ["the highest content", "TEST", 98, 117], ["HCoV", "TEST", 130, 134], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["content", "OBSERVATION_MODIFIER", 11, 18]]], ["The difference of TGTT frequency between different viruses is great.", [["TGTT", "GENE_OR_GENE_PRODUCT", 18, 22], ["TGTT", "PROTEIN", 18, 22], ["TGTT frequency", "PROBLEM", 18, 32], ["different viruses", "PROBLEM", 41, 58], ["difference", "OBSERVATION_MODIFIER", 4, 14], ["viruses", "OBSERVATION", 51, 58], ["great", "OBSERVATION_MODIFIER", 62, 67]]], ["Thus the richest tetranucleotide, TGTT, could be a common characteristic of coronaviruses.Codon usage bias comparison with other virusesDNA sequence data from various organisms have clearly shown that synonymous codons for each amino acid are not used with equal frequency, even though choices among the codons should be equivalent in terms of protein structures.", [["amino acid", "CHEMICAL", 228, 238], ["amino acid", "CHEMICAL", 228, 238], ["TGTT", "GENE_OR_GENE_PRODUCT", 34, 38], ["coronaviruses", "ORGANISM", 76, 89], ["amino acid", "AMINO_ACID", 228, 238], ["richest tetranucleotide", "DNA", 9, 32], ["TGTT", "DNA", 34, 38], ["virusesDNA sequence", "DNA", 129, 148], ["the richest tetranucleotide", "TREATMENT", 5, 32], ["TGTT", "TREATMENT", 34, 38], ["coronaviruses", "PROBLEM", 76, 89], ["other virusesDNA sequence data", "TEST", 123, 153], ["various organisms", "PROBLEM", 159, 176], ["synonymous codons", "TREATMENT", 201, 218], ["each amino acid", "TEST", 223, 238], ["coronaviruses", "OBSERVATION", 76, 89]]], ["The statistical data suggest that the choices among synonymous codons are consistently similar for all genes within a certain genome (5) (6) (7) .", [["The statistical data", "TEST", 0, 20], ["the choices among synonymous codons", "PROBLEM", 34, 69]]], ["Generally speaking, if two organisms were adjacent in evolution, their codon usage bias should be similar (7 ).", [["two organisms", "PROBLEM", 23, 36]]], ["We made statistics of the codon usage frequency of all viruses and computed the standard deviation of their codon usage frequency relative to BJ01.", [["BJ01", "DNA", 142, 146], ["all viruses", "PROBLEM", 51, 62], ["BJ01", "TEST", 142, 146]]], ["When we computed the codon usage frequency of the SARS-CoV, the five function-known gene-coding regions for the R, S (spike), E (envelope), M (membrane), N (nucleocapsid) and five putative uncharacterized proteins (PUP) were all analyzed (8 ) .", [["SARS", "DISEASE", 50, 54], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 50, 58], ["R, S (spike)", "GENE_OR_GENE_PRODUCT", 112, 124], ["E (envelope)", "GENE_OR_GENE_PRODUCT", 126, 138], ["M (membrane)", "GENE_OR_GENE_PRODUCT", 140, 152], ["PUP", "GENE_OR_GENE_PRODUCT", 215, 218], ["SARS-CoV", "DNA", 50, 58], ["S", "DNA", 115, 116], ["E", "DNA", 126, 127], ["N", "DNA", 154, 155], ["nucleocapsid", "PROTEIN", 157, 169], ["putative uncharacterized proteins", "PROTEIN", 180, 213], ["PUP", "PROTEIN", 215, 218], ["SARS-CoV", "SPECIES", 50, 58], ["the SARS", "PROBLEM", 46, 54], ["known gene-coding regions", "PROBLEM", 78, 103], ["the R, S (spike", "TEST", 108, 123], ["M (membrane), N (nucleocapsid)", "PROBLEM", 140, 170]]], ["Results show that all other coronaviruses have a small difference of codon usage frequency with the SARS-CoV.", [["coronaviruses", "ORGANISM", 28, 41], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 100, 108], ["SARS-CoV", "SPECIES", 100, 108], ["all other coronaviruses", "PROBLEM", 18, 41], ["a small difference of codon usage frequency", "PROBLEM", 47, 90], ["small", "OBSERVATION_MODIFIER", 49, 54], ["codon usage", "OBSERVATION", 69, 80]]], ["Astonishingly, some viruses that do not belong to coronavirus also have the same difference with the SARS-CoV, such as human papillomavirus (NCBI accession number: U85660).", [["SARS", "DISEASE", 101, 105], ["human papillomavirus", "DISEASE", 119, 139], ["coronavirus", "ORGANISM", 50, 61], ["SARS-CoV", "ORGANISM", 101, 109], ["human", "ORGANISM", 119, 124], ["papillomavirus", "ORGANISM", 125, 139], ["human", "SPECIES", 119, 124], ["papillomavirus", "SPECIES", 125, 139], ["SARS-CoV", "SPECIES", 101, 109], ["human papillomavirus", "SPECIES", 119, 139], ["Astonishingly", "PROBLEM", 0, 13], ["some viruses", "PROBLEM", 15, 27], ["coronavirus", "PROBLEM", 50, 61], ["viruses", "OBSERVATION", 20, 27]]], ["This fact suggests that the codon usage bias is not valid at all conditions.Codon usage bias comparison with other virusesFor the very similar codon usage of different strains of the same subspecies, we selected only one of the several isolates in Figure 6 .Function-known protein comparison with other virusesThe SARS-CoV has a similar genome organization, especially in its gene orders, with other members in coronavirus.", [["SARS", "DISEASE", 314, 318], ["SARS-CoV", "ORGANISM", 314, 322], ["coronavirus", "ORGANISM", 411, 422], ["coronavirus", "SPECIES", 411, 422], ["SARS-CoV", "SPECIES", 314, 322], ["the codon usage bias", "PROBLEM", 24, 44], ["Codon usage", "TREATMENT", 76, 87], ["other viruses", "PROBLEM", 109, 122], ["different strains", "PROBLEM", 158, 175], ["known protein comparison", "PROBLEM", 267, 291], ["other viruses", "PROBLEM", 297, 310], ["The SARS-CoV", "PROBLEM", 310, 322], ["coronavirus", "PROBLEM", 411, 422], ["SARS", "OBSERVATION", 314, 318], ["CoV", "OBSERVATION_MODIFIER", 319, 322], ["similar", "OBSERVATION_MODIFIER", 329, 336], ["genome organization", "OBSERVATION", 337, 356]]], ["This is good evidence that the SARS-CoV is closely related with coronavirus.", [["SARS", "DISEASE", 31, 35], ["SARS-CoV", "ORGANISM", 31, 39], ["coronavirus", "ORGANISM", 64, 75], ["SARS-CoV", "SPECIES", 31, 39], ["the SARS-CoV", "PROBLEM", 27, 39], ["coronavirus", "PROBLEM", 64, 75], ["good", "OBSERVATION_MODIFIER", 8, 12], ["SARS", "OBSERVATION", 31, 35]]], ["The five proteins of the SARS-CoV whose functions had been known were compared with the proteins of other viruses.", [["SARS", "DISEASE", 25, 29], ["SARS-CoV", "ORGANISM", 25, 33], ["SARS-CoV", "SPECIES", 25, 33], ["viruses", "OBSERVATION", 106, 113]]], ["The results demonstrated that these five proteins are similarest to the proteins of coronaviurses.Mutations analysisWe aligned 42 complete genome sequences of the SARS-CoV by using the software, Crossmatch (version 0.990329), to look for variations.", [["SARS", "DISEASE", 163, 167], ["coronaviurses", "GENE_OR_GENE_PRODUCT", 84, 97], ["coronaviurses", "PROTEIN", 84, 97], ["42 complete genome sequences", "DNA", 127, 155], ["SARS-CoV", "DNA", 163, 171], ["SARS-CoV", "SPECIES", 163, 171], ["Crossmatch", "TEST", 195, 205]]], ["With BJ01 as the reference, we found 338 substitution sites.", [["BJ01", "DNA", 5, 9], ["substitution sites", "TREATMENT", 41, 59], ["338 substitution", "OBSERVATION", 37, 53]]], ["All the results are listed in the supplementary table.Mutations analysisSubstitution errors replacing a purine with a purine and a pyrimidine with a pyrimidine were more easily made for steric reasons.", [["purine", "CHEMICAL", 104, 110], ["purine", "CHEMICAL", 118, 124], ["pyrimidine", "CHEMICAL", 131, 141], ["pyrimidine", "CHEMICAL", 149, 159], ["purine", "CHEMICAL", 104, 110], ["purine", "CHEMICAL", 118, 124], ["pyrimidine", "CHEMICAL", 131, 141], ["pyrimidine", "CHEMICAL", 149, 159], ["purine", "SIMPLE_CHEMICAL", 104, 110], ["purine", "SIMPLE_CHEMICAL", 118, 124], ["pyrimidine", "SIMPLE_CHEMICAL", 131, 141], ["pyrimidine", "SIMPLE_CHEMICAL", 149, 159], ["Mutations analysisSubstitution errors", "PROBLEM", 54, 91], ["a purine", "TREATMENT", 116, 124], ["a pyrimidine", "TREATMENT", 129, 141], ["a pyrimidine", "TREATMENT", 147, 159]]], ["Transversions, purine to pyrimidine changes and the reverse, are less likely made.", [["purine", "CHEMICAL", 15, 21], ["pyrimidine", "CHEMICAL", 25, 35], ["purine", "CHEMICAL", 15, 21], ["pyrimidine", "CHEMICAL", 25, 35], ["purine", "SIMPLE_CHEMICAL", 15, 21], ["pyrimidine", "SIMPLE_CHEMICAL", 25, 35], ["Transversions", "TREATMENT", 0, 13], ["purine to pyrimidine changes", "TREATMENT", 15, 43], ["purine to", "OBSERVATION", 15, 24], ["pyrimidine changes", "OBSERVATION", 25, 43], ["less likely", "UNCERTAINTY", 65, 76]]], ["When resulting in an amino-acid change, transversions often have a larger impact on the protein than transitions.", [["amino-acid", "CHEMICAL", 21, 31], ["amino-acid", "CHEMICAL", 21, 31], ["amino", "AMINO_ACID", 21, 26], ["an amino-acid change", "TREATMENT", 18, 38], ["transversions", "PROBLEM", 40, 53], ["larger", "OBSERVATION_MODIFIER", 67, 73]]], ["There are four possible transition errors (A\u2190\u2192G, C\u2190\u2192T) and eight possible transversion errors (A\u2190\u2192C, A\u2190\u2192T, G\u2190\u2192C, G\u2190\u2192T).", [["transition errors", "PROBLEM", 24, 41], ["transversion errors", "PROBLEM", 74, 93], ["A\u2190\u2192C", "TEST", 95, 99], ["possible", "UNCERTAINTY", 15, 23], ["transition errors", "OBSERVATION", 24, 41], ["possible", "UNCERTAINTY", 65, 73], ["transversion errors", "OBSERVATION", 74, 93]]], ["Therefore, if a mutation occurs randomly, a transversion would be more likely than a transition.", [["a mutation", "PROBLEM", 14, 24], ["a transversion", "PROBLEM", 42, 56]]], ["However, in many organisms, transitions are two times more likely to occur than transversions (9 ) .Mutations analysisOnly one substitution occurred at each of the 338 substitution sites, of which 225 were transitions, including 98 AG transitions and 127 CT transitions, and 113 were transversions, including 40 AC, 35 AT, 9 GC, and 29 GT specifically.", [["Mutations analysisOnly one substitution", "PROBLEM", 100, 139], ["CT transitions", "TEST", 255, 269], ["transversions", "TEST", 284, 297], ["AC", "TEST", 312, 314], ["GC", "TEST", 325, 327]]], ["The odds ratio of transition and tranversion was about 2.0 (225/113), which just equalled the universal possibility of 2.0.Mutations analysisThe statistics of types and codon phases of nucleotide substitution in coding region (Table 2) demonstrate that, as long as the substitution number or rate is concerned, there is no great difference among the three codon phases.", [["nucleotide", "CHEMICAL", 185, 195], ["nucleotide", "CHEMICAL", 185, 195], ["coding region", "DNA", 212, 225], ["tranversion", "TEST", 33, 44], ["Mutations analysis", "TEST", 123, 141], ["nucleotide substitution", "TREATMENT", 185, 208], ["nucleotide substitution", "OBSERVATION", 185, 208], ["no", "UNCERTAINTY", 320, 322], ["great", "OBSERVATION_MODIFIER", 323, 328]]], ["In the 98 mutations that happened at the first codon phase, the number of non-synonymous substitutions is 93 and the rate is 95% (93/98), which is very close to the statistical possibility of 96%.", [["non-synonymous substitutions", "TEST", 74, 102], ["the rate", "TEST", 113, 121], ["non-synonymous substitutions", "OBSERVATION", 74, 102]]], ["The 112 substitutions that happened at the second codon phase were all nonsynonymous substitutions.", [["The 112 substitutions", "PROBLEM", 0, 21], ["all nonsynonymous substitutions", "PROBLEM", 67, 98], ["nonsynonymous substitutions", "OBSERVATION", 71, 98]]], ["In the 119 substitutions that happened at the third codon phase, the number of non-synonymous substitutions is 18, and the rate is 15.13% (18/119), which is lower than the statistical possibility of 30%.", [["non-synonymous substitutions", "TEST", 79, 107], ["the rate", "TEST", 119, 127], ["non-synonymous substitutions", "OBSERVATION", 79, 107], ["lower", "OBSERVATION_MODIFIER", 157, 162]]], ["If we take the substitution type into consideration, the first two substitution types are with 92 AG and 125 CT, which constitute about 65.96% (217/329) of the total number.", [["CT", "TEST", 109, 111]]], ["The substitution number of CG is the smallest, only 9.", [["substitution", "OBSERVATION_MODIFIER", 4, 16], ["number", "OBSERVATION_MODIFIER", 17, 23], ["smallest", "OBSERVATION_MODIFIER", 37, 45]]], ["To eliminate mutational noises induced by sequencing errors or other factors, we only considered the forty-nine mutations found within two or more isolates.", [["mutational noises", "PROBLEM", 13, 30], ["sequencing errors", "PROBLEM", 42, 59]]], ["The total transition number was 37, including 13 AG and 24 CT.", [["The total transition number", "TEST", 0, 27], ["13 AG", "TEST", 46, 51], ["24 CT", "TEST", 56, 61], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The total tranversion number was 12, including 3 AC, 4 AT, and 5 GT.", [["The total tranversion number", "TEST", 0, 28], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The odds ratio of transition and tranversion was about 3.1 (37/12), larger than the universal possibility of 2.0.", [["tranversion", "TEST", 33, 44]]], ["This change of the odds ratio from 2.0 to 3.1 means that we omitted some real substitution sites when we only considered those that happened in at least two isolates.Mutations analysisAmong 42 isolates of the SARS-CoV compared with BJ01, ZYM1 has the highest substitution mutation rate.", [["SARS", "DISEASE", 209, 213], ["ZYM1", "CHEMICAL", 238, 242], ["SARS-CoV", "ORGANISM", 209, 217], ["ZYM1", "GENE_OR_GENE_PRODUCT", 238, 242], ["BJ01", "DNA", 232, 236], ["ZYM1", "DNA", 238, 242], ["SARS-CoV", "SPECIES", 209, 217], ["BJ01", "SPECIES", 232, 236], ["the odds ratio", "TEST", 15, 29], ["some real substitution sites", "PROBLEM", 68, 96], ["Mutations analysisAmong", "TEST", 166, 189], ["the SARS", "TEST", 205, 213], ["BJ01", "TEST", 232, 236]]], ["It has 86 mutation sites with 62 nonsynonymous substitutions, and the whole genome mutation rate is 0.29% (86/29726).", [["86 mutation sites", "DNA", 7, 24], ["62 nonsynonymous substitutions", "PROBLEM", 30, 60], ["the whole genome mutation rate", "TEST", 66, 96], ["nonsynonymous substitutions", "OBSERVATION", 33, 60]]], ["The strain that has the lowest substitution mutation rate is GD02, which has five mutation sites with four non-synonymous substitutions and the whole genome mutation rate is 0.017% (5/29726).", [["GD02", "GENE_OR_GENE_PRODUCT", 61, 65], ["GD02", "DNA", 61, 65], ["The strain", "PROBLEM", 0, 10], ["the lowest substitution mutation rate", "PROBLEM", 20, 57], ["five mutation sites", "PROBLEM", 77, 96], ["four non-synonymous substitutions", "PROBLEM", 102, 135], ["the whole genome mutation rate", "TEST", 140, 170], ["non-synonymous substitutions", "OBSERVATION", 107, 135]]], ["42 new sequences were produced by using the nucleotides at the 338 substitution sites to represent the 42 isolates of viruses.", [["nucleotides", "CHEMICAL", 44, 55], ["338 substitution sites", "DNA", 63, 85], ["new sequences", "TEST", 3, 16], ["the nucleotides", "TREATMENT", 40, 55], ["viruses", "PROBLEM", 118, 125], ["viruses", "OBSERVATION", 118, 125]]], ["The only difference lies in the branch lengths of the tree.", [["difference", "OBSERVATION_MODIFIER", 9, 19], ["branch", "ANATOMY_MODIFIER", 32, 38], ["lengths", "ANATOMY_MODIFIER", 39, 46], ["tree", "ANATOMY_MODIFIER", 54, 58]]], ["There are obviously four groups in the tree.", [["obviously", "OBSERVATION_MODIFIER", 10, 19], ["four", "OBSERVATION_MODIFIER", 20, 24], ["groups", "OBSERVATION_MODIFIER", 25, 31], ["tree", "ANATOMY_MODIFIER", 39, 43]]], ["FRA, Frankfurt1, and four isolates from Singapore (SP), constitute Group 4 which is named \"SP Group\".", [["FRA", "GENE_OR_GENE_PRODUCT", 0, 3], ["Frankfurt1", "GENE_OR_GENE_PRODUCT", 5, 15], ["FRA", "PROTEIN", 0, 3]]], ["The HK03 does not belong to any group because the difference between it and other isolates is maximal.", [["HK03", "GENE_OR_GENE_PRODUCT", 4, 8], ["HK03", "PROTEIN", 4, 8]]], ["This group division is different from the one that was made on geography, which suggests the complexity of virus propagation.Mutations analysisWe found that there are two specific genotypes after analyzing six mutation sites that happened in at least ten isolates.", [["virus propagation", "PROBLEM", 107, 124], ["analyzing six mutation sites", "PROBLEM", 196, 224], ["different", "OBSERVATION_MODIFIER", 23, 32], ["virus propagation", "OBSERVATION", 107, 124]]], ["The nucleotides of the eleven isolates (GD03, TC1, TC2, TC3, TWC2, TWC3, TWH, TWJ, TWK, TWS, TWY) (BJ01, BJ02, BJ03, BJ04, GD01, GD02, GD04, GD05, GD06, GD07, CUHK-W1) at the three positions are all G, C and C, respectively.", [["nucleotides", "CHEMICAL", 4, 15], ["CUHK-W1", "GENE_OR_GENE_PRODUCT", 159, 166], ["TWC3", "PROTEIN", 67, 71], ["TWH", "PROTEIN", 73, 76], ["TWJ", "PROTEIN", 78, 81], ["TWK", "PROTEIN", 83, 86], ["TWS", "PROTEIN", 88, 91], ["TWY", "PROTEIN", 93, 96], ["GD01", "DNA", 123, 127], ["GD02", "DNA", 129, 133], ["GD04", "DNA", 135, 139], ["GD05", "DNA", 141, 145], ["GD06", "DNA", 147, 151], ["GD07", "DNA", 153, 157], ["CUHK", "DNA", 159, 163], ["W1", "DNA", 164, 166], ["The nucleotides", "TEST", 0, 15], ["the eleven isolates", "TEST", 19, 38], ["GD03", "TEST", 40, 44], ["TC1", "TEST", 46, 49], ["TC2", "TEST", 51, 54], ["TC3", "TEST", 56, 59], ["TWC2", "TEST", 61, 65], ["TWC3", "TEST", 67, 71], ["TWH", "TEST", 73, 76], ["TWJ", "TEST", 78, 81], ["TWK", "TEST", 83, 86], ["TWS", "TEST", 88, 91], ["TWY", "TEST", 93, 96], ["BJ01", "TEST", 99, 103], ["BJ02", "TEST", 105, 109], ["BJ03", "TEST", 111, 115], ["BJ04", "TEST", 117, 121], ["GD01", "TEST", 123, 127], ["GD02", "TEST", 129, 133], ["GD04", "TEST", 135, 139], ["GD05", "TEST", 141, 145], ["GD06", "TEST", 147, 151], ["GD07", "TEST", 153, 157], ["CUHK", "TEST", 159, 163]]], ["Compared with the division result above, the eleven isolates corresponding to the first genotype all belong to \"TW Group\", whereas the eleven isolates corresponding to the second genotype all belong to \"BJ-GD Group\".", [["the eleven isolates", "PROBLEM", 41, 60]]], ["It is very unlikely that the C:T:G and G:C:C genotypes emerge by chance.", [["C:T:G", "GENE_OR_GENE_PRODUCT", 29, 34], ["G:C:C", "GENE_OR_GENE_PRODUCT", 39, 44], ["G", "TEST", 33, 34], ["very unlikely", "UNCERTAINTY", 6, 19]]], ["Rather, this should be the evidence for the genetic signature of strain differences in the SARS-CoV.Mutations analysisExcept for the single nucleotide substitutions, there were some big segment insertions or deletions.", [["SARS", "DISEASE", 91, 95], ["nucleotide", "CHEMICAL", 140, 150], ["nucleotide", "CHEMICAL", 140, 150], ["SARS-CoV", "ORGANISM", 91, 99], ["SARS-CoV", "SPECIES", 91, 99], ["strain differences", "PROBLEM", 65, 83], ["Mutations analysis", "TEST", 100, 118], ["the single nucleotide substitutions", "PROBLEM", 129, 164], ["some big segment insertions or deletions", "PROBLEM", 177, 217], ["big segment insertions", "OBSERVATION", 182, 204]]], ["The 29-nt insertion has been reported in our former paper (10 ) .", [["29-nt insertion", "DNA", 4, 19], ["The 29-nt insertion", "TREATMENT", 0, 19]]], ["Our research has discovered the 29nt insertion in two newly sequenced isolates (GD02, GD05), as well as a 54-nt deletion and a 386-nt deletion in GD06 and HK02, respectively ( Table 3 ).", [["GD05", "GENE_OR_GENE_PRODUCT", 86, 90], ["GD06", "GENE_OR_GENE_PRODUCT", 146, 150], ["29nt insertion", "DNA", 32, 46], ["GD02", "DNA", 80, 84], ["54-nt deletion", "DNA", 106, 120], ["386-nt deletion", "DNA", 127, 142], ["GD06", "DNA", 146, 150], ["HK02", "DNA", 155, 159], ["the 29nt insertion", "TREATMENT", 28, 46], ["a 54-nt deletion", "TREATMENT", 104, 120], ["a 386-nt deletion in GD06", "TREATMENT", 125, 150]]], ["The region near Codon 27,863 seems like a hotspot, because these five big segment insertions all occurred nearby.", [["Codon 27,863", "DNA", 16, 28], ["big segment insertions", "DNA", 70, 92], ["these five big segment insertions", "PROBLEM", 59, 92]]], ["The details will be shown in another paper.Possible recombination and horizontal transferThe recombination in the RNA virus genomes is a general phenomenon, and is considered to play a major role as a driving force in the virus variability and thus in virus evolution.", [["RNA virus genomes", "DNA", 114, 131], ["The recombination in the RNA virus genomes", "PROBLEM", 89, 131], ["a general phenomenon", "PROBLEM", 135, 155], ["the virus variability", "PROBLEM", 218, 239], ["RNA virus genomes", "OBSERVATION", 114, 131], ["general phenomenon", "OBSERVATION", 137, 155]]], ["An ever-increasing number of RNA viruses has been shown to undergo the RNA recombination, whether under natural or experimental conditions (11 ) .", [["RNA viruses", "PROBLEM", 29, 40], ["RNA viruses", "OBSERVATION", 29, 40]]], ["Recent reports strongly suggest that RNA recombination is related to the virus replication and occurs by a copy-choice mechanism (12 ) .Possible recombination and horizontal transferWe analyzed the possible recombination between the SARS-CoV and other viruses, especially other coronaviruses by using the software of SIMPLOT (version 2.5, http://sray.med.som.jhmi.edu/RaySoft/ SimPlot/), but didn't find any hint of recombinations between the SARS-CoV and other viruses.Possible recombination and horizontal transferThe HE (hemagglutinin-esterase) gene found in some of the coronaviruses in Group II is homologous to that of the influenza C virus.", [["SARS", "DISEASE", 233, 237], ["SARS", "DISEASE", 443, 447], ["influenza C", "DISEASE", 629, 640], ["SARS-CoV", "ORGANISM", 233, 241], ["coronaviruses", "ORGANISM", 278, 291], ["SARS-CoV", "ORGANISM", 443, 451], ["HE (hemagglutinin-esterase", "GENE_OR_GENE_PRODUCT", 520, 546], ["coronaviruses", "ORGANISM", 574, 587], ["Group II", "ORGANISM", 591, 599], ["influenza C virus", "ORGANISM", 629, 646], ["HE (hemagglutinin-esterase) gene", "DNA", 520, 552], ["influenza C virus", "SPECIES", 629, 646], ["SARS-CoV", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 443, 451], ["influenza C virus", "SPECIES", 629, 646], ["RNA recombination", "PROBLEM", 37, 54], ["the virus replication", "TREATMENT", 69, 90], ["the SARS", "PROBLEM", 229, 237], ["other viruses", "PROBLEM", 246, 259], ["SIMPLOT (version", "TREATMENT", 317, 333], ["the SARS", "PROBLEM", 439, 447], ["other viruses", "PROBLEM", 456, 469], ["The HE (hemagglutinin-esterase) gene", "TREATMENT", 516, 552], ["the coronaviruses", "PROBLEM", 570, 587], ["the influenza C virus", "PROBLEM", 625, 646], ["viruses", "OBSERVATION", 252, 259], ["viruses", "OBSERVATION", 462, 469], ["coronaviruses", "OBSERVATION", 574, 587], ["influenza", "OBSERVATION", 629, 638]]], ["The HE gene, which is present between the ORF1b and the S protein in Group I and sometimes in Group III, was not found in the SARS-CoV (13 ) .", [["SARS", "DISEASE", 126, 130], ["HE", "GENE_OR_GENE_PRODUCT", 4, 6], ["ORF1b", "GENE_OR_GENE_PRODUCT", 42, 47], ["SARS-CoV", "ORGANISM", 126, 134], ["HE gene", "DNA", 4, 11], ["ORF1b", "DNA", 42, 47], ["S protein", "PROTEIN", 56, 65], ["SARS-CoV", "SPECIES", 126, 134], ["CoV", "TEST", 131, 134]]], ["However, when we analyzed the comparison result manually, we found a region in the BJ01 genome has some similarity with the HE gene.", [["BJ01", "GENE_OR_GENE_PRODUCT", 83, 87], ["HE", "GENE_OR_GENE_PRODUCT", 124, 126], ["BJ01 genome", "DNA", 83, 94], ["HE gene", "DNA", 124, 131]]], ["Many specific segments existing in the HE gene sequence appear in this region, and the order of these segments is the same to that in HE gene.", [["HE", "GENE_OR_GENE_PRODUCT", 39, 41], ["HE", "GENE_OR_GENE_PRODUCT", 134, 136], ["HE gene sequence", "DNA", 39, 55], ["HE gene", "DNA", 134, 141], ["the HE gene sequence", "TEST", 35, 55], ["segments", "OBSERVATION_MODIFIER", 14, 22], ["segments", "ANATOMY_MODIFIER", 102, 110]]], ["So we postulate that the HE gene exists in the SARS-CoV genome, and a lot of mutations happened in this region have broken it and made it unfamiliar to us, since it is not very important for the life and propagation of the SARS-CoV.DataThe complete genome sequences of 2,497 isolates of viruses were obtained from GenBank (NCBI/GenBank/ftp.ncbi.nlm.nih.gov/Feb- 14, 2003) .", [["SARS", "DISEASE", 47, 51], ["SARS", "DISEASE", 223, 227], ["HE", "GENE_OR_GENE_PRODUCT", 25, 27], ["SARS-CoV", "ORGANISM", 47, 55], ["SARS-CoV", "ORGANISM", 223, 231], ["HE gene", "DNA", 25, 32], ["SARS-CoV genome", "DNA", 47, 62], ["SARS-CoV", "SPECIES", 47, 55], ["SARS-CoV", "SPECIES", 223, 231], ["a lot of mutations", "PROBLEM", 68, 86], ["The complete genome sequences", "TEST", 236, 265], ["viruses", "PROBLEM", 287, 294]]], ["They represent 493 species or subspecies, and among them, there are 11 isolates of coronaviruses (Table 4) .DataUntil August 17, 2003, 32 complete genome sequences of the SARS-CoV had been submitted to GenBank (Table 5) .", [["SARS", "DISEASE", 171, 175], ["SARS-CoV", "ORGANISM", 171, 179], ["SARS-CoV", "DNA", 171, 179], ["SARS-CoV", "SPECIES", 171, 179], ["the SARS", "PROBLEM", 167, 175]]], ["Besides, we have newly sequenced 10 complete SARS-CoV genomes ( Table 6 ).", [["SARS-CoV genomes", "DNA", 45, 61], ["SARS-CoV", "SPECIES", 45, 53]]], ["All of our analyses included are referred to the SARS-CoV Isolate BJ01 except those specially mentioned.Motif frequency profileAnalyses of the GC content or amino acid composition bias have long been a standard method in biological sequence research.", [["SARS", "DISEASE", 49, 53], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "CHEMICAL", 157, 167], ["amino acid", "AMINO_ACID", 157, 167], ["SARS-CoV Isolate BJ01", "SPECIES", 49, 70], ["Motif frequency profile", "TEST", 104, 127], ["the GC content", "TEST", 139, 153], ["amino acid composition bias", "TREATMENT", 157, 184], ["a standard method", "TREATMENT", 200, 217]]], ["By extending a single nucleotide to longer words, we could reveal more and more species-specific features (14 ) .", [["nucleotide", "CHEMICAL", 22, 32], ["nucleotide", "CHEMICAL", 22, 32]]], ["Recent investigations have reported differences in the frequency of occurrence of many short oligonucleotides, hereafter called \"motifs\".", [["Recent investigations", "TEST", 0, 21], ["many short oligonucleotides", "PROBLEM", 82, 109]]], ["The existence of specific MFP has been reported for all motif lengths, such as dinucleotides and trinucleotides.Motif frequency profileFor the sequence a with the length L, there are (L-m+1) overlapped motifs.", [["dinucleotides", "CHEMICAL", 79, 92], ["trinucleotides", "CHEMICAL", 97, 111], ["MFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["MFP", "PROTEIN", 26, 29], ["dinucleotides and trinucleotides", "TREATMENT", 79, 111], ["Motif frequency profile", "TEST", 112, 135]]], ["Computing the frequency of appearance of the N motif, and put these N values in a fixed order, we form a MFP vector A specific for the sequence a: A=(a 1 , a 2 , a 3 , \u00b7 \u00b7 \u00b7, a N ) Here, the a k , k=1 to N, is a motif with the length m.Motif frequency profileWhen m is 3 and a is the complete sequence of a gene, A represents the codon usage bias of the gene.Average absolute distanceSuppose A and B are two MFP vectors corresponding to sequence a and b respectively, A=(a 1 , a 2 , a 3 , \u00b7 \u00b7 \u00b7, a N ), B =(b 1 , b 2 , b 3 , \u00b7 \u00b7 \u00b7, b N ).", [["N", "CHEMICAL", 45, 46], ["N", "CHEMICAL", 498, 499], ["B", "GENE_OR_GENE_PRODUCT", 398, 399], ["\u00b7 \u00b7 \u00b7", "SIMPLE_CHEMICAL", 489, 494], ["b 1 , b 2 , b 3 , \u00b7 \u00b7 \u00b7, b N", "SIMPLE_CHEMICAL", 507, 535], ["N motif", "PROTEIN", 45, 52], ["MFP vectors", "DNA", 408, 419], ["the N motif", "TREATMENT", 41, 52], ["a motif with the length m.Motif frequency profile", "TREATMENT", 210, 259], ["A and B are two MFP vectors", "TREATMENT", 392, 419], ["B", "TEST", 503, 504], ["b", "TEST", 513, 514], ["b", "TEST", 519, 520], ["absolute distance", "OBSERVATION", 367, 384]]], ["A simple measure of the difference between A and B is the average absolute motif relative frequency difference.Chaos game representationChaos game representation (CGR) is a new tool derived from the \"chaotic dynamic systems\" theory.", [["simple", "OBSERVATION_MODIFIER", 2, 8], ["relative", "OBSERVATION_MODIFIER", 81, 89], ["frequency", "OBSERVATION_MODIFIER", 90, 99], ["difference", "OBSERVATION_MODIFIER", 100, 110]]], ["The whole set of frequencies of the motif found in a given genomic sequence can be displayed in the form of a single image in which each pixel is associated with a specific motif.", [["the motif", "PROBLEM", 32, 41], ["a single image", "TEST", 108, 122]]], ["Frequencies of motifs found in a sequence are displayed in a square image, with the location of a given motif being chosen according to a recursive procedure.", [["a sequence", "TEST", 31, 41], ["a given motif", "TREATMENT", 96, 109], ["a recursive procedure", "TREATMENT", 136, 157]]], ["The gray scale indicates the relative frequency per image of each motif: the darker the pixel, the greater the frequency (15 ) .", [["The gray scale", "TEST", 0, 14], ["greater", "OBSERVATION_MODIFIER", 99, 106]]], ["Figure 8 shows the different CGR arrangement images with motif length from 1 to 3 nt.", [["CGR", "DNA", 29, 32], ["motif length", "TEST", 57, 69]]], ["The programs to analyze the MFP of a given genomic sequence and to draw the CGR images were written by ourselves using the perl language.", [["genomic sequence", "DNA", 43, 59], ["genomic sequence", "TEST", 43, 59], ["the CGR images", "TEST", 72, 86]]]], "PMC7527147": [["Studies included in the review were not limited by publication year, but were included based on the following conditions: (1) peer-reviewed; (2) English-language; and (3) academic journals.", [["Studies", "TEST", 0, 7]]], ["After removing duplicates, the initial search provided 141 studies in which the author conducted additional reviews using the following three additional inclusion conditions: (4) included human participants across basic (conducted in laboratory settings to evaluate fundamental principles of behavior; Cooper, Heron, & Heward, 2007), applied (evaluating socially significant behaviors; Cooper et al., 2007), or translational (extending laboratory findings to clinical populations and problems; Lerman, 2003); studies (5) comparing two different conditions, such as rich versus lean schedules; and (6) evaluated the effect of a disruptor on behavior within the context of BMT.", [["human", "ORGANISM", 188, 193], ["human", "SPECIES", 188, 193], ["participants", "SPECIES", 194, 206], ["human", "SPECIES", 188, 193], ["a disruptor on behavior", "PROBLEM", 625, 648], ["BMT", "TREATMENT", 671, 674]]], ["Articles were excluded if their primary purpose involved evaluating behavioral relapse phenomena (e.g., reinstatement, renewal, resurgence), as behavioral relapse occurs with a previously extinguished behavior (Podlesnik & Shahan, 2009).", [["behavioral relapse phenomena", "PROBLEM", 68, 96], ["behavioral relapse", "PROBLEM", 144, 162]]], ["The full-text screening excluded 30 articles with a remaining 12 articles meeting the criteria.", [["The full-text screening", "TEST", 0, 23]]], ["The ancestral hand search involved reviewing every reference cited in the 12 original articles to determine whether cited studies also met the inclusion criteria.", [["hand", "ANATOMY", 14, 18], ["cited studies", "TEST", 116, 129]]], ["The final ancestral search resulted in an additional 12 articles for a total of 24 articles included in the review (see Fig. 1).Participant and Setting Characteristics ::: Coding Procedures ::: MethodParticipant and setting characteristics included gender, age, diagnosis, experimental setting, interventionists, and functional analysis results.", [["Participant", "SPECIES", 128, 139], ["functional analysis", "TEST", 317, 336]]], ["When coding participant\u2019s ages, reviewers coded whether the participant fell between 0 to 5 years old, 6 to 12 years old, 13 to 18 years old, or if they were older than 18 years.", [["participant", "SPECIES", 12, 23]]], ["Participant diagnosis codes included autism or pervasive developmental disorders (PDD), intellectual disability (ID), developmental delays (DD), multiple diagnoses, other diagnoses, or no diagnosis (i.e., participants were typically developing).", [["autism", "DISEASE", 37, 43], ["pervasive developmental disorders", "DISEASE", 47, 80], ["PDD", "DISEASE", 82, 85], ["intellectual disability", "DISEASE", 88, 111], ["ID", "DISEASE", 113, 115], ["developmental delays", "DISEASE", 118, 138], ["DD", "DISEASE", 140, 142], ["participants", "SPECIES", 205, 217], ["autism or pervasive developmental disorders", "PROBLEM", 37, 80], ["developmental delays", "PROBLEM", 118, 138]]], ["Experimental settings included hospital rooms, therapy or laboratory rooms, classrooms, work facilities, or living rooms, kitchens, or bedrooms, which were also coded as additional settings.", [["therapy", "TREATMENT", 47, 54]]], ["Functional analyses results included tangible, automatic, escape, attention, and multiply maintained.Experimental Characteristics ::: Coding Procedures ::: MethodExperimental characteristics included dependent variables, reinforcers, signaled or unsignaled stimuli through the incorporation of a discriminative stimulus, and disruptors.", [["Functional analyses", "TEST", 0, 19], ["dependent variables", "PROBLEM", 200, 219]]], ["Dependent variables included functional communicative responses (FCR), task completion, and problem behavior (e.g., aggression, self-injurious behavior, disruption).", [["aggression", "DISEASE", 116, 126], ["Dependent variables", "PROBLEM", 0, 19]]], ["The FCRs included various mand modalities such as various augmentative alternative communicative devices (e.g., picture cards, tablets, microswitches), manual sign, and vocal requests.", [["various mand modalities", "TREATMENT", 18, 41], ["various augmentative alternative communicative devices", "TREATMENT", 50, 104]]], ["Reinforcer codes included escape, attention, tangible, tokens, food, food compared to tokens and an \u201cother\u201d category.Experimental Characteristics ::: Coding Procedures ::: MethodWhen coding whether researchers included stimuli associated with different experimental conditions, the reviewers noted whether different color task materials, different therapists, or different backgrounds were associated with different experimental conditions.", [["different experimental conditions", "PROBLEM", 243, 276], ["different experimental conditions", "PROBLEM", 406, 439]]], ["Researchers coded \u201cno\u201d under the discriminative stimulus section if these components were not present in the experiment.Experimental Characteristics ::: Coding Procedures ::: MethodDisruptor codes included alternative stimuli, distractors, extinction, extinction and distraction, prefeeding, noncontingent reinforcement (NCR), or other distractors not falling into any of the six listed categories.", [["alternative stimuli", "TEST", 206, 225], ["distractors", "PROBLEM", 227, 238], ["extinction", "PROBLEM", 240, 250], ["distraction", "PROBLEM", 267, 278], ["noncontingent reinforcement (NCR", "TREATMENT", 292, 324], ["other distractors", "PROBLEM", 330, 347]]], ["Noncontingent reinforcement was coded when reinforcers were delivered independent of participant responding.", [["Noncontingent reinforcement", "TREATMENT", 0, 27]]], ["Alternative stimuli were defined as stimuli signaling the availability of an alternative concurrent schedule of reinforcement.", [["Alternative stimuli", "TEST", 0, 19], ["an alternative concurrent schedule of reinforcement", "TREATMENT", 74, 125]]], ["Prefeeding involved participant presession reinforcer consumption.Experimental Outcomes ::: Coding Procedures ::: MethodReviewers coded each comparison conducted within each experiment.", [["participant", "SPECIES", 20, 31], ["MethodReviewers", "TREATMENT", 114, 129]]], ["For example, if an experiment compared the effect of rich versus lean schedules (e.g. VI 10-s versus VI 30-s) on FCRs and task completion, the authors coded results related to rich versus lean schedules on FCRs in addition to coding results for the effect on task responding.", [["rich versus lean schedules", "TREATMENT", 53, 79], ["VI", "TEST", 86, 88]]], ["Independent variable comparisons included studies evaluating persistence of high versus low preferred mand modalities.", [["studies evaluating", "TEST", 42, 60]]], ["For example, evaluating the effect of disruption on a more preferred mand modality such as a picture exchange card compared to a less preferred mand modality such as vocalizations.", [["disruption", "PROBLEM", 38, 48], ["disruption", "OBSERVATION", 38, 48]]], ["The review also coded rich versus lean schedules of reinforcement.", [["lean schedules of reinforcement", "TREATMENT", 34, 65]]], ["For example, evaluating the effect of a rich (VI 30-s) versus lean (VI 60-s) schedule on response persistence, or evaluating the effect of a combined VI plus fixed time (FT) schedule compared to a VI schedule alone.", [["a combined VI plus fixed time (FT) schedule", "TREATMENT", 139, 182], ["a VI schedule", "TREATMENT", 195, 208]]], ["A third graduate student coded 20.83% (N = 5) of included articles, and 21.21% of total experiments (N = 7), using identical participant, experiment, and outcome coding templates described above.", [["articles", "TEST", 58, 66], ["total experiments", "TEST", 82, 99]]], ["Coding, conducted by the third graduate student, resulted in 93.62% overall interobserver agreement for participant, experiment, and outcome codes.Participant and Setting Characteristics ::: ResultsThe review comprised 151 experimental evaluations (see Table 1).", [["Participant", "SPECIES", 147, 158], ["experimental evaluations", "TEST", 223, 247]]], ["Reviewers coded participant characteristics every time the participant engaged in an experimental evaluation.", [["participant", "SPECIES", 59, 70], ["an experimental evaluation", "TEST", 82, 108]]], ["For example, Vargo and Ringdahl (2015) included multiple experiments with four to five participants.", [["participants", "SPECIES", 87, 99]]], ["Some participants were included in more than one experiment.", [["participants", "SPECIES", 5, 17]]], ["Likewise, Lionello-DeNolf, Dube, and McIlvane (2010) evaluated the effect of three different disruptors (alternative stimulus, prefeeding, distractor) with six participants and an additional distractor with five participants.", [["participants", "SPECIES", 160, 172], ["participants", "SPECIES", 212, 224], ["alternative stimulus", "TREATMENT", 105, 125], ["an additional distractor", "TREATMENT", 177, 201]]], ["When evaluating Lionello-DeNolf et al.\u2019s (2010) study, reviewers included participant demographic and setting codes for each disruptor evaluation for a total of 23 participant evaluations.Participant and Setting Characteristics ::: ResultsParticipant ages ranged from 1 to 68 years old with more than half of the participants under the age of 18 (64.9%).", [["Participant", "SPECIES", 188, 199], ["participants", "SPECIES", 313, 325], ["each disruptor evaluation", "TEST", 120, 145], ["participant evaluations", "TEST", 164, 187]]], ["Of the 151 participants, 69.54% (N = 105) were male, 23.18% (N = 35) were female, and 7.28% (N = 11) did not have a specified gender reported.", [["participants", "SPECIES", 11, 23]]], ["The review included participants diagnosed with intellectual disability (N = 38), autism or pervasive developmental disability (N = 70), developmental delays (N = 3), or multiple disabilities (N = 15).", [["intellectual disability", "DISEASE", 48, 71], ["autism", "DISEASE", 82, 88], ["developmental disability", "DISEASE", 102, 126], ["developmental delays", "DISEASE", 137, 157], ["multiple disabilities", "DISEASE", 170, 191], ["participants", "SPECIES", 20, 32], ["intellectual disability", "PROBLEM", 48, 71], ["autism or pervasive developmental disability", "PROBLEM", 82, 126], ["developmental delays", "PROBLEM", 137, 157]]], ["In addition, the experiments also included 20 participants without reported disabilities, which primarily participated in basic or translational experiments.", [["participants", "SPECIES", 46, 58]]], ["For example, Vargo and Ringdahl (2015) evaluated resistance to change with unconditioned and conditioned reinforcers with typically developing children.Participant and Setting Characteristics ::: ResultsThe review yielded five different settings in which the experiments were conducted.", [["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["Participant", "SPECIES", 152, 163]]], ["Furthermore, therapists or experimenters conducted the majority of the included experiments (N = 150, 99.34%), whereas a teacher/paraprofessional conducted one experiment (0.66%).Participant and Setting Characteristics ::: ResultsThe review included results of functional analyses when reported.", [["Participant", "SPECIES", 179, 190], ["functional analyses", "TEST", 261, 280]]], ["A tangible function was reported for 5.3% (N = 8) of participants, an escape function was reported for 1.99% (N = 3) of participants, and an attention function was reported for 4.64% (N = 7) of participants.", [["participants", "ORGANISM", 53, 65], ["participants", "ORGANISM", 120, 132], ["participants", "ORGANISM", 194, 206], ["participants", "SPECIES", 53, 65], ["participants", "SPECIES", 120, 132], ["participants", "SPECIES", 194, 206], ["A tangible function", "TEST", 0, 19], ["an escape function", "TEST", 67, 85]]], ["In addition, 0% of participants exhibited automatic or multiply maintained problem behavior; 88.08% (N = 133) of participants did not have a functional analysis conducted.Experimental Characteristics ::: ResultsAs previously described, dependent variables included FCRs, problem behavior, or task completion (see Table 2).", [["participants", "ORGANISM", 19, 31], ["participants", "ORGANISM", 113, 125], ["participants", "SPECIES", 19, 31], ["participants", "SPECIES", 113, 125], ["a functional analysis", "TEST", 139, 160]]], ["Task completion included experiments examining participant responses involving computer navigation such as Dube, Thompson, Silveira, and Nevin\u2019s (2017) study involving a computer game written in Python requiring participants to move icons using keys on a modified keyboard, or studies such as Vargo and Ringdahl\u2019s (2015) evaluating tasks such as number or letter tracing, and stringing beads.", [["participants", "SPECIES", 212, 224], ["a modified keyboard", "TREATMENT", 253, 272], ["letter tracing", "TEST", 356, 370]]], ["Over 80% of the included experiments evaluated task completion (N = 127), whereas the remaining 24 experiments evaluated problem behavior (N = 17), FCRs (N = 3), or a combination of problem behavior and FCR (N = 4).", [["problem behavior", "PROBLEM", 121, 137], ["problem behavior", "PROBLEM", 182, 198]]], ["The type of reinforcers in each experiment are also noted in Table 2, with almost half of the experiments (43.36%) using tangible items (N = 67) and 35.76% using tokens (N = 54).Experimental Characteristics ::: ResultsExperiments included disruptors such as extinction (N = 52, 34.44%).", [["tangible items", "TEST", 121, 135]]], ["Thirty-one (20.53%) experiments evaluated the effect of distractors such as videos (e.g., Mace et al., 1990), and 12 experiments (7.95%) evaluated the effect of prefeeding.", [["distractors", "PROBLEM", 56, 67]]], ["For example, during Vargo and Ringdahl\u2019s (2015) prefeeding disruptor phase, participants consumed food prior to beginning experimental sessions in addition to food consumption during intercomponent intervals.", [["participants", "SPECIES", 76, 88]]], ["Furthermore, 21.85% of the disruptors were coded as alternative stimuli.", [["alternative stimuli", "TEST", 52, 71]]], ["For example, Lionello-DeNolf and Dube\u2019s (2011) alternative stimulus test involved an additional stimulus associated with a VI 6-s presented concurrently with either the rich or lean components.Experimental Characteristics ::: ResultsOf the evaluated experiments, 88.08% (N = 133) involved a discriminative stimulus and 11.92% (N = 18) did not.", [["Lionello", "TEST", 13, 21], ["alternative stimulus test", "TEST", 47, 72], ["a discriminative stimulus", "TEST", 289, 314], ["lean", "OBSERVATION", 177, 181]]], ["Likewise, Lionello-DeNolf and Dube (2011) used different computer icons associated with either the rich or lean conditions (e.g., balloon and gift).Experimental Outcomes ::: ResultsExperimental outcomes are summarized in Tables 3 and 4.", [["balloon and gift", "TREATMENT", 130, 146]]], ["Table 3 displays the number of comparisons and the percent of comparisons displaying greater persistence across dependent variables.", [["greater", "OBSERVATION_MODIFIER", 85, 92], ["persistence", "OBSERVATION", 93, 104]]], ["The first independent variable comparison evaluates the effect of rich versus lean schedules on experiments evaluating problem behavior (N = 15) and task completion (N = 66).", [["rich versus lean schedules", "TREATMENT", 66, 92], ["problem behavior", "PROBLEM", 119, 135]]], ["For example, Mace et al. (1990) compared the effect of a rich (VI 30-s) versus lean (VI 60-s) schedule on response persistence, but other researchers, such as Lieving, DeLeon, Carreau-Webster, Triggs, and Frank-Crawford (2018), evaluated the combination of a VI plus fixed time (FT) schedule compared to a VI schedule alone.", [["a VI plus fixed time (FT) schedule", "TREATMENT", 257, 291], ["a VI schedule", "TREATMENT", 304, 317]]], ["Overall, the review discovered 73% of the included experiments indicated problem behavior responses persisted greater in rich compared to lean schedules.", [["the review", "TEST", 9, 19], ["problem behavior responses", "PROBLEM", 73, 99]]], ["In particular, comparisons involving DRA associated with rich versus DRA lean reinforcement schedules display greater persistence in 75% of included comparisons.Experimental Outcomes ::: ResultsHowever, when comparing the effect of different disruptor magnitudes on response persistence, task completion responses persisted more in conditions associated with lower magnitudes of reinforcement.", [["DRA", "DNA", 37, 40], ["DRA lean reinforcement schedules", "TREATMENT", 69, 101], ["different disruptor magnitudes", "PROBLEM", 232, 262], ["greater", "OBSERVATION_MODIFIER", 110, 117], ["persistence", "OBSERVATION_MODIFIER", 118, 129]]], ["For example, in Carr, Bailey, Ecott, Lucker, and Weil\u2019s (1998) study, task completion was disrupted with noncontingent reinforcement of low, medium, or high reinforcer magnitudes.", [["noncontingent reinforcement", "TREATMENT", 105, 132]]], ["In these comparisons, the participant\u2019s task completion persisted at a greater rate when disrupted with the lower reinforcer magnitude.Experimental Outcomes ::: ResultsIndependent variable comparisons also included experiments evaluating persistence of high versus low preferred mand modalities.", [["participant", "SPECIES", 26, 37], ["experiments evaluating", "TEST", 215, 237]]], ["For example, Ringdahl et al. (2018) evaluated persistence of FCRs associated with high preferred versus low preferred mands.", [["FCRs", "PROBLEM", 61, 65]]], ["In this example, reviewers coded the number of participants evaluated in each comparison as well as the number of participants exhibiting greater response persistence with high preferred versus low preferred mands (86%).Experimental Outcomes ::: ResultsTable 4 displays experimental outcomes by studies and also includes dependent variables, disruptors, the number of participant evaluations, independent variable comparisons, as well as comparison results.", [["participants", "SPECIES", 47, 59], ["participants", "SPECIES", 114, 126], ["participant evaluations", "TEST", 368, 391]]], ["In the second column, the author identifies independent variable comparisons.", [["second column", "ANATOMY_MODIFIER", 7, 20]]], ["For example, Carr et al. (1998) evaluated the effect of a noncontingent reinforcement schedule (NCR) on low verses medium, low versus high, and medium versus high magnitude reinforcers.", [["a noncontingent reinforcement schedule", "TREATMENT", 56, 94], ["low verses medium", "TREATMENT", 104, 121]]], ["The third column indicates the dependent variable, which the author coded as task completion in the Carr et al. (1998) experiment.", [["dependent", "OBSERVATION_MODIFIER", 31, 40], ["variable", "OBSERVATION_MODIFIER", 41, 49]]], ["Finally, the last five columns indicate the number of participants (N), and the percent of participants with greater persistence in the first comparison condition.", [["participants", "SPECIES", 54, 66], ["participants", "SPECIES", 91, 103], ["greater", "OBSERVATION_MODIFIER", 109, 116], ["persistence", "OBSERVATION_MODIFIER", 117, 128]]], ["For example, Lionello-DeNolf et al. (2010) evaluated response persistence on rich versus lean schedules when presented with an alternative stimulus, prefeeding, and distraction.Implications for Practice ::: DiscussionThe current review discovered 17 experiments evaluating response persistence of problem behavior.", [["lean schedules", "TREATMENT", 89, 103], ["distraction", "PROBLEM", 165, 176], ["problem behavior", "PROBLEM", 297, 313]]], ["It is interesting that 15 of these 17 experiments evaluated the effect of extinction as a disruptor whereas the remaining two evaluated the effect of motivating operation (MO) manipulation.", [["motivating operation (MO) manipulation", "TREATMENT", 150, 188]]], ["For example, Berg et al. (2000) evaluated the effect of presession attention on responding during attention session of a functional analysis for behavior that was determined to be maintained by attention.", [["a functional analysis", "TEST", 119, 140]]], ["Eleven of the 15 experiments evaluating response persistence of problem behavior in rich compared to lean schedules resulted in greater persistence in the richer schedule of reinforcement.", [["problem behavior", "PROBLEM", 64, 80], ["lean schedules", "TREATMENT", 101, 115], ["greater", "OBSERVATION_MODIFIER", 128, 135], ["persistence", "OBSERVATION_MODIFIER", 136, 147]]], ["As a result of this finding, practitioners might consider the implications of implementing an extinction component in contexts in which problem behaviors contacts rich schedules of reinforcement.", [["an extinction component", "TREATMENT", 91, 114]]], ["For example, practitioners should be aware that implementing an extinction-based procedure following a rich reinforcement schedule might require a longer time to be effective when compared to extinction-based procedures implemented following lean reinforcement schedules.Implications for Practice ::: DiscussionOn the other hand, the review also discovered 71% (N = 50) of studies demonstrated response persistence of FCR or task completion responses in rich compared to lean schedules.", [["lean", "ORGANISM_SUBDIVISION", 242, 246], ["an extinction-based procedure", "TREATMENT", 61, 90], ["a rich reinforcement schedule", "TREATMENT", 101, 130], ["lean reinforcement schedules", "TREATMENT", 242, 270], ["studies", "TEST", 373, 380]]], ["For example, if teaching a learner to mand, the literature suggests the mand is more likely to persist in the face of disruption, if the mand contacted a richer schedule of reinforcement prior to disruption.", [["more likely", "UNCERTAINTY", 80, 91], ["disruption", "OBSERVATION", 118, 128]]], ["Furthermore, because it is likely a newly acquired skill such as manding might contact disruptors outside of intervention contexts, programing rich schedules of reinforcement might create robust alternative behaviors, which are paramount for the learner\u2019s success.Implications for Practice ::: DiscussionSchieltz, Wacker, Ringdahl, and Berg (2017) described assessment and treatment decisions based on BMT.", [["reinforcement", "TREATMENT", 161, 174], ["BMT", "TREATMENT", 402, 405]]], ["The authors focused on discrepancies between two ways behavior analytic maintenance effects are measured: (1) treatment effects probed over long periods of time under prevailing treatment conditions (Durand & Carr, 1991); and (2) evaluating behavioral persistence following the presentation of a disruptor (e.g., extinction; Nevin & Wacker, 2013).", [["behavioral persistence", "PROBLEM", 241, 263]]], ["Schieltz et al. (2017) noted the former measurement system does not require an analytical evaluation directly tied to specific behavioral processes.", [["an analytical evaluation", "TEST", 76, 100]]], ["However, the latter definition provides practitioners with a format to evaluate and program durable maintenance effects during treatment rather than conducting post-hoc treatment evaluations.", [["treatment", "TREATMENT", 127, 136], ["conducting post-hoc treatment evaluations", "TEST", 149, 190]]], ["Although DRA interventions demonstrate decreased levels of problem behavior and increased rates of appropriate behavior, maintenance of these effects are seldom reported (Schieltz et al., 2017).", [["DRA interventions", "TREATMENT", 9, 26], ["decreased levels of problem behavior", "PROBLEM", 39, 75], ["increased rates of appropriate behavior", "PROBLEM", 80, 119], ["decreased", "OBSERVATION_MODIFIER", 39, 48], ["increased", "OBSERVATION_MODIFIER", 80, 89]]], ["Moreover, when maintenance effects are reported, they are often reported as effects over time rather than a systematic analysis providing information regarding the circumstances in which maintenance is likely or unlikely to occur (e.g., Nevin & Wacker, 2013; Schieltz et al., 2017).", [["a systematic analysis", "TEST", 106, 127]]], ["Evaluating maintenance based on BMT (i.e., evaluating persistence following disruption) provides a thorough assessment and treatment framework based on underlying behavioral processes (Schieltz et al., 2017).", [["BMT", "TREATMENT", 32, 35], ["a thorough assessment", "TEST", 97, 118], ["treatment framework", "TREATMENT", 123, 142]]], ["The second maintenance measurement method described by Schieltz et al. (2017), requires evaluating the effect of systematically manipulating the target response\u2019s history of reinforcement (i.e., magnitude and rate) and the presentation of different disruptors.Implications for Practice ::: DiscussionTherefore, evaluating the effect of different reinforcement and disruptor variables might prove instrumental in programming high levels of treatment durability when designing and monitoring intervention plans.", [["different disruptors", "PROBLEM", 239, 259], ["different reinforcement", "TREATMENT", 336, 359], ["disruptor variables", "PROBLEM", 364, 383], ["treatment durability", "TREATMENT", 439, 459], ["intervention plans", "TREATMENT", 490, 508]]], ["For instance, Ringdahl et al. (2018) indicated relatively preferred mand modalities (as demonstrated through a mand modality preference assessment) resulted in greater persistence when placed on extinction.", [["preference assessment", "TEST", 125, 146], ["greater", "OBSERVATION_MODIFIER", 160, 167], ["persistence", "OBSERVATION_MODIFIER", 168, 179]]], ["Perhaps practitioners can use similar evaluations to determine responses more likely to exhibit greater persistence when challenged.", [["similar evaluations", "TEST", 30, 49], ["greater", "OBSERVATION_MODIFIER", 96, 103], ["persistence", "OBSERVATION", 104, 115]]], ["Evaluating variables linked to BMT such as behavioral mass and various disruptors provide valuable information regarding treatment decisions.", [["BMT", "TREATMENT", 31, 34], ["behavioral mass", "PROBLEM", 43, 58], ["various disruptors", "PROBLEM", 63, 81], ["treatment decisions", "TREATMENT", 121, 140], ["mass", "OBSERVATION", 54, 58]]], ["For example, assessing maintenance through a BMT framework might allow practitioners to program high levels of treatment durability.", [["a BMT framework", "TREATMENT", 43, 58], ["treatment durability", "TREATMENT", 111, 131]]], ["Furthermore, after evaluating persistence and determining a behavior to be resistant to disruptors, this analysis might also provide a framework to systematically discontinue services.Implications for Research ::: DiscussionWhen evaluating behavioral mass, the current review indicated researchers often evaluate the effect rich versus lean reinforcement rates on responding during disruption.", [["lean", "ORGANISM_SUBDIVISION", 336, 340], ["this analysis", "TEST", 100, 113], ["behavioral mass", "PROBLEM", 240, 255], ["lean reinforcement rates", "TREATMENT", 336, 360], ["mass", "OBSERVATION", 251, 255]]], ["However, McComas, Hartman, and Jiminez (2008) evaluated the effect of high magnitude reinforcers compared to low magnitude reinforcers on persistence of computer clicks.", [["McComas", "TEST", 9, 16], ["high magnitude reinforcers", "TREATMENT", 70, 96], ["low magnitude", "OBSERVATION_MODIFIER", 109, 122]]], ["McComas et al. discovered greater response persistence in the components associated with higher reinforcer magnitudes (i.e., greater number of points).", [["greater", "OBSERVATION_MODIFIER", 26, 33], ["response", "OBSERVATION_MODIFIER", 34, 42], ["persistence", "OBSERVATION_MODIFIER", 43, 54], ["higher", "OBSERVATION_MODIFIER", 89, 95], ["reinforcer magnitudes", "OBSERVATION", 96, 117]]], ["Therefore, future investigations might evaluate the effect of manipulating additional reinforcer dimensions prior to disruption.", [["future investigations", "TEST", 11, 32], ["manipulating additional reinforcer dimensions", "TREATMENT", 62, 107], ["disruption", "PROBLEM", 117, 127]]], ["For example, though not specifically evaluating responding through a BMT framework, Athens and Vollmer (2010) manipulated three different reinforcer dimensions (quality, duration, delay) in a concurrent schedule arrangement.", [["a concurrent schedule arrangement", "TREATMENT", 190, 223]]], ["The results reported by Athens and Vollmer align with predictions made by matching law, a quantitative model of behavior that predicts response allocation under concurrent reinforcement schedule arrangements (Baum, 1974; Herrnstein, 1961), and also align with Trump, Ayres, Quinland, and Zabala (2020) literature review, which discovered effective treatment packages with concurrent schedules resulting in greater response allocation associated with the more favorable schedule.", [["effective treatment packages", "TREATMENT", 338, 366], ["concurrent schedules", "TREATMENT", 372, 392]]], ["Given that they demonstrated that reinforcement schedule dimensions such as magnitude and delay to reinforcement affected response allocation, it may be interesting to see if these same dimension affect responding under schedule arrangements relevant to BMT (i.e., multiple schedule arrangements).Implications for Research ::: DiscussionSimilar to evaluating different reinforcer dimensions, few experiments evaluated different disruptor dimensions.", [["reinforcement schedule dimensions", "TREATMENT", 34, 67]]], ["As previously discussed, BMT provides a framework for evaluating and predicting responding based on the target behavior\u2019s history of reinforcement and the presentation of a disruptor.", [["reinforcement", "TREATMENT", 133, 146]]], ["Numerous experiments evaluated different factors related to behavioral mass, but little or minimal variation exists when examining the effect of different disruptors.", [["behavioral mass", "PROBLEM", 60, 75], ["different disruptors", "PROBLEM", 145, 165], ["mass", "OBSERVATION", 71, 75], ["minimal", "OBSERVATION_MODIFIER", 91, 98], ["variation", "OBSERVATION", 99, 108]]], ["Moreover, few researchers evaluated different disruptor magnitudes (e.g., different distractor volumes) or disruptor combinations, and only 20.53% (N = 31) evaluated the effect of distractors.", [["different disruptor magnitudes", "PROBLEM", 36, 66], ["disruptor combinations", "PROBLEM", 107, 129], ["distractors", "PROBLEM", 180, 191]]], ["Therefore, future investigations might consider quantifying and evaluating the effect of different disruptor magnitudes (e.g., quiet compared to loud disruptors), distractors (e.g., preferred compared to nonpreferred videos), and presession conditions (e.g., evaluating the effect of satiation and deprivation).", [["future investigations", "TEST", 11, 32], ["different disruptor magnitudes", "PROBLEM", 89, 119], ["loud disruptors", "PROBLEM", 145, 160], ["distractors", "PROBLEM", 163, 174], ["satiation and deprivation", "TREATMENT", 284, 309]]], ["For example, in applied settings, teachers might play music during independent work time; however, the effect of type of music or the music\u2019s volume has not been evaluated within the context of BMT.Implications for Research ::: DiscussionIn addition, this review discovered 127 experiments evaluating the effect of disruptors on task completion.", [["BMT", "TREATMENT", 194, 197], ["task completion", "TREATMENT", 329, 344]]], ["Of these 20 experiments, only 35% evaluated the effect of computer tasks.", [["computer tasks", "TEST", 58, 72]]], ["Although task completion certainly involved experiments evaluating the effect of response persistence on computer related tasks (e.g., Kuroda, Cancado, & Podlesnik, 2016), additional tasks included spelling, math, stringing beads, and completing puzzles (Parry-Cruwys et al., 2011), as well as number and letter tracing (Vargo & Ringdahl, 2015).", [["letter tracing", "TEST", 305, 319]]], ["Therefore, future investigations might want to evaluate the effect of different disruptor variables on different types of tasks (e.g., academic tasks compared to computer tasks).", [["future investigations", "TEST", 11, 32], ["different disruptor variables", "PROBLEM", 70, 99], ["computer tasks", "TEST", 162, 176]]], ["For instance, does the presentation of a distractor (e.g., music or videos) affect academic tasks (e.g., Vargo & Ringdahl, 2015) differently than computer tasks (e.g., Dube et al., 2017)?", [["a distractor", "PROBLEM", 39, 51]]], ["In particular, future investigations might evaluate the effect of disruption on multistep or complex tasks (i.e., tasks requiring the individual to engage in covert verbal behavior) compared to one-step computer tasks requiring little to no covert verbal behavior.Implications for Research ::: DiscussionFurthermore, Schieltz et al. (2017) described the impact of the number of instances target behavior contacts extinction.", [["future investigations", "TEST", 15, 36], ["disruption on multistep or complex tasks", "PROBLEM", 66, 106]]], ["Therefore, Schieltz et al. suggested future research evaluating pre- and posttreatment exposures to extinction and reinforcement to determine whether or not reinforcement to extinction ratios influence treatment durability.", [["reinforcement", "TREATMENT", 115, 128], ["extinction ratios influence treatment durability", "TREATMENT", 174, 222]]], ["Likewise, researchers evaluating response persistence might consider evaluating the effect of number of exposures to disruptors on resistance to change.Implications for Research ::: DiscussionAlthough a majority of the included studies involved different stimuli associated with different conditions (i.e., blue card associated with VI 30-s and red card associated with VI 12-s), only two included articles (Dube & McIlvane, 2002; Saini & Fisher, 2016) specifically evaluated the effect of these stimuli or stimulus variations.", [["different stimuli", "PROBLEM", 245, 262], ["VI", "TEST", 333, 335], ["these stimuli", "TEST", 490, 503], ["stimulus variations", "PROBLEM", 507, 526]]], ["For example, Dube, McIlvane, Mazzitelli, and NcNamara (2003) evaluated the effect of stimuli with lower and high discrimination when challenged by a change in reinforcement schedules.", [["Dube", "TREATMENT", 13, 17], ["McIlvane", "TREATMENT", 19, 27], ["Mazzitelli", "TREATMENT", 29, 39], ["NcNamara", "TREATMENT", 45, 53], ["a change in reinforcement schedules", "TREATMENT", 147, 182]]], ["Likewise, Saini and Fisher (2016) evaluated the effect of different stimuli salience on response persistence.", [["different stimuli salience", "TREATMENT", 58, 84]]], ["Saini and Fisher stated BMT, \u201cpredicts that increasing the discriminability of the change from variable-interval to variable-time reinforcement should lead to faster reductions in responding\u201d (p.", [["variable-time reinforcement", "TREATMENT", 116, 143]]], ["Moreover, none of the studies evaluated the effect of verbal statements such as instructions on responding when challenged, despite experiments demonstrating response differences in the presence of verbal stimuli (G\u00fcnther & Dougher, 2013).Implications for Research ::: DiscussionFurthermore, although the purpose of this review was to synthesize the literature regarding changes in reinforcer conditions (i.e., response persistence), it should be noted that relapse paradigms, evaluating changes in treatment conditions (e.g., extinction; Podlesnik & Shahan, 2009) are also crucial to the field of applied behavior analysis.", [["the studies", "TEST", 18, 29], ["relapse paradigms", "TEST", 458, 475], ["changes in treatment conditions", "PROBLEM", 488, 519], ["behavior analysis", "TEST", 606, 623]]], ["Furthermore, treatment relapse involves the reemergence of a response following intervention conditions previously resulting in extinguished behaviors (Pritchard, Hoerger, & Mace, 2014a).", [["treatment relapse", "TREATMENT", 13, 30], ["intervention conditions", "TREATMENT", 80, 103]]], ["Reinstatement involves the delivery of the reinforcer maintaining rates of target behavior during baseline following extinction, which subsequently results in resumed rates of the target behavior (Pritchard et al., 2014a, b; Podlesnik & Shahan, 2009).", [["the reinforcer", "TREATMENT", 39, 53]]], ["Resurgence involves the reappearance of a previously extinguished behavior, extinguished through extinction and DRA, when the alternative behavior contacts extinction procedures (Doughty & Oken, 2008; Pritchard et al., 2014a).", [["DRA", "DNA", 112, 115], ["a previously extinguished behavior", "PROBLEM", 40, 74]]], ["The third relapse paradigm, renewal, involves extinguishing a target behavior in a context different from the baseline context, and the target behavior reappears upon returning to the baseline context (Pritchard et al., 2014a).Implications for Research ::: DiscussionEvaluating these three relapse paradigms through a framework of BMT might assist behavior analytic professionals in determining possible solutions to mitigate issues related to treatment relapse.", [["BMT", "TREATMENT", 331, 334], ["treatment relapse", "TREATMENT", 444, 461], ["third", "OBSERVATION_MODIFIER", 4, 9], ["relapse", "OBSERVATION", 10, 17]]], ["Therefore, the authors hope to see future reviews evaluating experiments involving behavioral relapse paradigms (e.g., reinstatement, renewal, and resurgence) such as Pritchard, Hoerger, Mace, Penney, and Harris\u2019s, (2014b) study evaluating the effect of high compared to low rates of reinforcement during treatment on reinstatement.", [["treatment", "TREATMENT", 305, 314], ["reinstatement", "TREATMENT", 318, 331]]], ["This finding is similar to the results identified in the current review indicating greater response persistence in contexts associated with richer schedules of reinforcement.Limitations ::: DiscussionAs with any systematic literature review, publication bias might limit search results (e.g., Sham & Smith, 2014; Tincani & Travers, 2018).", [["reinforcement", "TREATMENT", 160, 173], ["publication bias", "TEST", 242, 258], ["greater", "OBSERVATION_MODIFIER", 83, 90], ["response persistence", "OBSERVATION", 91, 111]]], ["Sham and Smith (2014) indicated publication bias occurs when journals reject publications indicating null effects.", [["publication bias", "PROBLEM", 32, 48], ["null effects", "PROBLEM", 101, 113], ["null effects", "OBSERVATION", 101, 113]]], ["Furthermore, publication bias occurs when researchers do not submit datasets that do not report large differences across conditions (Tincani & Travers, 2018).", [["publication bias", "PROBLEM", 13, 29], ["large differences across conditions", "PROBLEM", 96, 131]]], ["In addition to publication bias, search terms might not result in a comprehensive list of experiments related to the current review.", [["publication bias", "TEST", 15, 31]]], ["Therefore, the current review might not fully represent all of the BMT studies conducted with human participants.Limitations ::: DiscussionAs an additional limitation, the current review did not code the effect of repeated exposures to disruptors.", [["human", "ORGANISM", 94, 99], ["human", "SPECIES", 94, 99], ["participants", "SPECIES", 100, 112], ["human", "SPECIES", 94, 99], ["the BMT studies", "TEST", 63, 78]]], ["For example, although not included in the review, Wacker et al.\u2019s (2011) experiment evaluated persistence of treatment effects during long-term treatment.", [["treatment effects", "PROBLEM", 109, 126], ["long-term treatment", "TREATMENT", 134, 153], ["long-term treatment", "OBSERVATION_MODIFIER", 134, 153]]], ["In this experiment, Wacker et al. also conceptualized maintenance as treatment durability during treatment challenges.", [["treatment durability", "TREATMENT", 69, 89], ["treatment challenges", "TREATMENT", 97, 117]]], ["For example, evaluating whether problem behavior relapses when presented with a disruptor such as a newly acquired FCR contacting extinction.", [["a disruptor", "PROBLEM", 78, 89], ["a newly acquired FCR contacting extinction", "PROBLEM", 98, 140]]], ["The authors discovered decreased resistance to change over extended treatment periods, which implies longer treatment durations or repeated exposures to extinction might lead to more durable treatment outcomes.", [["decreased resistance", "PROBLEM", 23, 43], ["extended treatment periods", "TREATMENT", 59, 85], ["decreased resistance", "OBSERVATION", 23, 43]]], ["The current review did not code number of exposures to disruptors; therefore, this review does not provide information regarding the effect of continued exposure to disruptors on response persistence.Limitations ::: DiscussionIn summary, this review discovered several important factors regarding response persistence within the context of BMT as well as considerations for applied settings and future research.", [["BMT", "TREATMENT", 340, 343]]], ["For instance, future research could focus investigations on the phenomena described in the preceding pages, including, but not limited to, variables affecting appropriate and inappropriate behavior and how those variables might affect generalization and maintenance of responding resulting in improved quality of life for individuals exhibiting behavioral concerns.", [["behavioral concerns", "PROBLEM", 345, 364]]], ["Moreover, in light of recent events (i.e., the Covid-19 pandemic), perhaps researchers can evaluate variables influencing response persistence of behaviors related to public health behaviors such as mask wearing.", [["recent events", "PROBLEM", 22, 35], ["the Covid", "TEST", 43, 52], ["mask wearing", "TREATMENT", 199, 211]]], ["After all, behavior analysis is only restricted by its principles and methods (Lerman, Iwata, & Hanley, 2013).", [["behavior analysis", "TEST", 11, 28]]]], "18dc497dbade61ee314c46981c7d7260b21869b7": [["INTRODUCTIONAvian infectious bronchitis (IB) is a viral respiratory disease in chickens caused by avian infectious bronchitis virus (IBV) (Cook and Heijden, 2010) .", [["respiratory", "ANATOMY", 56, 67], ["infectious bronchitis (IB)", "DISEASE", 18, 44], ["viral respiratory disease", "DISEASE", 50, 75], ["avian infectious bronchitis virus", "DISEASE", 98, 131], ["chickens", "ORGANISM", 79, 87], ["avian infectious bronchitis virus", "ORGANISM", 98, 131], ["IBV", "ORGANISM", 133, 136], ["chickens", "SPECIES", 79, 87], ["avian infectious bronchitis virus", "SPECIES", 98, 131], ["chickens", "SPECIES", 79, 87], ["avian infectious bronchitis virus", "SPECIES", 98, 131], ["IBV", "SPECIES", 133, 136], ["INTRODUCTIONAvian infectious bronchitis", "PROBLEM", 0, 39], ["a viral respiratory disease", "PROBLEM", 48, 75], ["avian infectious bronchitis virus", "PROBLEM", 98, 131], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["bronchitis", "OBSERVATION", 29, 39], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["respiratory disease", "OBSERVATION", 56, 75], ["infectious", "OBSERVATION_MODIFIER", 104, 114]]], ["Infectious bronchitis virus is an enveloped, non-segmented, single-stranded, positive-sense RNA virus belonging to the genus Gammacoronavirus of the family Coronaviridae (Cheng et al., 2018; Haji-Abdolvahab et al., 2019) .", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus", "PROBLEM", 0, 27], ["sense RNA virus", "PROBLEM", 86, 101], ["enveloped", "OBSERVATION_MODIFIER", 34, 43]]], ["Infectious bronchitis virus genome is unstable and prone to point mutation, deletion, insertion, etc., which leads to continuous isolation of gene mutants.", [["Infectious bronchitis virus", "DISEASE", 0, 27], ["Infectious bronchitis virus", "ORGANISM", 0, 27], ["Infectious bronchitis virus genome", "DNA", 0, 34], ["Infectious bronchitis virus", "SPECIES", 0, 27], ["Infectious bronchitis virus genome", "PROBLEM", 0, 34], ["point mutation", "PROBLEM", 60, 74], ["deletion", "PROBLEM", 76, 84], ["insertion", "TREATMENT", 86, 95], ["gene mutants", "PROBLEM", 142, 154], ["unstable", "OBSERVATION_MODIFIER", 38, 46]]], ["In addition, there are many serotypes of IBV, and the cross-protection between different serotypes or genotypes is very weak (Leghari et al., 2016) , which makes the immune control of this disease constantly challenged (Faruku et al., 2015) .", [["IBV", "ORGANISM", 41, 44], ["IBV", "SPECIES", 41, 44], ["IBV", "TREATMENT", 41, 44], ["the cross-protection between different serotypes or genotypes", "PROBLEM", 50, 111], ["very weak", "PROBLEM", 115, 124], ["this disease", "PROBLEM", 184, 196], ["many", "OBSERVATION_MODIFIER", 23, 27], ["serotypes", "OBSERVATION", 28, 37], ["IBV", "OBSERVATION", 41, 44], ["weak", "OBSERVATION_MODIFIER", 120, 124]]], ["Therefore, although the disease has been reported for more than 60 yr, its prevention and control is still not good (Cook et al., 2012) .", [["the disease", "PROBLEM", 20, 31], ["disease", "OBSERVATION", 24, 31]]], ["The incidence of IBV is high, broilers infected with this virus will grow slowly and feed conversion ratio (FCR) will decline, and if laying hens are infected with IBV, it can lead to the decline of egg production and egg quality, so IB is one of the main infectious diseases detrimental to China's poultry industry.INTRODUCTIONIB is characterized by respiratory signs, kidney lesions, and proventriculus lesions (Zhao et al., 2014) .", [["egg", "ANATOMY", 199, 202], ["egg", "ANATOMY", 218, 221], ["respiratory", "ANATOMY", 351, 362], ["kidney lesions", "ANATOMY", 370, 384], ["proventriculus lesions", "ANATOMY", 390, 412], ["IBV", "DISEASE", 17, 20], ["kidney lesions", "DISEASE", 370, 384], ["IBV", "ORGANISM", 17, 20], ["IBV", "ORGANISM", 164, 167], ["egg", "ORGANISM_SUBSTANCE", 199, 202], ["egg", "ORGANISM_SUBDIVISION", 218, 221], ["kidney lesions", "PATHOLOGICAL_FORMATION", 370, 384], ["proventriculus lesions", "PATHOLOGICAL_FORMATION", 390, 412], ["IBV", "SPECIES", 17, 20], ["broilers", "SPECIES", 30, 38], ["IBV", "SPECIES", 164, 167], ["IBV", "PROBLEM", 17, 20], ["this virus", "PROBLEM", 53, 63], ["IBV", "TREATMENT", 164, 167], ["egg production", "PROBLEM", 199, 213], ["respiratory signs", "PROBLEM", 351, 368], ["kidney lesions", "PROBLEM", 370, 384], ["proventriculus lesions", "PROBLEM", 390, 412], ["IBV", "OBSERVATION", 17, 20], ["high", "OBSERVATION_MODIFIER", 24, 28], ["main", "OBSERVATION_MODIFIER", 251, 255], ["infectious", "OBSERVATION", 256, 266], ["respiratory signs", "OBSERVATION", 351, 368], ["kidney", "ANATOMY", 370, 376], ["lesions", "OBSERVATION", 377, 384], ["proventriculus", "ANATOMY", 390, 404], ["lesions", "OBSERVATION", 405, 412]]], ["The respiratory signs include coughing, sneezing, gasping, and tracheal rales, and there may be gray feces for some diseased chickens (Wu et al., 1998) .", [["respiratory", "ANATOMY", 4, 15], ["tracheal", "ANATOMY", 63, 71], ["respiratory signs", "DISEASE", 4, 21], ["coughing", "DISEASE", 30, 38], ["sneezing", "DISEASE", 40, 48], ["feces", "ORGANISM_SUBDIVISION", 101, 106], ["chickens", "ORGANISM", 125, 133], ["chickens", "SPECIES", 125, 133], ["chickens", "SPECIES", 125, 133], ["The respiratory signs", "TEST", 0, 21], ["coughing", "PROBLEM", 30, 38], ["sneezing", "PROBLEM", 40, 48], ["gasping", "PROBLEM", 50, 57], ["tracheal rales", "PROBLEM", 63, 77], ["gray feces", "TEST", 96, 106], ["some diseased chickens", "PROBLEM", 111, 133], ["respiratory", "ANATOMY", 4, 15], ["coughing", "OBSERVATION", 30, 38], ["sneezing", "OBSERVATION", 40, 48], ["tracheal", "ANATOMY", 63, 71], ["rales", "OBSERVATION", 72, 77]]], ["Necropsy showed catarrhal and hemorrhagic inflammatory lesions of the trachea.", [["hemorrhagic inflammatory lesions", "ANATOMY", 30, 62], ["trachea", "ANATOMY", 70, 77], ["hemorrhagic", "DISEASE", 30, 41], ["inflammatory lesions", "PATHOLOGICAL_FORMATION", 42, 62], ["trachea", "ORGAN", 70, 77], ["Necropsy", "TEST", 0, 8], ["catarrhal", "PROBLEM", 16, 25], ["hemorrhagic inflammatory lesions of the trachea", "PROBLEM", 30, 77], ["catarrhal", "OBSERVATION_MODIFIER", 16, 25], ["hemorrhagic", "OBSERVATION_MODIFIER", 30, 41], ["inflammatory", "OBSERVATION_MODIFIER", 42, 54], ["lesions", "OBSERVATION", 55, 62], ["trachea", "ANATOMY", 70, 77]]], ["Chickens of all ages can be infected with IBV, which is mainly found in respiratory epithelial cells, digestive tract, and other tissues such as kidney, fallopian tube, and testes (Cavanagh, 2007) .", [["respiratory epithelial cells", "ANATOMY", 72, 100], ["digestive tract", "ANATOMY", 102, 117], ["tissues", "ANATOMY", 129, 136], ["kidney", "ANATOMY", 145, 151], ["fallopian tube", "ANATOMY", 153, 167], ["testes", "ANATOMY", 173, 179], ["Chickens", "ORGANISM", 0, 8], ["IBV", "ORGANISM", 42, 45], ["respiratory epithelial cells", "CELL", 72, 100], ["digestive tract", "ORGAN", 102, 117], ["tissues", "TISSUE", 129, 136], ["kidney", "ORGAN", 145, 151], ["fallopian tube", "TISSUE", 153, 167], ["testes", "ORGAN", 173, 179], ["respiratory epithelial cells", "CELL_TYPE", 72, 100], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["IBV", "SPECIES", 42, 45], ["IBV", "PROBLEM", 42, 45], ["respiratory epithelial cells", "PROBLEM", 72, 100], ["digestive tract, and other tissues", "PROBLEM", 102, 136], ["kidney, fallopian tube", "TREATMENT", 145, 167], ["infected", "OBSERVATION", 28, 36], ["IBV", "OBSERVATION", 42, 45], ["respiratory epithelial cells", "OBSERVATION", 72, 100], ["digestive tract", "ANATOMY", 102, 117], ["kidney", "ANATOMY", 145, 151], ["fallopian tube", "OBSERVATION", 153, 167], ["testes", "ANATOMY", 173, 179]]], ["With clinical symptoms and pathological features similar to those of Newcastle disease (ND), avian influenza (AI), and infectious laryngotracheitis (ILT), IB is easy to be misdiagnosed (Giovanni et al., 2017) .", [["Newcastle disease", "DISEASE", 69, 86], ["ND", "DISEASE", 88, 90], ["avian influenza", "DISEASE", 93, 108], ["AI", "DISEASE", 110, 112], ["infectious laryngotracheitis", "DISEASE", 119, 147], ["ILT", "DISEASE", 149, 152], ["avian influenza", "ORGANISM", 93, 108], ["avian influenza", "SPECIES", 93, 108], ["clinical symptoms", "PROBLEM", 5, 22], ["pathological features", "PROBLEM", 27, 48], ["Newcastle disease (ND)", "PROBLEM", 69, 91], ["avian influenza (AI)", "PROBLEM", 93, 113], ["infectious laryngotracheitis", "PROBLEM", 119, 147], ["influenza", "OBSERVATION", 99, 108], ["infectious", "OBSERVATION_MODIFIER", 119, 129], ["laryngotracheitis", "OBSERVATION", 130, 147]]], ["The current methods for detection of IBV are conventional virus isolation (CVI), reverse transcriptionpolymerase chain reaction-agarose gel electrophoresis (RT-PCR-AGE), enzyme-linked immunosorbent assay (ELISA), and loop-mediated isothermal amplification (LAMP).", [["CVI", "DISEASE", 75, 78], ["IBV", "ORGANISM", 37, 40], ["IBV", "SPECIES", 37, 40], ["IBV", "PROBLEM", 37, 40], ["conventional virus isolation", "TREATMENT", 45, 73], ["CVI", "TEST", 75, 78], ["reverse transcriptionpolymerase chain reaction", "PROBLEM", 81, 127], ["agarose gel electrophoresis", "TEST", 128, 155], ["RT-PCR", "TEST", 157, 163], ["enzyme", "TEST", 170, 176], ["immunosorbent assay", "TEST", 184, 203], ["ELISA", "TEST", 205, 210], ["loop-mediated isothermal amplification", "TREATMENT", 217, 255]]], ["However, these methods often require expensive devices and professional operators, making it very 1 IBV-1-F TCCGTTGGGATTTTATTCCTCTGAATCGTG 468 to 498 IBV-1-R TACTGGTCTGGTATAGCACATGGTTGGGTC 683 to 703 IBV-2-F AGTATCTGGCATCGCCTCATTTCTTTCTAACC 238 to 270 IBV-2-R CCTACCACGATTCAGAGGAATAAAATCCCAACG 502 to 535 IBV-3-F GCCGATTTTGTAAACGTACCATTCCACCAG 684 to 711 IBV-3-R AACACGCCCATCCTTAATACCTTCCTCATT 814 to 844 IBV-4-F CGTCTTATAACTGGTAGATTGTCATCACTC 989 to 1019 IBV-4-R ATTACCACAAAAGGAGTACCTAGTAGACTG 1142 to 1172 inconvenient for veterinarians at the grass roots level in many regions.", [["roots", "ANATOMY", 552, 557], ["roots", "ORGAN", 552, 557], ["expensive devices", "TREATMENT", 37, 54], ["professional operators", "TREATMENT", 59, 81], ["TCCGTTGGGATTTTATTCCTCTGAATCGTG", "TEST", 108, 138], ["IBV", "TEST", 150, 153], ["TACTGGTCTGGTATAGCACATGGTTGGGTC", "TEST", 158, 188], ["IBV", "TEST", 200, 203], ["AGTATCTGGCATCGCCTCATTTCTTTCTAACC", "TEST", 208, 240], ["IBV", "TEST", 252, 255], ["CCTACCACGATTCAGAGGAATAAAATCCCAACG", "TEST", 260, 293], ["IBV", "TEST", 305, 308], ["GCCGATTTTGTAAACGTACCATTCCACCAG", "TEST", 313, 343], ["IBV", "TEST", 355, 358], ["AACACGCCCATCCTTAATACCTTCCTCATT", "TEST", 363, 393], ["IBV", "TEST", 405, 408], ["CGTCTTATAACTGGTAGATTGTCATCACTC", "TEST", 413, 443], ["IBV", "TEST", 456, 459], ["grass roots", "ANATOMY", 546, 557], ["regions", "ANATOMY_MODIFIER", 572, 579]]], ["Reverse transcription recombinase-aided amplification (RT-RAA), following the principle of recombinase polymerase amplification (RPA), is employed for simulating the enzymatic process of DNA replication in vivo, and amplifying the DNA template.", [["DNA", "CELLULAR_COMPONENT", 187, 190], ["DNA", "CELLULAR_COMPONENT", 231, 234], ["Reverse transcription recombinase", "DNA", 0, 33], ["recombinase polymerase", "PROTEIN", 91, 113], ["DNA template", "DNA", 231, 243], ["Reverse transcription recombinase", "TREATMENT", 0, 33], ["recombinase polymerase amplification", "TREATMENT", 91, 127], ["DNA replication", "TREATMENT", 187, 202], ["the DNA template", "TREATMENT", 227, 243]]], ["Using this technique, the reverse transcription of RNA and DNA amplification can be completed in a short time at a constant temperature of about 37 to 39\u00b0C. At the same time, the probes were labeled with 6-carboxyfluorescein (FAM) and primers were labeled with biotin in the experiment to form double-labeled amplification product that could be visually observed and determined by lateral flow dipstick (LFD) with FAM antibody test line and biotin antibody control line.", [["6-carboxyfluorescein", "CHEMICAL", 204, 224], ["FAM", "CHEMICAL", 226, 229], ["biotin", "CHEMICAL", 261, 267], ["FAM", "CHEMICAL", 414, 417], ["biotin", "CHEMICAL", 441, 447], ["6-carboxyfluorescein", "CHEMICAL", 204, 224], ["FAM", "CHEMICAL", 226, 229], ["biotin", "CHEMICAL", 261, 267], ["biotin", "CHEMICAL", 441, 447], ["DNA", "CELLULAR_COMPONENT", 59, 62], ["6-carboxyfluorescein", "SIMPLE_CHEMICAL", 204, 224], ["FAM", "SIMPLE_CHEMICAL", 226, 229], ["biotin", "SIMPLE_CHEMICAL", 261, 267], ["biotin", "SIMPLE_CHEMICAL", 441, 447], ["biotin antibody control line", "CELL_LINE", 441, 469], ["this technique", "TREATMENT", 6, 20], ["the reverse transcription of RNA", "TREATMENT", 22, 54], ["DNA amplification", "TREATMENT", 59, 76], ["a constant temperature", "TEST", 113, 135], ["the probes", "TEST", 175, 185], ["6-carboxyfluorescein (FAM)", "TREATMENT", 204, 230], ["primers", "TREATMENT", 235, 242], ["biotin", "TREATMENT", 261, 267], ["double-labeled amplification product", "TREATMENT", 294, 330], ["lateral flow dipstick", "TEST", 381, 402], ["FAM antibody test line", "TEST", 414, 436], ["biotin antibody control line", "TREATMENT", 441, 469]]], ["This method with high specificity and sensitivity was easy and convenient to use, and thus had broad application prospects in clinical diagnosis (Kim and Easley, 2011) .MaterialsInfectious bronchitis virus standard strain (AV1511) and infectious laryngotracheitis virus (ILTV) strain Wanggang (AV195) were purchased from China Institute of Veterinary Drug Control, and avian influenza virus (AIV) and Newcastle disease virus (NDV) were preserved after clinical detection in our laboratory.", [["Infectious bronchitis virus", "DISEASE", 178, 205], ["infectious laryngotracheitis", "DISEASE", 235, 263], ["Wanggang", "CHEMICAL", 284, 292], ["avian influenza virus (AIV) and Newcastle disease", "DISEASE", 369, 418], ["Infectious bronchitis virus", "ORGANISM", 178, 205], ["AV1511", "ORGANISM", 223, 229], ["infectious laryngotracheitis virus", "ORGANISM", 235, 269], ["avian influenza virus", "ORGANISM", 369, 390], ["AIV", "ORGANISM", 392, 395], ["Newcastle disease virus", "ORGANISM", 401, 424], ["NDV", "ORGANISM", 426, 429], ["infectious laryngotracheitis virus", "SPECIES", 235, 269], ["avian influenza virus", "SPECIES", 369, 390], ["Newcastle disease virus", "SPECIES", 401, 424], ["Infectious bronchitis virus", "SPECIES", 178, 205], ["AV1511", "SPECIES", 223, 229], ["infectious laryngotracheitis virus", "SPECIES", 235, 269], ["ILTV", "SPECIES", 271, 275], ["AV195", "SPECIES", 294, 299], ["avian influenza virus", "SPECIES", 369, 390], ["AIV", "SPECIES", 392, 395], ["Newcastle disease virus", "SPECIES", 401, 424], ["NDV", "SPECIES", 426, 429], ["This method", "TEST", 0, 11], ["MaterialsInfectious bronchitis virus standard strain (AV1511)", "PROBLEM", 169, 230], ["infectious laryngotracheitis virus", "PROBLEM", 235, 269], ["Veterinary Drug Control", "TREATMENT", 340, 363], ["avian influenza virus (AIV", "TREATMENT", 369, 395], ["Newcastle disease virus (NDV", "TREATMENT", 401, 429], ["clinical detection", "TEST", 452, 470], ["Infectious", "OBSERVATION_MODIFIER", 178, 188], ["bronchitis", "OBSERVATION", 189, 199], ["infectious", "OBSERVATION_MODIFIER", 235, 245], ["laryngotracheitis virus", "OBSERVATION", 246, 269]]], ["Virus genomic DNA/RNA extraction kit was bought from Tiangen Biotech Co., Ltd.; RT-RAA nucleic acid amplification kit was bought from Qitian Biotechnology Co., Ltd.; LFD (with FAM antibody test line and biotin antibody control line) was bought from Ustar Biotechnologies Co., Ltd.; T-Vector Pmd20 plasmid was bought from Takara Biomedical Technology Co., Ltd.; primers and probes were synthesized and labeled by Sangon Biotech Co., Ltd.Design and Screening of PrimersAccording to the requirements of RT-RAA nucleic acid amplification kit, 4 pairs of primers were designed by comparison with the sequences of IBV N gene (GenBank: EF602441.1) and IBV S 2 gene (GenBank: EF602461.1) (Table 1) .", [["nucleic acid", "CHEMICAL", 87, 99], ["biotin", "CHEMICAL", 203, 209], ["Virus", "ORGANISM", 0, 5], ["DNA", "CELLULAR_COMPONENT", 14, 17], ["biotin", "SIMPLE_CHEMICAL", 203, 209], ["Ltd", "GENE_OR_GENE_PRODUCT", 432, 435], ["IBV N gene", "GENE_OR_GENE_PRODUCT", 608, 618], ["IBV S 2", "GENE_OR_GENE_PRODUCT", 645, 652], ["biotin antibody", "PROTEIN", 203, 218], ["T-Vector Pmd20 plasmid", "DNA", 282, 304], ["IBV N gene", "DNA", 608, 618], ["IBV S 2 gene", "DNA", 645, 657], ["IBV", "SPECIES", 608, 611], ["Virus genomic DNA", "PROBLEM", 0, 17], ["RNA extraction", "TREATMENT", 18, 32], ["LFD", "TEST", 166, 169], ["FAM antibody test line", "TREATMENT", 176, 198], ["biotin antibody control line", "TREATMENT", 203, 231], ["T-Vector Pmd20 plasmid", "TREATMENT", 282, 304], ["RT", "TEST", 500, 502], ["RAA nucleic acid amplification kit", "TEST", 503, 537]]], ["Primers 1 to 3 were designed according to the sequence of IBV N gene, and primer 4 was designed according to the sequence of IBV S 2 gene.", [["3", "GENE_OR_GENE_PRODUCT", 13, 14], ["IBV", "ORGANISM", 58, 61], ["IBV S 2", "GENE_OR_GENE_PRODUCT", 125, 132], ["Primers 1 to 3", "DNA", 0, 14], ["IBV N gene", "DNA", 58, 68], ["primer 4", "DNA", 74, 82], ["IBV S 2 gene", "DNA", 125, 137], ["IBV", "SPECIES", 58, 61]]], ["RNA of IBV was extracted as a template.", [["IBV", "ORGANISM", 7, 10], ["RNA", "RNA", 0, 3], ["IBV", "SPECIES", 7, 10], ["IBV", "PROBLEM", 7, 10], ["IBV", "OBSERVATION", 7, 10]]], ["Reaction system: Reaction buffer 25 \u03bcL; upstream and downstream primers (10 \u03bcM) 2.1 \u03bcL each; template 1 \u03bcL; purified water 17.3 \u03bcL; magnesium acetate 2.5 \u03bcL.", [["magnesium acetate", "CHEMICAL", 132, 149], ["magnesium acetate", "CHEMICAL", 132, 149], ["magnesium acetate", "SIMPLE_CHEMICAL", 132, 149], ["upstream and downstream primers", "DNA", 40, 71], ["Reaction buffer", "TREATMENT", 17, 32], ["upstream and downstream primers", "TREATMENT", 40, 71], ["template", "TEST", 93, 101], ["purified water", "TREATMENT", 108, 122], ["magnesium acetate", "TREATMENT", 132, 149]]], ["After 30 min reaction at 39\u00b0C, electrophoresis in 2% agarose gels was used to test RT-RAA reaction products, and a pair of primers from which single and clear band as big as the target segment was amplified, were selected.", [["30 min reaction", "PROBLEM", 6, 21], ["electrophoresis", "TEST", 31, 46], ["2% agarose gels", "TREATMENT", 50, 65], ["test RT-RAA reaction products", "TREATMENT", 78, 107], ["a pair of primers", "PROBLEM", 113, 130], ["RAA", "ANATOMY", 86, 89]]], ["The selected downstream primer was labeled with biotin at its 5' end.", [["biotin", "CHEMICAL", 48, 54], ["biotin", "CHEMICAL", 48, 54], ["biotin", "SIMPLE_CHEMICAL", 48, 54], ["downstream primer", "DNA", 13, 30], ["5' end", "DNA", 62, 68], ["The selected downstream primer", "TREATMENT", 0, 30], ["biotin", "TREATMENT", 48, 54]]], ["The selected primers were compared with the gene sequence, and the probes were designed and labeled based on the requirements of kit.", [["the gene sequence", "TEST", 40, 57]]], ["Probe sequence: 5 -GTCACAACAGCGTGAGTTAGCCACGCAAAAG /idSp/ATTAATGAGTGTGTTA-3 .", [["ATTAATGAGTGTGTTA-3", "GENE_OR_GENE_PRODUCT", 57, 75]]], ["The probe was modified with a FAM fluorophore at its 5' end, there was a single-base gap at a position 31 bp from the 5' end, which was modified with tetrahydrofuran residue, and the 3' end was blocked by phosphorylation.", [["FAM", "CHEMICAL", 30, 33], ["tetrahydrofuran", "CHEMICAL", 150, 165], ["FAM", "CHEMICAL", 30, 33], ["tetrahydrofuran", "CHEMICAL", 150, 165], ["FAM fluorophore", "SIMPLE_CHEMICAL", 30, 45], ["tetrahydrofuran", "SIMPLE_CHEMICAL", 150, 165], ["5' end", "DNA", 53, 59], ["5' end", "DNA", 118, 124], ["3' end", "DNA", 183, 189], ["The probe", "TREATMENT", 0, 9], ["a FAM fluorophore", "TREATMENT", 28, 45], ["bp", "TEST", 106, 108], ["tetrahydrofuran residue", "TREATMENT", 150, 173], ["tetrahydrofuran residue", "OBSERVATION", 150, 173]]], ["The labeled primers and probes were used in follow-on experiment.Design and Screening of PrimersEstablishment of RT-RAA-LFD Assay Reaction system: Reaction buffer 25 \u03bcL; upstream and downstream primers (10 \u03bcM) 2.1 \u03bcL each; probe 0.6 \u03bcL; template 1 \u03bcL; purified water 16.7 \u03bcL; magnesium acetate 2.5 \u03bcL.", [["magnesium acetate", "CHEMICAL", 276, 293], ["magnesium acetate", "CHEMICAL", 276, 293], ["magnesium acetate", "SIMPLE_CHEMICAL", 276, 293], ["upstream and downstream primers", "DNA", 170, 201], ["The labeled primers and probes", "TREATMENT", 0, 30], ["PrimersEstablishment", "TEST", 89, 109], ["RT", "TEST", 113, 115], ["downstream primers", "TEST", 183, 201], ["probe", "TEST", 223, 228], ["template", "TEST", 237, 245], ["purified water", "TEST", 252, 266], ["magnesium acetate", "TREATMENT", 276, 293]]], ["For the negative control, purified water was used instead of template.", [["water", "SIMPLE_CHEMICAL", 35, 40], ["purified water", "TREATMENT", 26, 40]]], ["After 25 min reaction at 39\u00b0C, 10 \u03bcL of RT-RAA products were transferred to the test area of dipstick, the dipstick was inserted into a 2 mL centrifuge tube with 100 \u03bcL of buffer, and the results were observed after 3 min.Design and Screening of PrimersDipstick criteria: It was positive when 2 red bands appeared, one in the quality control area and the other in the test area, and positive results showed that nucleic acid fragments to be detected were contained in the sample; it was negative if there was a red band in the quality control area while no red band was found in the test area, and negative results showed that no nucleic acid fragment for detection was contained in the sample.Design and Screening of PrimersOptimization of Reaction Conditions Optimization of reaction temperature: 33, 35, 37, 39, and 41\u00b0C were selected as reaction temperatures, respectively.Design and Screening of PrimersOptimization of reaction time: At the optimal temperature of 37\u00b0C, 16, 18, 20, 22 and 24 min were selected as reaction time, respectively.Design and Screening of PrimersOptimization of primer and probe concentration: At the optimized temperature and reaction time, primer concentration and probe concentrations were optimized on the basis of 10,000, 5,000, 2,500, 1,250, 625 nmol/L. Criteria for the best reaction conditions: Clear and obvious quality control line, shortest reaction time, lowest primer or probe concentration.Design and Screening of PrimersSpecificity Test The genomes of ILTV, NDV, and AIV were extracted by the virus genomic DNA/RNA extraction kit.", [["sample", "ANATOMY", 472, 478], ["sample", "ANATOMY", 687, 693], ["nucleic acid", "CHEMICAL", 412, 424], ["nucleic acid", "CHEMICAL", 630, 642], ["RT-RAA", "SIMPLE_CHEMICAL", 40, 46], ["C", "SIMPLE_CHEMICAL", 822, 823], ["ILTV", "GENE_OR_GENE_PRODUCT", 1498, 1502], ["NDV", "ORGANISM", 1504, 1507], ["AIV", "ORGANISM", 1513, 1516], ["DNA", "CELLULAR_COMPONENT", 1553, 1556], ["nucleic acid fragment", "PROTEIN", 630, 651], ["virus genomic DNA", "DNA", 1539, 1556], ["NDV", "SPECIES", 1504, 1507], ["ILTV", "SPECIES", 1498, 1502], ["NDV", "SPECIES", 1504, 1507], ["AIV", "SPECIES", 1513, 1516], ["RT-RAA products", "TREATMENT", 40, 55], ["dipstick", "TEST", 93, 101], ["the dipstick", "TEST", 103, 115], ["a 2 mL centrifuge tube", "TREATMENT", 134, 156], ["buffer", "TREATMENT", 172, 178], ["2 red bands", "PROBLEM", 293, 304], ["nucleic acid fragments", "PROBLEM", 412, 434], ["a red band in the quality control area", "PROBLEM", 509, 547], ["red band", "PROBLEM", 557, 565], ["the test area", "TEST", 579, 592], ["nucleic acid fragment", "PROBLEM", 630, 651], ["temperature", "TEST", 786, 797], ["the optimal temperature", "TEST", 942, 965], ["PrimersOptimization of primer", "TREATMENT", 1070, 1099], ["primer concentration", "TEST", 1173, 1193], ["probe concentrations", "TEST", 1198, 1218], ["Screening of PrimersSpecificity", "TEST", 1446, 1477], ["ILTV", "PROBLEM", 1498, 1502], ["NDV", "PROBLEM", 1504, 1507], ["AIV", "PROBLEM", 1513, 1516], ["the virus genomic DNA/RNA extraction", "TREATMENT", 1535, 1571], ["positive", "OBSERVATION", 279, 287], ["red band", "OBSERVATION", 511, 519], ["obvious", "OBSERVATION_MODIFIER", 1344, 1351], ["quality", "OBSERVATION_MODIFIER", 1352, 1359], ["control line", "OBSERVATION", 1360, 1372]]], ["RNA of IBV, NDV, and AIV and DNA of ILTV were used as templates, and the specificity of RT-RAA-LFD was verified by RT-RAA reaction and LFD assay.Design and Screening of PrimersSensitivity Test Preparation of recombinant plasmids: The template cDNA was obtained by reverse transcription of IBV genomic RNA, and primer was IBV-4-F/IBV-4-R.", [["plasmids", "ANATOMY", 220, 228], ["IBV", "ORGANISM", 7, 10], ["NDV", "ORGANISM", 12, 15], ["AIV", "ORGANISM", 21, 24], ["DNA", "CELLULAR_COMPONENT", 29, 32], ["ILTV", "CELL", 36, 40], ["IBV", "ORGANISM", 289, 292], ["IBV-4-F", "ORGANISM", 321, 328], ["IBV", "ORGANISM", 329, 332], ["RNA", "RNA", 0, 3], ["ILTV", "DNA", 36, 40], ["RT-RAA-LFD", "DNA", 88, 98], ["recombinant plasmids", "DNA", 208, 228], ["template cDNA", "DNA", 234, 247], ["IBV genomic RNA", "RNA", 289, 304], ["IBV", "SPECIES", 7, 10], ["NDV", "SPECIES", 12, 15], ["AIV", "SPECIES", 21, 24], ["IBV", "SPECIES", 289, 292], ["IBV", "TREATMENT", 7, 10], ["NDV", "PROBLEM", 12, 15], ["AIV", "TREATMENT", 21, 24], ["DNA of ILTV", "TREATMENT", 29, 40], ["RT", "TEST", 115, 117], ["LFD assay", "TEST", 135, 144], ["The template cDNA", "TEST", 230, 247], ["IBV genomic RNA", "TREATMENT", 289, 304], ["primer", "TEST", 310, 316], ["IBV", "TEST", 321, 324], ["IBV", "TEST", 329, 332], ["IBV", "OBSERVATION", 7, 10], ["NDV", "OBSERVATION", 12, 15], ["RAA", "ANATOMY", 118, 121], ["genomic RNA", "OBSERVATION", 293, 304]]], ["It was the optimal primer obtained by screening, the primer length was modified according to the requirements of conventional PCR, and sequence was F:5 -CGTCTTATAACTGGTAGATTG-3 , R:5 -ATTACCACAAAAGGAGTACCT-3 .", [["R:5 -ATTACCACAAAAGGAGTACCT-3", "GENE_OR_GENE_PRODUCT", 179, 207], ["primer length", "DNA", 53, 66], ["F:5", "DNA", 148, 151], ["R:5 -ATTACCACAAAAGGAGTACCT-3", "DNA", 179, 207], ["conventional PCR", "TEST", 113, 129], ["sequence", "TEST", 135, 143], ["F:5", "TEST", 148, 151], ["CGTCTTATAACTGGTAGATTG", "TEST", 153, 174]]], ["50 \u03bcL reaction system: 2 \u00d7 Taq Mix 25 \u03bcL; cDNA template 2 \u03bcL; upstream and downstream primers (10 \u03bcM) 1 \u03bcL each; replenished with 21 \u03bcL of ddH2O.", [["ddH2O", "CHEMICAL", 139, 144], ["cDNA template 2 \u03bcL; upstream and downstream primers", "DNA", 42, 93], ["Taq Mix", "TREATMENT", 27, 34], ["cDNA template", "TREATMENT", 42, 55], ["upstream and downstream primers", "TREATMENT", 62, 93], ["ddH2O", "TREATMENT", 139, 144]]], ["Reaction system: It was predenaturalized at 94\u00b0C for 5 min; denaturalized at 94\u00b0C for 45 s; annealed at 56\u00b0C for 45 s; extended at 72\u00b0C for 60 s, a total of 35 cycles of amplification; extended at 72\u00b0C for 10 min, and then stored at 4\u00b0C. The purified target fragment was ligated to pMD20 plasmid after gel extraction of PCR products.", [["plasmid", "ANATOMY", 288, 295], ["pMD20", "GENE_OR_GENE_PRODUCT", 282, 287], ["purified target fragment", "DNA", 242, 266], ["pMD20 plasmid", "DNA", 282, 295], ["a total of 35 cycles of amplification", "TREATMENT", 146, 183], ["The purified target fragment", "TREATMENT", 238, 266], ["pMD20 plasmid", "TREATMENT", 282, 295], ["gel extraction of PCR products", "TREATMENT", 302, 332], ["target", "OBSERVATION_MODIFIER", 251, 257], ["fragment", "OBSERVATION", 258, 266]]], ["The standard plasmid was constructed after purification and screening, and the DNA copy number in the standard plasmid was calculated after the nucleic acid content was determined.Design and Screening of PrimersPlasmid copy number (copies/L) = [plasmid concentration (g \u00b7 \u03bcL \u22121 ) \u00d7 6.02 \u00d7 10 23 ]/ [total fragment length (bp) \u00d7 660ng/mol];Design and Screening of PrimersTotal fragment length = vector length (bp) + fragment length (bp) .Design and Screening of PrimersThe standard plasmid constructed was diluted to a concentration gradient of 10 0 to 10 7 copies/\u03bcL, and the sensitivity of conventional PCR assay, RT-RAA-LFD assay, and RFQ-PCR assay to IBV was compared.Design and Screening of PrimersConventional PCR system (25 \u03bcL): 2 \u00d7 Gflex PCR Buffer (Mg 2+ , dNTP plus) 12.5 \u03bcL; upstream and downstream primers (10 \u03bcM) 0.5 \u03bcL each; Tks Gflex DNA polymerase (1.25 units/\u03bcL) 0.5 \u03bcL; template 1 \u03bcL; the final volume was made up to 25 \u03bcL with ddH 2 O. Reaction system: It was predenaturalized at 94\u00b0C for 1 min; denaturalized at 98\u00b0C for 10 s; annealed at 55\u00b0C for 15 s; extended at 68\u00b0C for 30 s, a total of 30 cycles; finally extended at 68\u00b0C for 5 min.", [["plasmid", "ANATOMY", 13, 20], ["plasmid", "ANATOMY", 111, 118], ["nucleic acid", "CHEMICAL", 144, 156], ["Mg", "CHEMICAL", 757, 759], ["NTP", "CHEMICAL", 766, 769], ["Mg 2+ , dNTP", "CHEMICAL", 757, 769], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["IBV", "ORGANISM", 654, 657], ["Mg 2+", "SIMPLE_CHEMICAL", 757, 762], ["upstream and downstream primers", "DNA", 785, 816], ["Tks Gflex DNA polymerase", "DNA", 838, 862], ["IBV", "SPECIES", 654, 657], ["The standard plasmid", "TREATMENT", 0, 20], ["screening", "TEST", 60, 69], ["the DNA copy", "TEST", 75, 87], ["the standard plasmid", "TREATMENT", 98, 118], ["the nucleic acid content", "TEST", 140, 164], ["plasmid concentration", "TEST", 245, 266], ["g", "TEST", 268, 269], ["\u03bcL", "TEST", 272, 274], ["\u00d7", "TEST", 287, 288], ["total fragment length", "TEST", 299, 320], ["bp", "TEST", 322, 324], ["\u00d7", "TEST", 326, 327], ["Design", "TEST", 339, 345], ["Screening", "TEST", 350, 359], ["Primers", "TEST", 363, 370], ["Total fragment length", "TEST", 370, 391], ["vector length", "TEST", 394, 407], ["bp", "TEST", 409, 411], ["fragment length", "TEST", 415, 430], ["bp", "TEST", 432, 434], ["Screening of Primers", "TREATMENT", 448, 468], ["The standard plasmid", "TREATMENT", 468, 488], ["a concentration gradient", "TEST", 516, 540], ["conventional PCR assay", "TEST", 591, 613], ["RT", "TEST", 615, 617], ["RAA", "TEST", 618, 621], ["RFQ", "TEST", 637, 640], ["PCR", "TEST", 641, 644], ["IBV", "PROBLEM", 654, 657], ["PrimersConventional PCR system", "TEST", 695, 725], ["Buffer", "TEST", 749, 755], ["Mg", "TEST", 757, 759], ["NTP", "TEST", 766, 769], ["downstream primers", "TEST", 798, 816], ["Tks Gflex DNA polymerase", "TEST", 838, 862], ["template", "TEST", 887, 895], ["the final volume", "TEST", 902, 918], ["fragment", "OBSERVATION_MODIFIER", 415, 423], ["length", "OBSERVATION_MODIFIER", 424, 430]]], ["RFQ-PCR system (25 \u03bcL) (primers the same as those in conventional PCR): TB Green Premix DimerEraser (2X) 12 \u03bcL; upstream and downstream primers (10 \u03bcM) 0.75 \u03bcL each; template 2 \u03bcL; the final volume was made up to 25 \u03bcL with ddH 2 O. Reaction system: It was predenaturalized at 95\u00b0C for 30 s; denaturalized at 95\u00b0C for 5 s; annealed at 55\u00b0C for 30 s; extended at 72\u00b0C for 30 s, a total of 40 cycles.Design and Screening of PrimersReverse transcription recombinase-aided amplification reaction system was based on the optimized reaction conditions, and the template in the reaction system was standard plasmid with a concentration gradient of 10 0 to 10 7 copies/\u03bcL.", [["plasmid", "ANATOMY", 600, 607], ["RFQ", "DNA", 0, 3], ["upstream and downstream primers", "DNA", 112, 143], ["RFQ", "TEST", 0, 3], ["PCR system", "TEST", 4, 14], ["conventional PCR", "TEST", 53, 69], ["downstream primers", "TEST", 125, 143], ["template", "TEST", 166, 174], ["the final volume", "TEST", 181, 197], ["Screening of Primers", "TEST", 409, 429], ["a concentration gradient", "TEST", 613, 637]]], ["Clinical Sample Test A total of 57 suspected IBV samples in clinical diagnosis were tested by RT-RAA-LFD assay and conventional PCR assay, and the coincidence rate of the 2 assays was compared.RT-RAA Primer ScreeningFour pairs of primers were designed in accordance with the requirements of RT-RAA nucleic acid amplification.", [["samples", "ANATOMY", 49, 56], ["nucleic acid", "CHEMICAL", 298, 310], ["IBV", "ORGANISM", 45, 48], ["IBV", "SPECIES", 45, 48], ["Clinical Sample Test", "TEST", 0, 20], ["IBV samples", "TEST", 45, 56], ["RT", "TEST", 94, 96], ["RAA", "TEST", 97, 100], ["conventional PCR assay", "TEST", 115, 137], ["the coincidence rate", "TEST", 143, 163], ["RT-RAA Primer Screening", "TEST", 193, 216], ["RT-RAA nucleic acid amplification", "TREATMENT", 291, 324]]], ["After the products were amplified by RT-RAA nucleic acid amplification kit, they were screened by 2% agarose electrophoresis.", [["agarose", "SIMPLE_CHEMICAL", 101, 108], ["agarose electrophoresis", "TEST", 101, 124]]], ["The results showed that only IBV-4-F/IBV-4-R amplified a single and clear band of the expected size (target segment 153 bp).", [["IBV-4-F", "ORGANISM", 29, 36], ["IBV", "ORGANISM", 37, 40], ["4-R", "GENE_OR_GENE_PRODUCT", 41, 44], ["IBV-4-F/IBV-4-R", "DNA", 29, 44], ["IBV", "TEST", 29, 32], ["IBV", "TEST", 37, 40], ["bp", "TEST", 120, 122], ["size", "OBSERVATION_MODIFIER", 95, 99]]], ["Therefore, IBV-4-F/IBV4-R was selected as the primer for the follow-on experiment.", [["IBV-4-F", "ORGANISM", 11, 18], ["IBV4-R", "GENE_OR_GENE_PRODUCT", 19, 25], ["IBV-4-F/IBV4-R", "DNA", 11, 25], ["IBV", "TEST", 11, 14], ["IBV4", "TREATMENT", 19, 23]]], ["The results are shown in Figure 1 .Optimal Reaction ConditionsThe reaction time, temperature, and primer concentration were optimized in this experiment.", [["Optimal Reaction Conditions", "PROBLEM", 35, 62], ["temperature", "TEST", 81, 92], ["primer concentration", "TREATMENT", 98, 118]]], ["There were optimal reaction conditions when quality control line was clear, reaction time was the shortest, and primer concentration was the lowest.", [["optimal reaction conditions", "PROBLEM", 11, 38], ["primer concentration", "TEST", 112, 132]]], ["Finally, the optimal reaction conditions were determined as follows: reaction time 24 min; reaction temperature 37\u00b0C; primer concentration 1,250 nmol/L (Figures 2 to 4) .Specificity TestWith the RNA of IBV, NDV, AIV and the DNA of ILTV as templates, the products were amplified in RT-RAA reaction system, and by LFD assay, only the RT-RAA product of IBV showed both test line and quality control line on dipstick.", [["IBV", "ORGANISM", 202, 205], ["NDV", "ORGANISM", 207, 210], ["AIV", "ORGANISM", 212, 215], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["ILTV", "GENE_OR_GENE_PRODUCT", 231, 235], ["IBV", "ORGANISM", 350, 353], ["IBV, NDV, AIV and the DNA", "DNA", 202, 227], ["ILTV", "DNA", 231, 235], ["NDV", "SPECIES", 207, 210], ["IBV", "SPECIES", 202, 205], ["NDV", "SPECIES", 207, 210], ["AIV", "SPECIES", 212, 215], ["IBV", "SPECIES", 350, 353], ["temperature", "TEST", 100, 111], ["primer concentration", "TEST", 118, 138], ["Specificity", "TEST", 170, 181], ["IBV", "PROBLEM", 202, 205], ["NDV", "PROBLEM", 207, 210], ["AIV", "TREATMENT", 212, 215], ["the DNA of ILTV", "TREATMENT", 220, 235], ["the products", "TREATMENT", 250, 262], ["IBV", "PROBLEM", 350, 353], ["dipstick", "TEST", 404, 412], ["test line", "OBSERVATION", 366, 375]]], ["However, the products of other viruses and negative control could only show quality control line, which indicated that the specificity of RT-RAA-LFD assay was good, and this method was tenable.", [["other viruses", "PROBLEM", 25, 38], ["RT-RAA-LFD assay", "TEST", 138, 154], ["this method", "TREATMENT", 169, 180], ["viruses", "OBSERVATION", 31, 38]]], ["The results are shown in Figure 5 .Sensitivity TestThe standard plasmid was diluted by 10-fold gradient, and the sensitivity of conventional PCR, RFQ-PCR and RT-RAA-LFD was compared based on the concentration of 10 0 to 10 7 copies/\u03bcL.", [["plasmid", "ANATOMY", 64, 71], ["RFQ", "DNA", 146, 149], ["Sensitivity", "TEST", 35, 46], ["The standard plasmid", "TREATMENT", 51, 71], ["conventional PCR", "TEST", 128, 144], ["RFQ", "TEST", 146, 149], ["PCR", "TEST", 150, 153], ["RT", "TEST", 158, 160]]], ["Sensitivity of conventional PCR assay.", [["conventional PCR assay", "TEST", 15, 37]]], ["M: marker, 1: 10 7 copies/\u03bcL, 2: 10 6 copies/\u03bcL, 3: 10 5 copies/\u03bcL, 4: 10 4 copies/\u03bcL, 5: 10 3 copies/\u03bcL, 6: 10 2 copies/\u03bcL, 7: 10 1 copies/\u03bcL, 8: 10\u00b0copies/\u03bcL, 9: negative control. the lowest detectable limit (LDL) was 10 4 copies/\u03bcL for conventional PCR, 10 1 copies/\u03bcL for RFQ-PCR, and 10 2 copies/\u03bcL for RT-RAA-LFD.", [["RFQ", "DNA", 276, 279], ["\u00b0copies", "TEST", 149, 156], ["conventional PCR", "TEST", 239, 255], ["RFQ", "TEST", 276, 279], ["PCR", "TEST", 280, 283], ["RT", "TEST", 308, 310], ["negative", "OBSERVATION", 164, 172], ["LFD", "ANATOMY", 315, 318]]], ["The sensitivity of RT-RAA-LFD assay was 100 times higher than that of conventional PCR assay, but lower than that of RFQ-PCR assay (Figures 6 to 8) .Clinical Sample TestA total of 57 suspected IB samples from chickens with clinical respiratory symptoms were detected, of which 48 were positive and 9 were negative by RT-RAA-LFD, 43 were positive and 15 were negative by conventional PCR.", [["samples", "ANATOMY", 196, 203], ["respiratory", "ANATOMY", 232, 243], ["respiratory symptoms", "DISEASE", 232, 252], ["IB samples", "CANCER", 193, 203], ["chickens", "ORGANISM", 209, 217], ["chickens", "SPECIES", 209, 217], ["chickens", "SPECIES", 209, 217], ["The sensitivity", "TEST", 0, 15], ["RT-RAA", "TEST", 19, 25], ["LFD assay", "TEST", 26, 35], ["conventional PCR assay", "TEST", 70, 92], ["RFQ", "TEST", 117, 120], ["PCR assay", "TEST", 121, 130], ["Figures", "TEST", 132, 139], ["Clinical Sample TestA total", "TEST", 149, 176], ["IB samples", "TEST", 193, 203], ["clinical respiratory symptoms", "PROBLEM", 223, 252], ["RT", "TEST", 317, 319], ["RAA", "TEST", 320, 323], ["LFD", "TEST", 324, 327], ["conventional PCR", "TEST", 370, 386]]], ["The detection rate of RT-RAA-LFD assay was higher than that of conventional PCR, which indicated that the RT-RAA-LFD assay established in this study could be used for detection of IBV.DISCUSSIONIB is responsible for substantial economic loss within the poultry industry, so it is very important to explore a specific, convenient, and sensitive detection method to better prevent and control IB.DISCUSSIONThe clinical symptoms and pathological changes of IB are similar to those of ND and ILT, so it is easy to be misdiagnosed, which brings some difficulties to clinical diagnosis.", [["ND", "DISEASE", 481, 483], ["IBV", "ORGANISM", 180, 183], ["IBV", "SPECIES", 180, 183], ["The detection rate", "TEST", 0, 18], ["RT", "TEST", 22, 24], ["RAA", "TEST", 25, 28], ["LFD assay", "TEST", 29, 38], ["conventional PCR", "TEST", 63, 79], ["the RT-RAA-LFD assay", "TEST", 102, 122], ["this study", "TEST", 138, 148], ["IBV", "PROBLEM", 180, 183], ["substantial economic loss", "PROBLEM", 216, 241], ["The clinical symptoms", "PROBLEM", 404, 425], ["pathological changes of IB", "PROBLEM", 430, 456], ["responsible for", "UNCERTAINTY", 200, 215], ["substantial", "OBSERVATION_MODIFIER", 216, 227], ["economic", "OBSERVATION_MODIFIER", 228, 236], ["loss", "OBSERVATION", 237, 241]]], ["Conventional virus isolation (CVI) is the most classical and reliable method for the diagnosis of IB, but it has the disadvantages of long period and high technical requirements.", [["CVI", "DISEASE", 30, 33], ["Conventional virus isolation", "TREATMENT", 0, 28], ["IB", "PROBLEM", 98, 100], ["high technical requirements", "PROBLEM", 150, 177], ["virus", "OBSERVATION", 13, 18]]], ["Serological diagnosis is also a common technique in the actual detection of IB, but most of the commercial IBV antibody kits are coated with whole virions, having a strong cross-reaction with local strains of different serotypes, as a result, the application of commercial IBV antibody detection kit is limited (Lin et al., 1991) .", [["virions", "ANATOMY", 147, 154], ["IBV", "ORGANISM", 107, 110], ["IBV", "ORGANISM", 273, 276], ["IBV", "SPECIES", 107, 110], ["IBV", "SPECIES", 273, 276], ["IB", "PROBLEM", 76, 78], ["the commercial IBV antibody kits", "TEST", 92, 124], ["whole virions", "PROBLEM", 141, 154], ["a strong cross-reaction", "PROBLEM", 163, 186], ["different serotypes", "PROBLEM", 209, 228], ["commercial IBV antibody detection kit", "TEST", 262, 299]]], ["Conventional PCR and RFQ-PCR are sensitive and specific in nucleic acid diagnosis, but they still have the shortcomings of long period, carcinogen EB pollution and need for expensive instruments .", [["EB", "CHEMICAL", 147, 149], ["EB", "SIMPLE_CHEMICAL", 147, 149], ["RFQ", "DNA", 21, 24], ["Conventional PCR", "TEST", 0, 16], ["RFQ-PCR", "TEST", 21, 28], ["nucleic acid diagnosis", "TEST", 59, 81], ["carcinogen EB pollution", "TREATMENT", 136, 159], ["expensive instruments", "TREATMENT", 173, 194]]], ["Reverse transcription recombinase-aided amplification is a rapid, specific, sensitive, and reliable technique for isothermal gene amplification (Daher et al., 2016) .", [["isothermal gene amplification", "TREATMENT", 114, 143]]], ["The whole reaction is simple, rapid, and does not require high temperature cycling, so it is particularly suitable for use in non-laboratory testing sites with a large number of samples (Piepenburg et al., 2006) .", [["The whole reaction", "PROBLEM", 0, 18], ["high temperature cycling", "PROBLEM", 58, 82], ["non-laboratory testing sites", "TEST", 126, 154], ["simple", "OBSERVATION_MODIFIER", 22, 28], ["rapid", "OBSERVATION_MODIFIER", 30, 35], ["large", "OBSERVATION_MODIFIER", 162, 167]]], ["Sensitivity of RFQ-PCR assay.", [["RFQ", "DNA", 15, 18], ["Sensitivity", "TEST", 0, 11], ["RFQ", "TEST", 15, 18], ["PCR assay", "TEST", 19, 28]]], ["7: 10 6 copies/\u03bcL, 6: 10 5 copies/\u03bcL, 5: 10 4 copies/\u03bcL, 4: 10 3 copies/\u03bcL, 3: 10 2 copies/\u03bcL, 2: 10 1 copies/\u03bcL, 1: 10\u00b0copies/\u03bcL, 0: negative control.", [["copies", "TEST", 65, 71], ["copies", "TEST", 103, 109], ["L", "TEST", 111, 112], ["\u00b0copies", "TEST", 119, 126], ["negative", "OBSERVATION", 134, 142]]], ["Sensitivity of RT-RAA-LFD assay.", [["Sensitivity", "TEST", 0, 11], ["RT", "TEST", 15, 17], ["RAA", "TEST", 18, 21], ["RAA", "ANATOMY", 18, 21], ["LFD", "ANATOMY", 22, 25]]], ["1: 10 6 copies/\u03bcL, 2: 10 5 copies/\u03bcL, 3: 10 4 copies/\u03bcL, 4: 10 3 copies/\u03bcL, 5: 10 2 copies/\u03bcL, 6: 10 1 copies/\u03bcL, 7: 10\u00b0copies/\u03bcL, 8: negative control.DISCUSSIONIn this experiment, RT-RAA was combined with LFD to detect IBV.", [["IBV", "ORGANISM", 220, 223], ["IBV", "SPECIES", 220, 223], ["copies", "TEST", 46, 52], ["copies", "TEST", 65, 71], ["copies", "TEST", 84, 90], ["L", "TEST", 92, 93], ["copies", "TEST", 103, 109], ["L", "TEST", 111, 112], ["\u00b0copies", "TEST", 119, 126], ["RT-RAA", "TREATMENT", 181, 187], ["LFD", "TREATMENT", 206, 209], ["IBV", "PROBLEM", 220, 223], ["negative", "OBSERVATION", 134, 142], ["IBV", "OBSERVATION", 220, 223]]], ["After screening the primers, the downstream primer was labeled with biotin, and the designed probe was modified with a FAM fluorophore at its 5' end.", [["biotin", "CHEMICAL", 68, 74], ["FAM", "CHEMICAL", 119, 122], ["biotin", "CHEMICAL", 68, 74], ["FAM", "CHEMICAL", 119, 122], ["biotin", "SIMPLE_CHEMICAL", 68, 74], ["FAM fluorophore", "SIMPLE_CHEMICAL", 119, 134], ["downstream primer", "DNA", 33, 50], ["5' end", "DNA", 142, 148], ["screening the primers", "TEST", 6, 27], ["the downstream primer", "PROBLEM", 29, 50], ["biotin", "TREATMENT", 68, 74], ["a FAM fluorophore", "TREATMENT", 117, 134]]], ["A single-base gap at a position 30 bp from the 5' end was modified with tetrahydrofuran residue, the 3' end was blocked by phosphorylation, and a compatible probe was helpful to improve the specificity of RT-RAA reaction.", [["tetrahydrofuran", "CHEMICAL", 72, 87], ["tetrahydrofuran", "CHEMICAL", 72, 87], ["5' end", "DNA", 47, 53], ["3' end", "DNA", 101, 107], ["bp", "TEST", 35, 37], ["tetrahydrofuran residue", "TREATMENT", 72, 95], ["a compatible probe", "TREATMENT", 144, 162], ["RT-RAA reaction", "PROBLEM", 205, 220], ["tetrahydrofuran residue", "OBSERVATION", 72, 95], ["RAA", "ANATOMY", 208, 211]]], ["Notably, the RT-RAA kit completed reverse transcription and DNA amplification in 1 step, saving detection time and reagents.", [["DNA", "CELLULAR_COMPONENT", 60, 63], ["RAA", "PROTEIN", 16, 19], ["reverse transcription", "TREATMENT", 34, 55], ["DNA amplification", "TREATMENT", 60, 77], ["RAA", "ANATOMY", 16, 19]]], ["Finally, the double-labeled products amplified by RT-RAA could be detected directly by LFD and visually observed.", [["RT-RAA", "SIMPLE_CHEMICAL", 50, 56], ["double-labeled products", "PROTEIN", 13, 36], ["RAA", "PROTEIN", 53, 56], ["the double-labeled products", "TREATMENT", 9, 36]]], ["Reaction could be completed by this technique at a constant temperature of 37\u00b0C, amplification did not need complex instruments, and amplification products could be visually detected by LFD.", [["complex instruments", "TREATMENT", 108, 127], ["amplification products", "TREATMENT", 133, 155]]], ["It was proved that the specificity of RT-RAA was good, and the sensitivity of this method was slightly lower than that of RFQ-PCR, but 100 times higher than that of conventional PCR.CONCLUSIONThe RT-RAA-LFD assay had good specificity for detection of IBV and there was no cross reaction with the nucleic acids of other similar avian pathogens.", [["nucleic acids", "CHEMICAL", 296, 309], ["IBV", "ORGANISM", 251, 254], ["avian", "ORGANISM", 327, 332], ["IBV", "SPECIES", 251, 254], ["this method", "TEST", 78, 89], ["RFQ", "TEST", 122, 125], ["PCR", "TEST", 126, 129], ["conventional PCR", "TEST", 165, 181], ["RT-RAA-LFD assay", "TEST", 196, 212], ["IBV", "PROBLEM", 251, 254], ["cross reaction", "PROBLEM", 272, 286], ["the nucleic acids", "TEST", 292, 309], ["other similar avian pathogens", "PROBLEM", 313, 342], ["RAA", "ANATOMY", 199, 202], ["IBV", "OBSERVATION", 251, 254]]], ["It was highly sensitive, and its LDL was 10 2 copies/\u03bcL, which was 100 times higher than that of conventional PCR (10 4 copies/\u03bcL).", [["LDL", "SIMPLE_CHEMICAL", 33, 36], ["LDL", "PROTEIN", 33, 36], ["its LDL", "TEST", 29, 36], ["conventional PCR", "TEST", 97, 113]]], ["The operation was simple, and results could be visually observed and determined by LFD within 3 min after 20 min reaction under isothermal condition (37\u00b0C), so it is very suitable for clinical veterinary and grass-roots laboratories.", [["The operation", "TREATMENT", 0, 13]]]], "e142768c2ba12ffccbe0c96e3be8f0d7873739a9": [["INTRODUCTIONCOVID-19 is a global pandemic caused by the novel SARS-CoV-2 betacoronavirus [1] .", [["SARS-CoV-2", "ORGANISM", 62, 72], ["CoV-2 betacoronavirus", "SPECIES", 67, 88], ["SARS-CoV-2 betacoronavirus", "SPECIES", 62, 88], ["a global pandemic", "PROBLEM", 24, 41], ["the novel SARS", "PROBLEM", 52, 66], ["CoV", "TEST", 67, 70]]], ["T cells are crucial for clearing respiratory viral infections and providing longterm immune memory [2, 3] .", [["T cells", "ANATOMY", 0, 7], ["respiratory viral infections", "DISEASE", 33, 61], ["T cells", "CELL", 0, 7], ["T cells", "CELL_TYPE", 0, 7], ["T cells", "PROBLEM", 0, 7], ["clearing respiratory viral infections", "PROBLEM", 24, 61], ["viral infections", "OBSERVATION", 45, 61]]], ["Two major subsets of T cells participate in the immune response to viral infection in different ways: activated CD8+ T cells directly kill infected cells, while subpopulations of CD4+ T cells produce signaling molecules that regulate myeloid cell behaviour, drive and support CD8 response and the formation of long-term CD8 memory, and participate in the selection and affinity maturation of antigen specific Bcells, ultimately leading to the generation of neutralizing antibodies.", [["T cells", "ANATOMY", 21, 28], ["CD8+", "ANATOMY", 112, 116], ["T cells", "ANATOMY", 117, 124], ["cells", "ANATOMY", 148, 153], ["CD4+", "ANATOMY", 179, 183], ["T cells", "ANATOMY", 184, 191], ["myeloid cell", "ANATOMY", 234, 246], ["Bcells", "ANATOMY", 409, 415], ["viral infection", "DISEASE", 67, 82], ["T cells", "CELL", 21, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 112, 115], ["T cells", "CELL", 117, 124], ["cells", "CELL", 148, 153], ["CD4", "GENE_OR_GENE_PRODUCT", 179, 182], ["T cells", "CELL", 184, 191], ["myeloid cell", "CELL", 234, 246], ["CD8", "GENE_OR_GENE_PRODUCT", 276, 279], ["CD8", "GENE_OR_GENE_PRODUCT", 320, 323], ["Bcells", "GENE_OR_GENE_PRODUCT", 409, 415], ["T cells", "CELL_TYPE", 21, 28], ["CD8", "PROTEIN", 112, 115], ["T cells", "CELL_TYPE", 117, 124], ["infected cells", "CELL_TYPE", 139, 153], ["CD4", "PROTEIN", 179, 182], ["T cells", "CELL_TYPE", 184, 191], ["signaling molecules", "PROTEIN", 200, 219], ["CD8", "PROTEIN", 276, 279], ["antigen specific Bcells", "PROTEIN", 392, 415], ["neutralizing antibodies", "PROTEIN", 457, 480], ["T cells", "TREATMENT", 21, 28], ["viral infection", "PROBLEM", 67, 82], ["T cells", "PROBLEM", 117, 124], ["infected cells", "PROBLEM", 139, 153], ["CD4", "TEST", 179, 182], ["signaling molecules", "PROBLEM", 200, 219], ["myeloid cell behaviour", "PROBLEM", 234, 256], ["antigen specific Bcells", "PROBLEM", 392, 415], ["neutralizing antibodies", "PROBLEM", 457, 480], ["T cells", "OBSERVATION", 21, 28], ["viral infection", "OBSERVATION", 67, 82], ["CD4", "OBSERVATION", 179, 182], ["signaling molecules", "OBSERVATION", 200, 219], ["myeloid cell behaviour", "OBSERVATION", 234, 256], ["neutralizing antibodies", "OBSERVATION", 457, 480]]], ["In SARS-1 survivors, antigen-specific memory T cells were detected up to 11 years after the initial infection, when viral-specific antibodies were undetectable [4, 5] .", [["memory T cells", "ANATOMY", 38, 52], ["SARS", "DISEASE", 3, 7], ["infection", "DISEASE", 100, 109], ["antigen", "GENE_OR_GENE_PRODUCT", 21, 28], ["memory T cells", "CELL", 38, 52], ["memory T cells", "CELL_TYPE", 38, 52], ["viral-specific antibodies", "PROTEIN", 116, 141], ["SARS", "TEST", 3, 7], ["antigen", "TEST", 21, 28], ["the initial infection", "PROBLEM", 88, 109], ["viral-specific antibodies", "TEST", 116, 141], ["infection", "OBSERVATION", 100, 109]]], ["The T cell response was shown to be critical for protection in SARS-1-infected mice [6] .", [["T cell", "ANATOMY", 4, 10], ["SARS-1-infected", "DISEASE", 63, 78], ["T cell", "CELL", 4, 10], ["SARS-1", "ORGANISM", 63, 69], ["mice", "ORGANISM", 79, 83], ["mice", "SPECIES", 79, 83], ["SARS-1", "SPECIES", 63, 69], ["mice", "SPECIES", 79, 83], ["SARS", "TEST", 63, 67]]], ["Pa-tients with X-linked agammaglobulinemia, a genetic disorder associated with lack of B cells, have been reported to recover from symptomatic COVID-19 [7, 8] , suggesting that in some cases T cells are sufficient for viral clearance.", [["B cells", "ANATOMY", 87, 94], ["T cells", "ANATOMY", 191, 198], ["agammaglobulinemia", "DISEASE", 24, 42], ["genetic disorder", "DISEASE", 46, 62], ["B cells", "CELL", 87, 94], ["T cells", "CELL", 191, 198], ["B cells", "CELL_TYPE", 87, 94], ["T cells", "CELL_TYPE", 191, 198], ["X-linked agammaglobulinemia", "PROBLEM", 15, 42], ["a genetic disorder", "PROBLEM", 44, 62], ["lack of B cells", "PROBLEM", 79, 94], ["symptomatic COVID", "TEST", 131, 148], ["some cases T cells", "PROBLEM", 180, 198], ["viral clearance", "PROBLEM", 218, 233], ["agammaglobulinemia", "OBSERVATION", 24, 42]]], ["Theravajan et al. showed that activated CD8+HLA-DR+CD38+ T cells in a mild case of COVID-19 significantly expand following symptom onset, reaching their peak frequency of 12% of CD8+ T cells on day 9 after symptom onset, and contract thereafter [9] .", [["CD8+HLA-DR+CD38+ T cells", "ANATOMY", 40, 64], ["CD8+ T cells", "ANATOMY", 178, 190], ["CD8", "GENE_OR_GENE_PRODUCT", 40, 43], ["CD38", "GENE_OR_GENE_PRODUCT", 51, 55], ["CD8", "GENE_OR_GENE_PRODUCT", 178, 181], ["CD8", "PROTEIN", 40, 43], ["DR", "PROTEIN", 48, 50], ["CD38", "PROTEIN", 51, 55], ["T cells", "CELL_TYPE", 57, 64], ["CD8", "PROTEIN", 178, 181], ["T cells", "CELL_TYPE", 183, 190], ["activated CD8", "TEST", 30, 43], ["HLA", "TEST", 44, 47], ["CD38", "TEST", 51, 55], ["T cells", "PROBLEM", 57, 64], ["COVID", "TEST", 83, 88], ["symptom onset", "PROBLEM", 123, 136], ["symptom onset", "PROBLEM", 206, 219]]], ["Given the average time of 5 days from infection to the onset of symptoms [10] , the dynamics and magnitude of T cell response to SARS-CoV-2 is similar to that observed after immunization with live vaccines [11] .", [["T cell", "ANATOMY", 110, 116], ["infection", "DISEASE", 38, 47], ["SARS", "DISEASE", 129, 133], ["T cell", "CELL", 110, 116], ["SARS-CoV-2", "ORGANISM", 129, 139], ["SARS-CoV", "SPECIES", 129, 137], ["infection", "PROBLEM", 38, 47], ["symptoms", "PROBLEM", 64, 72], ["T cell response", "PROBLEM", 110, 125], ["SARS", "TEST", 129, 133], ["CoV", "TEST", 134, 137], ["immunization with live vaccines", "TREATMENT", 174, 205]]], ["SARS-CoV-2specific T cells were detected in COVID-19 survivors by activation following stimulation with SARS-CoV-2 proteins [12] , or by viral protein-derived peptide pools [13] [14] [15] [16] [17] [18] [19] .", [["2specific T cells", "ANATOMY", 9, 26], ["SARS", "DISEASE", 0, 4], ["[13] [14] [15] [16] [17] [18] [19]", "CHEMICAL", 173, 207], ["T cells", "CELL", 19, 26], ["COVID-19", "CELL", 44, 52], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 104, 114], ["[13] [14] [15] [16] [17] [18] [19]", "SIMPLE_CHEMICAL", 173, 207], ["SARS-CoV-2specific T cells", "CELL_LINE", 0, 26], ["SARS-CoV-2 proteins", "PROTEIN", 104, 123], ["viral protein", "PROTEIN", 137, 150], ["SARS", "TEST", 0, 4], ["CoV-2specific T cells", "PROBLEM", 5, 26], ["COVID", "TEST", 44, 49], ["stimulation", "TEST", 87, 98], ["SARS", "TEST", 104, 108], ["CoV", "TEST", 109, 112], ["viral protein", "TEST", 137, 150]]], ["Some of the T cells activated by peptide stimulation were shown to have a memory phenotype [13, 16, 20] , and some potentially cross-reactive CD4+ T cells were found 2 in healthy donors [14, 18, 21, 22] .INTRODUCTIONT cells recognise short pathogen-derived peptides presented on the cell surface of the Major Histocompatibility Complex (MHC) using hypervariable T cell receptors (TCR).", [["T cells", "ANATOMY", 12, 19], ["CD4+ T cells", "ANATOMY", 142, 154], ["cells", "ANATOMY", 218, 223], ["cell surface", "ANATOMY", 283, 295], ["T cell", "ANATOMY", 362, 368], ["T cells", "CELL", 12, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 142, 145], ["donors", "ORGANISM", 179, 185], ["cells", "CELL", 218, 223], ["cell surface", "CELLULAR_COMPONENT", 283, 295], ["hypervariable T cell receptors", "GENE_OR_GENE_PRODUCT", 348, 378], ["TCR", "GENE_OR_GENE_PRODUCT", 380, 383], ["T cells", "CELL_TYPE", 12, 19], ["CD4", "PROTEIN", 142, 145], ["T cells", "CELL_TYPE", 147, 154], ["Major Histocompatibility Complex", "PROTEIN", 303, 335], ["MHC", "PROTEIN", 337, 340], ["hypervariable T cell receptors", "PROTEIN", 348, 378], ["TCR", "PROTEIN", 380, 383], ["the T cells", "TREATMENT", 8, 19], ["peptide stimulation", "TREATMENT", 33, 52], ["T cells", "PROBLEM", 147, 154], ["short pathogen", "PROBLEM", 234, 248], ["derived peptides", "PROBLEM", 249, 265], ["hypervariable T cell receptors", "TREATMENT", 348, 378], ["cross-reactive CD4", "OBSERVATION", 127, 145]]], ["TCR repertoire sequencing allows for the quantitative tracking of T cell clones in time, as they go through the expansion and contraction phases of the response.", [["T cell clones", "ANATOMY", 66, 79], ["TCR", "CHEMICAL", 0, 3], ["TCR", "GENE_OR_GENE_PRODUCT", 0, 3], ["T cell clones", "CELL", 66, 79], ["TCR", "PROTEIN", 0, 3], ["T cell clones", "CELL_LINE", 66, 79], ["TCR repertoire sequencing", "TEST", 0, 25], ["cell clones", "OBSERVATION", 68, 79]]], ["It was previously shown that quantitative longitudinal TCR sequencing is able to identify antigen-specific expanding and contracting T cells in response to yellow fever vaccination with high sensitivity and specificity [23] [24] [25] .", [["T cells", "ANATOMY", 133, 140], ["fever", "DISEASE", 163, 168], ["TCR", "GENE_OR_GENE_PRODUCT", 55, 58], ["T cells", "CELL", 133, 140], ["TCR", "PROTEIN", 55, 58], ["contracting T cells", "CELL_TYPE", 121, 140], ["quantitative longitudinal TCR sequencing", "TEST", 29, 69], ["antigen", "TEST", 90, 97], ["contracting T cells", "PROBLEM", 121, 140], ["yellow fever vaccination", "PROBLEM", 156, 180], ["high sensitivity", "PROBLEM", 186, 202], ["specificity", "TEST", 207, 218]]], ["Not only clonal expansion but also significant contraction from the peak of the response are distinctive traits of T cell clones specific to the virus [24] .INTRODUCTIONIn this study we use longitudinal TCRalpha and TCRbeta repertoire sequencing to quantitatively track T cell clones that significantly expand and contract after recovery from a mild COVID-19 infection, and determine their phenotype.", [["T cell clones", "ANATOMY", 115, 128], ["T cell clones", "ANATOMY", 270, 283], ["infection", "DISEASE", 359, 368], ["clonal", "CELL", 9, 15], ["T cell clones", "CELL", 115, 128], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 203, 211], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 216, 223], ["T cell clones", "CELL", 270, 283], ["T cell clones", "CELL_LINE", 115, 128], ["T cell clones", "CELL_LINE", 270, 283], ["clonal expansion", "PROBLEM", 9, 25], ["significant contraction", "PROBLEM", 35, 58], ["T cell clones", "PROBLEM", 115, 128], ["the virus", "PROBLEM", 141, 150], ["this study", "TEST", 172, 182], ["longitudinal TCRalpha and TCRbeta repertoire sequencing", "TREATMENT", 190, 245], ["a mild COVID-19 infection", "PROBLEM", 343, 368], ["clonal", "OBSERVATION_MODIFIER", 9, 15], ["expansion", "OBSERVATION", 16, 25], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["contraction", "OBSERVATION", 47, 58], ["cell clones", "OBSERVATION", 117, 128], ["mild", "OBSERVATION_MODIFIER", 345, 349], ["infection", "OBSERVATION", 359, 368]]], ["We reveal the dynamics and the phenotype of the memory cells formed after infection, identify pre-existing T cell memory clones participating in the response, and describe public TCR sequence motifs of SARS-CoV-2-reactive clones, suggesting a response to immunodominant epitopes.Longitudinal tracking of TCR repertoires of COVID-19 patientsIn the middle of March (day 0) donor W female and donor M (male, both healthy young adults), returned to their home country from the one of the centers of the COVID-19 outbreak in Europe at the time.", [["memory cells", "ANATOMY", 48, 60], ["T cell", "ANATOMY", 107, 113], ["clones", "ANATOMY", 222, 228], ["infection", "DISEASE", 74, 83], ["memory cells", "CELL", 48, 60], ["T cell memory clones", "CELL", 107, 127], ["TCR", "GENE_OR_GENE_PRODUCT", 179, 182], ["SARS-CoV-2", "ORGANISM", 202, 212], ["clones", "CELL", 222, 228], ["TCR", "GENE_OR_GENE_PRODUCT", 304, 307], ["patients", "ORGANISM", 332, 340], ["memory cells", "CELL_TYPE", 48, 60], ["T cell memory clones", "CELL_LINE", 107, 127], ["TCR sequence motifs", "DNA", 179, 198], ["immunodominant epitopes", "PROTEIN", 255, 278], ["TCR", "PROTEIN", 304, 307], ["patients", "SPECIES", 332, 340], ["infection", "PROBLEM", 74, 83], ["pre-existing T cell memory clones", "PROBLEM", 94, 127], ["public TCR sequence motifs", "TEST", 172, 198], ["SARS", "TEST", 202, 206], ["CoV", "TEST", 207, 210], ["reactive clones", "PROBLEM", 213, 228], ["immunodominant epitopes", "PROBLEM", 255, 278], ["COVID", "TEST", 323, 328], ["cell memory clones", "OBSERVATION", 109, 127], ["reactive clones", "OBSERVATION", 213, 228], ["middle", "ANATOMY_MODIFIER", 347, 353]]], ["On day 3 of selfisolation both developed low grade fever, fatigue and myalgia, which lasted 4 days and was followed by a temporary loss of smell for donor M. On days 15, 30, 37, 45 and 85 we collected peripheral blood samples from both donors (Fig. 1a) .", [["peripheral blood samples", "ANATOMY", 201, 225], ["fever", "DISEASE", 51, 56], ["fatigue", "DISEASE", 58, 65], ["myalgia", "DISEASE", 70, 77], ["loss of smell", "DISEASE", 131, 144], ["peripheral blood samples", "ORGANISM_SUBSTANCE", 201, 225], ["donors", "ORGANISM", 236, 242], ["selfisolation", "TREATMENT", 12, 25], ["low grade fever", "PROBLEM", 41, 56], ["fatigue", "PROBLEM", 58, 65], ["myalgia", "PROBLEM", 70, 77], ["a temporary loss of smell", "PROBLEM", 119, 144], ["peripheral blood samples", "TEST", 201, 225], ["low grade", "OBSERVATION_MODIFIER", 41, 50], ["fever", "OBSERVATION", 51, 56], ["myalgia", "OBSERVATION", 70, 77]]], ["The presence of IgG and IgM SARS-CoV-2 specific antibodies in the plasma was measured at all timepoints using SARS-CoV-2 S-RBD domain specific ELISA (Fig. S1) .", [["plasma", "ANATOMY", 66, 72], ["IgG", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgM SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 24, 38], ["plasma", "ORGANISM_SUBSTANCE", 66, 72], ["S1", "GENE_OR_GENE_PRODUCT", 155, 157], ["IgG", "PROTEIN", 16, 19], ["IgM SARS-CoV-2 specific antibodies", "PROTEIN", 24, 58], ["RBD domain", "PROTEIN", 123, 133], ["S1", "PROTEIN", 155, 157], ["IgG", "TEST", 16, 19], ["IgM SARS", "TEST", 24, 32], ["CoV", "TEST", 33, 36], ["specific antibodies", "TEST", 39, 58], ["the plasma", "TEST", 62, 72], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118]]], ["From each blood sample we isolated PBMCs (peripheral blood mononuclear cells, in two biological replicates), CD4+, and CD8+ T cells.", [["blood sample", "ANATOMY", 10, 22], ["PBMCs", "ANATOMY", 35, 40], ["peripheral blood mononuclear cells", "ANATOMY", 42, 76], ["CD4+", "ANATOMY", 109, 113], ["CD8+ T cells", "ANATOMY", 119, 131], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["PBMCs", "CELL", 35, 40], ["peripheral blood mononuclear cells", "CELL", 42, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD8", "GENE_OR_GENE_PRODUCT", 119, 122], ["PBMCs", "CELL_TYPE", 35, 40], ["peripheral blood mononuclear cells", "CELL_TYPE", 42, 76], ["CD4", "PROTEIN", 109, 112], ["CD8+ T cells", "CELL_TYPE", 119, 131], ["each blood sample", "TEST", 5, 22], ["PBMCs", "TEST", 35, 40], ["peripheral blood mononuclear cells", "TEST", 42, 76], ["CD4", "TEST", 109, 112], ["isolated PBMCs", "OBSERVATION", 26, 40], ["mononuclear cells", "OBSERVATION", 59, 76], ["T cells", "OBSERVATION", 124, 131]]], ["Additionally, on days 30, 45 and 85 we isolated four T cell memory subpopulations (Fig. S2 ): Effector Memory (EM: CCR7-CD45RA-), Effector Memory with CD45RA re-expression (EMRA: CCR7-CD45RA+), Central Memory (CM: CCR7+CD45RA-), and Stem Cell-like Memory (SCM: CCR7+CD45RA+CD95+).", [["T cell", "ANATOMY", 53, 59], ["CM", "ANATOMY", 210, 212], ["CCR7+CD45RA-)", "ANATOMY", 214, 227], ["Stem Cell-like Memory (SCM: CCR7+CD45RA+CD95+", "ANATOMY", 233, 278], ["T cell memory subpopulations", "CELL", 53, 81], ["CCR7", "GENE_OR_GENE_PRODUCT", 115, 119], ["CD45RA", "GENE_OR_GENE_PRODUCT", 120, 126], ["CD45RA", "GENE_OR_GENE_PRODUCT", 151, 157], ["EMRA", "GENE_OR_GENE_PRODUCT", 173, 177], ["CCR7", "GENE_OR_GENE_PRODUCT", 179, 183], ["CD45RA", "GENE_OR_GENE_PRODUCT", 184, 190], ["CCR7", "GENE_OR_GENE_PRODUCT", 214, 218], ["CD45RA", "GENE_OR_GENE_PRODUCT", 219, 225], ["Stem Cell", "CELL", 233, 242], ["CCR7", "GENE_OR_GENE_PRODUCT", 261, 265], ["CD45RA", "GENE_OR_GENE_PRODUCT", 266, 272], ["CD95", "GENE_OR_GENE_PRODUCT", 273, 277], ["T cell memory subpopulations", "CELL_TYPE", 53, 81], ["S2", "PROTEIN", 88, 90], ["CCR7", "PROTEIN", 115, 119], ["CD45RA", "PROTEIN", 120, 126], ["CD45RA", "PROTEIN", 151, 157], ["EMRA", "PROTEIN", 173, 177], ["CCR7", "PROTEIN", 179, 183], ["CD45RA", "PROTEIN", 184, 190], ["CCR7", "PROTEIN", 214, 218], ["CD45RA", "PROTEIN", 219, 225], ["CCR7", "PROTEIN", 261, 265], ["CD45RA", "PROTEIN", 266, 272], ["CD95", "PROTEIN", 273, 277], ["CCR7", "TEST", 115, 119], ["CCR7", "TEST", 179, 183], ["CCR7", "TEST", 214, 218], ["CD45RA", "TEST", 219, 225], ["Stem Cell", "TEST", 233, 242], ["CCR7", "TEST", 261, 265], ["CD45RA", "TEST", 266, 272], ["CD95", "TEST", 273, 277], ["four T cell memory subpopulations", "OBSERVATION", 48, 81], ["CCR7", "ANATOMY", 179, 183], ["Stem Cell", "ANATOMY", 233, 242]]], ["From all samples we isolated RNA and performed TCRalpha and TCRbeta repertoire sequencing as previously described [26] .", [["samples", "ANATOMY", 9, 16], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 47, 55], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 60, 67], ["TCRalpha", "PROTEIN", 47, 55]]], ["For both donors, TCRalpha and TCRbeta repertoires were obtained for other projects one and two years prior to infection.", [["infection", "DISEASE", 110, 119], ["donors", "ORGANISM", 9, 15], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 17, 25], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 30, 37], ["TCRalpha", "PROTEIN", 17, 25], ["TCRbeta", "PROTEIN", 30, 37], ["TCRalpha and TCRbeta repertoires", "TREATMENT", 17, 49], ["infection", "PROBLEM", 110, 119], ["infection", "OBSERVATION", 110, 119]]], ["Additionally, TCR repertoires of multiple sam-ples for donor M -including sorted memory subpopulations -are available from a published longitudinal TCR sequencing study after yellow fever vaccination (donor M1 samples in [23] ).Two waves of T-cell clone responseFrom previously described activated T cell dynamics for SARS-CoV-2 [9] , and immunization with live vaccines [11] , the peak of the T cell expansion is expected around day 15 post-infection, and responding T cells significantly contract afterwards.", [["samples", "ANATOMY", 210, 217], ["T-cell", "ANATOMY", 241, 247], ["T cell", "ANATOMY", 298, 304], ["T cell", "ANATOMY", 394, 400], ["T cells", "ANATOMY", 468, 475], ["TCR", "CHEMICAL", 148, 151], ["yellow fever", "DISEASE", 175, 187], ["infection", "DISEASE", 442, 451], ["TCR", "GENE_OR_GENE_PRODUCT", 14, 17], ["sam", "GENE_OR_GENE_PRODUCT", 42, 45], ["T-cell clone", "CELL", 241, 253], ["T cell", "CELL", 298, 304], ["T cell", "CELL", 394, 400], ["T cells", "CELL", 468, 475], ["TCR", "PROTEIN", 14, 17], ["sorted memory subpopulations", "CELL_TYPE", 74, 102], ["TCR", "PROTEIN", 148, 151], ["T cells", "CELL_TYPE", 468, 475], ["SARS-CoV", "SPECIES", 318, 326], ["donor M", "TEST", 55, 62], ["a published longitudinal TCR sequencing study", "TEST", 123, 168], ["yellow fever vaccination", "PROBLEM", 175, 199], ["Two waves of T-cell clone", "PROBLEM", 228, 253], ["SARS", "TEST", 318, 322], ["CoV", "TEST", 323, 326], ["immunization", "TREATMENT", 339, 351], ["live vaccines", "TREATMENT", 357, 370], ["the T cell expansion", "PROBLEM", 390, 410], ["infection", "PROBLEM", 442, 451], ["cell clone", "OBSERVATION", 243, 253], ["cell expansion", "OBSERVATION", 396, 410], ["infection", "OBSERVATION", 442, 451]]], ["However, Weiskopf et al. [13] reports an increase of SARS-CoV-2-reactive T cells at later timepoints, peaking in some donors after 30 days following symptom onset.", [["T cells", "ANATOMY", 73, 80], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 53, 63], ["T cells", "CELL", 73, 80], ["donors", "ORGANISM", 118, 124], ["reactive T cells", "CELL_TYPE", 64, 80], ["an increase of SARS", "PROBLEM", 38, 57], ["CoV", "TEST", 58, 61], ["reactive T cells", "PROBLEM", 64, 80], ["symptom onset", "PROBLEM", 149, 162], ["increase", "OBSERVATION_MODIFIER", 41, 49], ["reactive T cells", "OBSERVATION", 64, 80]]], ["To identify groups of T cell clones with similar dynamics in an unbiased way, we used Principal Component Analysis (PCA) in the space of T cell clonal trajectories ( Fig. 1b and c) .", [["T cell clones", "ANATOMY", 22, 35], ["T cell", "ANATOMY", 137, 143], ["T cell clones", "CELL", 22, 35], ["T cell", "CELL", 137, 143], ["T cell clones", "CELL_LINE", 22, 35], ["T cell clones", "PROBLEM", 22, 35], ["Principal Component Analysis (PCA", "TREATMENT", 86, 119], ["cell clones", "OBSERVATION", 24, 35]]], ["This exploratory data analysis method allows us to visualize major trends in the dynamics of abundant TCR clonotypes (occuring within top 1000 on any post-infection timepoints) between multiple timepoints.Two waves of T-cell clone responseIn both donors, and in both TCRalpha and TCRbeta repertoires, we identified three clusters of clones with distinct dynamics.", [["T-cell", "ANATOMY", 218, 224], ["TCR", "CHEMICAL", 102, 105], ["TCR", "GENE_OR_GENE_PRODUCT", 102, 105], ["T-cell clone", "CELL", 218, 230], ["donors", "ORGANISM", 247, 253], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 267, 275], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 280, 287], ["clones", "CELL", 333, 339], ["TCR clonotypes", "PROTEIN", 102, 116], ["TCRalpha", "PROTEIN", 267, 275], ["This exploratory data analysis", "TEST", 0, 30], ["abundant TCR clonotypes", "PROBLEM", 93, 116], ["Two waves of T-cell clone response", "PROBLEM", 205, 239], ["TCR clonotypes", "OBSERVATION", 102, 116], ["T-cell clone", "OBSERVATION", 218, 230], ["both", "OBSERVATION_MODIFIER", 242, 246], ["donors", "OBSERVATION", 247, 253], ["both", "ANATOMY_MODIFIER", 262, 266], ["TCRalpha", "ANATOMY", 267, 275], ["TCRbeta repertoires", "OBSERVATION", 280, 299], ["distinct", "OBSERVATION_MODIFIER", 345, 353], ["dynamics", "OBSERVATION_MODIFIER", 354, 362]]], ["The first cluster (Fig. 1bc , purple) corresponded to abundant TCR clonotypes which had constant concentrations across timepoints, the second cluster (Fig. 1bc , green) showed contraction dynamics from day 15 to day 85, and the third cluster (Fig. 1bc , yellow), showed an unexpected clonal expansion from day 15 with a peak on day 37 followed by contraction.", [["TCR", "CHEMICAL", 63, 66], ["TCR", "GENE_OR_GENE_PRODUCT", 63, 66], ["TCR clonotypes", "PROTEIN", 63, 77], ["abundant TCR clonotypes", "PROBLEM", 54, 77], ["constant concentrations across timepoints", "PROBLEM", 88, 129], ["contraction dynamics", "PROBLEM", 176, 196], ["yellow", "TEST", 254, 260], ["an unexpected clonal expansion", "PROBLEM", 270, 300], ["abundant", "OBSERVATION_MODIFIER", 54, 62], ["TCR clonotypes", "OBSERVATION", 63, 77], ["clonal expansion", "OBSERVATION", 284, 300]]], ["The clustering and dynamics are similar in both donors and are reproduced in TCRbeta (Fig. 1bc) and TCRalpha (Fig. S3ab) repertoires.", [["donors", "ORGANISM", 48, 54], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 77, 84], ["Fig. 1bc", "GENE_OR_GENE_PRODUCT", 86, 94], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 100, 108], ["S3ab", "GENE_OR_GENE_PRODUCT", 115, 119], ["TCRbeta", "PROTEIN", 77, 84], ["TCRalpha", "PROTEIN", 100, 108], ["S3ab", "PROTEIN", 115, 119], ["TCRalpha (Fig. S3ab)", "TREATMENT", 100, 120], ["similar", "OBSERVATION_MODIFIER", 32, 39], ["TCRalpha", "ANATOMY", 100, 108]]], ["We next used edgeR, a software for differential gene expression analysis [27] and NoisET, a Bayesian differential expansion model [28] , to specifically detect changes in clonotype concentration between pairs of timepoints in a statistically reliable way and without limiting the analysis to the most abundant clonotypes.", [["edgeR", "DNA", 13, 18], ["differential gene expression analysis", "TEST", 35, 72], ["a Bayesian differential expansion model", "TEST", 90, 129], ["changes in clonotype concentration", "PROBLEM", 160, 194], ["the analysis", "TEST", 276, 288]]], ["Both NoisET and edgeR use biological replicate samples collected at each timepoint to train a noise model for sequence counts.", [["samples", "ANATOMY", 47, 54], ["NoisET", "DNA", 5, 11], ["edgeR", "DNA", 16, 21], ["a noise model", "TEST", 92, 105], ["sequence counts", "TEST", 110, 125]]], ["We identified 291 TCRalpha and 295 TCRbeta clonotypes in donor W, and 607 TCRalpha and 616 TCRbeta in donor M significantly contracted from day 15 to day 85 (largely overlapping with cluster 2 of clonal trajectories, Fig. S5 ).", [["TCRalpha", "GENE_OR_GENE_PRODUCT", 18, 26], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 35, 42], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 74, 82], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 91, 98], ["TCRalpha", "PROTEIN", 18, 26], ["TCRbeta clonotypes", "CELL_TYPE", 35, 53], ["TCRalpha", "PROTEIN", 74, 82], ["TCRbeta", "PROTEIN", 91, 98], ["TCRalpha", "TEST", 18, 26], ["TCRbeta clonotypes", "TEST", 35, 53], ["donor W", "TEST", 57, 64], ["TCRalpha", "TEST", 74, 82], ["TCRbeta", "TEST", 91, 98]]], ["176 TCRalpha and 278 TCRbeta for donor W, and 293 TCRalpha and 427 TCRbeta clonotypes for donor M were significantly expanded from day 15 to 37 (corresponding to cluster 3 of clonal trajectories).Two waves of T-cell clone responseNote that, to identify putatively SARS-CoV-2 reactive clones, we only used post-infection timepoints, so that our analysis can be reproduced in other patients and studies where pre-infection timepoints are unavailable.", [["T-cell", "ANATOMY", 209, 215], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 4, 12], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 21, 28], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 50, 58], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 67, 74], ["T-cell clone", "CELL", 209, 221], ["clones", "CELL", 284, 290], ["patients", "ORGANISM", 380, 388], ["TCRalpha", "PROTEIN", 4, 12], ["TCRbeta", "PROTEIN", 21, 28], ["293 TCRalpha and 427 TCRbeta clonotypes", "CELL_LINE", 46, 85], ["patients", "SPECIES", 380, 388], ["TCRalpha", "TEST", 4, 12], ["TCRbeta", "TEST", 21, 28], ["donor W", "TEST", 33, 40], ["TCRalpha", "TEST", 50, 58], ["TCRbeta clonotypes", "TEST", 67, 85], ["donor M", "TEST", 90, 97], ["Two waves of T-cell clone response", "PROBLEM", 196, 230], ["SARS", "TEST", 264, 268], ["CoV", "TEST", 269, 272], ["2 reactive clones", "PROBLEM", 273, 290], ["our analysis", "TEST", 340, 352], ["studies where pre-infection timepoints", "TEST", 393, 431], ["T-cell clone", "OBSERVATION", 209, 221], ["reactive clones", "OBSERVATION", 275, 290]]], ["S5 shows overlap between clonal trajectory clusters and edgeR/NoisET hits).", [["S5", "PROTEIN", 0, 2], ["edgeR", "DNA", 56, 61], ["NoisET hits", "DNA", 62, 73], ["clonal", "OBSERVATION_MODIFIER", 25, 31], ["trajectory", "OBSERVATION_MODIFIER", 32, 42]]], ["Right: each curve shows the average \u00b1 2.96 SE of normalized clonal frequencies from each cluster.", [["each curve", "TEST", 7, 17], ["clonal frequencies", "OBSERVATION", 60, 78]]], ["Contracting (d) and expanding (e) clones include both CD4+ and CD8+ T cells, and are less abundant in pre-infection repertoires.", [["clones", "ANATOMY", 34, 40], ["CD4+", "ANATOMY", 54, 58], ["CD8+", "ANATOMY", 63, 67], ["T cells", "ANATOMY", 68, 75], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["CD8", "GENE_OR_GENE_PRODUCT", 63, 66], ["T cells", "CELL", 68, 75], ["CD4", "PROTEIN", 54, 57], ["CD8", "PROTEIN", 63, 66], ["T cells", "CELL_TYPE", 68, 75], ["Contracting (d) and expanding (e) clones", "PROBLEM", 0, 40], ["CD4", "TEST", 54, 57], ["less", "OBSERVATION_MODIFIER", 85, 89], ["abundant", "OBSERVATION_MODIFIER", 90, 98]]], ["T cell clones significantly contracted from day 15 to day 85 (d) and significantly expanded from day 15 to day 37 (e) were identified in both donors.", [["T cell clones", "ANATOMY", 0, 13], ["T cell clones", "CELL", 0, 13], ["donors", "ORGANISM", 142, 148], ["T cell clones", "CELL_LINE", 0, 13], ["T cell clones", "PROBLEM", 0, 13], ["cell clones", "OBSERVATION", 2, 13]]], ["The fraction of contracting (d) and expanding (e) TCRbeta clonotypes in the total repertoire (calculated as the sum of frequencies of these clonotypes in the second PBMC replicate at a given timepoint and corresponding to the fraction of responding cells of all T cells) is plotted in log-scale for all reactive clones (left), reactive clones with the CD4 (middle) and CD8 (right) phenotypes.", [["PBMC", "ANATOMY", 165, 169], ["cells", "ANATOMY", 249, 254], ["T cells", "ANATOMY", 262, 269], ["clones", "ANATOMY", 312, 318], ["left", "ANATOMY", 320, 324], ["clones", "ANATOMY", 336, 342], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 50, 57], ["PBMC", "CELL", 165, 169], ["cells", "CELL", 249, 254], ["T cells", "CELL", 262, 269], ["clones", "CELL", 312, 318], ["clones", "CELL", 336, 342], ["CD4", "GENE_OR_GENE_PRODUCT", 352, 355], ["CD8", "GENE_OR_GENE_PRODUCT", 369, 372], ["TCRbeta clonotypes", "CELL_TYPE", 50, 68], ["PBMC", "CELL_TYPE", 165, 169], ["T cells", "CELL_TYPE", 262, 269], ["reactive clones", "CELL_LINE", 303, 318], ["CD4", "PROTEIN", 352, 355], ["CD8", "PROTEIN", 369, 372], ["expanding (e) TCRbeta clonotypes", "TREATMENT", 36, 68], ["these clonotypes", "PROBLEM", 134, 150], ["the second PBMC replicate", "TREATMENT", 154, 179], ["all reactive clones", "PROBLEM", 299, 318], ["reactive clones", "PROBLEM", 327, 342], ["the CD4", "TEST", 348, 355], ["CD8 (right) phenotypes", "PROBLEM", 369, 391], ["fraction", "OBSERVATION_MODIFIER", 4, 12], ["TCRbeta clonotypes", "OBSERVATION", 50, 68], ["reactive clones", "OBSERVATION", 303, 318], ["left", "ANATOMY_MODIFIER", 320, 324], ["reactive clones", "OBSERVATION", 327, 342], ["middle", "ANATOMY_MODIFIER", 357, 363], ["right", "ANATOMY_MODIFIER", 374, 379]]], ["Similar dynamics were observed in TCRalpha repertoires (Fig. S3) , and for significantly expanded/contracted clones identified with the NoisET Bayesian differential expansion statistical model alone (Fig. S4 ).Two waves of T-cell clone responseHowever, tracking the identified responding clones back to pre-infection timepoints reveals strong clonal expansions from pre-to post-infection (Fig. 1de, Fig. S3cd ).", [["clones", "ANATOMY", 109, 115], ["T-cell", "ANATOMY", 223, 229], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 34, 42], ["clones", "CELL", 109, 115], ["T-cell clone", "CELL", 223, 235], ["clones", "CELL", 288, 294], ["TCRalpha repertoires", "PROTEIN", 34, 54], ["expanded/contracted clones", "CELL_LINE", 89, 115], ["significantly expanded/contracted clones", "PROBLEM", 75, 115], ["Two waves of T-cell clone", "PROBLEM", 210, 235], ["responding clones", "PROBLEM", 277, 294], ["pre-infection timepoints", "PROBLEM", 303, 327], ["strong clonal expansions", "PROBLEM", 336, 360], ["contracted clones", "OBSERVATION", 98, 115], ["-cell clone", "OBSERVATION", 224, 235], ["strong", "OBSERVATION_MODIFIER", 336, 342], ["clonal expansions", "OBSERVATION", 343, 360]]], ["For brevity, we further refer to clonotypes significantly contracted from day 15 to 85 as contracting clones and clonotypes significantly expanding from day 15 to 37 as expanding clones.", [["clones", "CELL", 102, 108], ["clones", "CELL", 179, 185], ["contracting clones", "PROBLEM", 90, 108], ["clonotypes", "PROBLEM", 113, 123]]], ["Contracting clones corresponded to 2.5% and 0.9% of T cells on day 15 post-infection, expanding clones reached 1.1% and 0.8% on day 37 for donors M and W respectively (Fig. 1de, left) .", [["clones", "ANATOMY", 12, 18], ["T cells", "ANATOMY", 52, 59], ["infection", "DISEASE", 75, 84], ["clones", "CELL", 12, 18], ["T cells", "CELL", 52, 59], ["clones", "CELL", 96, 102], ["T cells", "CELL_TYPE", 52, 59], ["Contracting clones", "PROBLEM", 0, 18], ["infection", "PROBLEM", 75, 84], ["expanding clones", "PROBLEM", 86, 102], ["infection", "OBSERVATION", 75, 84], ["left", "ANATOMY_MODIFIER", 178, 182]]], ["This magnitude of the T cell response is of the same order of magnitude as previously observed after live yellow fever vaccine immunization of donor M (6.7% T cells on day 15 post-vaccination).", [["T cell", "ANATOMY", 22, 28], ["T cells", "ANATOMY", 157, 164], ["fever", "DISEASE", 113, 118], ["T cell", "CELL", 22, 28], ["T cells", "CELL", 157, 164], ["T cells", "CELL_TYPE", 157, 164], ["live yellow fever vaccine immunization", "TREATMENT", 101, 139], ["donor M (6.7% T cells", "TREATMENT", 143, 164]]], ["For each contracting and expanding clone we determined their CD4/CD8 phenotype using separately sequenced repertoires of CD4+ and CD8+ subpopulations (see Methods).", [["CD4+", "ANATOMY", 121, 125], ["CD8+ subpopulations", "ANATOMY", 130, 149], ["clone", "CELL", 35, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 61, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD4", "GENE_OR_GENE_PRODUCT", 121, 124], ["CD8", "GENE_OR_GENE_PRODUCT", 130, 133], ["CD4", "PROTEIN", 61, 64], ["CD8", "PROTEIN", 65, 68], ["CD4", "PROTEIN", 121, 124], ["CD8", "PROTEIN", 130, 133], ["expanding clone", "PROBLEM", 25, 40], ["their CD4", "TEST", 55, 64], ["CD4", "TEST", 121, 124]]], ["Both CD4+ and CD8+ subsets participated actively in the response (Fig. 1de) .", [["CD4+", "ANATOMY", 5, 9], ["CD8+ subsets", "ANATOMY", 14, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 14, 17], ["CD4", "PROTEIN", 5, 8], ["CD8", "PROTEIN", 14, 17], ["Both CD4", "TEST", 0, 8], ["CD4", "OBSERVATION", 5, 8]]], ["Interestingly, clonotypes expanding after day 15 were significantly biased towards the CD4+ phenotype, while contracting clones had balanced CD4/CD8 phenotype fractions in both donors (Fisher exact test, p < 0.01 for both donors).Memory formation and pre-existing memoryOn days 30, 45 and 85 we identified both contracting ( Fig. 2a -c) and expanding ( Fig. S6a -c) T cell clones in the memory subpopulations of peripheral blood.", [["clones", "ANATOMY", 121, 127], ["CD4/CD8", "ANATOMY", 141, 148], ["Fig. S6a -c) T cell clones", "ANATOMY", 353, 379], ["memory subpopulations", "ANATOMY", 387, 408], ["peripheral blood", "ANATOMY", 412, 428], ["CD4", "GENE_OR_GENE_PRODUCT", 87, 90], ["clones", "CELL", 121, 127], ["CD4", "GENE_OR_GENE_PRODUCT", 141, 144], ["CD8", "GENE_OR_GENE_PRODUCT", 145, 148], ["donors", "ORGANISM", 177, 183], ["donors", "ORGANISM", 222, 228], ["T cell clones", "CELL", 366, 379], ["peripheral blood", "ORGANISM_SUBSTANCE", 412, 428], ["CD4", "PROTEIN", 87, 90], ["CD4", "PROTEIN", 141, 144], ["CD8", "PROTEIN", 145, 148], ["expanding ( Fig. S6a -c) T cell clones", "CELL_LINE", 341, 379], ["memory subpopulations", "CELL_TYPE", 387, 408], ["phenotype", "PROBLEM", 92, 101], ["CD8 phenotype fractions", "PROBLEM", 145, 168], ["Fisher exact test", "TEST", 185, 202], ["pre-existing memoryOn days", "TEST", 251, 277], ["expanding ( Fig. S6a -c", "TEST", 341, 364], ["T cell clones", "PROBLEM", 366, 379], ["peripheral blood", "PROBLEM", 412, 428], ["cell clones", "OBSERVATION", 368, 379], ["memory subpopulations", "OBSERVATION", 387, 408], ["peripheral", "ANATOMY_MODIFIER", 412, 422], ["blood", "ANATOMY", 423, 428]]], ["Both CD4+ and CD8+ responding clones were found in the CM and EM subsets, however CD4+ were more biased towards CM (with exception of donor W day 30 timepoint, where a considerable fraction of CD8+ clones were found in CM), and CD8+ clones more represented in the EMRA subset.", [["CD4+", "ANATOMY", 5, 9], ["CD8+ responding clones", "ANATOMY", 14, 36], ["CM", "ANATOMY", 55, 57], ["CM", "ANATOMY", 112, 114], ["CD8+ clones", "ANATOMY", 193, 204], ["CM", "ANATOMY", 219, 221], ["CD8+ clones", "ANATOMY", 228, 239], ["CM", "DISEASE", 55, 57], ["CM", "DISEASE", 112, 114], ["CM", "DISEASE", 219, 221], ["CD4", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 14, 17], ["CM", "CELL", 55, 57], ["EM subsets", "CELL", 62, 72], ["CD4", "GENE_OR_GENE_PRODUCT", 82, 85], ["CD8", "GENE_OR_GENE_PRODUCT", 193, 196], ["CM", "CANCER", 219, 221], ["CD8", "GENE_OR_GENE_PRODUCT", 228, 231], ["EMRA", "CANCER", 264, 268], ["CD4", "PROTEIN", 5, 8], ["CD8", "PROTEIN", 14, 17], ["CD4", "PROTEIN", 82, 85], ["CD8", "PROTEIN", 193, 196], ["CM", "CELL_LINE", 219, 221], ["CD8+ clones", "CELL_LINE", 228, 239], ["EMRA subset", "CELL_LINE", 264, 275], ["Both CD4", "TEST", 0, 8], ["CD8", "TEST", 14, 17], ["responding clones", "PROBLEM", 19, 36], ["EM subsets", "TEST", 62, 72], ["CD4", "TEST", 82, 85], ["CD8+ clones", "PROBLEM", 193, 204], ["CD8+ clones", "PROBLEM", 228, 239], ["CD4", "OBSERVATION", 5, 8]]], ["A small number of both CD4+ and CD8+ responding clonotypes were also identified in the SCM subpopulation, which was previously shown to be a long-lived T cell memory subset [29] .", [["CD4+", "ANATOMY", 23, 27], ["SCM subpopulation", "ANATOMY", 87, 104], ["T cell", "ANATOMY", 152, 158], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD8", "GENE_OR_GENE_PRODUCT", 32, 35], ["SCM subpopulation", "CELL", 87, 104], ["T cell", "CELL", 152, 158], ["CD4", "PROTEIN", 23, 26], ["CD8", "PROTEIN", 32, 35], ["SCM subpopulation", "CELL_LINE", 87, 104], ["both CD4", "TEST", 18, 26], ["CD8+ responding clonotypes", "PROBLEM", 32, 58], ["small", "OBSERVATION_MODIFIER", 2, 7], ["number", "OBSERVATION_MODIFIER", 8, 14], ["both", "OBSERVATION_MODIFIER", 18, 22], ["CD4", "OBSERVATION", 23, 26], ["SCM", "OBSERVATION_MODIFIER", 87, 90], ["subpopulation", "OBSERVATION_MODIFIER", 91, 104]]], ["Note that we sequenced more cells from PBMC than from the memory subpopulations (Table S1 ), so that some low-abundant responding T cell clones are not sampled in the memory subpopulations.", [["cells", "ANATOMY", 28, 33], ["PBMC", "ANATOMY", 39, 43], ["memory subpopulations", "ANATOMY", 58, 79], ["T cell clones", "ANATOMY", 130, 143], ["cells", "CELL", 28, 33], ["PBMC", "CELL", 39, 43], ["T cell clones", "CELL", 130, 143], ["PBMC", "CELL_TYPE", 39, 43], ["memory subpopulations", "CELL_TYPE", 58, 79], ["T cell clones", "CELL_LINE", 130, 143], ["memory subpopulations", "CELL_TYPE", 167, 188], ["PBMC", "TEST", 39, 43], ["some low-abundant responding T cell clones", "PROBLEM", 101, 143], ["low", "OBSERVATION_MODIFIER", 106, 109], ["abundant", "OBSERVATION_MODIFIER", 110, 118], ["responding T cell clones", "OBSERVATION", 119, 143], ["memory subpopulations", "OBSERVATION", 167, 188]]], ["Intriguingly, a number of responding CD4+ clones, and fewer CD8+ clones, were also represented in the repertoires of both donors 1 and 2 years before the infection.", [["CD4+ clones", "ANATOMY", 37, 48], ["CD8+ clones", "ANATOMY", 60, 71], ["infection", "DISEASE", 154, 163], ["CD4", "GENE_OR_GENE_PRODUCT", 37, 40], ["CD8", "GENE_OR_GENE_PRODUCT", 60, 63], ["donors", "ORGANISM", 122, 128], ["CD4+ clones", "CELL_LINE", 37, 48], ["CD8+ clones", "CELL_LINE", 60, 71], ["responding CD4+ clones", "PROBLEM", 26, 48], ["the infection", "PROBLEM", 150, 163], ["fewer", "OBSERVATION_MODIFIER", 54, 59], ["CD8+ clones", "OBSERVATION", 60, 71], ["infection", "OBSERVATION", 154, 163]]], ["Pre-existing clones were expanded after infection, and contracted afterwards for both donors (Fig. S7 ).", [["clones", "ANATOMY", 13, 19], ["infection", "DISEASE", 40, 49], ["clones", "CELL", 13, 19], ["donors", "ORGANISM", 86, 92], ["Pre-existing clones", "PROBLEM", 0, 19], ["infection", "PROBLEM", 40, 49], ["clones", "OBSERVATION", 13, 19], ["expanded", "OBSERVATION_MODIFIER", 25, 33], ["infection", "OBSERVATION", 40, 49]]], ["For donor M, for whom we had previously sequenced memory subpopulations before the infection [23] , we were able to identify pre-existing SARS-CoV-2reactive CD4+ clones in the CM subpopulation 1 year before the infection and a group of CD8+ clones in the pre-infection EM subpopulation.", [["CD4+ clones", "ANATOMY", 157, 168], ["CM subpopulation", "ANATOMY", 176, 192], ["CD8+ clones", "ANATOMY", 236, 247], ["infection", "DISEASE", 83, 92], ["CM", "DISEASE", 176, 178], ["infection", "DISEASE", 211, 220], ["CoV", "ORGANISM", 143, 146], ["CD4", "GENE_OR_GENE_PRODUCT", 157, 160], ["CD8", "GENE_OR_GENE_PRODUCT", 236, 239], ["memory subpopulations", "CELL_TYPE", 50, 71], ["SARS-CoV-2reactive CD4+ clones", "CELL_LINE", 138, 168], ["CD8+ clones", "CELL_LINE", 236, 247], ["the infection", "PROBLEM", 79, 92], ["pre-existing SARS", "PROBLEM", 125, 142], ["CoV", "TEST", 143, 146], ["2reactive CD4+ clones", "PROBLEM", 147, 168], ["the infection", "PROBLEM", 207, 220], ["infection", "OBSERVATION", 211, 220]]], ["Interestingly, on day 30 after infection the majority of pre-infection CM clones were detected in the EM subpopulation, suggesting recent T cell activation and a switch of the phenotype from memory to effector.", [["CM clones", "ANATOMY", 71, 80], ["EM subpopulation", "ANATOMY", 102, 118], ["T cell", "ANATOMY", 138, 144], ["CM", "DISEASE", 71, 73], ["CM clones", "CELL", 71, 80], ["EM subpopulation", "CELL", 102, 118], ["T cell", "CELL", 138, 144], ["pre-infection CM clones", "CELL_LINE", 57, 80], ["infection", "PROBLEM", 31, 40], ["pre-infection CM clones", "PROBLEM", 57, 80], ["recent T cell activation", "PROBLEM", 131, 155], ["infection", "OBSERVATION", 31, 40], ["T cell activation", "OBSERVATION", 138, 155]]], ["These clones might represent memory T cells cross-reactive for other infections, e.g. other human coronaviruses.Memory formation and pre-existing memoryA search for TCRbeta amino acid sequences of responding clones in VDJdb [30] -a database of TCRs with known specificities -resulted in essentially no overlap with TCRs not specific for SARS-CoV-2 epitopes: only two clonotypes matched.", [["clones", "ANATOMY", 6, 12], ["memory T cells", "ANATOMY", 29, 43], ["clones", "ANATOMY", 208, 214], ["infections", "DISEASE", 69, 79], ["amino acid", "CHEMICAL", 173, 183], ["amino acid", "CHEMICAL", 173, 183], ["clones", "CELL", 6, 12], ["memory T cells", "CELL", 29, 43], ["human", "ORGANISM", 92, 97], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 165, 172], ["amino acid", "AMINO_ACID", 173, 183], ["clones", "CELL", 208, 214], ["TCRs", "GENE_OR_GENE_PRODUCT", 244, 248], ["TCRs", "GENE_OR_GENE_PRODUCT", 315, 319], ["memory T cells", "CELL_TYPE", 29, 43], ["TCRbeta amino acid sequences", "PROTEIN", 165, 193], ["TCRs", "PROTEIN", 244, 248], ["TCRs", "PROTEIN", 315, 319], ["SARS-CoV-2 epitopes", "PROTEIN", 337, 356], ["human", "SPECIES", 92, 97], ["human coronaviruses", "SPECIES", 92, 111], ["memory T cells", "PROBLEM", 29, 43], ["other infections", "PROBLEM", 63, 79], ["other human coronaviruses", "PROBLEM", 86, 111], ["Memory formation", "PROBLEM", 112, 128], ["pre-existing memoryA search", "PROBLEM", 133, 160], ["TCRbeta amino acid sequences", "TEST", 165, 193], ["responding clones", "PROBLEM", 197, 214], ["TCRs", "PROBLEM", 244, 248], ["known specificities", "PROBLEM", 254, 273], ["overlap with TCRs", "PROBLEM", 302, 319], ["SARS", "PROBLEM", 337, 341], ["CoV", "TEST", 342, 345]]], ["One match corresponded to the CMV (cytomegalovirus) epitope presented by the HLA-A02 allele.", [["CMV", "ORGANISM", 30, 33], ["cytomegalovirus", "ORGANISM", 35, 50], ["HLA-A02", "GENE_OR_GENE_PRODUCT", 77, 84], ["CMV (cytomegalovirus) epitope", "PROTEIN", 30, 59], ["HLA-A02 allele", "DNA", 77, 91], ["the CMV (cytomegalovirus) epitope", "PROBLEM", 26, 59], ["CMV", "OBSERVATION", 30, 33]]], ["The absence of matches suggests that contracting and expanding clones are unlikely to be specific for immunodominant epitopes of common pathogens covered in VDJdb.", [["clones", "CELL", 63, 69], ["VDJdb", "CANCER", 157, 162], ["immunodominant epitopes", "PROTEIN", 102, 125], ["expanding clones", "PROBLEM", 53, 69], ["immunodominant epitopes of common pathogens", "PROBLEM", 102, 145], ["common", "OBSERVATION_MODIFIER", 129, 135], ["pathogens", "OBSERVATION", 136, 145]]], ["We next asked if we could map specificites of our responding clones to SARS-CoV-2 epitopes.Validation by MHC tetramer-staining assayOn day 25 post-infection donor M participated in study by Shomuradova et al. [31] (as donor p1434), where his CD8+ T cells were stained with HLA-A02:01-YLQPRTFLL MHC-I tetramer-specific TCRs were matched to the peptide pool YLQPRTFL,YLQPRTFLL,YYVGYLQPRTF in the MIRA dataset.", [["CD8+ T cells", "ANATOMY", 242, 254], ["SARS", "DISEASE", 71, 75], ["clones", "CELL", 61, 67], ["MHC tetramer", "GENE_OR_GENE_PRODUCT", 105, 117], ["CD8", "GENE_OR_GENE_PRODUCT", 242, 245], ["TCRs", "GENE_OR_GENE_PRODUCT", 318, 322], ["SARS-CoV-2 epitopes", "PROTEIN", 71, 90], ["MHC tetramer", "PROTEIN", 105, 117], ["CD8+ T cells", "CELL_TYPE", 242, 254], ["HLA", "PROTEIN", 273, 276], ["A02:01", "PROTEIN", 277, 283], ["YLQPRTFLL MHC-I tetramer", "PROTEIN", 284, 308], ["TCRs", "PROTEIN", 318, 322], ["SARS-CoV", "SPECIES", 71, 79], ["our responding clones", "PROBLEM", 46, 67], ["SARS", "PROBLEM", 71, 75], ["CoV", "TEST", 76, 79], ["his CD8", "TEST", 238, 245], ["HLA", "TEST", 273, 276], ["specific TCRs", "TREATMENT", 309, 322], ["YLQPRTFLL", "TREATMENT", 365, 374], ["YYVGYLQPRTF", "TREATMENT", 375, 386]]], ["Another large group of matches corresponded to the HLA-B15:01 epitope from HKU1 or OC43, common human betacoronaviruses.", [["HKU1", "GENE_OR_GENE_PRODUCT", 75, 79], ["OC43", "GENE_OR_GENE_PRODUCT", 83, 87], ["human", "ORGANISM", 96, 101], ["betacoronaviruses", "CANCER", 102, 119], ["HLA-B15:01 epitope", "PROTEIN", 51, 69], ["OC43", "PROTEIN", 83, 87], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["the HLA", "TEST", 47, 54], ["HKU1", "PROBLEM", 75, 79], ["OC43", "PROBLEM", 83, 87], ["large", "OBSERVATION_MODIFIER", 8, 13]]], ["To predict potential pairings between TCRalpha and TCRbeta motifs, we used a method of alpha/beta clonal trajectory matching described in [23] (see Methods for details).", [["TCRalpha", "GENE_OR_GENE_PRODUCT", 38, 46], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 51, 58], ["alpha/beta", "GENE_OR_GENE_PRODUCT", 87, 97], ["TCRalpha and TCRbeta motifs", "DNA", 38, 65], ["TCRalpha and TCRbeta motifs", "TREATMENT", 38, 65], ["a method of alpha/beta clonal trajectory matching", "TREATMENT", 75, 124]]], ["We found consistent pairing between one of the motifs in TCRalpha to the largest motif in TCRbeta T cells, which is associated to HLA-B07:01 allele, while the motif from donor M appears to be associated with HLA-DRB102:01 haplotype.", [["TCRbeta T cells", "ANATOMY", 90, 105], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 57, 65], ["TCRbeta T", "GENE_OR_GENE_PRODUCT", 90, 99], ["HLA-B07:01", "GENE_OR_GENE_PRODUCT", 130, 140], ["HLA-DRB102:01", "GENE_OR_GENE_PRODUCT", 208, 221], ["TCRalpha", "PROTEIN", 57, 65], ["TCRbeta T cells", "CELL_TYPE", 90, 105], ["HLA-B07:01 allele", "DNA", 130, 147], ["HLA-DRB102:01 haplotype", "DNA", 208, 231], ["HLA", "TEST", 130, 133], ["HLA", "TEST", 208, 211], ["haplotype", "PROBLEM", 222, 231], ["largest", "OBSERVATION_MODIFIER", 73, 80], ["TCRbeta T cells", "OBSERVATION", 90, 105]]], ["The frequency of sequences corresponding to these motifs can then be used to identify SARS-CoV-2 infected donors with matching HLA alleles (Fig. S11 ).DISCUSSIONUsing longitudinal repertoire sequencing, we identified a group of CD4+ and CD8+ T cell clones that contract after recovery from a SARS-CoV-2 infection.", [["T cell clones", "ANATOMY", 242, 255], ["SARS-CoV-2 infection", "DISEASE", 292, 312], ["SARS-CoV-2", "ORGANISM", 86, 96], ["donors", "ORGANISM", 106, 112], ["CD4", "GENE_OR_GENE_PRODUCT", 228, 231], ["CD8", "GENE_OR_GENE_PRODUCT", 237, 240], ["T cell clones", "CELL", 242, 255], ["SARS-CoV-2", "ORGANISM", 292, 302], ["HLA alleles", "DNA", 127, 138], ["CD4", "PROTEIN", 228, 231], ["CD8", "PROTEIN", 237, 240], ["T cell clones", "CELL_LINE", 242, 255], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV-2", "SPECIES", 292, 302], ["SARS", "PROBLEM", 86, 90], ["matching HLA alleles", "TREATMENT", 118, 138], ["longitudinal repertoire sequencing", "TEST", 167, 201], ["CD4", "TEST", 228, 231], ["T cell clones", "PROBLEM", 242, 255], ["a SARS", "PROBLEM", 290, 296], ["CoV-2 infection", "PROBLEM", 297, 312], ["cell clones", "OBSERVATION", 244, 255], ["infection", "OBSERVATION", 303, 312]]], ["Our response timelines agree with T cell dynamics reported by Theravajan et al. [9] for mild COVID-19, as well as with dynamics of T cell response to live vaccines [11] .", [["T cell", "ANATOMY", 34, 40], ["T cell", "ANATOMY", 131, 137], ["T cell", "CELL", 34, 40], ["T cell", "CELL", 131, 137], ["mild COVID", "PROBLEM", 88, 98]]], ["We further mapped the specificities of contracting CD8+ T cells using sequences of SARS-CoV-2 specific T cells identified with tetramer staining in the same donor, and as well as the large set of SARS-CoV-2 peptide stimulated TCRbeta sequences from ref.", [["CD8+ T cells", "ANATOMY", 51, 63], ["T cells", "ANATOMY", 103, 110], ["CD8", "GENE_OR_GENE_PRODUCT", 51, 54], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["T cells", "CELL", 103, 110], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 226, 233], ["contracting CD8+ T cells", "CELL_TYPE", 39, 63], ["T cells", "CELL_TYPE", 103, 110], ["TCRbeta sequences", "DNA", 226, 243], ["SARS-CoV", "SPECIES", 83, 91], ["contracting CD8+ T cells", "PROBLEM", 39, 63], ["SARS", "TEST", 83, 87], ["CoV", "TEST", 88, 91], ["tetramer staining", "PROBLEM", 127, 144], ["SARS", "TEST", 196, 200], ["CoV", "TEST", 201, 204]]], ["For large CD4+ TCRbeta motifs we show strong association with COVID-19 by analysing the occurence patterns and frequencies FIG.", [["CD4", "GENE_OR_GENE_PRODUCT", 10, 13], ["CD4", "PROTEIN", 10, 13], ["TCRbeta motifs", "DNA", 15, 29], ["COVID-19", "DNA", 62, 70], ["large CD4+ TCRbeta motifs", "PROBLEM", 4, 29], ["COVID", "TEST", 62, 67], ["large", "OBSERVATION_MODIFIER", 4, 9], ["CD4", "OBSERVATION", 10, 13]]], ["4 . a, Analysis of TCR amino acid sequences of CD4+ contracting clones reveal distinctive motifs.", [["amino acid", "CHEMICAL", 23, 33], ["amino acid", "CHEMICAL", 23, 33], ["TCR", "GENE_OR_GENE_PRODUCT", 19, 22], ["amino acid", "AMINO_ACID", 23, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 47, 50], ["TCR amino acid sequences", "PROTEIN", 19, 43], ["CD4", "PROTEIN", 47, 50], ["TCR amino acid sequences", "TEST", 19, 43], ["CD4", "TEST", 47, 50], ["distinctive motifs", "PROBLEM", 78, 96], ["distinctive motifs", "OBSERVATION", 78, 96]]], ["Each vertex in the similarity network corresponds to a contracting clonotype.", [["a contracting clonotype", "PROBLEM", 53, 76], ["vertex", "ANATOMY_MODIFIER", 5, 11], ["contracting clonotype", "OBSERVATION", 55, 76]]], ["An edge indicates 2 or less amino acid mismatches in the CDR3 region (and identical V and J segments).", [["amino acid", "CHEMICAL", 28, 38], ["amino acid", "CHEMICAL", 28, 38], ["amino acid", "AMINO_ACID", 28, 38], ["CDR3 region", "DNA", 57, 68], ["J segments", "PROTEIN", 90, 100], ["less amino acid mismatches in the CDR3 region", "PROBLEM", 23, 68], ["edge", "OBSERVATION_MODIFIER", 3, 7], ["acid mismatches", "OBSERVATION", 34, 49], ["CDR3", "ANATOMY", 57, 61], ["region", "ANATOMY_MODIFIER", 62, 68], ["J segments", "ANATOMY_MODIFIER", 90, 100]]], ["Networks are plotted separately for CD4alpha (a), CD4beta (b), contracting clonotypes.", [["CD4alpha", "GENE_OR_GENE_PRODUCT", 36, 44], ["CD4beta (b)", "GENE_OR_GENE_PRODUCT", 50, 61], ["CD4alpha", "PROTEIN", 36, 44], ["CD4beta (b)", "PROTEIN", 50, 61]]], ["Sequence logos corresponding to the largest clusters are shown under the corresponding network plots. c, d, Clonotypes forming the two largest motifs are significantly more clonally expanded (p<0.001, one sided t-test) in a cohort of COVID-19 patients [15] than in a cohort of control donors [35] .", [["patients", "ORGANISM", 243, 251], ["donors", "ORGANISM", 285, 291], ["patients", "SPECIES", 243, 251], ["Sequence logos", "TEST", 0, 14], ["one sided t-test", "TEST", 201, 217], ["COVID", "TEST", 234, 239], ["a cohort of control donors", "TREATMENT", 265, 291], ["largest", "OBSERVATION_MODIFIER", 36, 43]]], ["Each dot corresponds to the total frequency of clonotypes from motifs shaded on (b) in the TCRbeta repertoire of a given donor. of these sequences in a large cohort of COVID-19 patients.", [["TCRbeta", "GENE_OR_GENE_PRODUCT", 91, 98], ["patients", "ORGANISM", 177, 185], ["TCRbeta repertoire", "PROTEIN", 91, 109], ["patients", "SPECIES", 177, 185], ["these sequences", "TEST", 131, 146]]], ["Surprisingly, in both donors we also identified a group of predominantly CD4+ clonotypes which expanded from day 15 to day 37 after the infection.", [["CD4+ clonotypes", "ANATOMY", 73, 88], ["infection", "DISEASE", 136, 145], ["donors", "ORGANISM", 22, 28], ["CD4", "GENE_OR_GENE_PRODUCT", 73, 76], ["CD4", "PROTEIN", 73, 76], ["predominantly CD4+ clonotypes", "PROBLEM", 59, 88], ["the infection", "PROBLEM", 132, 145], ["predominantly", "OBSERVATION_MODIFIER", 59, 72], ["CD4+ clonotypes", "OBSERVATION", 73, 88], ["infection", "OBSERVATION", 136, 145]]], ["One possible explanation for this second wave of expansion is the priming of CD4+ T cells by antigen-specific B-cells, but there might be other mechanisms such as the migration of SARS-CoV-2 specific T cells from lymphoid organs or bystander activation of non-SARS-CoV-2 specific T cells.", [["T cells", "ANATOMY", 82, 89], ["B-cells", "ANATOMY", 110, 117], ["T cells", "ANATOMY", 200, 207], ["lymphoid organs", "ANATOMY", 213, 228], ["T cells", "ANATOMY", 280, 287], ["CD4", "GENE_OR_GENE_PRODUCT", 77, 80], ["T cells", "CELL", 82, 89], ["antigen", "GENE_OR_GENE_PRODUCT", 93, 100], ["B-cells", "CELL", 110, 117], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 180, 190], ["T cells", "CELL", 200, 207], ["lymphoid organs", "MULTI-TISSUE_STRUCTURE", 213, 228], ["non-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 256, 270], ["T cells", "CELL", 280, 287], ["CD4", "PROTEIN", 77, 80], ["T cells", "CELL_TYPE", 82, 89], ["B-cells", "CELL_TYPE", 110, 117], ["T cells", "CELL_TYPE", 200, 207], ["non-SARS-CoV-2 specific T cells", "CELL_LINE", 256, 287], ["this second wave of expansion", "PROBLEM", 29, 58], ["T cells", "TEST", 82, 89], ["antigen", "TEST", 93, 100], ["SARS", "PROBLEM", 180, 184], ["CoV", "TEST", 185, 188], ["lymphoid organs", "PROBLEM", 213, 228], ["non-SARS", "TEST", 256, 264], ["CoV", "TEST", 265, 268], ["possible explanation for", "UNCERTAINTY", 4, 28], ["lymphoid organs", "OBSERVATION", 213, 228]]], ["It is also possible that later expanding T cells are triggered by another infection, simultaneously and asymptomatically occurring in both donors around day 30.", [["T cells", "ANATOMY", 41, 48], ["infection", "DISEASE", 74, 83], ["T cells", "CELL", 41, 48], ["donors", "ORGANISM", 139, 145], ["T cells", "CELL_TYPE", 41, 48], ["later expanding T cells", "PROBLEM", 25, 48], ["another infection", "PROBLEM", 66, 83], ["also possible", "UNCERTAINTY", 6, 19], ["infection", "OBSERVATION", 74, 83]]], ["In contrast with the first wave of response identified by contracting clones, for now we do not have confirmation that this second wave of expansion corresponds to SARS-CoV-2 specific T cells.", [["T cells", "ANATOMY", 184, 191], ["SARS", "DISEASE", 164, 168], ["clones", "CELL", 70, 76], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 164, 174], ["T cells", "CELL", 184, 191], ["contracting clones", "CELL_LINE", 58, 76], ["SARS-CoV-2 specific T cells", "CELL_LINE", 164, 191], ["this second wave of expansion", "PROBLEM", 119, 148], ["SARS", "PROBLEM", 164, 168], ["CoV", "TEST", 169, 172]]], ["Accumulation of TCR sequences for CD4+ SARS-CoV-2 epitope specific T cells may further address this question.", [["T cells", "ANATOMY", 67, 74], ["TCR", "GENE_OR_GENE_PRODUCT", 16, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["T cells", "CELL", 67, 74], ["TCR sequences", "DNA", 16, 29], ["CD4", "PROTEIN", 34, 37], ["T cells", "CELL_TYPE", 67, 74], ["Accumulation of TCR sequences", "TEST", 0, 29], ["CD4", "TEST", 34, 37], ["SARS", "PROBLEM", 39, 43], ["CoV", "TEST", 44, 47], ["2 epitope specific T cells", "TREATMENT", 48, 74]]], ["We showed that a large fraction of putatively SARS-CoV-2 reactive T cell clones are later found in memory subpopulations and remain there at least 3 months after infection.", [["T cell clones", "ANATOMY", 66, 79], ["infection", "DISEASE", 162, 171], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 46, 56], ["T cell clones", "CELL", 66, 79], ["SARS-CoV-2 reactive T cell clones", "CELL_LINE", 46, 79], ["memory subpopulations", "CELL_TYPE", 99, 120], ["putatively SARS", "PROBLEM", 35, 50], ["CoV", "TEST", 51, 54], ["2 reactive T cell clones", "PROBLEM", 55, 79], ["infection", "PROBLEM", 162, 171], ["large", "OBSERVATION_MODIFIER", 17, 22], ["fraction", "OBSERVATION_MODIFIER", 23, 31], ["reactive", "OBSERVATION_MODIFIER", 57, 65], ["cell clones", "OBSERVATION", 68, 79], ["memory subpopulations", "OBSERVATION", 99, 120], ["infection", "OBSERVATION", 162, 171]]], ["Impor-tantly, some of responding clones are found in long-lived stem cell-like (SCM) memory subset, as also reported for SARS-CoV-2 convalescent patients in ref.", [["stem cell", "ANATOMY", 64, 73], ["SCM", "ANATOMY", 80, 83], ["clones", "CELL", 33, 39], ["stem cell", "CELL", 64, 73], ["SCM", "CELL", 80, 83], ["SARS-CoV-2", "ORGANISM", 121, 131], ["convalescent", "ORGANISM", 132, 144], ["patients", "ORGANISM", 145, 153], ["responding clones", "CELL_LINE", 22, 39], ["long-lived stem cell-like (SCM) memory subset", "CELL_LINE", 53, 98], ["patients", "SPECIES", 145, 153], ["responding clones", "PROBLEM", 22, 39], ["SARS", "PROBLEM", 121, 125], ["responding clones", "OBSERVATION", 22, 39]]], ["A subset of CD4+ clones were identified in pre-infection central memory subsets, and a subset of CD8+ T cells were found in effector memory.", [["CD4+ clones", "ANATOMY", 12, 23], ["CD8+", "ANATOMY", 97, 101], ["T cells", "ANATOMY", 102, 109], ["CD4", "GENE_OR_GENE_PRODUCT", 12, 15], ["pre-infection central memory subsets", "CELL", 43, 79], ["CD8", "GENE_OR_GENE_PRODUCT", 97, 100], ["T cells", "CELL", 102, 109], ["CD4+ clones", "CELL_LINE", 12, 23], ["pre-infection central memory subsets", "CELL_TYPE", 43, 79], ["CD8", "PROTEIN", 97, 100], ["T cells", "CELL_TYPE", 102, 109], ["CD4+ clones", "TREATMENT", 12, 23], ["central memory subsets", "OBSERVATION", 57, 79], ["effector memory", "OBSERVATION", 124, 139]]], ["Among these are CD8+ clones recognising NQKLIANQF, an immunodominant HLA-B15:01 cross-reactive epitope described above as a good starting point).", [["CD8+ clones", "ANATOMY", 16, 27], ["CD8", "GENE_OR_GENE_PRODUCT", 16, 19], ["NQKLIANQF", "GENE_OR_GENE_PRODUCT", 40, 49], ["CD8", "PROTEIN", 16, 19], ["NQKLIANQF", "PROTEIN", 40, 49], ["B15:01", "PROTEIN", 73, 79], ["an immunodominant HLA", "TEST", 51, 72], ["cross-reactive epitope", "PROBLEM", 80, 102]]], ["Larger studies with cohorts of severe and mild cases with pre-infection timepoints are needed to address this question.Donors and blood samplesPeripheral blood samples from two young healthy adult volunteers, donor W (female) and donor M (male) were collected with written informed consent in a certified diagnostics laboratory.", [["blood samples", "ANATOMY", 130, 143], ["Peripheral blood samples", "ANATOMY", 143, 167], ["Donors", "CELL", 119, 125], ["blood samples", "ORGANISM_SUBSTANCE", 130, 143], ["Peripheral blood samples", "ORGANISM_SUBSTANCE", 143, 167], ["volunteers", "ORGANISM", 197, 207], ["Larger studies", "TEST", 0, 14], ["severe and mild cases with pre-infection timepoints", "PROBLEM", 31, 82], ["Donors", "TREATMENT", 119, 125], ["blood samples", "TEST", 130, 143], ["Peripheral blood samples", "TEST", 143, 167], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["blood", "ANATOMY", 154, 159]]], ["Both donors gave written informed consent to participate in the study under the declaration of Helsinki.", [["donors", "ORGANISM", 5, 11], ["the study", "TEST", 60, 69]]], ["HLA alleles of both donors (Table S2) were determined by an in-house cDNA high-throughput sequencing method.SARS-CoV-2 S-RBD domain specific ELISAAn ELISA assay kit developed by the National Research Centre for Hematology was used for detection of anti-S-RBD IgG according to the manufacturer's protocol.", [["HLA", "GENE_OR_GENE_PRODUCT", 0, 3], ["HLA alleles", "DNA", 0, 11], ["SARS-CoV-2 S-RBD domain", "PROTEIN", 108, 131], ["anti-S-RBD IgG", "PROTEIN", 248, 262], ["anti-S-", "SPECIES", 248, 255], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["RBD", "PROBLEM", 121, 124], ["anti-S-RBD IgG", "TREATMENT", 248, 262], ["the manufacturer's protocol", "TREATMENT", 276, 303]]], ["The relative IgG level (OD/CO) was calculated by dividing the OD (optical density) values by the mean OD value of the cut-off positive control serum supplied with the Kit (CO).", [["serum", "ANATOMY", 143, 148], ["CO", "CHEMICAL", 172, 174], ["IgG", "GENE_OR_GENE_PRODUCT", 13, 16], ["serum", "ORGANISM_SUBSTANCE", 143, 148], ["Kit", "GENE_OR_GENE_PRODUCT", 167, 170], ["IgG", "PROTEIN", 13, 16], ["The relative IgG level", "TEST", 0, 22], ["OD/CO", "TEST", 24, 29], ["the mean OD value", "TEST", 93, 110], ["the cut-", "TEST", 114, 122]]], ["OD values of d37, d45 and d85 samples for donor M exceeded the limit of linearity for the Kit.", [["Kit", "GENE_OR_GENE_PRODUCT", 90, 93], ["OD values", "TEST", 0, 9], ["d37", "TREATMENT", 13, 16], ["d45", "TREATMENT", 18, 21], ["d85 samples", "TREATMENT", 26, 37], ["donor M", "TREATMENT", 42, 49], ["the Kit", "TEST", 86, 93]]], ["In order to properly compare the relative IgG levels between d30, d37, d45 and d85, these samples were diluted 1:400 instead of 1:100, the ratios d37:d30 and d45:d30 and d85:d30 were calculated and used to calculate the relative IgG level of d37, d45 and d85 by multiplying d30 OD/CO value by the corresponding ratio.", [["samples", "ANATOMY", 90, 97], ["CO", "CHEMICAL", 281, 283], ["IgG", "GENE_OR_GENE_PRODUCT", 42, 45], [":d30", "GENE_OR_GENE_PRODUCT", 161, 165], ["IgG", "GENE_OR_GENE_PRODUCT", 229, 232], ["IgG", "PROTEIN", 42, 45], ["d45", "PROTEIN", 158, 161], ["IgG", "PROTEIN", 229, 232], ["d37", "PROTEIN", 242, 245], ["the relative IgG levels", "TEST", 29, 52], ["d37", "TREATMENT", 66, 69], ["d45", "TREATMENT", 71, 74], ["d85", "TREATMENT", 79, 82], ["these samples", "TEST", 84, 97], ["d30", "TREATMENT", 174, 177], ["the relative IgG level", "TEST", 216, 238], ["d45", "TREATMENT", 247, 250], ["d85", "TREATMENT", 255, 258], ["CO value", "TEST", 281, 289], ["the corresponding ratio", "TEST", 293, 316]]], ["Relative anti-S-RBD IgM level was calculated using the same protocol with anti-human IgM-HRP conjugated secondary antibody.", [["anti-S-RBD", "GENE_OR_GENE_PRODUCT", 9, 19], ["IgM", "GENE_OR_GENE_PRODUCT", 85, 88], ["HRP", "GENE_OR_GENE_PRODUCT", 89, 92], ["RBD", "PROTEIN", 16, 19], ["IgM", "PROTEIN", 20, 23], ["IgM", "PROTEIN", 85, 88], ["HRP conjugated secondary antibody", "PROTEIN", 89, 122], ["Relative anti-S-RBD IgM level", "TEST", 0, 29], ["the same protocol", "TEST", 51, 68], ["anti-human IgM", "TEST", 74, 88]]], ["Since the control cut-off serum for IgM was not available from the Kit, on Fig. S1b . we show OD values for nine biobanked pre-pandemic serum samples from healthy donors.Isolation of PBMCs and T cell subpopulationsPBMCs were isolated with the Ficoll-Paque density gradient centrifugation protocol.", [["serum", "ANATOMY", 26, 31], ["serum samples", "ANATOMY", 136, 149], ["PBMCs", "ANATOMY", 183, 188], ["T cell", "ANATOMY", 193, 199], ["PBMCs", "ANATOMY", 214, 219], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["IgM", "GENE_OR_GENE_PRODUCT", 36, 39], ["serum samples", "ORGANISM_SUBSTANCE", 136, 149], ["donors", "ORGANISM", 163, 169], ["PBMCs", "CELL", 183, 188], ["T cell", "CELL", 193, 199], ["PBMCs", "CELL", 214, 219], ["IgM", "PROTEIN", 36, 39], ["PBMCs", "CELL_TYPE", 183, 188], ["T cell subpopulations", "CELL_TYPE", 193, 214], ["PBMCs", "CELL_TYPE", 214, 219], ["serum", "TEST", 26, 31], ["IgM", "TEST", 36, 39], ["OD values", "TEST", 94, 103], ["nine biobanked pre-pandemic serum samples", "TEST", 108, 149], ["Isolation of PBMCs", "TREATMENT", 170, 188], ["T cell subpopulationsPBMCs", "PROBLEM", 193, 219], ["the Ficoll-Paque density gradient centrifugation protocol", "TREATMENT", 239, 296], ["PBMCs", "ANATOMY", 183, 188], ["cell", "OBSERVATION", 195, 199], ["subpopulationsPBMCs", "OBSERVATION", 200, 219]]], ["CD4+ and CD8+ T cells were isolated from PBMCs with Dynabeads CD4+ and CD8+ positive selection kits (Invitrogen) respectively.", [["CD4+", "ANATOMY", 0, 4], ["CD8+ T cells", "ANATOMY", 9, 21], ["PBMCs", "ANATOMY", 41, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["PBMCs", "CELL", 41, 46], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["CD4", "PROTEIN", 0, 3], ["CD8+ T cells", "CELL_TYPE", 9, 21], ["PBMCs", "CELL_TYPE", 41, 46], ["CD4", "PROTEIN", 62, 65], ["CD8", "PROTEIN", 71, 74], ["CD4", "TEST", 0, 3], ["CD8", "TEST", 9, 12], ["T cells", "PROBLEM", 14, 21], ["PBMCs", "TEST", 41, 46], ["Dynabeads", "TEST", 52, 61], ["CD4", "TEST", 62, 65], ["CD8", "TEST", 71, 74]]], ["For isolation of EM, EMRA, CM and SCM memory subpopulations we stained PBMCs with the following antibody mix: anti-CD3-FITC (UCHT1, eBioscience), anti-CD45RA-eFluor450 (HI100, eBioscience), anti-CCR7-APC (3D12, eBioscience), anti-CD95-PE (DX2, eBioscience).", [["CM", "ANATOMY", 27, 29], ["SCM memory subpopulations", "ANATOMY", 34, 59], ["PBMCs", "ANATOMY", 71, 76], ["CM", "DISEASE", 27, 29], ["FITC", "CHEMICAL", 119, 123], ["EM", "CELL", 17, 19], ["CM", "CELL", 27, 29], ["SCM memory subpopulations", "CELL", 34, 59], ["PBMCs", "CELL", 71, 76], ["anti-CD3-FITC", "SIMPLE_CHEMICAL", 110, 123], ["UCHT1", "SIMPLE_CHEMICAL", 125, 130], ["anti-CD45RA-eFluor450", "SIMPLE_CHEMICAL", 146, 167], ["HI100", "SIMPLE_CHEMICAL", 169, 174], ["anti-CCR7-APC", "GENE_OR_GENE_PRODUCT", 190, 203], ["3D12", "SIMPLE_CHEMICAL", 205, 209], ["anti-CD95-PE", "SIMPLE_CHEMICAL", 225, 237], ["DX2", "SIMPLE_CHEMICAL", 239, 242], ["PBMCs", "CELL_TYPE", 71, 76], ["anti-CD3", "PROTEIN", 110, 118], ["FITC", "PROTEIN", 119, 123], ["UCHT1", "PROTEIN", 125, 130], ["eBioscience", "PROTEIN", 132, 143], ["anti-CD45RA", "PROTEIN", 146, 157], ["eFluor450", "PROTEIN", 158, 167], ["HI100", "PROTEIN", 169, 174], ["eBioscience", "PROTEIN", 176, 187], ["anti-CCR7", "PROTEIN", 190, 199], ["APC", "PROTEIN", 200, 203], ["3D12", "PROTEIN", 205, 209], ["eBioscience", "PROTEIN", 211, 222], ["anti-CD95", "PROTEIN", 225, 234], ["PE", "PROTEIN", 235, 237], ["DX2", "PROTEIN", 239, 242], ["eBioscience", "PROTEIN", 244, 255], ["PBMCs", "TEST", 71, 76], ["anti-CD3", "TEST", 110, 118], ["FITC", "TEST", 119, 123], ["UCHT1", "TEST", 125, 130], ["eBioscience", "TEST", 132, 143], ["anti-CD45RA", "TEST", 146, 157], ["eBioscience", "TEST", 176, 187], ["anti-CCR7", "TEST", 190, 199], ["APC", "TEST", 200, 203], ["anti-CD95", "TREATMENT", 225, 234], ["PE", "PROBLEM", 235, 237], ["PE", "OBSERVATION", 235, 237]]], ["Cell sorting was performed on FACS Aria III, all four isolated subpopulations were lysed with Trizol reagent immediately after sorting.TCR library preparation and sequencingTCRalpha and TCRbeta cDNA libraries preparation was performed as previously described in [26] .", [["Cell", "ANATOMY", 0, 4], ["TCR", "CHEMICAL", 135, 138], ["Cell", "CELL", 0, 4], ["TCR", "GENE_OR_GENE_PRODUCT", 135, 138], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 173, 181], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 186, 193], ["FACS Aria III", "CELL_LINE", 30, 43], ["TCR", "PROTEIN", 135, 138], ["TCRbeta cDNA libraries", "DNA", 186, 208], ["Cell sorting", "TEST", 0, 12], ["Trizol reagent", "TREATMENT", 94, 108], ["TCR library preparation", "TREATMENT", 135, 158], ["sequencingTCRalpha", "TREATMENT", 163, 181], ["TCRbeta cDNA libraries preparation", "TREATMENT", 186, 220]]], ["RNA was isolated from each sample using Trizol reagent according to the manufacturer's instructions.", [["sample", "ANATOMY", 27, 33], ["RNA", "RNA", 0, 3], ["Trizol reagent", "TREATMENT", 40, 54]]], ["A universal primer binding site, sample barcode and unique molecular identifier (UMI) sequences were introduced using the 5'RACE technology with TCRalpha and TCRbeta constant segment specific primers for cDNA synthesis. cDNA libraries were amplified in two PCR steps, with introduction of the second sample barcode and Illumina TruSeq adapter sequences at the second PCR step.", [["TCRalpha", "GENE_OR_GENE_PRODUCT", 145, 153], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 158, 165], ["primer binding site", "DNA", 12, 31], ["unique molecular identifier (UMI) sequences", "DNA", 52, 95], ["TCRalpha and TCRbeta constant segment", "DNA", 145, 182], ["cDNA libraries", "DNA", 220, 234], ["Illumina TruSeq adapter sequences", "DNA", 319, 352], ["A universal primer binding site", "PROBLEM", 0, 31], ["sample barcode", "TEST", 33, 47], ["the 5'RACE technology", "TREATMENT", 118, 139], ["TCRalpha and TCRbeta constant segment specific primers", "TREATMENT", 145, 199], ["cDNA synthesis", "PROBLEM", 204, 218], ["cDNA libraries", "TREATMENT", 220, 234], ["the second sample barcode", "TREATMENT", 289, 314], ["Illumina TruSeq adapter sequences", "TREATMENT", 319, 352]]], ["Libraries were sequenced using the Illumina NovaSeq platform (2x150bp read length).TCR repertoire data analysisRaw data preprocessing.", [["TCR", "CHEMICAL", 83, 86], ["TCR", "GENE_OR_GENE_PRODUCT", 83, 86], ["Illumina NovaSeq platform", "DNA", 35, 60], ["TCR", "PROTEIN", 83, 86], ["Libraries", "TREATMENT", 0, 9], ["the Illumina NovaSeq platform", "TREATMENT", 31, 60], ["TCR repertoire data analysis", "TEST", 83, 111]]], ["Raw sequencing data was demultiplexed and UMI guided consensuses were built using migec v.1.2.7 [39] .", [["UMI", "DNA", 42, 45], ["Raw sequencing data", "TEST", 0, 19]]], ["Resulting UMI consensuses were aligned to V and J genomic templates of the TRA and TRB locus and assembled into clonotypes with mixcr v.2.1.11 [40] .", [["TRA", "GENE_OR_GENE_PRODUCT", 75, 78], ["TRB", "GENE_OR_GENE_PRODUCT", 83, 86], ["UMI consensuses", "DNA", 10, 25], ["V and J genomic templates", "DNA", 42, 67], ["TRA and TRB locus", "DNA", 75, 92], ["Resulting UMI consensuses", "PROBLEM", 0, 25], ["mixcr", "TEST", 128, 133], ["TRA", "ANATOMY", 75, 78]]], ["See Table S1 for the number of cells, UMIs and unique clonotypes for each sample.TCR repertoire data analysisIdentification of clonotypes with active dynamics.", [["cells", "ANATOMY", 31, 36], ["sample", "ANATOMY", 74, 80], ["TCR", "CHEMICAL", 81, 84], ["cells", "CELL", 31, 36], ["TCR", "GENE_OR_GENE_PRODUCT", 81, 84], ["UMIs", "CELL_TYPE", 38, 42], ["TCR", "PROTEIN", 81, 84], ["UMIs", "PROBLEM", 38, 42], ["each sample", "TEST", 69, 80], ["TCR repertoire data analysis", "TEST", 81, 109]]], ["Principal component analysis (PCA) of clonal trajectories was performed as described before [23] .", [["Principal component analysis", "TEST", 0, 28], ["clonal trajectories", "TEST", 38, 57]]], ["First we selected clones which were present among the top 1000 abundant in any of post-infection PBMC repertoires, including biological replicates, i.e. considered clone abundant if it was found within top 1000 most abundant clonotypes in at least one of the replicate samples at one timepoint.", [["PBMC", "ANATOMY", 97, 101], ["samples", "ANATOMY", 269, 276], ["PBMC", "CELL", 97, 101], ["clone", "CELL", 164, 169], ["post-infection PBMC repertoires", "CELL_TYPE", 82, 113], ["PBMC repertoires", "TEST", 97, 113], ["abundant", "OBSERVATION_MODIFIER", 216, 224], ["clonotypes", "OBSERVATION", 225, 235]]], ["Next, for each such abundant clone we calculated its frequency at each post-infection timepoint and divided this frequency by the maximum frequency of this clone for normalization.", [["clone", "ANATOMY", 29, 34], ["clone", "CELL", 29, 34], ["clone", "CELL", 156, 161], ["each such abundant clone", "PROBLEM", 10, 34], ["this clone", "TREATMENT", 151, 161]]], ["Then we performed PCA on the resulting normalized clonal trajectory matrix and identified three clusters of trajectories with hierarchical clustering with average linkage, using Euclidean distances between trajectories.", [["matrix", "CELLULAR_COMPONENT", 68, 74], ["PCA", "TREATMENT", 18, 21], ["hierarchical clustering", "OBSERVATION", 126, 149]]], ["We identify statistically significant contractions and expansions with edgeR as previously described [24] , using FDR adjusted p < 0.01 and log 2 fold change threshold of 1.", [["edgeR", "PROTEIN", 71, 76], ["significant contractions and expansions with edgeR", "PROBLEM", 26, 76], ["FDR", "TEST", 114, 117], ["log 2 fold change threshold", "TEST", 140, 167], ["significant", "OBSERVATION_MODIFIER", 26, 37], ["contractions", "OBSERVATION", 38, 50], ["expansions", "OBSERVATION_MODIFIER", 55, 65]]], ["NoisET implements the Bayesian detection method described in [28] .", [["NoisET", "DNA", 0, 6]]], ["Briefly, a two-step noise model accounting for cell sampling and expression noise is inferred from replicates, and a second model of expansion is learned from the two timepoints to be compared.", [["cell", "ANATOMY", 47, 51], ["cell", "CELL", 47, 51], ["cell sampling", "TEST", 47, 60], ["expression noise", "PROBLEM", 65, 81], ["expansion", "OBSERVATION", 133, 142]]], ["The procedure outputs the posterior probability of expansion or contraction, and the median estimated log 2 fold change, whose thresholds are set to 0.05 and 1 respectively.TCR repertoire data analysisMapping of COVID-19 associated TCRs to the MIRA database.", [["TCR", "CHEMICAL", 173, 176], ["TCR", "GENE_OR_GENE_PRODUCT", 173, 176], ["TCRs", "GENE_OR_GENE_PRODUCT", 232, 236], ["TCR", "PROTEIN", 173, 176], ["COVID-19", "DNA", 212, 220], ["TCRs", "PROTEIN", 232, 236], ["The procedure", "TREATMENT", 0, 13], ["the median estimated log 2 fold change", "TREATMENT", 81, 119], ["COVID", "TEST", 212, 217], ["posterior", "OBSERVATION_MODIFIER", 26, 35], ["expansion", "OBSERVATION", 51, 60], ["contraction", "OBSERVATION_MODIFIER", 64, 75]]], ["TCRbeta sequences from T cells specific for SARS-CoV-2 peptide pools MIRA (Im-muneCODE release 2) were downloaded from https: //clients.adaptivebiotech.com/pub/covid-2020.", [["T cells", "ANATOMY", 23, 30], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 0, 7], ["T cells", "CELL", 23, 30], ["TCRbeta sequences", "DNA", 0, 17], ["T cells", "CELL_TYPE", 23, 30], ["TCRbeta sequences", "TEST", 0, 17], ["T cells", "TEST", 23, 30], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["MIRA (Im-muneCODE release", "TREATMENT", 69, 94]]], ["V and J genomic templates were aligned to TCR nucleotide sequences from the MIRA database using mixcr 2.1.11.", [["TCR", "CHEMICAL", 42, 45], ["nucleotide", "CHEMICAL", 46, 56], ["V", "GENE_OR_GENE_PRODUCT", 0, 1], ["TCR", "GENE_OR_GENE_PRODUCT", 42, 45], ["V and J genomic templates", "DNA", 0, 25], ["TCR nucleotide sequences", "DNA", 42, 66], ["J genomic templates", "TREATMENT", 6, 25], ["TCR nucleotide sequences", "TEST", 42, 66], ["mixcr", "TEST", 96, 101]]], ["We consider a TCRbeta from MIRA matched to a TCRbeta from our data, if it had the same V and J and at most one mismatch in CDR3 amino acid sequence.", [["amino acid", "CHEMICAL", 128, 138], ["amino acid", "CHEMICAL", 128, 138], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 14, 21], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 45, 52], ["amino acid", "AMINO_ACID", 128, 138], ["TCRbeta", "PROTEIN", 14, 21], ["TCRbeta", "PROTEIN", 45, 52], ["CDR3 amino acid sequence", "PROTEIN", 123, 147], ["CDR3 amino acid sequence", "TEST", 123, 147]]], ["We consider a TCRbeta sequence mapped to an epitope if it has at least two identical or highly similar (same V, J and up to one mismatch in CDR3 amino acid sequence) TCRbeta clonotypes reactive for this epitope in the MIRA database.TCR repertoire data analysisComputational alpha/beta pairing by clonal trajectories.", [["amino acid", "CHEMICAL", 145, 155], ["TCR", "CHEMICAL", 232, 235], ["amino acid", "CHEMICAL", 145, 155], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 14, 21], ["amino acid", "AMINO_ACID", 145, 155], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 166, 173], ["TCR", "GENE_OR_GENE_PRODUCT", 232, 235], ["alpha/beta", "GENE_OR_GENE_PRODUCT", 274, 284], ["TCRbeta sequence", "DNA", 14, 30], ["CDR3 amino acid sequence", "PROTEIN", 140, 164], ["TCRbeta clonotypes", "PROTEIN", 166, 184], ["TCR repertoire", "PROTEIN", 232, 246], ["a TCRbeta sequence", "TREATMENT", 12, 30], ["CDR3 amino acid sequence", "TEST", 140, 164], ["TCRbeta clonotypes reactive", "PROBLEM", 166, 193], ["this epitope", "PROBLEM", 198, 210], ["TCR repertoire data", "TEST", 232, 251], ["alpha/beta pairing", "TREATMENT", 274, 292], ["reactive", "OBSERVATION_MODIFIER", 185, 193]]], ["Computational alpha/beta pairing was performed as described in [23] .", [["alpha/beta", "GENE_OR_GENE_PRODUCT", 14, 24], ["Computational alpha/beta pairing", "TREATMENT", 0, 32]]], ["For each TCRbeta we determine the TCRalpha with the closest clonal trajectory (Tables S3 and S5 ).", [["TCRbeta", "GENE_OR_GENE_PRODUCT", 9, 16], ["TCRalpha", "GENE_OR_GENE_PRODUCT", 34, 42], ["TCRbeta", "PROTEIN", 9, 16], ["TCRalpha", "PROTEIN", 34, 42]]], ["We observe no stringent pairings between TCRbeta and TCRbeta motifs with exception of two contracting CD8 TCRbeta clusters: TRBV7-2/TRBJ1-2 NQKLIANQF-associated clones from donor M paired to TRAV21/TRAJ40 alphas from the same cluster (CASSLEDTNYGYTF-CAVHSSGTYKYIF and CASSLEDTIYGYTF-CAALTSGTYKYIF), and TRBV7-9/TRBJ2-3 beta cluster paired to largest alpha cluster (CASSPTGRGRTDTQYF-CAYRSGGSEKLVF and CASSPTGRGGTDTQYF-CAYRRPGGEKLTF).TCR repertoire data analysisComputational prediction of HLA-types.", [["TCR", "CHEMICAL", 432, 435], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 41, 48], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 53, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 106, 113], ["TRBV7-2", "GENE_OR_GENE_PRODUCT", 124, 131], ["TRBJ1-2", "GENE_OR_GENE_PRODUCT", 132, 139], ["NQKLIANQF", "GENE_OR_GENE_PRODUCT", 140, 149], ["TRAV21", "GENE_OR_GENE_PRODUCT", 191, 197], ["TRAJ40 alphas", "GENE_OR_GENE_PRODUCT", 198, 211], ["CASSLEDTIYGYTF-CAALTSGTYKYIF", "GENE_OR_GENE_PRODUCT", 268, 296], ["TRBV7-9", "GENE_OR_GENE_PRODUCT", 303, 310], ["TRBJ2-3 beta", "GENE_OR_GENE_PRODUCT", 311, 323], ["TCR", "GENE_OR_GENE_PRODUCT", 432, 435], ["TCRbeta and TCRbeta motifs", "DNA", 41, 67], ["CD8 TCRbeta clusters", "PROTEIN", 102, 122], ["TRBV7", "PROTEIN", 124, 129], ["TRBJ1", "DNA", 132, 137], ["NQKLIANQF", "DNA", 140, 149], ["TRAV21", "DNA", 191, 197], ["TRAJ40 alphas", "DNA", 198, 211], ["CASSLEDTNYGYTF", "DNA", 235, 249], ["CAVHSSGTYKYIF", "DNA", 250, 263], ["CASSLEDTIYGYTF", "DNA", 268, 282], ["CAALTSGTYKYIF", "DNA", 283, 296], ["TRBV7-9", "DNA", 303, 310], ["TRBJ2", "DNA", 311, 316], ["beta cluster", "DNA", 319, 331], ["alpha cluster", "DNA", 350, 363], ["CASSPTGRGRTDTQYF", "DNA", 365, 381], ["CAYRSGGSEKLVF", "DNA", 382, 395], ["CASSPTGRGGTDTQYF", "DNA", 400, 416], ["CAYRRPGGEKLTF", "DNA", 417, 430], ["TCR", "PROTEIN", 432, 435], ["stringent pairings", "PROBLEM", 14, 32], ["TCRbeta and TCRbeta motifs", "TREATMENT", 41, 67], ["TRBV7", "TEST", 124, 129], ["TRBJ1", "TEST", 132, 137], ["NQKLIANQF", "TEST", 140, 149], ["donor M", "TEST", 173, 180], ["TRAV21", "TEST", 191, 197], ["CASSLEDTNYGYTF", "TEST", 235, 249], ["CASSLEDTIYGYTF", "TEST", 268, 282], ["TRBV7", "TEST", 303, 308], ["TRBJ2", "TEST", 311, 316], ["CASSPTGRGRTDTQYF", "TEST", 365, 381], ["HLA", "TEST", 488, 491]]], ["To predict HLA-types from TCR repertoires of COVID-19 cohort we used sets of HLA-associated TCR sequences from [38] .", [["TCR", "GENE_OR_GENE_PRODUCT", 26, 29], ["HLA", "GENE_OR_GENE_PRODUCT", 77, 80], ["TCR", "GENE_OR_GENE_PRODUCT", 92, 95], ["TCR", "PROTEIN", 26, 29], ["TCR sequences", "DNA", 92, 105], ["HLA", "TEST", 11, 14], ["COVID", "TEST", 45, 50], ["HLA", "TEST", 77, 80], ["TCR sequences", "TEST", 92, 105]]], ["We use TCRbeta repertoires of 666 donors from cohort from [35] , for which HLA-typing information is available in ref.", [["TCRbeta", "GENE_OR_GENE_PRODUCT", 7, 14], ["donors", "ORGANISM", 34, 40], ["TCRbeta repertoires", "PROTEIN", 7, 26]]], ["[38] as a training set to fit logistic regression model, where presence or absense of given HLAallele is an outcome, and the number of allele-associated sequences in repertoire, as well as the total number of unique sequences in the repertoire, are the predictors.TCR repertoire data analysisA separate logistic regression model was fitted for each set of HLA-associated sequences from ref.", [["TCR", "CHEMICAL", 264, 267], ["TCR", "GENE_OR_GENE_PRODUCT", 264, 267], ["allele", "DNA", 135, 141], ["TCR", "PROTEIN", 264, 267], ["HLA-associated sequences", "DNA", 356, 380], ["a training", "TREATMENT", 8, 18]]], ["[38] , and then used to predict the probability p that a donor from the COVID-19 cohort has this allele.", [["allele", "DNA", 97, 103], ["a donor from the COVID", "TREATMENT", 55, 77]]], ["Donors with p < 0.2 were considered negative for a given allele.Data availabilityRaw sequencing data are deposited to the Short Read Archive (SRA) accession: PRJNA633317.", [["allele", "DNA", 57, 63], ["Short Read Archive (SRA) accession", "DNA", 122, 156], ["Raw sequencing data", "TEST", 81, 100]]], ["Processed TCRalpha and TCRbeta repertoire datasets, resulting repertoires of SARS-CoV-2-reactive clones, and raw data preprocessing instructions can be accessed from: https: //github.com/pogorely/Minervina_COVID.", [["TCRalpha", "GENE_OR_GENE_PRODUCT", 10, 18], ["TCRbeta", "GENE_OR_GENE_PRODUCT", 23, 30], ["clones", "CELL", 97, 103], ["TCRalpha", "PROTEIN", 10, 18], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["reactive clones", "PROBLEM", 88, 103], ["TCRalpha", "OBSERVATION", 10, 18], ["reactive clones", "OBSERVATION", 88, 103]]]], "PMC3986061": [["IntroductionLaboratory testing is the single highest-volume medical activity [1].", [["IntroductionLaboratory testing", "TEST", 0, 30]]], ["Its main role is to help adjust the level of clinical suspicion of a diagnosis to help rule it in or out; it is also used for disease monitoring.", [["disease monitoring", "TEST", 126, 144], ["main", "OBSERVATION_MODIFIER", 4, 8]]], ["Information that feeds into the clinical suspicion\u2014including the age and gender of the patient, prior diagnoses, and prior laboratory results\u2014thus may also influence the test result.IntroductionIn principle, this relationship can be used to improve laboratory testing by making it possible to estimate the pre-test probability of getting a given test result before ordering the test, and, in the limit, to reduce test utilization without adversely affecting patient outcomes.", [["patient", "ORGANISM", 87, 94], ["patient", "ORGANISM", 458, 465], ["patient", "SPECIES", 87, 94], ["patient", "SPECIES", 458, 465], ["the test result", "TEST", 166, 181], ["laboratory testing", "TEST", 249, 267], ["the test", "TEST", 374, 382]]], ["Indeed, ordering fewer tests, where warranted, might benefit outcomes by saving the patient the burden of following up false positives (or negatives) [2]\u2013[4].IntroductionConceptually, the relationship between clinical suspicion and pre-test probability is used routinely to help set guidelines regarding when and when not to order a given test.", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91], ["ordering fewer tests", "TEST", 8, 28], ["a given test", "TEST", 331, 343]]], ["For example, the pre-test probability of Lyme serology being positive given a targetoid rash is high enough that, given the test's sensitivity and specificity, ordering the test is contraindicated [5].", [["Lyme", "DISEASE", 41, 45], ["rash", "DISEASE", 88, 92], ["Lyme serology", "TEST", 41, 54], ["a targetoid rash", "PROBLEM", 76, 92], ["the test's sensitivity", "TEST", 120, 142], ["ordering the test", "TEST", 160, 177]]], ["Because of the large number of tests and clinical scenarios that exist, and in light of evidence from across medicine that utilization of laboratory testing can be improved [1], [6], it is of interest to understand whether analyzing large clinical databases using the robust application of standard statistical techniques can turn this relationship into actionable decision-support rules\u2014or whether progress toward better laboratory utilization might instead lie elsewhere.IntroductionWe sought to test the limits of rule-mining for this purpose.", [["tests", "TEST", 31, 36], ["laboratory testing", "TEST", 138, 156], ["standard statistical techniques", "TREATMENT", 290, 321], ["large", "OBSERVATION_MODIFIER", 15, 20]]], ["We addressed this question using generalized linear modeling (GLM), a generalized form of linear regression [7], and, for comparison, classification trees (CT) [8], [9].Generalized linear modeling (GLM) ::: MethodsWe sought to identify simple, robust subsets of our input data to evaluate as linear predictors (\u201crules\u201d) for whether a test result would be normal or abnormal.", [["generalized linear modeling (GLM)", "PROBLEM", 33, 66], ["linear regression", "PROBLEM", 90, 107], ["our input data", "TEST", 262, 276], ["a test result", "TEST", 332, 345], ["linear", "OBSERVATION_MODIFIER", 90, 96], ["linear", "OBSERVATION_MODIFIER", 181, 187]]], ["To do this, we used GLM twice: first to find rules based on a particular training set and a second time to find rules based on just those items that were common to rules found from a number of different training sets (to avoid overfitting any one training set).", [["a particular training", "TREATMENT", 60, 81], ["different training sets", "TREATMENT", 193, 216]]], ["We did this as follows, for each test of interest (the response variable or \u201cresponse\u201d).Generalized linear modeling (GLM) ::: MethodsWe first excluded those input variables (\u201cfeatures\u201d) that appeared with fewer than 5 percent of the response.", [["linear", "OBSERVATION_MODIFIER", 100, 106]]], ["We then temporarily set aside the most common features (those of the complete blood count and basic metabolic panel) as well as age and gender, and searched the remaining items for frequent featuresets (using the Apriori algorithm [10], [11]).", [["blood", "ANATOMY", 78, 83], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["the complete blood count", "TEST", 65, 89], ["basic metabolic panel", "TEST", 94, 115], ["frequent featuresets", "PROBLEM", 181, 201], ["the Apriori algorithm", "TREATMENT", 209, 230]]], ["This set-aside/add-back approach sped the search for featuresets without loss of comprehensiveness.Generalized linear modeling (GLM) ::: MethodsWe used each featureset to create a model for the test of interest using R's glm function (with the family argument set to \u201cBinomial\u201d).", [["featuresets", "PROBLEM", 53, 64], ["loss of comprehensiveness", "PROBLEM", 73, 98], ["MethodsWe", "TREATMENT", 137, 146], ["the test", "TEST", 190, 198], ["R's glm function", "TEST", 217, 233], ["linear", "OBSERVATION_MODIFIER", 111, 117]]], ["We used backward feature elimination to remove non-significant features one at a time from the featureset (using a significance threshold p-value of 1\u00d710\u22125; see below) until the only features that remained were all significantly correlated with the response.", [["non-significant features", "PROBLEM", 47, 71]]], ["We also removed features that are used to calculate the result for the test of interest\u2014e.g., CD4 and CD8 count for T-cell count, which is the sum of CD4 and CD8\u2014for all but proof-of-principle runs.Generalized linear modeling (GLM) ::: MethodsThe significance threshold was corrected for multiple comparisons by dividing the traditional threshold of p = 0.05 by the product of the total number of tests considered and the average number of rules generated for each test.", [["T-cell", "ANATOMY", 116, 122], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["T-cell", "CELL", 116, 122], ["CD4", "GENE_OR_GENE_PRODUCT", 150, 153], ["CD8", "GENE_OR_GENE_PRODUCT", 158, 161], ["CD4", "PROTEIN", 94, 97], ["CD8", "PROTEIN", 102, 105], ["CD4", "PROTEIN", 150, 153], ["CD8", "PROTEIN", 158, 161], ["the test of interest\u2014e", "TEST", 67, 89], ["CD4", "TEST", 94, 97], ["CD8 count", "TEST", 102, 111], ["T-cell count", "TEST", 116, 128], ["CD4", "TEST", 150, 153], ["Generalized linear modeling (GLM)", "PROBLEM", 198, 231], ["Methods", "TREATMENT", 236, 243], ["tests", "TEST", 397, 402], ["each test", "TEST", 460, 469], ["linear", "OBSERVATION_MODIFIER", 210, 216]]], ["The combined total number of features (in-house tests plus sendout tests plus diagnoses) was 170+81+434 = 685.", [["total", "OBSERVATION_MODIFIER", 13, 18], ["number", "OBSERVATION_MODIFIER", 19, 25]]], ["The average number of rules after application of GLM for the first time for each test is 6.", [["application of GLM", "TREATMENT", 34, 52], ["each test", "TEST", 76, 85], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18]]], ["Thus our threshold p-value was 0.05/(6*685) = 1.2\u00d710\u22125, which we rounded to 1\u00d710\u22125.Generalized linear modeling (GLM) ::: MethodsWe constructed a model for the result by running glm a second time on a training set (see below) based on this reduced featureset.", [["our threshold p-value", "TEST", 5, 26], ["a training set", "TREATMENT", 198, 212], ["this reduced featureset", "PROBLEM", 234, 257], ["rounded", "OBSERVATION_MODIFIER", 65, 72], ["linear", "OBSERVATION_MODIFIER", 95, 101]]], ["Of note, there was no guarantee that any feature would be significantly correlated (p\u22641\u00d710\u22125) or that there would be enough instances (glm's threshold was 200) of the test appearing with all features of even the reduced featureset for glm to produce a model.", [["glm", "PROTEIN", 235, 238], ["glm's threshold", "TEST", 135, 150], ["the test", "TEST", 163, 171], ["the reduced featureset", "PROBLEM", 208, 230]]], ["When feature elimination resulted in no significant features or too few instances, no model was constructed.", [["significant features", "PROBLEM", 40, 60], ["no", "UNCERTAINTY", 37, 39]]], ["We scored models using PPV, NPV, and ROC AUC.Generalized linear modeling (GLM) ::: MethodsWe were interested only in models that were robust to the size and choice of training set.", [["PPV", "TEST", 23, 26], ["NPV", "TEST", 28, 31], ["ROC AUC", "TEST", 37, 44], ["Generalized linear modeling (GLM)", "PROBLEM", 45, 78], ["Methods", "TREATMENT", 83, 90], ["linear", "OBSERVATION_MODIFIER", 57, 63], ["size", "OBSERVATION_MODIFIER", 148, 152]]], ["For each split, we ran the above process 10 times and found the number of rules with AUC\u22650.75.", [["AUC", "TEST", 85, 88]]], ["We decided on using a 60-40 split for downstream analyses as this split generated a total number of rules comparable to 70-30 and 80-20 splits but with less training data (Fig. 1).Generalized linear modeling (GLM) ::: MethodsFinally, for each test of interest, we selected features that appeared in a strict majority of rules for that test and reran glm using only those features.", [["reran glm", "CELL_LINE", 344, 353], ["downstream analyses", "TEST", 38, 57], ["that test", "TEST", 330, 339], ["linear", "OBSERVATION_MODIFIER", 192, 198]]], ["This made rules both simpler and more robust by removing features whose presence was contingent on a particular choice of training or test set.Classification and Regression Trees (CART) ::: MethodsFor each of the inhouse and sendout tests we used CART, implemented as RPART in R (rpart v3.1-50; CRAN.R-project.org/package = rpart), to predict the response from all input features, using 60\u223640 training\u2236test-set splits.", [["test set", "TEST", 134, 142], ["sendout tests", "TEST", 225, 238], ["CART", "TREATMENT", 247, 251], ["RPART", "TEST", 268, 273], ["rpart", "TEST", 280, 285]]], ["We fixed some of the metrics (see below) that were used in building the final tree.", [["tree", "ANATOMY_MODIFIER", 78, 82]]], ["The CART grows classification tree in two stages.", [["CART", "DNA", 4, 8], ["tree", "OBSERVATION_MODIFIER", 30, 34]]], ["In stage one, a tree is grown by finding a feature which best splits the data into two groups.", [["stage one", "OBSERVATION_MODIFIER", 3, 12]]], ["Then, in top-down fashion, these two subgroups are further divided in a recursive manner until the subgroups reach a minimum size (minsplit = 20 records) or until no further improvement can be made.", [["size", "OBSERVATION_MODIFIER", 125, 129]]], ["The resulting tree may overfit the training data.", [["the training data", "TEST", 31, 48], ["tree", "OBSERVATION_MODIFIER", 14, 18]]], ["To avoid this, cross-validation (xval = 10; 10-fold cross-validation) was used in the second stage by pruning the tree.", [["cross-validation", "TEST", 15, 31], ["fold cross-validation)", "TREATMENT", 47, 69], ["tree", "ANATOMY_MODIFIER", 114, 118]]], ["We fixed the maximum depth (maxdepth) of the tree, i.e., the maximum number of branchings from stem to leaf, to be 20.", [["stem", "ANATOMY", 95, 99], ["leaf", "ANATOMY", 103, 107], ["stem", "TISSUE", 95, 99], ["leaf", "ORGAN", 103, 107], ["maximum", "OBSERVATION_MODIFIER", 13, 20], ["depth", "OBSERVATION_MODIFIER", 21, 26], ["tree", "ANATOMY_MODIFIER", 45, 49], ["maximum", "OBSERVATION_MODIFIER", 61, 68], ["number", "OBSERVATION_MODIFIER", 69, 75], ["stem", "ANATOMY_MODIFIER", 95, 99]]], ["The final models were tested on the test data and performance statistics are found.", [["the test data", "TEST", 32, 45], ["performance statistics", "TEST", 50, 72]]], ["We repeated model-building 10 times for each test and summarized the statistics.Classification and Regression Trees (CART) ::: MethodsData-processing was performed in Python (Enthought Canopy Python version 2.7.3.", [["each test", "TEST", 40, 49]]], ["R (version 2.15.3) was used for statistical analysis and reports generation.ResultsTo determine how well sendout and in-house test results can be anticipated based on basic information available in the medical record, we used two independent methods\u2014generalized linear modeling (GLM) and classification and regression trees (CART)\u2014to build simple, robust test-result predictors and then evaluated the performance of these predictors according to the standard clinical metrics of positive predictive value (PPV) and negative predictive value (NPV), as well as sensitivity and specificity via the receiver-operator curve (ROC) area under the curve (AUC).ResultsAs proof of principle for GLM, we first tested it on the anion gap, a result calculated by subtracting the serum concentrations of the anions chloride and bicarbonate from those of the cations sodium and potassium, and confirmed that our methods found a rule for elevated anion gap based on these four items.ResultsWe next applied GLM to 81 sendout tests ordered regularly at our hospital.", [["serum", "ANATOMY", 766, 771], ["anions chloride", "CHEMICAL", 794, 809], ["bicarbonate", "CHEMICAL", 814, 825], ["sodium", "CHEMICAL", 852, 858], ["potassium", "CHEMICAL", 863, 872], ["chloride", "CHEMICAL", 801, 809], ["bicarbonate", "CHEMICAL", 814, 825], ["sodium", "CHEMICAL", 852, 858], ["potassium", "CHEMICAL", 863, 872], ["anion", "SIMPLE_CHEMICAL", 716, 721], ["serum", "ORGANISM_SUBSTANCE", 766, 771], ["chloride", "SIMPLE_CHEMICAL", 801, 809], ["bicarbonate", "SIMPLE_CHEMICAL", 814, 825], ["cations", "SIMPLE_CHEMICAL", 844, 851], ["sodium", "SIMPLE_CHEMICAL", 852, 858], ["potassium", "SIMPLE_CHEMICAL", 863, 872], ["anion", "SIMPLE_CHEMICAL", 931, 936], ["statistical analysis", "TEST", 32, 52], ["generalized linear modeling (GLM)", "PROBLEM", 250, 283], ["PPV", "TEST", 506, 509], ["NPV", "TEST", 542, 545], ["the receiver-operator curve", "TEST", 591, 618], ["the anion gap", "TEST", 712, 725], ["the anions chloride", "TREATMENT", 790, 809], ["bicarbonate", "TREATMENT", 814, 825], ["the cations sodium", "TEST", 840, 858], ["potassium", "TREATMENT", 863, 872], ["our methods", "TEST", 893, 904], ["elevated anion gap", "PROBLEM", 922, 940], ["GLM", "TEST", 990, 993], ["tests", "TEST", 1008, 1013], ["anion gap", "OBSERVATION", 931, 940]]], ["GLM generated rules for just 11 of these tests.", [["these tests", "TEST", 35, 46]]], ["For the remaining tests, either no recent diagnosis or in-house test result (or age or gender) was sufficiently correlated with the sendout test result, or there were not enough instances in which correlated items appeared with the result, to generate a rule.", [["the remaining tests", "TEST", 4, 23], ["the sendout test", "TEST", 128, 144]]], ["Only two tests\u2014for high corticotropin (ACTH) and for low ceruloplasmin\u2014had NPV\u22650.95.", [["corticotropin", "GENE_OR_GENE_PRODUCT", 24, 37], ["ACTH", "GENE_OR_GENE_PRODUCT", 39, 43]]], ["Of these, ceruloplasmin had a PPV\u22650.94.", [["ceruloplasmin", "GENE_OR_GENE_PRODUCT", 10, 23], ["ceruloplasmin", "PROTEIN", 10, 23], ["ceruloplasmin", "TEST", 10, 23], ["a PPV", "TEST", 28, 33]]], ["The mean AUC for all rules was 0.69, with models for only three tests having an average AUC\u22650.75 over 10 repeat runs.", [["The mean AUC", "TEST", 0, 12], ["three tests", "TEST", 58, 69], ["an average AUC", "TEST", 77, 91], ["repeat runs", "TEST", 105, 116]]], ["Removal of features that did not appear in a majority of rules had essentially no effect on these AUCs (difference in mean AUC\u22640.02).ResultsCART generated rules for 60 tests.", [["Removal", "TREATMENT", 0, 7], ["these AUCs", "TEST", 92, 102], ["mean AUC", "TEST", 118, 126], ["60 tests", "TEST", 165, 173], ["no", "UNCERTAINTY", 79, 81], ["effect", "OBSERVATION_MODIFIER", 82, 88]]], ["However, the AUC for most of these rules was low, with only five tests having AUC\u22650.75: free T3, alpha-macroglobulin, CA27-29, hyaluronic acid, and alpha fetoprotein (AUC 0.75\u20130.79).ResultsWe next applied GLM to in-house tests.", [["CA27-29, hyaluronic acid", "CHEMICAL", 118, 142], ["T3", "SIMPLE_CHEMICAL", 93, 95], ["alpha-macroglobulin", "SIMPLE_CHEMICAL", 97, 116], ["CA27-29", "SIMPLE_CHEMICAL", 118, 125], ["hyaluronic acid", "SIMPLE_CHEMICAL", 127, 142], ["alpha fetoprotein", "GENE_OR_GENE_PRODUCT", 148, 165], ["alpha fetoprotein", "PROTEIN", 148, 165], ["the AUC", "TEST", 9, 16], ["AUC", "TEST", 78, 81], ["free T3", "TEST", 88, 95], ["alpha-macroglobulin", "TEST", 97, 116], ["CA27", "TEST", 118, 122], ["hyaluronic acid", "TEST", 127, 142], ["alpha fetoprotein", "TEST", 148, 165], ["AUC", "TEST", 167, 170], ["alpha fetoprotein", "ANATOMY", 148, 165]]], ["A number of rules exhibited a high PPV (the probability of seeing an abnormal value given a prediction of an abnormal value by the rule) or NPV (the probability of seeing a normal value given prediction of a normal value).", [["a high PPV", "PROBLEM", 28, 38], ["an abnormal value", "PROBLEM", 66, 83], ["an abnormal value", "PROBLEM", 106, 123], ["NPV", "PROBLEM", 140, 143]]], ["These were mostly components of the complete blood count (CBC) and metabolic panels.", [["blood", "ANATOMY", 45, 50], ["blood", "ORGANISM_SUBSTANCE", 45, 50], ["the complete blood count", "TEST", 32, 56], ["CBC", "TEST", 58, 61], ["metabolic panels", "TEST", 67, 83]]], ["Interestingly, the predictive power of these rules was almost exclusively based on a previous measurement of the test in question: in other words, the best rules were for repeat tests, and the best predictor of a result being normal or abnormal was whether it had been normal or abnormal within the previous seven days.", [["the test", "TEST", 109, 117], ["repeat tests", "TEST", 171, 183]]], ["For example, the NPV for a low red blood cell count was 0.95 (with PPV = 0.75), with a rule that depended most on the previous red blood cell count also having been low, and the PPV for high total calcium was 0.98 (NPV = 0.76) and based exclusively on the previous total calcium having been high.ResultsFor comparison, we applied CART to in-house tests, again including in the input data the most recent result for that test if performed within a week of the order.", [["red blood cell", "ANATOMY", 31, 45], ["red blood cell", "ANATOMY", 127, 141], ["calcium", "CHEMICAL", 197, 204], ["calcium", "CHEMICAL", 271, 278], ["calcium", "CHEMICAL", 197, 204], ["calcium", "CHEMICAL", 271, 278], ["red blood cell", "CELL", 31, 45], ["red blood cell", "CELL", 127, 141], ["calcium", "SIMPLE_CHEMICAL", 197, 204], ["calcium", "SIMPLE_CHEMICAL", 271, 278], ["the NPV", "TEST", 13, 20], ["a low red blood cell count", "TEST", 25, 51], ["PPV", "TEST", 67, 70], ["the previous red blood cell count", "TEST", 114, 147], ["the PPV", "TEST", 174, 181], ["high total calcium", "TEST", 186, 204], ["NPV", "TEST", 215, 218], ["the previous total calcium", "TEST", 252, 278], ["CART", "TREATMENT", 330, 334], ["low", "OBSERVATION_MODIFIER", 165, 168]]], ["Again, a number of rules exhibited a high PPV (\u22650.95), and again these were often tests of the CBC and metabolic panels, with rules based almost exclusively on a previous abnormal value.", [["CBC", "CELL", 95, 98], ["a high PPV", "PROBLEM", 35, 45], ["the CBC", "TEST", 91, 98], ["metabolic panels", "TEST", 103, 119], ["a previous abnormal value", "PROBLEM", 160, 185], ["metabolic panels", "OBSERVATION", 103, 119]]], ["Examples included low white blood cell count (WBC; PPV = 0.97, NPV = 0.79), platelet count (0.95, 0.88), and serum sodium (0.96, 0.65), and high total calcium (0.99, 0.67), mean corpuscular volume (0.98, 0.84), and iron (0.97, 0.56) all of which were determined almost exclusively from the previous value being low or high (Table 1).", [["white blood cell", "ANATOMY", 22, 38], ["platelet", "ANATOMY", 76, 84], ["serum", "ANATOMY", 109, 114], ["corpuscular", "ANATOMY", 178, 189], ["sodium", "CHEMICAL", 115, 121], ["calcium", "CHEMICAL", 151, 158], ["iron", "CHEMICAL", 215, 219], ["sodium", "CHEMICAL", 115, 121], ["calcium", "CHEMICAL", 151, 158], ["iron", "CHEMICAL", 215, 219], ["white blood cell", "CELL", 22, 38], ["platelet", "CELL", 76, 84], ["serum", "ORGANISM_SUBSTANCE", 109, 114], ["sodium", "SIMPLE_CHEMICAL", 115, 121], ["calcium", "SIMPLE_CHEMICAL", 151, 158], ["corpuscular", "ORGANISM_SUBSTANCE", 178, 189], ["iron", "SIMPLE_CHEMICAL", 215, 219], ["low white blood cell count", "PROBLEM", 18, 44], ["WBC", "TEST", 46, 49], ["PPV", "TEST", 51, 54], ["NPV", "TEST", 63, 66], ["platelet count", "TEST", 76, 90], ["serum sodium", "TEST", 109, 121], ["high total calcium", "TEST", 140, 158], ["mean corpuscular volume", "TEST", 173, 196], ["iron", "TEST", 215, 219]]], ["Overall, there was good agreement in PPV between GLM and CART for tests for which both methods found rules, but CART outperformed GLM noticeably in NPV (Fig. 2).DiscussionThe growing availability of large clinical databases has raised interest in the possibility of using systematic rule-mining for clinical decision support [12]\u2013[15].", [["tests", "TEST", 66, 71], ["NPV", "TEST", 148, 151]]], ["One popular and well characterized approach has been logistic regression [16]\u2013[18], a special case of generalized linear modeling (GLM).", [["logistic regression", "TEST", 53, 72], ["generalized linear modeling (GLM)", "PROBLEM", 102, 135], ["generalized", "OBSERVATION_MODIFIER", 102, 113], ["linear", "OBSERVATION_MODIFIER", 114, 120]]], ["Researchers have applied these approaches for diverse health-related purposes including prediction of cardiovascular risk [19], mortality in head trauma [18], texture analysis of magnetic resonance images [16], and many other applications [17], [20], [21].", [["cardiovascular", "ANATOMY", 102, 116], ["head", "ANATOMY", 141, 145], ["trauma", "DISEASE", 146, 152], ["cardiovascular", "ANATOMICAL_SYSTEM", 102, 116], ["head", "ORGANISM_SUBDIVISION", 141, 145], ["[20]", "SIMPLE_CHEMICAL", 245, 249], ["cardiovascular risk", "TEST", 102, 121], ["mortality in head trauma", "PROBLEM", 128, 152], ["texture analysis", "TEST", 159, 175], ["magnetic resonance images", "TEST", 179, 204], ["head", "ANATOMY", 141, 145]]], ["However, we note that GLM does not easily incorporate missing values, as it removes records with missing features; a feature will be \u201cmissing\u201d for any record in which that test (the feature) was not performed.DiscussionOther methods, such as classification and regression trees (CART) and artificial neural networks [18], have also been applied.", [["missing features", "PROBLEM", 97, 113], ["artificial neural networks", "TREATMENT", 289, 315]]], ["Most of these studies were limited in scope to predicting risk of a particular diagnosis.", [["these studies", "TEST", 8, 21]]], ["Harper [22] compared four classification techniques (regression, CART, artificial neural networks, and discriminant analysis) on four different datasets and concluded that there was no obvious best choice for their data; while CART performed best, regression was fastest and nearly as good.", [["CART", "TREATMENT", 65, 69], ["artificial neural networks", "TREATMENT", 71, 97], ["discriminant analysis", "TEST", 103, 124]]], ["Similar comparative studies on coronary artery disease [20] and Alzheimer disease [23] indicated that newer algorithms such as ANN and random forests [24] have little advantage over simpler, more traditional approaches.", [["coronary artery", "ANATOMY", 31, 46], ["coronary artery disease", "DISEASE", 31, 54], ["Alzheimer disease", "DISEASE", 64, 81], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 31, 46], ["coronary artery disease", "PROBLEM", 31, 54], ["Alzheimer disease", "PROBLEM", 64, 81], ["coronary artery", "ANATOMY", 31, 46]]], ["However, while CART is both a top performer and overcomes GLM's problem with missing values, it is also more computationally intensive and potentially less sensitive to simple algebraic relationships among features (e.g., among sodium, chloride and bicarbonate and the anion gap).", [["sodium, chloride", "CHEMICAL", 228, 244], ["bicarbonate", "CHEMICAL", 249, 260], ["sodium", "CHEMICAL", 228, 234], ["chloride", "CHEMICAL", 236, 244], ["bicarbonate", "CHEMICAL", 249, 260], ["sodium", "SIMPLE_CHEMICAL", 228, 234], ["chloride", "SIMPLE_CHEMICAL", 236, 244], ["bicarbonate", "SIMPLE_CHEMICAL", 249, 260], ["CART", "PROTEIN", 15, 19], ["GLM's problem", "PROBLEM", 58, 71], ["missing values", "PROBLEM", 77, 91], ["sodium", "TEST", 228, 234], ["chloride", "TEST", 236, 244], ["bicarbonate", "TREATMENT", 249, 260], ["the anion gap", "TEST", 265, 278]]], ["Therefore we chose GLM as a well-understood approach with strong performance and excellent speed, and CART as the best-performing complementary approach for purposes of comparison.DiscussionGiven the importance of laboratory testing, we asked how much information regression- or classification tree-based rules could provide in assessing the pre-test probability of a test result being abnormal for 251 commonly ordered in-house and sendout tests at our hospital.DiscussionData-mining can sometimes find spurious correlations, artifacts of the particular partitioning of the data into training and test set.", [["CART", "TREATMENT", 102, 106], ["laboratory testing", "TEST", 214, 232], ["a test result", "TEST", 366, 379]]], ["To avoid such artifacts, we repeated our regression on multiple independent partitions of the data and kept only items that appeared in a majority of the resulting rules.", [["such artifacts", "PROBLEM", 9, 23]]], ["This safeguard also had the effect of simplifying rules by making each rule dependent on a smaller number of items.", [["smaller", "OBSERVATION_MODIFIER", 91, 98]]], ["The rules we found do not exist in a vacuum but are \u201ccontingent\u201d in the sense that they depend on current clinical practice.", [["vacuum", "OBSERVATION", 37, 43]]], ["Certain tests and panels are ordered in patterns.", [["Certain tests and panels", "TEST", 0, 24]]], ["In a sense, contingency is a form of selection bias: there may well be other diagnoses or test result results that correlate with the result for the test of interest that are not routinely measured according to current best practices.", [["the test", "TEST", 145, 153]]], ["As long as one is clear that one is looking for relationships in a current practice process, and not among all things that could possibly be measured, any rules that are discovered will by construction be setting-appropriate.DiscussionBut while our rules appear to be plausible and setting-appropriate, the motivating question behind this study is whether the rules we found could be useful clinically.", [["this study", "TEST", 334, 344], ["clear", "OBSERVATION", 18, 23]]], ["One way to approach this question is by considering the positive and negative predictive value of each rule (PPV and NPV).", [["PPV", "TEST", 109, 112], ["NPV", "TEST", 117, 120]]], ["A PPV of 0.95 means that when a rule suggests that the test result will be abnormal, the result actually will be abnormal 95 percent of the time.", [["A PPV", "TEST", 0, 5], ["the test", "TEST", 51, 59]]], ["A NPV of 0.95 means that when a rule suggests that the test result will be normal, the result actually will be normal 95 percent of the time.DiscussionWe found rules with PPV and/or NPV\u22650.95 (by GLM) for only two tests that are sendouts at our hospital\u2014one of which is ceruloplasmin, which we have previously suggested is overordered via chart review [25].", [["ceruloplasmin", "GENE_OR_GENE_PRODUCT", 269, 282], ["ceruloplasmin", "PROTEIN", 269, 282], ["A NPV", "TEST", 0, 5], ["the test", "TEST", 51, 59], ["PPV", "TEST", 171, 174], ["NPV", "TEST", 182, 185], ["two tests", "TEST", 209, 218]]], ["Interestingly, the main determinant for rules for in-house tests was a normal or abnormal result for the same test within the previous seven days.", [["main", "OBSERVATION_MODIFIER", 19, 23]]], ["Although in this study we did not set out explicitly to make a statement about repeat laboratory testing, the appropriateness of which has been investigated elsewhere [4], these results suggest that repeat laboratory testing within one week does not always add information that could not have been anticipated from the previous result.", [["this study", "TEST", 12, 22], ["repeat laboratory testing", "TEST", 79, 104], ["repeat laboratory testing", "TEST", 199, 224]]], ["Refining this observation using the same unbiased approach we have followed here is potentially an area for future investigation.DiscussionOur results should not be taken as a categorical criticism of repeat testing.", [["future investigation", "TEST", 108, 128], ["repeat testing", "TEST", 201, 215]]], ["First, while the PPV was \u22650.95 in several cases, the NPV was more typically 0.70\u20130.85.", [["the PPV", "TEST", 13, 20], ["the NPV", "TEST", 49, 56]]], ["Therefore use of a rule depends on the subtle distinction of whether the clinical question is \u201cwill the result be abnormal\u201d vs. \u201cwill the result be normal.\u201d", [["abnormal\u201d", "PROBLEM", 114, 123], ["normal", "OBSERVATION", 148, 154]]], ["Thus while the rules we found can inform clinical decision-makers, the information they provide rarely replaces the information obtained from actually performing these tests.DiscussionIt is interesting to note that on average, our simple rules yielded a PPV of 0.84 and an NPV of 0.75.", [["these tests", "TEST", 162, 173], ["a PPV", "TEST", 252, 257], ["an NPV", "TEST", 270, 276]]], ["This means that on average, rules will correctly predict an abnormal laboratory result 5 times out of 6 (5/6\u22480.84) and correctly predict a normal result 3 times out of 4.", [["an abnormal laboratory result", "PROBLEM", 57, 86]]], ["While not good enough to replace testing (especially for rules that depend on previous test results), these observations raise the question of how much better prediction can get.", [["testing", "TEST", 33, 40], ["previous test results", "TEST", 78, 99]]], ["Integration of information not considered in the present study, including vital signs, chief complaints, and physical findings, may improve prediction by these methods.", [["the present study", "TEST", 45, 62], ["vital signs", "TEST", 74, 85]]]], "PMC7202245": [["Reagents, Samples, and Instrumentation ::: ExperimentTris(1,3-diphenyl-1,3-propanedionato)(1,10-phenanthroline)europium(III)(Eu(DPP)3Phen), styrene (St), acrylic acid (AA),2,2\u2032-azobis(isobutyronitrile) (AIBN), andcetyltrimethylammonium (CTMA) were purchased from Tokyo ChemicalIndustry Co. (Tokyo, Japan).", [["ExperimentTris", "CHEMICAL", 43, 57], ["1,3-diphenyl-1,3-propanedionato", "CHEMICAL", 58, 89], ["1,10-phenanthroline", "CHEMICAL", 91, 110], ["europium", "CHEMICAL", 111, 119], ["Eu", "CHEMICAL", 125, 127], ["3Phen", "CHEMICAL", 132, 137], ["styrene", "CHEMICAL", 140, 147], ["St", "CHEMICAL", 149, 151], ["acrylic acid", "CHEMICAL", 154, 166], ["AA", "CHEMICAL", 168, 170], ["2,2\u2032-azobis(isobutyronitrile", "CHEMICAL", 172, 200], ["AIBN", "CHEMICAL", 203, 207], ["andcetyltrimethylammonium", "CHEMICAL", 210, 235], ["CTMA", "CHEMICAL", 237, 241], ["ExperimentTris(1,3-diphenyl-1,3-propanedionato)", "CHEMICAL", 43, 90], ["1,10-phenanthroline", "CHEMICAL", 91, 110], ["europium(III)", "CHEMICAL", 111, 124], ["Eu(DPP)3Phen", "CHEMICAL", 125, 137], ["styrene", "CHEMICAL", 140, 147], ["acrylic acid", "CHEMICAL", 154, 166], ["2,2\u2032-azobis(isobutyronitrile)", "CHEMICAL", 172, 201], ["AIBN", "CHEMICAL", 203, 207], ["andcetyltrimethylammonium", "CHEMICAL", 210, 235], ["CTMA", "CHEMICAL", 237, 241], ["ExperimentTris(1,3-diphenyl-1,3-propanedionato)(1,10-phenanthroline)europium(III)", "SIMPLE_CHEMICAL", 43, 124], ["Eu(DPP)3Phen", "SIMPLE_CHEMICAL", 125, 137], ["styrene", "SIMPLE_CHEMICAL", 140, 147], ["St)", "SIMPLE_CHEMICAL", 149, 152], ["acrylic acid", "SIMPLE_CHEMICAL", 154, 166], ["AA", "SIMPLE_CHEMICAL", 168, 170], ["2,2\u2032-azobis(isobutyronitrile)", "SIMPLE_CHEMICAL", 172, 201], ["AIBN", "SIMPLE_CHEMICAL", 203, 207], ["andcetyltrimethylammonium", "SIMPLE_CHEMICAL", 210, 235], ["CTMA", "SIMPLE_CHEMICAL", 237, 241], ["Samples", "TEST", 10, 17], ["Instrumentation", "TEST", 23, 38], ["ExperimentTris", "TEST", 43, 57], ["diphenyl", "TREATMENT", 62, 70], ["acrylic acid (AA)", "TREATMENT", 154, 171], ["2,2\u2032-azobis(isobutyronitrile)", "TREATMENT", 172, 201]]], ["2-(N-morpholino)ethanesulfonic acid (MES), surfactant (including polyvinylpyrrolidone(PVP) and TritonX-100), carboxyl activating agents (including1-ethyl-3-(3-(dimethylamino)propyl) carbodimide hydrochloride (EDC)and N-hydroxy-sulfosuccinimide (sulfo-NHS)), andProclin-300 were obtained from Sigma\u2013Aldrich (St. Louis, MO,USA).", [["2-(N-morpholino)ethanesulfonic acid", "CHEMICAL", 0, 35], ["MES", "CHEMICAL", 37, 40], ["surfactant", "CHEMICAL", 43, 53], ["polyvinylpyrrolidone", "CHEMICAL", 65, 85], ["PVP", "CHEMICAL", 86, 89], ["TritonX-100", "CHEMICAL", 95, 106], ["including1-ethyl-3-(3-(dimethylamino)propyl) carbodimide hydrochloride", "CHEMICAL", 137, 207], ["EDC", "CHEMICAL", 209, 212], ["N-hydroxy-sulfosuccinimide", "CHEMICAL", 217, 243], ["sulfo-NHS", "CHEMICAL", 245, 254], ["Proclin-300", "CHEMICAL", 261, 272], ["2-(N-morpholino)ethanesulfonic acid", "CHEMICAL", 0, 35], ["MES", "CHEMICAL", 37, 40], ["polyvinylpyrrolidone", "CHEMICAL", 65, 85], ["PVP", "CHEMICAL", 86, 89], ["TritonX-100", "CHEMICAL", 95, 106], ["carboxyl", "CHEMICAL", 109, 117], ["including1-ethyl-3-(3-(dimethylamino)propyl) carbodimide hydrochloride", "CHEMICAL", 137, 207], ["EDC", "CHEMICAL", 209, 212], ["N-hydroxy-sulfosuccinimide", "CHEMICAL", 217, 243], ["sulfo-NHS", "CHEMICAL", 245, 254], ["Proclin-300", "CHEMICAL", 261, 272], ["2-(N-morpholino)ethanesulfonic acid", "SIMPLE_CHEMICAL", 0, 35], ["MES", "SIMPLE_CHEMICAL", 37, 40], ["surfactant", "SIMPLE_CHEMICAL", 43, 53], ["polyvinylpyrrolidone", "SIMPLE_CHEMICAL", 65, 85], ["PVP", "SIMPLE_CHEMICAL", 86, 89], ["TritonX-100", "SIMPLE_CHEMICAL", 95, 106], ["carboxyl activating agents", "SIMPLE_CHEMICAL", 109, 135], ["including1-ethyl-3-(3-(dimethylamino)propyl) carbodimide hydrochloride", "SIMPLE_CHEMICAL", 137, 207], ["EDC", "SIMPLE_CHEMICAL", 209, 212], ["N-hydroxy-sulfosuccinimide", "SIMPLE_CHEMICAL", 217, 243], ["sulfo-NHS", "SIMPLE_CHEMICAL", 245, 254], ["Proclin-300", "SIMPLE_CHEMICAL", 261, 272], ["St. Louis", "ORGANISM", 307, 316], ["N-morpholino)ethanesulfonic acid (MES)", "TREATMENT", 3, 41], ["surfactant", "TREATMENT", 43, 53], ["polyvinylpyrrolidone(PVP)", "TREATMENT", 65, 90], ["TritonX", "TREATMENT", 95, 102], ["carboxyl activating agents", "TREATMENT", 109, 135], ["ethyl", "TREATMENT", 148, 153], ["(dimethylamino)propyl", "TREATMENT", 159, 180], ["carbodimide hydrochloride (EDC)", "TREATMENT", 182, 213], ["N-hydroxy", "TREATMENT", 217, 226], ["sulfosuccinimide", "TREATMENT", 227, 243], ["Proclin", "TREATMENT", 261, 268]]], ["Functional block polymer, Tetronic 1307 (surfactant S9), wasobtained from BASF Corp. (Florham Park, NJ, USA).", [["Tetronic 1307", "CHEMICAL", 26, 39], ["surfactant S9", "CHEMICAL", 41, 54], ["Tetronic 1307", "CHEMICAL", 26, 39], ["Tetronic 1307", "SIMPLE_CHEMICAL", 26, 39], ["surfactant S9", "SIMPLE_CHEMICAL", 41, 54], ["Functional block polymer", "TREATMENT", 0, 24]]], ["Rabbit IgG and goatanti-rabbit IgG were purchased from Rockland Immunochemicals(Limerick, PA, USA).", [["Rabbit", "ORGANISM", 0, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 7, 10], ["goatanti-rabbit IgG", "GENE_OR_GENE_PRODUCT", 15, 34], ["Rabbit IgG", "PROTEIN", 0, 10], ["goatanti-rabbit IgG", "PROTEIN", 15, 34], ["Rabbit", "SPECIES", 0, 6], ["Rabbit", "SPECIES", 0, 6], ["goatanti-rabbit", "SPECIES", 15, 30], ["Rabbit IgG", "TEST", 0, 10], ["goatanti-rabbit IgG", "TREATMENT", 15, 34]]], ["Mouse anti-human IgG was obtained from Abcam(Cambridge, MA, USA).", [["Mouse", "ORGANISM", 0, 5], ["anti-human", "ORGANISM", 6, 16], ["IgG", "GENE_OR_GENE_PRODUCT", 17, 20], ["Abcam", "GENE_OR_GENE_PRODUCT", 39, 44], ["Mouse anti-human IgG", "PROTEIN", 0, 20], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-human IgG", "TREATMENT", 0, 20]]], ["Nitrocellulose (NC) membranes, glass fiberconjugate pads, and cellulosic absorbent pads were purchased fromMillipore (Hong Kong, China).", [["membranes", "ANATOMY", 20, 29], ["Nitrocellulose", "CHEMICAL", 0, 14], ["NC", "CHEMICAL", 16, 18], ["Nitrocellulose", "CHEMICAL", 0, 14], ["Nitrocellulose", "SIMPLE_CHEMICAL", 0, 14], ["Nitrocellulose (NC) membranes", "TREATMENT", 0, 29], ["glass fiberconjugate pads", "TREATMENT", 31, 56], ["cellulosic absorbent pads", "TREATMENT", 62, 87]]], ["Cellulosic sample pads were from JieyiBiotechnology Co., Ltd.", [["Cellulosic sample pads", "TREATMENT", 0, 22]]], ["Bovine serum albumin (BSA)was obtained from Roche Diagnostics (Hong Kong, China).", [["serum", "ANATOMY", 7, 12], ["Bovine", "ORGANISM", 0, 6], ["serum", "ORGANISM_SUBSTANCE", 7, 12], ["albumin", "GENE_OR_GENE_PRODUCT", 13, 20], ["BSA", "SIMPLE_CHEMICAL", 22, 25], ["Bovine", "SPECIES", 0, 6], ["Bovine", "SPECIES", 0, 6], ["Bovine serum albumin (BSA", "TEST", 0, 25]]], ["Otherchemicals used in this study were of analytic grade and used withoutfurther treatment.", [["this study", "TEST", 23, 33], ["treatment", "TREATMENT", 81, 90]]], ["Ultrapure water, obtained using a Milli-Q AdvantageA10 purification system (Millipore), was used in all experiments.Reagents, Samples, and Instrumentation ::: ExperimentThe following buffer solutions were used: coating buffer (0.3% trehalose[w/v] and 0.1% NaN3 [w/v] in 100 mM citrate-buffered saline[CBS], pH 8.5); sample pad treatment buffer (100 mMNa2B4O7\u00b710H2O,1% PVP [w/v], 0.2% casein-Na [w/v], 1% TritonX-100 [v/v], and 0.1%NaN3 [w/v]); conjugate pad treatment buffer (0.5%poly(vinyl alcohol) [PVA] [w/v], 0.5% BSA [w/v], and 1% TritonX-100[v/v] in 50 mM phosphate buffer, pH 7.4); activating buffer (50 mMMES, pH 5.1); binding buffer (10 mM phosphate buffer, pH 7.0); washingbuffer (0.2% Tween-20 [v/v], 0.9% NaCl [w/v], and 0.05% Proclin-300[v/v] in 25 mM Tris-HCl, pH 7.8); storage buffer (1% BSA [w/v], 5%trehalose [w/v], 20% sucrose [w/v],and 0.05% Proclin-300 [v/v] in 25mM Tris-HCl, pH 9.0); and assay buffer (7.5% BSA [w/v], 0.3%TritonX-100 [v/v], and 0.1% surfactant S9 [w/v] in 10 mM PBS, pH 7.4).All solutions in this study were freshly prepared before use.Reagents, Samples, and Instrumentation ::: ExperimentSerum samples were obtained from Guangzhou Eighth People\u2019sHospital and Nanfang Hospital and stored at \u221220 \u00b0C untiluse.", [["samples", "ANATOMY", 1134, 1141], ["trehalose", "CHEMICAL", 232, 241], ["citrate", "CHEMICAL", 277, 284], ["Na", "CHEMICAL", 391, 393], ["poly(vinyl alcohol", "CHEMICAL", 480, 498], ["PVA", "CHEMICAL", 501, 504], ["phosphate", "CHEMICAL", 562, 571], ["phosphate", "CHEMICAL", 649, 658], ["NaCl", "CHEMICAL", 717, 721], ["Tris-HCl", "CHEMICAL", 765, 773], ["trehalose", "CHEMICAL", 816, 825], ["sucrose", "CHEMICAL", 837, 844], ["Tris-HCl", "CHEMICAL", 887, 895], ["trehalose", "CHEMICAL", 232, 241], ["NaN3", "CHEMICAL", 256, 260], ["citrate", "CHEMICAL", 277, 284], ["PVP", "CHEMICAL", 368, 371], ["Na", "CHEMICAL", 391, 393], ["NaN3", "CHEMICAL", 431, 435], ["poly(vinyl alcohol)", "CHEMICAL", 480, 499], ["PVA", "CHEMICAL", 501, 504], ["phosphate", "CHEMICAL", 562, 571], ["phosphate", "CHEMICAL", 649, 658], ["Tween-20", "CHEMICAL", 696, 704], ["NaCl", "CHEMICAL", 717, 721], ["Tris-HCl", "CHEMICAL", 765, 773], ["trehalose", "CHEMICAL", 816, 825], ["sucrose", "CHEMICAL", 837, 844], ["Tris-HCl", "CHEMICAL", 887, 895], ["NaN3", "SIMPLE_CHEMICAL", 256, 260], ["citrate-buffered saline", "SIMPLE_CHEMICAL", 277, 300], ["casein-Na", "SIMPLE_CHEMICAL", 384, 393], ["v/v]", "SIMPLE_CHEMICAL", 417, 421], ["NaN3", "SIMPLE_CHEMICAL", 431, 435], ["poly(vinyl alcohol", "SIMPLE_CHEMICAL", 480, 498], ["BSA", "SIMPLE_CHEMICAL", 518, 521], ["Tris-HCl", "SIMPLE_CHEMICAL", 765, 773], ["trehalose", "SIMPLE_CHEMICAL", 816, 825], ["Tris-HCl", "SIMPLE_CHEMICAL", 887, 895], ["v/v]", "SIMPLE_CHEMICAL", 957, 961], ["ExperimentSerum samples", "CANCER", 1118, 1141], ["People", "SPECIES", 1178, 1184], ["Ultrapure water", "TREATMENT", 0, 15], ["a Milli-Q AdvantageA10 purification system", "TREATMENT", 32, 74], ["The following buffer solutions", "TREATMENT", 169, 199], ["coating buffer", "TREATMENT", 211, 225], ["CBS", "TEST", 301, 304], ["pH", "TEST", 307, 309], ["sample pad treatment buffer", "TREATMENT", 316, 343], ["mMNa", "TEST", 349, 353], ["TritonX", "TEST", 404, 411], ["NaN3 [w/v])", "TREATMENT", 431, 442], ["conjugate pad treatment buffer", "TREATMENT", 444, 474], ["TritonX", "TEST", 536, 543], ["v/v] in 50 mM phosphate buffer", "TREATMENT", 548, 578], ["pH", "TEST", 580, 582], ["activating buffer", "TREATMENT", 589, 606], ["pH", "TEST", 618, 620], ["binding buffer (10 mM phosphate buffer", "TREATMENT", 627, 665], ["pH", "TEST", 667, 669], ["washingbuffer", "TEST", 676, 689], ["Proclin", "TEST", 739, 746], ["Tris", "TEST", 765, 769], ["pH", "TEST", 775, 777], ["storage buffer", "TREATMENT", 784, 798], ["Tris", "TEST", 887, 891], ["pH", "TEST", 897, 899], ["assay buffer", "TREATMENT", 910, 922], ["pH", "TEST", 1006, 1008], ["All solutions", "TREATMENT", 1014, 1027], ["this study", "TEST", 1031, 1041]]], ["This study was approved by the Ethics Committee of the Scienceand Technology Department of Southern Medical University (Guangzhou,China).Expression of Recombinant SARS-CoV-2 NucleocapsidPhosphoprotein ::: ExperimentThe RNA genome of SARS-CoV-2 was kindly provided by DAAN Gene Co.(Guangzhou, China).", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 163, 173], ["SARS-CoV-2", "ORGANISM", 233, 243], ["Recombinant SARS-CoV-2 NucleocapsidPhosphoprotein", "DNA", 151, 200], ["RNA genome", "DNA", 219, 229], ["SARS-CoV", "SPECIES", 233, 241], ["This study", "TEST", 0, 10], ["Recombinant SARS", "TEST", 151, 167], ["CoV", "TEST", 168, 171], ["SARS", "PROBLEM", 233, 237], ["CoV", "TEST", 238, 241]]], ["Reverse transcription was performed to generatecDNA using PrimeScript II first Strand cDNA Synthesis Kit (Takara Bio,Otsu, Japan; Catalog No. 6210A).", [["PrimeScript II", "DNA", 58, 72], ["Reverse transcription", "TREATMENT", 0, 21]]], ["The full-length nucleocapsidphosphoprotein gene was amplified from the cDNA by PCR using thefollowing primers: 5\u2032-ATG TCT GAT AAT GGA CCC CAA AATC-3\u2032 (forward) and 5\u2032-TTA GGC CTG AGT TGA GTC AGC\u22123\u2032 (reverse), which were designed based on sequences inGenBank (MN908947.3).", [["nucleocapsidphosphoprotein", "GENE_OR_GENE_PRODUCT", 16, 42], ["full-length nucleocapsidphosphoprotein gene", "DNA", 4, 47], ["cDNA", "DNA", 71, 75], ["thefollowing primers", "DNA", 89, 109], ["MN908947.3", "DNA", 259, 269], ["The full-length nucleocapsidphosphoprotein gene", "TREATMENT", 0, 47], ["thefollowing primers", "TEST", 89, 109], ["ATG TCT", "TEST", 114, 121], ["GGA", "TEST", 130, 133], ["CCC", "TEST", 134, 137], ["CAA", "TEST", 138, 141], ["AATC", "TEST", 142, 146], ["TTA GGC", "TEST", 167, 174], ["CTG", "TEST", 175, 178], ["AGT", "TEST", 179, 182], ["TGA", "TEST", 183, 186], ["AGC", "TEST", 191, 194]]], ["PCR products were sequenced and cloned into thepMD-19T backbone vector; the resultant pMD-19T-N plasmid was fusedwith the linear pET-32a vector (Not I), using a Seamless Cloning andAssembly Kit (Beijing Zoman Biotechnology, Beijing, China; Catalog No.ZC231), from which the nucleocapsid phosphoprotein gene was amplifiedusing the primers 5\u2032-AG CTC CGT CGA CAA GCT TGC ATG TCT GAT AATGGA CCC CAA AAT-3\u2032 (forward) and 5\u2032-TG GTG GTG GTG GTGCTC GAG TGC GGC CGC GGC CTG AGT TGA GTC AGC ACT-3\u2032 (reverse).The target protein was expressed in Escherichia coliBL21 competent cells by induction with isopropyl\u03b2-d-1-thiogalactopyranoside, with the induction timeoptimized to ensure maximal expression.", [["cells", "ANATOMY", 565, 570], ["isopropyl\u03b2-d-1-thiogalactopyranoside", "CHEMICAL", 589, 625], ["isopropyl\u03b2-d-1-thiogalactopyranoside", "CHEMICAL", 589, 625], ["Escherichia coliBL21", "CELL", 534, 554], ["cells", "CELL", 565, 570], ["isopropyl\u03b2-d-1-thiogalactopyranoside", "SIMPLE_CHEMICAL", 589, 625], ["PCR products", "DNA", 0, 12], ["thepMD-19T backbone vector", "DNA", 44, 70], ["pMD-19T-N plasmid", "DNA", 86, 103], ["linear pET-32a vector", "DNA", 122, 143], ["Not I", "DNA", 145, 150], ["nucleocapsid phosphoprotein gene", "DNA", 274, 306], ["primers 5\u2032-AG CTC", "DNA", 330, 347], ["TG", "DNA", 419, 421], ["Escherichia coliBL21 competent cells", "CELL_LINE", 534, 570], ["thepMD-19T", "SPECIES", 44, 54], ["Escherichia coliBL21", "SPECIES", 534, 554], ["PCR products", "TREATMENT", 0, 12], ["the nucleocapsid phosphoprotein gene", "TREATMENT", 270, 306], ["the primers", "TEST", 326, 337], ["CGT", "TEST", 348, 351], ["CGA", "TEST", 352, 355], ["CAA", "TEST", 356, 359], ["GCT", "TEST", 360, 363], ["TGC", "TEST", 364, 367], ["ATG", "TEST", 368, 371], ["TCT", "TEST", 372, 375], ["GAT", "TEST", 376, 379], ["AATGGA", "TEST", 380, 386], ["CCC", "TEST", 387, 390], ["CAA", "TEST", 391, 394], ["AAT", "TEST", 395, 398], ["TG", "TEST", 419, 421], ["GTG", "TEST", 422, 425], ["GTG", "TEST", 426, 429], ["GTG", "TEST", 430, 433], ["GTGCTC", "TEST", 434, 440], ["GAG", "TEST", 441, 444], ["TGC", "TEST", 445, 448], ["GGC", "TEST", 449, 452], ["CGC", "TEST", 453, 456], ["GGC", "TEST", 457, 460], ["CTG", "TEST", 461, 464], ["AGT", "TEST", 465, 468], ["TGA", "TEST", 469, 472], ["AGC ACT", "TEST", 477, 484], ["The target protein", "TEST", 498, 516], ["isopropyl\u03b2", "TREATMENT", 589, 599], ["thiogalactopyranoside", "TREATMENT", 604, 625], ["the induction timeoptimized", "TREATMENT", 632, 659], ["Escherichia coliBL21 competent cells", "OBSERVATION", 534, 570], ["maximal expression", "OBSERVATION", 670, 688]]], ["Positive serum samples wereused to confirm the antigenicity of the purified recombinant proteinby Western blotting.Preparation of LNPs ::: ExperimentThe LNPs were synthesized by miniemulsion polymerization.", [["serum samples", "ANATOMY", 9, 22], ["LNPs", "ANATOMY", 153, 157], ["serum samples", "ORGANISM_SUBSTANCE", 9, 22], ["LNPs", "SIMPLE_CHEMICAL", 130, 134], ["LNPs", "SIMPLE_CHEMICAL", 153, 157], ["miniemulsion", "SIMPLE_CHEMICAL", 178, 190], ["serum samples", "TEST", 9, 22], ["miniemulsion polymerization", "TREATMENT", 178, 205], ["miniemulsion polymerization", "OBSERVATION", 178, 205]]], ["Briefly, 200 mgof Eu(DPP)3Phen and 20 mg of AIBN were dissolved in 2 g ofSt in a glass vial; and 60 mg of CTMA and 100 mg of AA were dissolvedin 15 mL of deionized water.", [["Eu(DPP)3Phen", "CHEMICAL", 18, 30], ["AIBN", "CHEMICAL", 44, 48], ["ofSt", "CHEMICAL", 71, 75], ["CTMA", "CHEMICAL", 106, 110], ["AA", "CHEMICAL", 125, 127], ["dissolvedin", "CHEMICAL", 133, 144], ["Eu(DPP)3Phen", "CHEMICAL", 18, 30], ["AIBN", "CHEMICAL", 44, 48], ["CTMA", "CHEMICAL", 106, 110], ["Eu(DPP)3Phen", "SIMPLE_CHEMICAL", 18, 30], ["AIBN", "SIMPLE_CHEMICAL", 44, 48], ["CTMA", "SIMPLE_CHEMICAL", 106, 110], ["AA", "SIMPLE_CHEMICAL", 125, 127], ["3Phen", "TREATMENT", 25, 30], ["AIBN", "TREATMENT", 44, 48], ["a glass vial", "TREATMENT", 79, 91], ["CTMA", "TREATMENT", 106, 110], ["AA", "TREATMENT", 125, 127]]], ["The aqueous and monomer solutions weremixed with a magnetic stirrer for 10 min and miniemulsions wereprepared with an ultrasonicator for 20 min in an ice bath.", [["aqueous", "SIMPLE_CHEMICAL", 4, 11], ["The aqueous and monomer solutions", "TREATMENT", 0, 33], ["a magnetic stirrer", "TREATMENT", 49, 67], ["an ultrasonicator", "TREATMENT", 115, 132], ["an ice bath", "TREATMENT", 147, 158]]], ["Nitrogengas was bubbled for 2 h at room temperature to remove oxygen from themixture, and the emulsion was then stirred at room temperature for 20h.", [["Nitrogengas", "CHEMICAL", 0, 11], ["oxygen", "CHEMICAL", 62, 68], ["Nitrogengas", "CHEMICAL", 0, 11], ["oxygen", "CHEMICAL", 62, 68], ["Nitrogengas", "SIMPLE_CHEMICAL", 0, 11], ["oxygen", "SIMPLE_CHEMICAL", 62, 68], ["themixture", "SIMPLE_CHEMICAL", 74, 84], ["Nitrogengas", "TREATMENT", 0, 11], ["oxygen", "TREATMENT", 62, 68], ["themixture", "TREATMENT", 74, 84]]], ["The resultant LNPs were dispersed in water (5% w/v) andstored as stock at 4 \u00b0C.Functionalizing LNPs with Protein Molecules ::: ExperimentLNPs were functionalized with mouse anti-human IgG antibody (M-HIgG) andrabbit IgG (RIgG) as previously described,20 withsome modifications.", [["LNPs", "ANATOMY", 14, 18], ["LNPs", "SIMPLE_CHEMICAL", 14, 18], ["LNPs", "SIMPLE_CHEMICAL", 95, 99], ["ExperimentLNPs", "SIMPLE_CHEMICAL", 127, 141], ["mouse", "ORGANISM", 167, 172], ["M-HIgG", "GENE_OR_GENE_PRODUCT", 198, 204], ["mouse anti-human IgG antibody", "PROTEIN", 167, 196], ["M", "PROTEIN", 198, 199], ["HIgG", "PROTEIN", 200, 204], ["andrabbit IgG", "PROTEIN", 206, 219], ["RIgG", "PROTEIN", 221, 225], ["mouse", "SPECIES", 167, 172], ["mouse", "SPECIES", 167, 172], ["The resultant LNPs", "TREATMENT", 0, 18], ["Protein Molecules", "TEST", 105, 122], ["ExperimentLNPs", "TEST", 127, 141], ["mouse anti-human IgG antibody", "TEST", 167, 196], ["M-HIgG", "TEST", 198, 204], ["IgG", "TEST", 216, 219], ["resultant", "OBSERVATION_MODIFIER", 4, 13], ["LNPs", "OBSERVATION_MODIFIER", 14, 18], ["dispersed", "OBSERVATION_MODIFIER", 24, 33]]], ["A two-step procedure was used to preventaggregating between LNPs via cross-linking of antibody molecules.Briefly, 20 \u03bcL of EDC (1% EDC [w/v] in activating buffer) and180 \u03bcL of sulfo-NHS (1% sulfo-NHS [w/v] in activating buffer)solutions were mixed and added to 2 mg of LNPs resuspended in 0.8 mLof activating buffer.", [["EDC", "CHEMICAL", 123, 126], ["sulfo-NHS", "CHEMICAL", 176, 185], ["sulfo-NHS", "CHEMICAL", 190, 199], ["LNPs", "CHEMICAL", 269, 273], ["EDC", "CHEMICAL", 123, 126], ["sulfo-NHS", "CHEMICAL", 176, 185], ["sulfo-NHS", "CHEMICAL", 190, 199], ["LNPs", "SIMPLE_CHEMICAL", 60, 64], ["EDC", "SIMPLE_CHEMICAL", 123, 126], ["sulfo-NHS", "SIMPLE_CHEMICAL", 176, 185], ["sulfo-NHS", "SIMPLE_CHEMICAL", 190, 199], ["LNPs", "SIMPLE_CHEMICAL", 269, 273], ["antibody molecules", "PROTEIN", 86, 104], ["A two-step procedure", "TREATMENT", 0, 20], ["cross-linking of antibody molecules", "TREATMENT", 69, 104], ["activating buffer", "TREATMENT", 144, 161], ["sulfo-NHS", "TREATMENT", 176, 185], ["v] in activating buffer)solutions", "TREATMENT", 203, 236], ["LNPs", "TREATMENT", 269, 273], ["antibody molecules", "OBSERVATION", 86, 104]]], ["To remove unreacted components, the LNPswas washed three times by centrifugation at 18000gfor 10 min with binding buffer after NHS-ester was formed.", [["NHS-ester", "CHEMICAL", 127, 136], ["NHS-ester", "CHEMICAL", 127, 136], ["LNPswas", "SIMPLE_CHEMICAL", 36, 43], ["NHS-ester", "SIMPLE_CHEMICAL", 127, 136], ["unreacted components", "PROBLEM", 10, 30], ["unreacted", "OBSERVATION_MODIFIER", 10, 19], ["components", "OBSERVATION_MODIFIER", 20, 30]]], ["The pelletwas ultrasonically resuspended in 0.95 mL of binding buffer.", [["The pelletwas ultrasonically", "TREATMENT", 0, 28], ["binding buffer", "TREATMENT", 55, 69]]], ["Theantibodies were purified and diluted in binding buffer at aconcentration of 1 mg/mL; 50 \u03bcL of as-prepared antibody solution(M-HIgG or RIgG) was added into the activated LNPs suspension.", [["LNPs", "ANATOMY", 172, 176], ["Theantibodies", "SIMPLE_CHEMICAL", 0, 13], ["M-HIgG", "SIMPLE_CHEMICAL", 127, 133], ["RIgG", "SIMPLE_CHEMICAL", 137, 141], ["LNPs", "SIMPLE_CHEMICAL", 172, 176], ["HIgG", "PROTEIN", 129, 133], ["RIgG", "PROTEIN", 137, 141], ["prepared antibody solution", "TREATMENT", 100, 126], ["M-HIgG or RIgG)", "TREATMENT", 127, 142], ["the activated LNPs suspension", "TREATMENT", 158, 187]]], ["A 4-hincubation with gentle rotation was applied, then 1.5 \u03bcL ofethanolamine was added and the admixture was further incubated for 10min.", [["ofethanolamine", "CHEMICAL", 62, 76], ["ofethanolamine", "CHEMICAL", 62, 76], ["ofethanolamine", "SIMPLE_CHEMICAL", 62, 76], ["A 4-hincubation", "TREATMENT", 0, 15], ["gentle rotation", "TREATMENT", 21, 36], ["1.5 \u03bcL ofethanolamine", "TREATMENT", 55, 76]]], ["In order to purify the functionalized LNPs, the washing processwas repeated three times before adding blocking buffer (2% BSA in 25mM phosphate buffer, pH 7.4).", [["phosphate", "CHEMICAL", 134, 143], ["phosphate", "CHEMICAL", 134, 143], ["LNPs", "SIMPLE_CHEMICAL", 38, 42], ["BSA", "SIMPLE_CHEMICAL", 122, 125], ["the functionalized LNPs", "TREATMENT", 19, 42], ["the washing processwas", "TEST", 44, 66], ["blocking buffer", "TREATMENT", 102, 117], ["2% BSA in 25mM phosphate buffer", "TREATMENT", 119, 150], ["pH", "TEST", 152, 154]]], ["The functionalized LNPs wereultrasonically resuspended in blocking buffer, and a 30-min incubationwith gentle mixing was employed to block any remaining unreactedhydrophobic sites on the surface of LNPs and to form a thin hydrationlayer to prevent aggregation.", [["surface", "ANATOMY", 187, 194], ["LNPs", "CHEMICAL", 19, 23], ["aggregation", "DISEASE", 248, 259], ["LNPs", "SIMPLE_CHEMICAL", 19, 23], ["surface", "CELLULAR_COMPONENT", 187, 194], ["LNPs", "SIMPLE_CHEMICAL", 198, 202], ["LNPs", "PROTEIN", 198, 202], ["The functionalized LNPs", "TREATMENT", 0, 23], ["blocking buffer", "TREATMENT", 58, 73], ["gentle mixing", "TREATMENT", 103, 116], ["LNPs", "TREATMENT", 198, 202], ["a thin hydrationlayer", "TREATMENT", 215, 236], ["aggregation", "PROBLEM", 248, 259], ["aggregation", "OBSERVATION", 248, 259]]], ["The antibody-enameled LNPs were cleansedthree times with washing buffer and were resuspended in storagebuffer.Fabrication of LFIA Strips ::: ExperimentLFIA strips were prepared as described in our previous work.21 The sample pad was immersed in a sample padtreatment buffer for 1 h and dried at 37 \u00b0C for 24 h.", [["sample", "ANATOMY", 247, 253], ["LNPs", "SIMPLE_CHEMICAL", 22, 26], ["The antibody", "TEST", 0, 12], ["LNPs", "TREATMENT", 22, 26], ["washing buffer", "TREATMENT", 57, 71], ["ExperimentLFIA strips", "TREATMENT", 141, 162], ["The sample pad", "TREATMENT", 214, 228], ["a sample padtreatment buffer", "TREATMENT", 245, 273]]], ["Theconjugate pad was saturated with a conjugate pad treatment buffer atroom temperature for 1.5 h and also dried at 37 \u00b0C for 24 h.M-HIgG@LNPs and RIgG@LNPs were diluted in storage buffer (0.125 and0.05 mg/mL, respectively) and combined; the mixture was dispensed ontothe conjugate pad at 1 \u03bcL/cm using a Biolet Quanti dispenser(BioDot, Shanghai, China), and dried at 37 \u00b0C before being storedin a dry cabinet at room temperature until use.", [["RIgG@LNPs", "CHEMICAL", 147, 156], ["h.M-HIgG@LNPs", "SIMPLE_CHEMICAL", 129, 142], ["RIgG@LNPs", "SIMPLE_CHEMICAL", 147, 156], ["Theconjugate pad", "TREATMENT", 0, 16], ["a conjugate pad treatment buffer atroom temperature", "TREATMENT", 36, 87], ["HIgG@LNPs", "TREATMENT", 133, 142], ["RIgG@LNPs", "TREATMENT", 147, 156], ["conjugate pad", "TREATMENT", 272, 285], ["a Biolet Quanti dispenser", "TREATMENT", 303, 328]]], ["Recombinantnucleocapsid phosphoprotein and goat anti-rabbit IgG were diluted withcoating buffer at concentration of 2 mg/mL, then dispensed onto an NCmembrane (Millipore; Catalog No.", [["Recombinantnucleocapsid phosphoprotein", "GENE_OR_GENE_PRODUCT", 0, 38], ["goat anti-rabbit IgG", "GENE_OR_GENE_PRODUCT", 43, 63], ["Recombinantnucleocapsid phosphoprotein", "PROTEIN", 0, 38], ["goat anti-rabbit IgG", "PROTEIN", 43, 63], ["goat", "SPECIES", 43, 47], ["anti-rabbit", "SPECIES", 48, 59], ["goat", "SPECIES", 43, 47], ["anti-rabbit", "SPECIES", 48, 59], ["Recombinantnucleocapsid phosphoprotein", "TREATMENT", 0, 38], ["goat anti-rabbit IgG", "TREATMENT", 43, 63], ["an NCmembrane (Millipore", "TREATMENT", 145, 169]]], ["HF13502XSS) at 1 and 0.8 \u03bcL/cm,respectively, as test and control lines.", [["test", "TEST", 48, 52], ["control lines", "TREATMENT", 57, 70]]], ["The membrane was dried at 37\u00b0C for 4 h.", [["membrane", "ANATOMY", 4, 12], ["membrane", "CELLULAR_COMPONENT", 4, 12]]], ["The NC membrane, absorbent pad, conjugate pad andsample pad were sequentially laminated together onto a backing card,as shown in Figure 1.", [["NC membrane", "ANATOMY", 4, 15], ["NC membrane", "CELLULAR_COMPONENT", 4, 15], ["The NC membrane", "TREATMENT", 0, 15], ["absorbent pad", "TREATMENT", 17, 30], ["conjugate pad andsample pad", "TREATMENT", 32, 59], ["NC membrane", "OBSERVATION", 4, 15], ["absorbent pad", "OBSERVATION", 17, 30]]], ["The assembled test strips were stored in amoisture-proof cabinet.Analytical Procedure and Statistical Analysis ::: ExperimentAs shown in Figure 1, serumsamples were diluted with assay buffer (1:1000), and 100 \u03bcL ofdiluted sample was added to the sample well of a LFIA strip.", [["sample", "ANATOMY", 222, 228], ["sample", "ANATOMY", 246, 252], ["The assembled test strips", "TEST", 0, 25], ["Statistical Analysis", "TEST", 90, 110], ["assay buffer", "TREATMENT", 178, 190], ["a LFIA strip", "TREATMENT", 261, 273]]], ["As theliquid migrated from the sample pad toward the absorbent pad,functionalized LNPs were captured at the test and control lines.", [["LNPs", "SIMPLE_CHEMICAL", 82, 86], ["the sample pad", "TREATMENT", 27, 41], ["the absorbent pad", "TREATMENT", 49, 66], ["functionalized LNPs", "TREATMENT", 67, 86], ["the test", "TEST", 104, 112], ["absorbent pad", "OBSERVATION", 53, 66]]], ["Aftera 10-min incubation, the strip was loaded into the portablefluorescence reader for detection of fluorescence at excitation andemission wavelengths of 365 and 615 nm, respectively, with the delaytime set at 20 \u03bcs.", [["the strip", "TREATMENT", 26, 35]]], ["Excitation of the fixed LNPs produced abright fluorescent zone on the membrane.", [["LNPs", "ANATOMY", 24, 28], ["membrane", "ANATOMY", 70, 78], ["LNPs", "SIMPLE_CHEMICAL", 24, 28], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["the fixed LNPs", "TEST", 14, 28], ["fixed", "OBSERVATION_MODIFIER", 18, 23], ["abright", "OBSERVATION_MODIFIER", 38, 45], ["fluorescent", "OBSERVATION_MODIFIER", 46, 57], ["zone", "OBSERVATION_MODIFIER", 58, 62], ["membrane", "ANATOMY_MODIFIER", 70, 78]]], ["The results are denoted asthe fluorescence peak area of the test line (At) andcontrol line (Ac).", [["test line (At) andcontrol line", "CELL_LINE", 60, 90], ["Ac", "CELL_LINE", 92, 94], ["the test line", "TREATMENT", 56, 69], ["test line", "OBSERVATION", 60, 69]]], ["TheAt/Ac ratio(R) was calculated to determine theanti-SARS-CoV-2 IgG concentration in the serum.Characterization of LNPs and Functionalized LNP Probe ::: Results and DiscussionMost biochemical assays are performed in solution.", [["serum", "ANATOMY", 90, 95], ["IgG", "GENE_OR_GENE_PRODUCT", 65, 68], ["serum", "ORGANISM_SUBSTANCE", 90, 95], ["LNPs", "SIMPLE_CHEMICAL", 116, 120], ["IgG", "PROTEIN", 65, 68], ["LNPs", "DNA", 116, 120], ["TheAt/Ac ratio", "TEST", 0, 14], ["theanti-SARS", "TEST", 46, 58], ["CoV", "TEST", 59, 62], ["Most biochemical assays", "TEST", 176, 199]]], ["In aqueousenvironments, the emission of lanthanide chelates is stronglysuppressed due to energy loss through the nonradiative activation ofthe 5D0 state to the O\u2013H vibration of watermolecules.22 Thus, it is preferable toencapsulate lanthanide chelates in water-dispersible spheres.", [["lanthanide chelates", "CHEMICAL", 40, 59], ["lanthanide", "CHEMICAL", 40, 50], ["O\u2013H", "CHEMICAL", 160, 163], ["lanthanide", "CHEMICAL", 232, 242], ["lanthanide chelates", "SIMPLE_CHEMICAL", 40, 59], ["watermolecules", "SIMPLE_CHEMICAL", 177, 191], ["toencapsulate lanthanide chelates", "SIMPLE_CHEMICAL", 218, 251], ["water-dispersible spheres", "SIMPLE_CHEMICAL", 255, 280], ["5D0 state", "PROTEIN", 143, 152], ["watermolecules", "PROTEIN", 177, 191], ["the emission of lanthanide chelates", "TREATMENT", 24, 59], ["energy loss", "PROBLEM", 89, 100], ["lanthanide chelates", "TREATMENT", 232, 251]]], ["Themaximal fluorescence emission peak of LNPs was obtained at \u223c615nm; the peak was narrow and symmetric (Figure 2a).", [["LNPs", "SIMPLE_CHEMICAL", 41, 45], ["LNPs", "PROTEIN", 41, 45], ["Themaximal fluorescence emission peak", "TEST", 0, 37], ["LNPs", "TEST", 41, 45], ["narrow", "OBSERVATION_MODIFIER", 83, 89], ["symmetric", "OBSERVATION_MODIFIER", 94, 103]]], ["Dynamic light scattering analysiswas performed for physical characterization of LNPs before and afterfunctionalization.", [["LNPs", "SIMPLE_CHEMICAL", 80, 84], ["Dynamic light scattering analysiswas", "TEST", 0, 36], ["physical characterization", "TEST", 51, 76]]], ["The change in the size and surface zeta potentialof LNPs (Figures 2b and 2c) indicated that the M-HIgG and RIgG antibodieswere successfully conjugated.Optimization ::: Results and DiscussionImmunoreaction time significantly influences fluorescence signals.", [["surface", "ANATOMY", 27, 34], ["M-HIgG", "SIMPLE_CHEMICAL", 96, 102], ["RIgG", "SIMPLE_CHEMICAL", 107, 111], ["surface zeta potentialof LNPs", "PROTEIN", 27, 56], ["HIgG", "PROTEIN", 98, 102], ["RIgG", "PROTEIN", 107, 111], ["The change in the size", "PROBLEM", 0, 22], ["surface zeta", "TEST", 27, 39], ["LNPs", "TEST", 52, 56], ["Figures", "TEST", 58, 65], ["the M-HIgG", "TEST", 92, 102], ["RIgG antibodieswere", "TREATMENT", 107, 126], ["fluorescence signals", "TEST", 235, 255], ["change", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 18, 22], ["surface", "OBSERVATION_MODIFIER", 27, 34], ["zeta", "OBSERVATION_MODIFIER", 35, 39]]], ["Inthis assay, a positive sample was measured to establish the optimalassay time.", [["sample", "ANATOMY", 25, 31], ["Inthis assay", "TEST", 0, 12], ["a positive sample", "PROBLEM", 14, 31]]], ["The At/Ac ratio(R) was measured every 2 min over a period of0\u201316 min from the start of incubation.", [["The At/Ac ratio", "TEST", 0, 15]]], ["Rincreased rapidly over the first 4 min and reached a plateau at 10 min(see Figure 3).", [["rapidly", "OBSERVATION_MODIFIER", 11, 18], ["plateau", "ANATOMY", 54, 61]]], ["Based on thisresult, the total assay time was determined as 10 min.Reproducibility ::: Results and DiscussionThe reproducibility of our assay was evaluated based on intra-assay andinter-assay variations.", [["the total assay time", "TEST", 21, 41], ["our assay", "TEST", 132, 141], ["intra-assay andinter", "TEST", 165, 185]]], ["Four samples were measured five times a dayfor five consecutive days, and the coefficient of variation (CV)values were calculated.", [["samples", "ANATOMY", 5, 12], ["Four samples", "TEST", 0, 12], ["variation (CV)values", "TEST", 93, 113]]], ["The intra-assay and inter-assay CVs were7.71%\u20139.69% and 11.51%\u201314.63%, respectively (see Table 1).", [["The intra-assay", "TEST", 0, 15], ["inter-assay CVs", "TEST", 20, 35]]], ["Since the CVs wereall <15%, we concluded that our assay is reproducible.Clinical Sample Tests ::: Results and DiscussionIn order to define the appropriate cutoff value for our assay, we tested51 normal serum samples and 7 samples that were determined to bepositive by RT-PCR.", [["serum samples", "ANATOMY", 202, 215], ["samples", "ANATOMY", 222, 229], ["serum samples", "ORGANISM_SUBSTANCE", 202, 215], ["the CVs", "TEST", 6, 13], ["our assay", "TEST", 46, 55], ["our assay", "TEST", 172, 181], ["RT", "TEST", 268, 270], ["PCR", "TEST", 271, 274]]], ["The cutoff value of R (the meanof normal samples plus 3 times the standard deviation) was calculatedas 0.0666.", [["The cutoff value", "TEST", 0, 16], ["calculatedas", "TEST", 90, 102]]], ["All 7 samples that were positive by RT-PCR had anR value of >0.0666 (Figure4), indicating that the developedassay can detect anti-SARS-CoV-2 IgG in positive samples.Clinical Sample Tests ::: Results and DiscussionTo confirm the diagnostic accuracy of our assay, we used it to test 7samples that were positive by RT-PCR and 12 that were negative butclinically suspect.", [["samples", "ANATOMY", 6, 13], ["samples", "ANATOMY", 157, 164], ["samples", "CANCER", 6, 13], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 125, 144], ["anti-SARS-CoV-2 IgG", "PROTEIN", 125, 144], ["All 7 samples", "TEST", 0, 13], ["RT", "TEST", 36, 38], ["PCR", "TEST", 39, 42], ["anR value", "TEST", 47, 56], ["anti-SARS", "TEST", 125, 134], ["CoV", "TEST", 135, 138], ["2 IgG in positive samples", "PROBLEM", 139, 164], ["our assay", "TEST", 251, 260], ["test 7samples", "TEST", 276, 289], ["RT-PCR", "TEST", 312, 318]]], ["The \u03c72 test showed that theP-value of the McNemar test was 1.0, and thevalue obtained with the kappa test was 0.890 (P <0.001) (see Table 2).", [["The \u03c72 test", "TEST", 0, 11], ["theP", "TEST", 24, 28], ["the McNemar test", "TEST", 38, 54], ["the kappa test", "TEST", 91, 105]]], ["Thus,there was no statistically significant difference between the resultsobtained with our developed assay versus those obtained by RT-PCR.Clinical Sample Tests ::: Results and DiscussionOne of the 12 clinically suspicious samples that were negative by RT-PCRwas found to be SARS-CoV-2 IgG positive with our assay.", [["samples", "ANATOMY", 224, 231], ["samples", "CANCER", 224, 231], ["SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 276, 290], ["IgG", "PROTEIN", 287, 290], ["assay", "TEST", 102, 107], ["PCR", "TEST", 136, 139], ["suspicious samples", "TEST", 213, 231], ["RT", "TEST", 254, 256], ["PCRwas", "TEST", 257, 263], ["SARS", "TEST", 276, 280], ["CoV", "TEST", 281, 284], ["IgG", "TEST", 287, 290], ["our assay", "TEST", 305, 314]]], ["Unlike othersuspected cases, this case did not only have the fever and came withhigh clinical suspicion.", [["fever", "DISEASE", 61, 66], ["the fever", "PROBLEM", 57, 66]]], ["The negative result of RT-PCR test raisedclinical concerns about the management of this case.", [["RT-PCR test", "TEST", 23, 34]]], ["Base on our IgGtest result, the RT-PCR test result was more likely to be a falsenegative.", [["the RT-PCR test", "TEST", 28, 43], ["a falsenegative", "PROBLEM", 73, 88], ["falsenegative", "OBSERVATION", 75, 88]]], ["At present, prevention of cross-infection is very essentialin outbreak control; timely isolation and treatment should be adoptedfor this case.ConclusionThe present study describes a simple and rapid LNP-based immunoassay fordetecting anti-SARS-CoV-2 IgG in human serum.", [["serum", "ANATOMY", 263, 268], ["anti-SARS-CoV-2 IgG", "GENE_OR_GENE_PRODUCT", 234, 253], ["human", "ORGANISM", 257, 262], ["serum", "ORGANISM_SUBSTANCE", 263, 268], ["anti-SARS-CoV-2 IgG", "PROTEIN", 234, 253], ["human", "SPECIES", 257, 262], ["human", "SPECIES", 257, 262], ["cross-infection", "PROBLEM", 26, 41], ["treatment", "TREATMENT", 101, 110], ["The present study", "TEST", 152, 169], ["rapid LNP", "TREATMENT", 193, 202], ["immunoassay", "TEST", 209, 220], ["anti-SARS", "TEST", 234, 243], ["CoV", "TEST", 244, 247], ["IgG in human serum", "TEST", 250, 268], ["cross-infection", "OBSERVATION", 26, 41]]], ["Because there is presently noofficial anti-SARS-CoV-2 IgG standard available, the assay cannot beimproved from semiquantitative to accurate quantification.", [["anti-SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 38, 53], ["anti-SARS", "PROTEIN", 38, 47], ["IgG", "PROTEIN", 54, 57], ["CoV", "TEST", 48, 51], ["the assay", "TEST", 78, 87]]], ["However, theresults of the validation experiment meet the requirements for clinicaldiagnostic reagents.", [["clinicaldiagnostic reagents", "TREATMENT", 75, 102]]], ["Our assay can be used to monitor the progression ofCOVID-19, as well as responses to treatment.", [["Our assay", "TEST", 0, 9], ["the progression ofCOVID", "TEST", 33, 56], ["treatment", "TREATMENT", 85, 94]]], ["We expect this assay to behighly useful for helping to contain the COVID-19 outbreak by allowingtimely diagnosis through early detection of SARS-CoV-2.", [["SARS", "DISEASE", 140, 144], ["SARS-CoV-2", "ORGANISM", 140, 150], ["SARS-CoV", "SPECIES", 140, 148], ["this assay", "TEST", 10, 20], ["SARS", "PROBLEM", 140, 144], ["CoV", "TEST", 145, 148]]]], "9432cf9d2e9dd9bde3fa9d3ef07dde254a739069": [["3BackgroundThe risk of severe COVID-19 disease is known to be higher in older individuals and those with underlying health conditions.", [["COVID", "DISEASE", 30, 35], ["severe COVID-19 disease", "PROBLEM", 23, 46], ["underlying health conditions", "PROBLEM", 105, 133], ["severe", "OBSERVATION_MODIFIER", 23, 29], ["19 disease", "OBSERVATION", 36, 46]]], ["Understanding the number of individuals at increased risk of severe COVID-19 illness, and how this varies between countries may inform the design of possible strategies to shield those at highest risk.MethodsWe estimated the number of individuals at increased risk of severe COVID-19 disease by age (5-year age groups), sex and country (n=188) based on prevalence data from the Global Burden of Disease (GBD) study for 2017 and United Nations population estimates for 2020.", [["COVID", "DISEASE", 68, 73], ["COVID", "DISEASE", 275, 280], ["Burden of Disease", "DISEASE", 385, 402], ["severe COVID-19 illness", "PROBLEM", 61, 84], ["severe COVID-19 disease", "PROBLEM", 268, 291], ["prevalence data", "TEST", 353, 368], ["the Global Burden of Disease", "PROBLEM", 374, 402], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["severe", "OBSERVATION_MODIFIER", 268, 274], ["Disease", "OBSERVATION", 395, 402]]], ["We also calculated the number of individuals without an underlying condition that could be considered at-risk because of their age, using thresholds from 50-70 years.", [["an underlying condition", "PROBLEM", 53, 76]]], ["The list of underlying conditions relevant to COVID-19 disease was determined by mapping conditions listed in GBD to the guidelines published by WHO and public health agencies in the UK and US.", [["underlying conditions", "PROBLEM", 12, 33], ["COVID-19 disease", "PROBLEM", 46, 62]]], ["We analysed data from two large multimorbidity studies to determine appropriate adjustment factors for clustering and multimorbidity.ResultsWe estimate that 1.7 (1.0 -2.4) billion individuals (22% [15-28%] of the global population) are at increased risk of severe COVID-19 disease.", [["multimorbidity", "DISEASE", 118, 132], ["COVID", "DISEASE", 264, 269], ["individuals", "ORGANISM", 180, 191], ["two large multimorbidity studies", "TEST", 22, 54], ["multimorbidity", "PROBLEM", 118, 132], ["ResultsWe estimate", "TEST", 133, 151], ["billion individuals", "TEST", 172, 191], ["severe COVID-19 disease", "PROBLEM", 257, 280], ["increased", "OBSERVATION_MODIFIER", 239, 248], ["severe", "OBSERVATION_MODIFIER", 257, 263], ["19 disease", "OBSERVATION", 270, 280]]], ["The share of the population at increased risk ranges from 16% in Africa to 31% in Europe.", [["population", "OBSERVATION_MODIFIER", 17, 27], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["risk", "OBSERVATION_MODIFIER", 41, 45], ["ranges", "OBSERVATION_MODIFIER", 46, 52]]], ["Chronic kidney disease (CKD), cardiovascular disease (CVD), diabetes and chronic respiratory disease (CRD) were the most prevalent conditions in males and females aged 50+ years.", [["kidney", "ANATOMY", 8, 14], ["cardiovascular", "ANATOMY", 30, 44], ["respiratory", "ANATOMY", 81, 92], ["Chronic kidney disease", "DISEASE", 0, 22], ["CKD", "DISEASE", 24, 27], ["cardiovascular disease", "DISEASE", 30, 52], ["CVD", "DISEASE", 54, 57], ["diabetes", "DISEASE", 60, 68], ["chronic respiratory disease", "DISEASE", 73, 100], ["CRD", "DISEASE", 102, 105], ["kidney", "ORGAN", 8, 14], ["Chronic kidney disease", "PROBLEM", 0, 22], ["CKD)", "PROBLEM", 24, 28], ["cardiovascular disease (CVD)", "PROBLEM", 30, 58], ["diabetes", "PROBLEM", 60, 68], ["chronic respiratory disease (CRD)", "PROBLEM", 73, 106], ["kidney", "ANATOMY", 8, 14], ["disease", "OBSERVATION", 15, 22], ["CKD", "OBSERVATION", 24, 27], ["cardiovascular", "ANATOMY", 30, 44], ["disease", "OBSERVATION", 45, 52], ["diabetes", "OBSERVATION", 60, 68], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["respiratory disease", "OBSERVATION", 81, 100], ["most prevalent", "OBSERVATION_MODIFIER", 116, 130]]], ["African countries with a high prevalence of HIV/AIDS and Island countries with a high prevalence of diabetes, also had a high share of the population at increased risk.", [["HIV/AIDS", "DISEASE", 44, 52], ["diabetes", "DISEASE", 100, 108], ["HIV", "SPECIES", 44, 47], ["HIV/AIDS", "PROBLEM", 44, 52], ["diabetes", "PROBLEM", 100, 108], ["diabetes", "OBSERVATION", 100, 108]]], ["The prevalence of multimorbidity (>1 underlying conditions) was three times higher in Europe than in Africa (10% vs 3%).ConclusionBased on current guidelines and prevalence data from GBD, we estimate that one in five individuals worldwide has a condition that is on the list of those at increased risk of severe COVID-19 disease.", [["multimorbidity", "DISEASE", 18, 32], ["COVID", "DISEASE", 312, 317], ["individuals", "ORGANISM", 217, 228], ["multimorbidity", "PROBLEM", 18, 32], ["severe COVID-19 disease", "PROBLEM", 305, 328], ["multimorbidity", "OBSERVATION", 18, 32], ["severe", "OBSERVATION_MODIFIER", 305, 311], ["19 disease", "OBSERVATION", 318, 328]]], ["However, for many of these individuals the underlying condition will be undiagnosed or not severe enough to be captured in health systems, and in some cases the increase in risk may be quite modest.", [["undiagnosed", "PROBLEM", 72, 83], ["increase", "OBSERVATION_MODIFIER", 161, 169], ["may be quite", "UNCERTAINTY", 178, 190], ["modest", "OBSERVATION_MODIFIER", 191, 197]]], ["There is an urgent need for robust analyses of the risks associated with different underlying conditions so that countries can identify the highest risk groups and develop targeted shielding policies to mitigate the effects of the COVID-19 pandemic.Research in contextEvidence before this study As the COVID-19 pandemic evolves, countries are considering policies of 'shielding' the most vulnerable, but there is currently very limited evidence on the number of individuals that might need to be shielded.", [["different underlying conditions", "PROBLEM", 73, 104], ["targeted shielding policies", "TREATMENT", 172, 199], ["the COVID", "TEST", 227, 236], ["this study", "TEST", 284, 294], ["most vulnerable", "OBSERVATION_MODIFIER", 383, 398]]], ["Guidelines on who is currently believed to be at increased risk of severe COVID-19 illness have been published online by the WHO and public health agencies in the UK and US.", [["COVID", "DISEASE", 74, 79], ["severe COVID-19 illness", "PROBLEM", 67, 90], ["severe", "OBSERVATION_MODIFIER", 67, 73]]], ["Evidence from China, Italy and the USA indicates that older individuals, males and those with underlying conditions, such as CVD, diabetes and CRD, are at greater risk of severe COVID-19 illness and death.Added value of this studyThis study combines evidence from large international databases and new analysis of large multimorbidity studies to inform policymakers about the number of individuals that may be at increased risk of severe COVID-19 illness in different countries.", [["CVD", "DISEASE", 125, 128], ["diabetes", "DISEASE", 130, 138], ["CRD", "DISEASE", 143, 146], ["COVID", "DISEASE", 178, 183], ["illness", "DISEASE", 187, 194], ["death", "DISEASE", 199, 204], ["COVID", "DISEASE", 438, 443], ["illness", "DISEASE", 447, 454], ["individuals", "ORGANISM", 386, 397], ["underlying conditions", "PROBLEM", 94, 115], ["CVD", "PROBLEM", 125, 128], ["diabetes", "PROBLEM", 130, 138], ["CRD", "PROBLEM", 143, 146], ["severe COVID-19 illness", "PROBLEM", 171, 194], ["death", "PROBLEM", 199, 204], ["this study", "TEST", 220, 230], ["This study", "TEST", 230, 240], ["large international databases", "PROBLEM", 264, 293], ["new analysis", "TEST", 298, 310], ["large multimorbidity studies", "PROBLEM", 314, 342], ["severe COVID", "PROBLEM", 431, 443], ["diabetes", "OBSERVATION", 130, 138], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["large", "OBSERVATION_MODIFIER", 264, 269], ["new", "OBSERVATION_MODIFIER", 298, 301], ["large", "OBSERVATION_MODIFIER", 314, 319], ["multimorbidity", "OBSERVATION", 320, 334], ["may be", "UNCERTAINTY", 403, 409], ["severe", "OBSERVATION_MODIFIER", 431, 437]]], ["We developed a tool for rapid assessments of the number and percentage of country populations that would need to be targeted under different shielding policies.Implications of all the available evidenceQuantifying how many and who is at increased risk of severe COVID-19 illness is critical to help countries design more effective interventions to protect vulnerable individuals and reduce pressure on health systems.", [["COVID", "DISEASE", 262, 267], ["illness", "DISEASE", 271, 278], ["rapid assessments", "TEST", 24, 41], ["different shielding policies", "TREATMENT", 131, 159], ["severe COVID", "PROBLEM", 255, 267], ["effective interventions", "TREATMENT", 321, 344], ["vulnerable individuals", "PROBLEM", 356, 378], ["pressure on health systems", "PROBLEM", 390, 416], ["severe", "OBSERVATION_MODIFIER", 255, 261], ["pressure", "OBSERVATION_MODIFIER", 390, 398]]], ["This information can also inform a broader assessment of the health, social and economic implications of shielding various groups.IntroductionEmerging evidence from China, Europe and the USA has shown a consistently higher risk of severe COVID-19 disease in older individuals and those with underlying health conditions.", [["a broader assessment", "TEST", 33, 53], ["shielding various groups", "TREATMENT", 105, 129], ["the USA", "TEST", 183, 190], ["severe COVID-19 disease in older individuals", "PROBLEM", 231, 275], ["underlying health conditions", "PROBLEM", 291, 319], ["severe", "OBSERVATION_MODIFIER", 231, 237]]], ["1-3 Mild and moderate cases are those with symptoms but without evidence of pneumonia or dyspnea, and low mortality is expected in this group.", [["pneumonia", "DISEASE", 76, 85], ["dyspnea", "DISEASE", 89, 96], ["3 Mild and moderate cases", "PROBLEM", 2, 27], ["symptoms", "PROBLEM", 43, 51], ["pneumonia", "PROBLEM", 76, 85], ["dyspnea", "PROBLEM", 89, 96], ["low mortality", "PROBLEM", 102, 115], ["Mild", "OBSERVATION_MODIFIER", 4, 8], ["moderate", "OBSERVATION_MODIFIER", 13, 21], ["cases", "OBSERVATION", 22, 27], ["without evidence of", "UNCERTAINTY", 56, 75], ["pneumonia", "OBSERVATION", 76, 85], ["dyspnea", "OBSERVATION", 89, 96], ["low", "OBSERVATION_MODIFIER", 102, 105], ["mortality", "OBSERVATION_MODIFIER", 106, 115]]], ["Severe cases have those symptoms, would require hospitalisation if available, and are at risk of increased mortality.", [["Severe cases", "PROBLEM", 0, 12], ["those symptoms", "PROBLEM", 18, 32], ["increased mortality", "PROBLEM", 97, 116], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["mortality", "OBSERVATION", 107, 116]]], ["4, 5 In a recent report from the USA, underlying conditions were reported in 71% (732/1037) of individuals hospitalised with COVID-19 and 94% (173/184) of deaths.", [["COVID", "DISEASE", 125, 130], ["deaths", "DISEASE", 155, 161], ["COVID", "TEST", 125, 130]]], ["1 The World Health Organization (WHO) as well as public health agencies in countries including the UK and US, have issued guidelines on who is considered to be at increased risk of severe COVID-19 illness.", [["COVID", "DISEASE", 188, 193], ["severe COVID-19 illness", "PROBLEM", 181, 204], ["severe", "OBSERVATION_MODIFIER", 181, 187]]], ["[6] [7] [8] This includes individuals with cardiovascular disease (CVD), chronic kidney disease (CKD), diabetes, chronic respiratory disease (CRD) and a range of other chronic conditions.", [["cardiovascular", "ANATOMY", 43, 57], ["kidney", "ANATOMY", 81, 87], ["respiratory", "ANATOMY", 121, 132], ["cardiovascular disease", "DISEASE", 43, 65], ["CVD", "DISEASE", 67, 70], ["chronic kidney disease", "DISEASE", 73, 95], ["CKD", "DISEASE", 97, 100], ["diabetes", "DISEASE", 103, 111], ["chronic respiratory disease", "DISEASE", 113, 140], ["CRD", "DISEASE", 142, 145], ["cardiovascular", "ANATOMICAL_SYSTEM", 43, 57], ["kidney", "ORGAN", 81, 87], ["cardiovascular disease (CVD)", "PROBLEM", 43, 71], ["chronic kidney disease", "PROBLEM", 73, 95], ["CKD)", "PROBLEM", 97, 101], ["diabetes", "PROBLEM", 103, 111], ["chronic respiratory disease (CRD)", "PROBLEM", 113, 146], ["other chronic conditions", "PROBLEM", 162, 186], ["cardiovascular", "ANATOMY", 43, 57], ["disease", "OBSERVATION", 58, 65], ["chronic", "OBSERVATION_MODIFIER", 73, 80], ["kidney", "ANATOMY", 81, 87], ["disease", "OBSERVATION", 88, 95], ["CKD", "OBSERVATION", 97, 100], ["diabetes", "OBSERVATION", 103, 111], ["chronic", "OBSERVATION_MODIFIER", 113, 120], ["respiratory disease", "OBSERVATION", 121, 140], ["chronic", "OBSERVATION_MODIFIER", 168, 175], ["conditions", "OBSERVATION", 176, 186]]], ["Such conditions increase the risk of needing hospital-based treatment such as oxygen supplementation or mechanical ventilation.", [["oxygen", "CHEMICAL", 78, 84], ["oxygen", "CHEMICAL", 78, 84], ["oxygen", "SIMPLE_CHEMICAL", 78, 84], ["Such conditions", "PROBLEM", 0, 15], ["hospital-based treatment", "TREATMENT", 45, 69], ["oxygen supplementation", "TREATMENT", 78, 100], ["mechanical ventilation", "TREATMENT", 104, 126], ["mechanical ventilation", "OBSERVATION", 104, 126]]], ["A large proportion of the additional health care burden of COVID-19 epidemics is likely to result from infection of those with underlying conditions.", [["COVID", "DISEASE", 59, 64], ["infection", "DISEASE", 103, 112], ["COVID", "TEST", 59, 64], ["epidemics", "PROBLEM", 68, 77], ["infection", "PROBLEM", 103, 112], ["underlying conditions", "PROBLEM", 127, 148], ["large", "OBSERVATION_MODIFIER", 2, 7], ["proportion", "OBSERVATION_MODIFIER", 8, 18], ["likely to", "UNCERTAINTY", 81, 90], ["infection", "OBSERVATION", 103, 112]]], ["Identifying at-risk populations is important not only for making projections of the likely health burden in countries, 9, 10 but also for the design of effective strategies that aim to reduce the risk of transmission to people in target groups.", [["people", "ORGANISM", 220, 226], ["people", "SPECIES", 220, 226], ["effective strategies", "TREATMENT", 152, 172]]], ["This is sometimes termed shielding, defined as \"a measure to protect extremely vulnerable people by minimising interaction between those who are extremely vulnerable and others.\" 11 It has the potential to reduce mortality in vulnerable groups (direct benefits), while at the same time mitigating the expected surge in demand for hospital beds (indirect benefits), which is critical where systems risk being strained by the national epidemic.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["A detailed assessment of the number of at-risk individuals can inform possible shielding strategies.", [["A detailed assessment", "TEST", 0, 21], ["shielding strategies", "TREATMENT", 79, 99]]], ["If a vaccine becomes available in the future, it could also be used to inform the process of prioritising different groups, based on risk.IntroductionThe aim of this work is to provide global, regional and national estimates of the numbers of individuals at increased risk of severe COVID-19 disease by virtue of their underlying medical conditions during 2020.", [["COVID", "DISEASE", 283, 288], ["a vaccine", "TREATMENT", 3, 12], ["prioritising different groups", "TREATMENT", 93, 122], ["severe COVID-19 disease", "PROBLEM", 276, 299], ["severe", "OBSERVATION_MODIFIER", 276, 282]]], ["The risk of severe COVID-19 disease is not binary, but unless tiered approaches are adopted, the criterion for whom to shield is, so our estimates seek to capture all those 'at increased risk' (UK terminology) or 'at higher risk' (US terminology) based on current guidelines.Prevalence of underlying health conditionsWe used the list of conditions thought to increase the risk of severe COVID-19 illness, based on current guidelines from WHO and public health agencies in the UK and US (supplementary appendix) [6] [7] [8] and mapped these to eleven categories of underlying health conditions in the Global Burden of Disease Study (GBD).", [["COVID", "DISEASE", 19, 24], ["COVID", "DISEASE", 387, 392], ["illness", "DISEASE", 396, 403], ["Burden of Disease", "DISEASE", 607, 624], ["severe COVID-19 disease", "PROBLEM", 12, 35], ["underlying health conditions", "PROBLEM", 289, 317], ["severe COVID-19 illness", "PROBLEM", 380, 403], ["underlying health conditions", "PROBLEM", 564, 592], ["severe", "OBSERVATION_MODIFIER", 12, 18], ["severe", "OBSERVATION_MODIFIER", 380, 386], ["Disease", "OBSERVATION", 617, 624]]], ["Prevalence estimates were extracted for the following disease categories by age, sex and country:Prevalence of underlying health conditions(1) CVD, including CVD caused by hypertension; (2) CKD, including CKD caused by hypertension; (3) CRD; (4) chronic liver disease; (5) diabetes; (6) cancers with direct immunosuppression; (7) cancers without direct immunosuppression, but with possible immunosuppression caused by treatment; (8) HIV/AIDS; (9) tuberculosis; (10) chronic neurological disorders; and (11) sickle cell disorders.Prevalence of underlying health conditionsWe estimate the current number of individuals with underlying conditions making them at risk of severe COVID-19 disease by age (5-year age groups), sex and country for 188 countries.", [["liver", "ANATOMY", 254, 259], ["cancers", "ANATOMY", 287, 294], ["cancers", "ANATOMY", 330, 337], ["neurological", "ANATOMY", 474, 486], ["sickle cell", "ANATOMY", 507, 518], ["CVD", "DISEASE", 143, 146], ["CVD", "DISEASE", 158, 161], ["hypertension", "DISEASE", 172, 184], ["CKD", "DISEASE", 190, 193], ["CKD", "DISEASE", 205, 208], ["hypertension", "DISEASE", 219, 231], ["CRD", "DISEASE", 237, 240], ["chronic liver disease", "DISEASE", 246, 267], ["diabetes", "DISEASE", 273, 281], ["cancers", "DISEASE", 287, 294], ["cancers", "DISEASE", 330, 337], ["HIV/AIDS", "DISEASE", 433, 441], ["tuberculosis", "DISEASE", 447, 459], ["chronic neurological disorders", "DISEASE", 466, 496], ["sickle cell disorders", "DISEASE", 507, 528], ["COVID", "DISEASE", 674, 679], ["liver", "ORGAN", 254, 259], ["cancers", "CANCER", 287, 294], ["cancers", "CANCER", 330, 337], ["sickle cell", "CELL", 507, 518], ["HIV", "SPECIES", 433, 436], ["CVD", "PROBLEM", 143, 146], ["CVD", "PROBLEM", 158, 161], ["hypertension", "PROBLEM", 172, 184], ["CKD", "PROBLEM", 190, 193], ["CKD", "PROBLEM", 205, 208], ["hypertension", "PROBLEM", 219, 231], ["CRD", "PROBLEM", 237, 240], ["chronic liver disease", "PROBLEM", 246, 267], ["diabetes", "PROBLEM", 273, 281], ["cancers", "PROBLEM", 287, 294], ["direct immunosuppression", "TREATMENT", 300, 324], ["cancers", "PROBLEM", 330, 337], ["direct immunosuppression", "TREATMENT", 346, 370], ["immunosuppression", "TREATMENT", 390, 407], ["HIV/AIDS", "PROBLEM", 433, 441], ["tuberculosis", "PROBLEM", 447, 459], ["chronic neurological disorders", "PROBLEM", 466, 496], ["sickle cell disorders", "PROBLEM", 507, 528], ["underlying health conditions", "PROBLEM", 543, 571], ["underlying conditions", "PROBLEM", 622, 643], ["severe COVID-19 disease", "PROBLEM", 667, 690], ["hypertension", "OBSERVATION", 172, 184], ["CKD", "OBSERVATION", 205, 208], ["hypertension", "OBSERVATION", 219, 231], ["chronic", "OBSERVATION_MODIFIER", 246, 253], ["liver", "ANATOMY", 254, 259], ["disease", "OBSERVATION", 260, 267], ["tuberculosis", "OBSERVATION", 447, 459], ["chronic", "OBSERVATION_MODIFIER", 466, 473], ["neurological disorders", "OBSERVATION", 474, 496], ["sickle cell disorders", "OBSERVATION", 507, 528], ["severe", "OBSERVATION_MODIFIER", 667, 673]]], ["Data on the prevalence of underlying conditions were extracted by age, sex and country from the GBD study for 2017 12 and combined with United Nations mid-year population estimates for 2020.", [["underlying conditions", "PROBLEM", 26, 47], ["the GBD study", "TEST", 92, 105]]], ["13 For this analysis, older individuals without underlying conditions were not considered to be at increased risk.Prevalence of underlying health conditionsAsthma is relatively common, and mild asthma is not listed as a high risk group for shielding so we modified GBD estimates of asthma to account only for moderate-to-severe cases (defined as British Thoracic Society Steps 4, 5 and 6).", [["Asthma", "DISEASE", 156, 162], ["asthma", "DISEASE", 194, 200], ["asthma", "DISEASE", 282, 288], ["individuals", "ORGANISM", 28, 39], ["this analysis", "TEST", 7, 20], ["underlying conditions", "PROBLEM", 48, 69], ["Asthma", "PROBLEM", 156, 162], ["mild asthma", "PROBLEM", 189, 200], ["asthma", "PROBLEM", 282, 288], ["moderate-to-severe cases", "PROBLEM", 309, 333], ["mild", "OBSERVATION_MODIFIER", 189, 193], ["asthma", "OBSERVATION", 194, 200], ["asthma", "OBSERVATION", 282, 288], ["Thoracic", "ANATOMY", 354, 362]]], ["14 Based on published evidence from the UK we assumed these were 15% of total asthma cases aged <5 years, 17% aged 5-19 years, 23% aged 20-54 years, and 43% in those aged 55+ years.", [["asthma", "DISEASE", 78, 84], ["total asthma cases", "PROBLEM", 72, 90]]], ["15 For HIV/AIDS, we included all populations, including those on ART.", [["HIV/AIDS", "DISEASE", 7, 15], ["HIV", "SPECIES", 7, 10], ["HIV", "SPECIES", 7, 10], ["HIV/AIDS", "PROBLEM", 7, 15]]], ["However, we carried out a sensitivity analysis to determine how estimates would change if we removed individuals using antiretroviral therapy (ART) for instance if there is found to be no additional risk of HIV in individuals on ART.", [["HIV", "ORGANISM", 207, 210], ["HIV", "SPECIES", 207, 210], ["a sensitivity analysis", "TEST", 24, 46], ["antiretroviral therapy", "TREATMENT", 119, 141], ["HIV", "PROBLEM", 207, 210], ["HIV", "OBSERVATION", 207, 210]]], ["We used WHO national estimates for ART coverage among those living with HIV/AIDS.", [["HIV/AIDS", "DISEASE", 72, 80], ["HIV", "SPECIES", 72, 75], ["HIV", "SPECIES", 72, 75], ["ART coverage", "TREATMENT", 35, 47]]], ["16Proportion with at least one underlying condition relevant to severe COVID-19 diseaseThe GBD study provides prevalence estimates for each disease category separately, but not for the prevalence of people in at least 1 of these categories.", [["COVID-19 disease", "DISEASE", 71, 87], ["people", "ORGANISM", 199, 205], ["people", "SPECIES", 199, 205], ["severe COVID-19 disease", "PROBLEM", 64, 87], ["The GBD study", "TEST", 87, 100], ["severe", "OBSERVATION_MODIFIER", 64, 70]]], ["One problem was that diseases may cluster, for example if they are causally related, and we incorporated this effect for each country, sex and age group (but we omit subscripts for clarity).", [["diseases", "PROBLEM", 21, 29], ["diseases", "OBSERVATION", 21, 29]]], ["We first calculated , which is the expected proportion of individuals with at least one condition assuming that the prevalences of the underlying conditions are independent (e.g. the fact that someone has diabetes does not affect their risk of getting cancer) as 1 minus the probability of not having any of the conditions c1, c2, c3\u2026.i.e.", [["cancer", "ANATOMY", 252, 258], ["diabetes", "DISEASE", 205, 213], ["cancer", "DISEASE", 252, 258], ["cancer", "CANCER", 252, 258], ["the underlying conditions", "PROBLEM", 131, 156], ["diabetes", "PROBLEM", 205, 213], ["cancer", "PROBLEM", 252, 258], ["c2", "ANATOMY", 327, 329]]], ["1 -(1 -p_c1) x (1 -p_c2) x (1 -p_c3)\u2026.", [["1 -(1 -p_c1) x (1 -p_c2) x (1 -p_c3", "SIMPLE_CHEMICAL", 0, 35], ["p_c1) x (1 -p_c2)", "TREATMENT", 7, 24]]], ["We then estimated the proportion , who have at least one underlying condition as = \u00d7 , where is the ratio between the observed and expected percentage of individuals with at least one condition.", [["condition", "OBSERVATION", 68, 77]]], ["The ratio is drawn from evidence from two large cross-sectional multimorbidity studies in Scotland 17 and Southern China 18 (supplementary appendix).Adjustment for multimorbidityIn addition to providing estimates for , the studies in Scotland and Southern China were also used to calculate the multimorbidity fraction i.e. the proportion of individuals with multiple (two or more) underlying conditions among those with at least one, by age group and sex.", [["appendix", "ORGAN", 139, 147], ["The ratio", "TEST", 0, 9], ["multimorbidity", "PROBLEM", 164, 178], ["the studies", "TEST", 219, 230], ["multiple (two or more) underlying conditions", "PROBLEM", 358, 402], ["large", "OBSERVATION_MODIFIER", 42, 47], ["multimorbidity", "OBSERVATION", 164, 178]]], ["All analyses were done using disease categories that matched as closely as possible to the COVID-19-relevant categories defined in our analysis.", [["COVID-19", "DNA", 91, 99], ["All analyses", "TEST", 0, 12], ["disease categories", "TREATMENT", 29, 47], ["the COVID", "TEST", 87, 96], ["our analysis", "TEST", 131, 143]]], ["In both studies this included: CVD (defined as the presence of one or more of coronary heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, heart failure, or atrial fibrillation); chronic neurological disease (defined as one or more of dementia, multiple sclerosis and Parkinson's disease); and CRD (defined as one or both of chronic obstructive pulmonary disease and bronchiectasis).", [["coronary", "ANATOMY", 78, 86], ["heart", "ANATOMY", 87, 92], ["cerebrovascular", "ANATOMY", 116, 131], ["peripheral arterial", "ANATOMY", 141, 160], ["heart", "ANATOMY", 170, 175], ["atrial", "ANATOMY", 188, 194], ["neurological", "ANATOMY", 218, 230], ["pulmonary", "ANATOMY", 376, 385], ["CVD", "DISEASE", 31, 34], ["coronary heart disease", "DISEASE", 78, 100], ["hypertension", "DISEASE", 102, 114], ["cerebrovascular disease", "DISEASE", 116, 139], ["peripheral arterial disease", "DISEASE", 141, 168], ["heart failure", "DISEASE", 170, 183], ["atrial fibrillation", "DISEASE", 188, 207], ["chronic neurological disease", "DISEASE", 210, 238], ["dementia", "DISEASE", 266, 274], ["multiple sclerosis", "DISEASE", 276, 294], ["Parkinson's disease", "DISEASE", 299, 318], ["CRD", "DISEASE", 325, 328], ["chronic obstructive pulmonary disease", "DISEASE", 356, 393], ["bronchiectasis", "DISEASE", 398, 412], ["heart", "ORGAN", 87, 92], ["cerebrovascular", "MULTI-TISSUE_STRUCTURE", 116, 131], ["peripheral arterial", "MULTI-TISSUE_STRUCTURE", 141, 160], ["heart", "ORGAN", 170, 175], ["pulmonary", "ORGAN", 376, 385], ["CVD", "PROBLEM", 31, 34], ["coronary heart disease", "PROBLEM", 78, 100], ["hypertension", "PROBLEM", 102, 114], ["cerebrovascular disease", "PROBLEM", 116, 139], ["peripheral arterial disease", "PROBLEM", 141, 168], ["heart failure", "PROBLEM", 170, 183], ["atrial fibrillation", "PROBLEM", 188, 207], ["chronic neurological disease", "PROBLEM", 210, 238], ["dementia", "PROBLEM", 266, 274], ["multiple sclerosis", "PROBLEM", 276, 294], ["Parkinson's disease)", "PROBLEM", 299, 319], ["CRD", "PROBLEM", 325, 328], ["chronic obstructive pulmonary disease", "PROBLEM", 356, 393], ["bronchiectasis", "PROBLEM", 398, 412], ["coronary heart", "ANATOMY", 78, 92], ["disease", "OBSERVATION", 93, 100], ["hypertension", "OBSERVATION", 102, 114], ["cerebrovascular disease", "OBSERVATION", 116, 139], ["peripheral", "ANATOMY_MODIFIER", 141, 151], ["arterial", "ANATOMY", 152, 160], ["disease", "OBSERVATION", 161, 168], ["heart", "ANATOMY", 170, 175], ["failure", "OBSERVATION", 176, 183], ["atrial", "ANATOMY", 188, 194], ["fibrillation", "OBSERVATION", 195, 207], ["chronic", "OBSERVATION_MODIFIER", 210, 217], ["neurological disease", "OBSERVATION", 218, 238], ["multiple", "OBSERVATION_MODIFIER", 276, 284], ["sclerosis", "OBSERVATION", 285, 294], ["chronic", "OBSERVATION_MODIFIER", 356, 363], ["obstructive", "OBSERVATION_MODIFIER", 364, 375], ["pulmonary", "ANATOMY", 376, 385], ["disease", "OBSERVATION", 386, 393], ["bronchiectasis", "OBSERVATION", 398, 412]]], ["The GBD provide separate estimates for hypertensive heart disease and CKD due to hypertension, but it was not possible to make this distinction in the multimorbidity datasets, so all hypertension was included in the CVD category.Adjustment for multimorbidityUsing the data from both studies, we calculated pooled estimates of the ratio , and the multimorbidity fraction by age and sex (supplementary appendix) and extrapolated these pooled estimates to all countries included in the analysis.Adjustment for multimorbidity.", [["heart", "ANATOMY", 52, 57], ["hypertensive heart disease", "DISEASE", 39, 65], ["CKD", "DISEASE", 70, 73], ["hypertension", "DISEASE", 81, 93], ["hypertension", "DISEASE", 183, 195], ["CVD", "DISEASE", 216, 219], ["heart", "ORGAN", 52, 57], ["GBD", "PROTEIN", 4, 7], ["hypertensive heart disease", "PROBLEM", 39, 65], ["CKD", "PROBLEM", 70, 73], ["hypertension", "PROBLEM", 81, 93], ["all hypertension", "PROBLEM", 179, 195], ["multimorbidity", "PROBLEM", 244, 258], ["both studies", "TEST", 278, 290], ["the ratio", "TEST", 326, 335], ["the multimorbidity fraction", "PROBLEM", 342, 369], ["the analysis", "TEST", 479, 491], ["multimorbidity", "PROBLEM", 507, 521], ["heart", "ANATOMY", 52, 57], ["disease", "OBSERVATION", 58, 65], ["CKD", "OBSERVATION", 70, 73], ["hypertension", "OBSERVATION", 81, 93], ["hypertension", "OBSERVATION", 183, 195], ["multimorbidity", "OBSERVATION", 244, 258], ["appendix", "ANATOMY", 400, 408], ["multimorbidity", "OBSERVATION", 507, 521]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)Adjustment for multimorbidityThe copyright holder for this preprint this version posted April 22, 2020Inclusion of older individuals without underlying conditionsSome countries have also considered older age as proxy for frailty and increased risk of severe COVID-19 illness.", [["CC", "CHEMICAL", 0, 2], ["frailty", "DISEASE", 417, 424], ["COVID", "DISEASE", 454, 459], ["CC", "TEST", 0, 2], ["multimorbidity", "PROBLEM", 211, 225], ["The copyright holder", "TREATMENT", 225, 245], ["underlying conditions", "PROBLEM", 337, 358], ["frailty", "PROBLEM", 417, 424], ["severe COVID", "PROBLEM", 447, 459], ["med", "ANATOMY", 99, 102], ["multimorbidity", "OBSERVATION", 211, 225], ["severe", "OBSERVATION_MODIFIER", 447, 453]]], ["Although frailty correlates much more closely with mortality than chronological age, there is a well-established non-linear association between increasing age and frailty.", [["frailty", "DISEASE", 163, 170]]], ["19 We therefore calculated the number of individuals without an underlying condition that could be considered at-risk because of their age, using age thresholds ranging from 50-70 years.", [["an underlying condition", "PROBLEM", 61, 84]]], ["To calculate the total number at increased risk for different age thresholds, we added the number of older individuals without underlying conditions to our earlier estimates of the number of individuals with at least one underlying condition.UncertaintyWe generated low and high estimates using the lower and upper 95% confidence limits for the country population size, individual disease prevalences and age-specific multimorbidity fraction.", [["underlying conditions", "PROBLEM", 127, 148], ["individual disease prevalences", "PROBLEM", 370, 400], ["low", "OBSERVATION_MODIFIER", 266, 269], ["high", "OBSERVATION_MODIFIER", 274, 278], ["lower", "ANATOMY_MODIFIER", 299, 304], ["size", "OBSERVATION_MODIFIER", 364, 368]]], ["We also varied , the ratio between the observed and expected percentage of individuals with at least one condition, by a range informed by the multimorbidity studies.UncertaintyAll analyses are provided in an Excel spreadsheet, available at https://cmmid.github.io/topics/covid19/.Individuals with at least one underlying condition at risk of severe COVID-19 diseaseWe estimate that 1.7 billion (1.0 -2.4) individuals (22% [15-28%] of the global population) have at least one underlying condition that could increase their risk of severe COVID-19 disease (table 1, supplementary appendix).", [["COVID", "DISEASE", 538, 543], ["individuals", "ORGANISM", 406, 417], ["appendix", "ORGAN", 579, 587], ["the multimorbidity studies", "TEST", 139, 165], ["severe COVID", "PROBLEM", 343, 355], ["individuals", "TEST", 406, 417], ["severe COVID-19 disease", "PROBLEM", 531, 554], ["severe", "OBSERVATION_MODIFIER", 343, 349], ["severe", "OBSERVATION_MODIFIER", 531, 537], ["appendix", "ANATOMY", 579, 587]]], ["This value does not include older individuals without underlying conditions.", [["underlying conditions", "PROBLEM", 54, 75]]], ["The most prevalent conditions in those aged 50+ years were CKD, CVD, CRD and diabetes.Individuals with at least one underlying condition at risk of severe COVID-19 diseaseBased on crude proportions without age-standardisation, the share of the population at-risk ranged from 16% in Africa to 31% in Europe (table 1)(figures 2 and 3).", [["CKD", "DISEASE", 59, 62], ["CVD", "DISEASE", 64, 67], ["CRD", "DISEASE", 69, 72], ["diabetes", "DISEASE", 77, 85], ["COVID", "DISEASE", 155, 160], ["CKD", "PROBLEM", 59, 62], ["CVD", "PROBLEM", 64, 67], ["CRD", "PROBLEM", 69, 72], ["diabetes", "PROBLEM", 77, 85], ["severe COVID", "PROBLEM", 148, 160], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["CRD", "OBSERVATION_MODIFIER", 69, 72], ["diabetes", "OBSERVATION", 77, 85]]], ["The highest estimates were in European and other high-income countries with a high prevalence of CKD, CVD, diabetes and CRD in older ages.", [["CKD", "DISEASE", 97, 100], ["CVD", "DISEASE", 102, 105], ["diabetes", "DISEASE", 107, 115], ["CRD", "DISEASE", 120, 123], ["CKD", "PROBLEM", 97, 100], ["CVD", "PROBLEM", 102, 105], ["diabetes", "PROBLEM", 107, 115], ["CRD", "PROBLEM", 120, 123], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["CKD", "OBSERVATION", 97, 100], ["diabetes", "OBSERVATION", 107, 115], ["CRD", "OBSERVATION_MODIFIER", 120, 123]]], ["African countries with a high prevalence of HIV/AIDS and Island countries with a high prevalence of diabetes, also had a high share of the population at increased risk.Individuals with at least one underlying condition at risk of severe COVID-19 diseaseIn African countries with high HIV prevalence excluding those on ART reduced the at-risk proportion e.g. from 27 to 20% in Botswana, 30 to 24% in Lesotho, 27 to 23% in South Africa and 29 to 19% in Swaziland.Individuals with at least one underlying condition at risk of severe COVID-19 diseaseWe estimate that 23% (range 15-38%) of the working age population (15-64 years) have at least one underlying condition (figure 4).", [["HIV/AIDS", "DISEASE", 44, 52], ["diabetes", "DISEASE", 100, 108], ["COVID", "DISEASE", 237, 242], ["COVID", "DISEASE", 530, 535], ["HIV", "SPECIES", 44, 47], ["HIV", "SPECIES", 284, 287], ["HIV/AIDS", "PROBLEM", 44, 52], ["diabetes", "PROBLEM", 100, 108], ["severe COVID", "PROBLEM", 230, 242], ["South Africa", "TEST", 421, 433], ["severe COVID", "PROBLEM", 523, 535], ["diabetes", "OBSERVATION", 100, 108], ["severe", "OBSERVATION_MODIFIER", 523, 529]]], ["This proportion was particularly high in some European countries, and Island countries with high rates of diabetes (figure 3).", [["diabetes", "DISEASE", 106, 114], ["diabetes", "PROBLEM", 106, 114], ["high", "OBSERVATION_MODIFIER", 33, 37]]], ["CKD and diabetes were the most common conditions in this age range.Individuals with multimorbidities associated with severe COVID-19 diseaseAmong the 1.7 billion individuals estimated to be at increased risk, we estimate that 0.4 billion (0.2 -0.7) individuals (6% [3-8%] of the global population) are living with two or more conditions relevant to COVID-19 outcomes in the year 2020 (table 1, supplementary appendix).", [["CKD", "DISEASE", 0, 3], ["diabetes", "DISEASE", 8, 16], ["multimorbidities", "DISEASE", 84, 100], ["COVID", "DISEASE", 124, 129], ["appendix", "ORGAN", 408, 416], ["CKD", "PROBLEM", 0, 3], ["diabetes", "PROBLEM", 8, 16], ["multimorbidities", "PROBLEM", 84, 100], ["severe COVID-19 diseaseAmong", "PROBLEM", 117, 145], ["individuals", "TEST", 249, 260], ["COVID", "TEST", 349, 354], ["diabetes", "OBSERVATION", 8, 16], ["most common", "OBSERVATION_MODIFIER", 26, 37], ["appendix", "ANATOMY", 408, 416]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprint proportion was higher in regions with an older age profile.", [["medRxiv", "GENE_OR_GENE_PRODUCT", 17, 24], ["higher", "OBSERVATION_MODIFIER", 49, 55]]], ["The prevalence of multimorbidity (two or more underlying conditions) was three times higher in Europe than in Africa (10% vs 3%) (table 1) .Inclusion of older individuals without underlying conditionsThe number of individuals without an underlying condition that could be considered at-risk solely because of their age varied by region and choice of age threshold (table 1).", [["multimorbidity", "DISEASE", 18, 32], ["multimorbidity", "PROBLEM", 18, 32], ["underlying conditions", "PROBLEM", 179, 200], ["an underlying condition", "PROBLEM", 234, 257], ["multimorbidity", "OBSERVATION", 18, 32], ["conditions", "OBSERVATION", 190, 200]]], ["In Africa, around 5% of individuals aged 50+ years are estimated to have no underlying conditions linked to severe COVID-19 disease.", [["COVID", "DISEASE", 115, 120], ["individuals", "ORGANISM", 24, 35], ["underlying conditions", "PROBLEM", 76, 97], ["severe COVID-19 disease", "PROBLEM", 108, 131], ["severe", "OBSERVATION_MODIFIER", 108, 114], ["19 disease", "OBSERVATION", 121, 131]]], ["A similar proportion is estimated at age 65+ years in Europe, North America and Oceania, and at 60+ years in Asia and Latin America.New analysis of cross-sectional multimorbidity studiesThe ratio was broadly consistent by age, sex and study (supplementary appendix).", [["New analysis", "TEST", 132, 144], ["cross-sectional multimorbidity studies", "TEST", 148, 186], ["The ratio", "TEST", 186, 195]]], ["When extrapolating this value to other countries, we used a transparent ratio of 0.9 for all age groups and varied this between 0.7 and 1.0 in our low and high estimates.", [["a transparent ratio", "TEST", 58, 77]]], ["The resulting national estimates of were constrained to be no less than each country's single most prevalent condition.New analysis of cross-sectional multimorbidity studiesWe estimated that <10% of individuals with underlying conditions have multiple conditions before 30 years of age, but this increased to about 40% by age 70 years (supplementary appendix).", [["appendix", "ORGAN", 350, 358], ["New analysis", "TEST", 119, 131], ["cross-sectional multimorbidity studies", "TEST", 135, 173], ["underlying conditions", "PROBLEM", 216, 237], ["appendix", "ANATOMY", 350, 358]]], ["The most common combinations in both studies were CVD plus diabetes, CVD plus CKD and CVD plus CRD.DiscussionBased on current guidelines and prevalence estimates from GBD, we calculate that one in every five individuals worldwide has a condition that is on the list of those at increased risk of severe COVID-19 disease.", [["CVD", "DISEASE", 50, 53], ["diabetes", "DISEASE", 59, 67], ["CVD", "DISEASE", 69, 72], ["CKD", "DISEASE", 78, 81], ["CVD", "DISEASE", 86, 89], ["CRD", "DISEASE", 95, 98], ["COVID", "DISEASE", 303, 308], ["CVD", "PROBLEM", 50, 53], ["diabetes", "PROBLEM", 59, 67], ["CVD", "PROBLEM", 69, 72], ["CKD", "PROBLEM", 78, 81], ["CVD", "PROBLEM", 86, 89], ["CRD", "PROBLEM", 95, 98], ["severe COVID-19 disease", "PROBLEM", 296, 319], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["CKD", "OBSERVATION", 78, 81], ["severe", "OBSERVATION_MODIFIER", 296, 302], ["19 disease", "OBSERVATION", 309, 319]]], ["However, for many of these individuals the underlying condition will be undiagnosed or not severe enough to be captured in health systems.", [["undiagnosed", "PROBLEM", 72, 83]]], ["Indeed, most will not progress to severe COVID-19 disease or death if infected with SARS-Cov-2.", [["COVID", "DISEASE", 41, 46], ["death", "DISEASE", 61, 66], ["SARS", "DISEASE", 84, 88], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 84, 94], ["severe COVID-19 disease", "PROBLEM", 34, 57], ["death", "PROBLEM", 61, 66], ["SARS", "PROBLEM", 84, 88]]], ["1 However, because severe COVID-19 outcomes are disproportionately found in individuals with underlying conditions, 1 protecting these groups may be one of the most effective ways to reduce mortality and demand for hospital beds.", [["severe COVID-19 outcomes", "PROBLEM", 19, 43], ["underlying conditions", "PROBLEM", 93, 114], ["hospital beds", "TREATMENT", 215, 228], ["severe", "OBSERVATION_MODIFIER", 19, 25]]], ["The GBD study produces estimates of disease prevalence for all ages, both sexes, and for 195 territories and countries from 1990-2017.", [["The GBD study", "TEST", 0, 13], ["disease prevalence", "PROBLEM", 36, 54], ["disease", "OBSERVATION", 36, 43]]], ["21 Because the GBD produces internally comparable estimates for a comprehensive list of diseases, these estimates are well suited to compare prevalence of disease across locations.DiscussionA recent analysis from Sweden 22 provides an opportunity to evaluate our method, and compare GBD prevalence estimates to those derived from electronic health record (EHR) data.", [["GBD", "PROTEIN", 15, 18], ["diseases", "PROBLEM", 88, 96], ["disease across locations", "PROBLEM", 155, 179], ["diseases", "OBSERVATION", 88, 96], ["disease", "OBSERVATION", 155, 162]]], ["When we applied our method, based on the calculation of and , to the prevalence of each condition reported in the study, we were able to reproduce the same percentage share of the population at increased risk.", [["the study", "TEST", 110, 119], ["increased", "OBSERVATION_MODIFIER", 194, 203]]], ["The GBD prevalence estimates for Sweden were substantially higher than the estimates from the EHR data, and so we estimate a much higher proportion of the population to be at increased risk (35 vs 22%).", [["the EHR data", "TEST", 90, 102]]], ["For example, over half of the CKD cases included in GBD prevalence estimates represent early stage disease (CKD stage 1 or 2) which is common and rarely has symptoms.", [["CKD", "DISEASE", 30, 33], ["CKD", "DISEASE", 108, 111], ["the CKD cases", "PROBLEM", 26, 39], ["early stage disease (CKD stage 1", "PROBLEM", 87, 119], ["symptoms", "PROBLEM", 157, 165], ["CKD", "OBSERVATION", 30, 33], ["early stage", "OBSERVATION_MODIFIER", 87, 98], ["disease", "OBSERVATION", 99, 106]]], ["23 Several other underlying conditions estimated by GBD are also likely to be undiagnosed in many individuals e.g. hypertensive heart disease, compensated chronic liver disease, .", [["heart", "ANATOMY", 128, 133], ["liver", "ANATOMY", 163, 168], ["hypertensive", "DISEASE", 115, 127], ["heart disease", "DISEASE", 128, 141], ["chronic liver disease", "DISEASE", 155, 176], ["heart", "ORGAN", 128, 133], ["liver", "ORGAN", 163, 168], ["Several other underlying conditions", "PROBLEM", 3, 38], ["hypertensive heart disease", "PROBLEM", 115, 141], ["compensated chronic liver disease", "PROBLEM", 143, 176], ["conditions", "OBSERVATION", 28, 38], ["likely to be", "UNCERTAINTY", 65, 77], ["undiagnosed", "OBSERVATION", 78, 89], ["hypertensive", "OBSERVATION", 115, 127], ["heart", "ANATOMY", 128, 133], ["disease", "OBSERVATION", 134, 141], ["compensated", "OBSERVATION_MODIFIER", 143, 154], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["liver", "ANATOMY", 163, 168], ["disease", "OBSERVATION", 169, 176]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprint early onset diabetes etc. This has important implications for the interpretation of our estimates because it suggests, based on this initial comparison exercise for one country, that around one-third of those estimated to have an underlying condition may be undiagnosed or not severe enough to be captured in EHRs.", [["diabetes etc", "DISEASE", 46, 58], ["early onset diabetes etc", "PROBLEM", 34, 58], ["an underlying condition", "PROBLEM", 261, 284], ["diabetes", "OBSERVATION", 46, 54]]], ["For these individuals, shielding policies may not identify them, and perhaps more importantly, their increase in risk may be quite modest.(which was not certified by peer review)If a safe and effective vaccine is produced, then our estimates provide an indication of the volumes that would be required for vaccination of at-risk individuals globally.", [["shielding policies", "TREATMENT", 23, 41], ["a safe and effective vaccine", "TREATMENT", 181, 209], ["vaccination", "TREATMENT", 306, 317]]], ["In the absence of a vaccine, a key option to mitigate the pandemic is to shield at-risk individuals by more intensive physicaldistancing measures than those in the wider population.", [["a vaccine", "TREATMENT", 18, 27], ["intensive physicaldistancing measures", "TREATMENT", 108, 145]]], ["Other infection control measures include provision of personal protective equipment and intensive testing of health and social care workers in maximum contact with at-risk individuals.", [["infection", "DISEASE", 6, 15], ["Other infection control measures", "PROBLEM", 0, 32], ["personal protective equipment", "TREATMENT", 54, 83], ["infection", "OBSERVATION", 6, 15]]], ["This would allow practical individual-level steps to be taken, such as increased hygiene, physical isolation and home-delivered food and medical care.", [["physical isolation", "TREATMENT", 90, 108], ["medical care", "TREATMENT", 137, 149]]], ["6 As more evidence emerges on the risk associated with different conditions, guidelines could be refined and shielding policies tailored to different risk groups e.g. isolation for those at very high risk, and less stringent measures (e.g. social distancing) for those with a lower level of increased risk.", [["shielding policies", "TREATMENT", 109, 127], ["increased risk", "PROBLEM", 291, 305], ["increased risk", "OBSERVATION", 291, 305]]], ["Community-level shielding approaches, including vacating houses or public buildings to physically isolate small groups of people at increased risk, may also be considered, though these will require stringent infection control arrangements, especially in crowded settings, 24 and adherence may be low if at-risk individuals are daily wage earners or people caring for children e.g. grandparents.", [["infection", "DISEASE", 208, 217], ["people", "ORGANISM", 122, 128], ["people", "ORGANISM", 349, 355], ["children", "ORGANISM", 367, 375], ["people", "SPECIES", 122, 128], ["people", "SPECIES", 349, 355], ["children", "SPECIES", 367, 375], ["Community-level shielding approaches", "TREATMENT", 0, 36], ["stringent infection control arrangements", "TREATMENT", 198, 238], ["may also be considered", "UNCERTAINTY", 148, 170], ["infection", "OBSERVATION", 208, 217]]], ["25 The association between the prevalence of underlying conditions and other national characteristics, such as economic development, is complex.", [["underlying conditions", "PROBLEM", 45, 66]]], ["The prevalence of many of these conditions (HIV/AIDS may be an exception) reflect the epidemiological transition 26 but survival with these conditions may reflect the performance of the health system.", [["HIV/AIDS", "DISEASE", 44, 52], ["HIV", "SPECIES", 44, 47], ["these conditions", "PROBLEM", 26, 42], ["HIV/AIDS", "PROBLEM", 44, 52]]], ["We provide a spreadsheet tool (available at https://cmmid.github.io/topics/covid19/) that can be used for rapid assessment (and visualisation) of the estimated number and percentage of country populations targeted under different shielding policies.", [["a spreadsheet tool", "TEST", 11, 29], ["rapid assessment", "TEST", 106, 122], ["visualisation", "TEST", 128, 141], ["different shielding policies", "TREATMENT", 220, 248], ["percentage", "OBSERVATION_MODIFIER", 171, 181]]], ["This allows different health conditions to be included/excluded, different age thresholds to be assessed, and different choices about key assumptions e.g. estimates of the ratio , and the multimorbidity fraction by age.", [["the ratio", "TEST", 168, 177]]], ["Prevalence data included in our spreadsheet can be updated as more evidence emerges on the importance (or otherwise) of specific conditions and their severities e.g. early stage CKD, simple hypertension etc.(which was not certified by peer review)Our analysis found a substantial number of at-risk individuals in the working age range.", [["CKD", "DISEASE", 178, 181], ["hypertension", "DISEASE", 190, 202], ["early stage CKD", "PROBLEM", 166, 181], ["simple hypertension etc", "PROBLEM", 183, 206], ["Our analysis", "TEST", 247, 259], ["CKD", "OBSERVATION", 178, 181], ["simple", "OBSERVATION_MODIFIER", 183, 189], ["hypertension", "OBSERVATION", 190, 202], ["substantial", "OBSERVATION_MODIFIER", 268, 279], ["number", "OBSERVATION_MODIFIER", 280, 286]]], ["Strict shielding measures could cause considerable economic disruption to these individuals and their families and have a detrimental effect on the wider economy.", [["Strict shielding measures", "TREATMENT", 0, 25], ["considerable economic disruption", "PROBLEM", 38, 70]]], ["For example, there is growing evidence in support of face-masks as a means to prevent transmission by those wearing them.", [["face-masks", "TREATMENT", 53, 63], ["growing", "OBSERVATION_MODIFIER", 22, 29]]], ["Alternative shielding approaches, so that target groups are supported to reduce physical contacts (e.g. through incentives to reduce or abstain from work), can also be considered.(which was not certified by peer review)We based our analysis on underlying conditions listed in guidelines published by the WHO and public health agencies in the UK and US.", [["Alternative shielding approaches", "TREATMENT", 0, 32], ["our analysis", "TEST", 228, 240]]], ["As with seasonal influenza vaccination, these guidelines tend not .", [["influenza", "DISEASE", 17, 26], ["seasonal influenza vaccination", "TREATMENT", 8, 38]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprint to be exhaustive, and deliberately permit clinical judgement.", [["medRxiv", "TREATMENT", 17, 24]]], ["As our understanding of this disease evolves, it should be possible to provide greater clarity on the risk of severe COVID -19 disease associated with different underlying conditions at different severities e.g. early stage CKD, compensated liver cirrhosis, moderately severe asthma etc. 6 A detailed multivariate analysis of risk is urgently needed because nearly all underlying conditions are likely to be at least partly confounded by age.", [["liver", "ANATOMY", 241, 246], ["CKD", "DISEASE", 224, 227], ["liver cirrhosis", "DISEASE", 241, 256], ["asthma", "DISEASE", 276, 282], ["liver", "ORGAN", 241, 246], ["this disease evolves", "PROBLEM", 24, 44], ["severe COVID -19 disease", "PROBLEM", 110, 134], ["different underlying conditions", "PROBLEM", 151, 182], ["early stage CKD", "PROBLEM", 212, 227], ["compensated liver cirrhosis", "PROBLEM", 229, 256], ["moderately severe asthma etc", "PROBLEM", 258, 286], ["A detailed multivariate analysis", "TEST", 290, 322], ["severe", "OBSERVATION_MODIFIER", 110, 116], ["early stage", "OBSERVATION_MODIFIER", 212, 223], ["CKD", "OBSERVATION", 224, 227], ["compensated", "OBSERVATION_MODIFIER", 229, 240], ["liver", "ANATOMY", 241, 246], ["cirrhosis", "OBSERVATION", 247, 256], ["moderately", "OBSERVATION_MODIFIER", 258, 268], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["asthma", "OBSERVATION", 276, 282]]], ["Knowledge of the mode of action of the virus is increasing rapidly, especially in relation to its action on cells with ACE2 receptors other than in the lung, in particular in the endothelium and pancreas, which the inflammatory processes associated with diabetes may be involved in cytokine storms that can be fatal.", [["cells", "ANATOMY", 108, 113], ["lung", "ANATOMY", 152, 156], ["endothelium", "ANATOMY", 179, 190], ["pancreas", "ANATOMY", 195, 203], ["diabetes", "DISEASE", 254, 262], ["cells", "CELL", 108, 113], ["ACE2", "GENE_OR_GENE_PRODUCT", 119, 123], ["lung", "ORGAN", 152, 156], ["endothelium", "TISSUE", 179, 190], ["pancreas", "ORGAN", 195, 203], ["ACE2 receptors", "PROTEIN", 119, 133], ["cytokine", "PROTEIN", 282, 290], ["the virus", "PROBLEM", 35, 44], ["ACE2 receptors", "TREATMENT", 119, 133], ["the inflammatory processes", "PROBLEM", 211, 237], ["diabetes", "PROBLEM", 254, 262], ["cytokine storms", "PROBLEM", 282, 297], ["virus", "OBSERVATION", 39, 44], ["increasing", "OBSERVATION_MODIFIER", 48, 58], ["lung", "ANATOMY", 152, 156], ["endothelium", "ANATOMY", 179, 190], ["pancreas", "ANATOMY", 195, 203], ["inflammatory", "OBSERVATION_MODIFIER", 215, 227], ["diabetes", "OBSERVATION", 254, 262]]], ["30 We estimated a similar number of males and females to be at increased risk, although early evidence from China, and later studies in other countries show a higher proportion of deaths in males.", [["deaths", "DISEASE", 180, 186], ["later studies", "TEST", 119, 132], ["similar", "OBSERVATION_MODIFIER", 18, 25], ["number", "OBSERVATION_MODIFIER", 26, 32], ["males", "OBSERVATION", 36, 41]]], ["31 Earlier research in mice infected with SARS coronavirus also found an increased male susceptibility mediated by differences in oestrogen receptor signalling, 32 while others have noted the concentration of genes involved in the immune system on the x chromosome.", [["immune system", "ANATOMY", 231, 244], ["x chromosome", "ANATOMY", 252, 264], ["SARS coronavirus", "DISEASE", 42, 58], ["oestrogen", "CHEMICAL", 130, 139], ["mice", "ORGANISM", 23, 27], ["SARS coronavirus", "ORGANISM", 42, 58], ["oestrogen receptor", "GENE_OR_GENE_PRODUCT", 130, 148], ["x chromosome", "CELLULAR_COMPONENT", 252, 264], ["oestrogen receptor", "PROTEIN", 130, 148], ["x chromosome", "DNA", 252, 264], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 23, 27], ["SARS coronavirus", "SPECIES", 42, 58], ["SARS coronavirus", "PROBLEM", 42, 58], ["an increased male susceptibility", "PROBLEM", 70, 102], ["oestrogen receptor signalling", "TEST", 130, 159], ["increased", "OBSERVATION_MODIFIER", 73, 82]]], ["33 This is a clearly priority for further research.(which was not certified by peer review)We focused our analysis on the list of underlying chronic causes of disease available in GBD2017, and did not include risk factors, such as pregnancy, smoking, under-nutrition, obesity, working in the health and social care system, homelessness and general frailty e.g. individuals living in care homes and other facilities.", [["smoking", "CHEMICAL", 242, 249], ["obesity", "DISEASE", 268, 275], ["homelessness", "DISEASE", 323, 335], ["our analysis", "TEST", 102, 114], ["disease", "PROBLEM", 159, 166], ["obesity", "PROBLEM", 268, 275], ["chronic", "OBSERVATION_MODIFIER", 141, 148], ["disease", "OBSERVATION", 159, 166], ["obesity", "OBSERVATION", 268, 275]]], ["The importance of these factors on the severity of COVID-19 is still to be determined, although some national guidelines already include frailty in decisions about treatment.", [["treatment", "TREATMENT", 164, 173]]], ["34 We found that the age threshold for older people without underlying conditions led to a substantial increase in the overall number of people that may be considered at increased risk of severe COVID-19 disease.", [["people", "ORGANISM", 45, 51], ["people", "ORGANISM", 137, 143], ["people", "SPECIES", 45, 51], ["people", "SPECIES", 137, 143], ["underlying conditions", "PROBLEM", 60, 81], ["severe COVID-19 disease", "PROBLEM", 188, 211], ["substantial", "OBSERVATION_MODIFIER", 91, 102], ["increase", "OBSERVATION_MODIFIER", 103, 111], ["may be considered", "UNCERTAINTY", 149, 166], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["19 disease", "OBSERVATION", 201, 211]]], ["Individuals in developing countries may be frailer than those of an equivalent age in developed countries, and there may be other societal and economic considerations.", [["may be", "UNCERTAINTY", 117, 123]]], ["Older individuals without these underlying conditions could suffer adverse mental health consequences from long periods of isolation.", [["these underlying conditions", "PROBLEM", 26, 53], ["adverse mental health consequences", "PROBLEM", 67, 101]]], ["However, of the approximately 1 billion individuals aged 50+ years that we estimate to be at increased risk of severe COVID-19 disease (table 1) many may not be aware of their underlying condition.", [["COVID", "DISEASE", 118, 123], ["severe COVID-19 disease", "PROBLEM", 111, 134], ["severe", "OBSERVATION_MODIFIER", 111, 117]]], ["35 For example, CKD has a very high prevalence in many countries, but more than 90% of these cases are likely to be undiagnosed.", [["CKD", "DISEASE", 16, 19], ["CKD", "PROBLEM", 16, 19], ["undiagnosed", "PROBLEM", 116, 127], ["CKD", "OBSERVATION", 16, 19], ["very", "OBSERVATION_MODIFIER", 26, 30], ["high prevalence", "OBSERVATION_MODIFIER", 31, 46], ["likely to be", "UNCERTAINTY", 103, 115], ["undiagnosed", "OBSERVATION", 116, 127]]], ["Indeed, while our analysis quantifies numbers who could benefit from shielding, in practice the low coverage of diagnosis and treatment for many chronic conditions in low-income settings means that the age threshold could largely determine the effective target group.(which was not certified by peer review)With the exception of HIV/AIDS our estimates do not account for the role of treatment or control of the underlying condition: for example, while some conditions are less prevalent in Africa than Europe, African patients may on average be at higher risk as they have less access to diagnosis and effective treatment.", [["HIV/AIDS", "DISEASE", 329, 337], ["HIV", "ORGANISM", 329, 332], ["patients", "ORGANISM", 518, 526], ["patients", "SPECIES", 518, 526], ["HIV", "SPECIES", 329, 332], ["treatment", "TREATMENT", 126, 135], ["many chronic conditions", "PROBLEM", 140, 163], ["HIV/AIDS", "PROBLEM", 329, 337], ["treatment", "TREATMENT", 383, 392], ["effective treatment", "TREATMENT", 602, 621], ["chronic", "OBSERVATION_MODIFIER", 145, 152]]], ["It is not yet known whether those with HIV are at increased risk of severe disease with COVID-19.", [["HIV", "ORGANISM", 39, 42], ["HIV", "SPECIES", 39, 42], ["HIV", "SPECIES", 39, 42], ["HIV", "PROBLEM", 39, 42], ["severe disease", "PROBLEM", 68, 82], ["COVID", "TEST", 88, 93], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["disease", "OBSERVATION", 75, 82]]], ["Whilst it has been shown that widespread introduction of ART reduced the risk of hospitalisation and death associated with seasonal influenza, 36 a substantial proportion of those on ART remain somewhat immunocompromised.", [["death", "DISEASE", 101, 106], ["influenza", "DISEASE", 132, 141], ["death", "PROBLEM", 101, 106], ["seasonal influenza", "PROBLEM", 123, 141], ["somewhat immunocompromised", "PROBLEM", 194, 220], ["widespread", "OBSERVATION_MODIFIER", 30, 40], ["immunocompromised", "OBSERVATION", 203, 220]]], ["37, 38 Recent evidence from South Africa has shown that individuals living with HIV have an eight-fold higher risk of pneumonia hospitalisation associated with seasonal influenza, and a three-fold higher risk of pneumonia death.", [["HIV", "DISEASE", 80, 83], ["pneumonia", "DISEASE", 118, 127], ["influenza", "DISEASE", 169, 178], ["pneumonia", "DISEASE", 212, 221], ["death", "DISEASE", 222, 227], ["individuals", "ORGANISM", 56, 67], ["HIV", "ORGANISM", 80, 83], ["HIV", "SPECIES", 80, 83], ["HIV", "PROBLEM", 80, 83], ["pneumonia hospitalisation", "PROBLEM", 118, 143], ["seasonal influenza", "PROBLEM", 160, 178], ["pneumonia death", "PROBLEM", 212, 227], ["pneumonia", "OBSERVATION", 118, 127], ["influenza", "OBSERVATION", 169, 178], ["pneumonia", "OBSERVATION", 212, 221]]], ["39 Until more evidence emerges, it may be necessary to include these individuals in shielding strategies, irrespective of ART status, with priority given to those not yet receiving treatment.", [["shielding strategies", "TREATMENT", 84, 104], ["treatment", "TREATMENT", 181, 190]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprint We used data from two large studies to adjust for multimorbidity.", [["multimorbidity", "DISEASE", 84, 98], ["two large studies", "TEST", 52, 69], ["multimorbidity", "PROBLEM", 84, 98]]], ["Both studies could underestimate the prevalence of some conditions and therefore the extent of multimorbidity, although in Scotland, most of the included conditions were well recorded in routine health care, and in the Southern China study, underlying conditions were well communicated to patients, whose information was collected in a community household survey following a standard protocol.", [["multimorbidity", "DISEASE", 95, 109], ["patients", "ORGANISM", 289, 297], ["patients", "SPECIES", 289, 297], ["Both studies", "TEST", 0, 12], ["some conditions", "PROBLEM", 51, 66], ["multimorbidity", "PROBLEM", 95, 109], ["a standard protocol", "TREATMENT", 373, 392], ["multimorbidity", "OBSERVATION", 95, 109]]], ["These studies cannot capture the global diversity of patterns of multimorbidity, which will differ in regions where, for example, there are high prevalences of HIV or sickle cell disorders.", [["sickle cell", "ANATOMY", 167, 178], ["multimorbidity", "DISEASE", 65, 79], ["sickle cell disorders", "DISEASE", 167, 188], ["HIV", "ORGANISM", 160, 163], ["sickle cell", "CELL", 167, 178], ["HIV", "SPECIES", 160, 163], ["HIV", "SPECIES", 160, 163], ["These studies", "TEST", 0, 13], ["multimorbidity", "PROBLEM", 65, 79], ["HIV", "PROBLEM", 160, 163], ["sickle cell disorders", "PROBLEM", 167, 188], ["global", "OBSERVATION_MODIFIER", 33, 39], ["diversity", "OBSERVATION_MODIFIER", 40, 49], ["multimorbidity", "OBSERVATION", 65, 79], ["sickle cell disorders", "OBSERVATION", 167, 188]]], ["As multivariate analysis of the risk of serious COVID-19 become available, results that include combinations may provide more nuanced information to inform decisions about shielding.(which was not certified by peer review)Over the coming weeks and months, countries will need to determine mitigation strategies for the pandemic.", [["multivariate analysis", "TEST", 3, 24], ["serious COVID", "TEST", 40, 53], ["mitigation strategies", "TREATMENT", 289, 310], ["the pandemic", "PROBLEM", 315, 327]]], ["Where feasible, shielding strategies could reduce the overall health burden by decreasing risk of infection to those most likely to experience severe disease and thus require health care.", [["infection", "DISEASE", 98, 107], ["shielding strategies", "TREATMENT", 16, 36], ["infection", "PROBLEM", 98, 107], ["severe disease", "PROBLEM", 143, 157], ["health care", "TREATMENT", 175, 186], ["infection", "OBSERVATION", 98, 107], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["disease", "OBSERVATION", 150, 157]]], ["This may have a substantial impact on working-age people if they and their household contacts are less economically active for longer than the general population.(which was not certified by peer review)There is an urgent need for robust analyses of the risks associated with different underlying conditions so that countries can identify the highest risk groups and develop targeted shielding policies to mitigate the effects of the COVID-19 pandemic.(which was not certified by peer review).", [["people", "ORGANISM", 50, 56], ["people", "SPECIES", 50, 56], ["different underlying conditions", "PROBLEM", 275, 306], ["targeted shielding policies", "TREATMENT", 374, 401], ["the COVID", "TEST", 429, 438], ["substantial", "OBSERVATION_MODIFIER", 16, 27]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.18.20064774 doi: medRxiv preprintFigure 1.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv preprintFigure", "TREATMENT", 321, 343], ["med", "ANATOMY", 99, 102]]], ["Proportion of individuals with at least one underlying condition by age, sex, country and region; and prevalence of each underlying condition by age and regionWe excluded latent tuberculosis from our analysis but include it here to show the extent of overall TB that was excluded.", [["tuberculosis", "DISEASE", 178, 190], ["TB", "DISEASE", 259, 261], ["each underlying condition", "PROBLEM", 116, 141], ["latent tuberculosis", "PROBLEM", 171, 190], ["our analysis", "TEST", 196, 208], ["overall TB", "PROBLEM", 251, 261], ["latent", "OBSERVATION_MODIFIER", 171, 177], ["tuberculosis", "OBSERVATION", 178, 190], ["overall", "OBSERVATION_MODIFIER", 251, 258], ["TB", "OBSERVATION", 259, 261]]], ["Only the global estimates (solid black line) and country lines are shown (thin lines), but thin lines are coloured to indicate the UN population region they belong to.", [["country lines", "CELL", 49, 62], ["lines", "CELL", 96, 101], ["country lines", "CELL_LINE", 49, 62], ["solid black line", "TREATMENT", 27, 43], ["country lines", "TREATMENT", 49, 62], ["thin lines", "PROBLEM", 91, 101], ["global", "OBSERVATION_MODIFIER", 9, 15]]], ["For example, some African countries (green) have a high HIV prevalence, and some Island countries in Oceania (purple) have a high prevalence of diabetes.Figure 1.", [["diabetes", "DISEASE", 144, 152], ["HIV", "SPECIES", 56, 59], ["a high HIV prevalence", "PROBLEM", 49, 70], ["diabetes", "PROBLEM", 144, 152], ["Island", "OBSERVATION_MODIFIER", 81, 87], ["high prevalence", "OBSERVATION_MODIFIER", 125, 140], ["diabetes", "OBSERVATION", 144, 152]]], ["Proportion of individuals with at least one underlying condition by age, sex, country and region; and prevalence of each underlying condition by age and region.", [["each underlying condition", "PROBLEM", 116, 141]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprintFigure 2.", [["medRxiv preprintFigure", "TREATMENT", 17, 39]]], ["Population and number of individuals with 1 and 2+ conditions by age and region (left); prevalence of 1 and 2+ conditions by age and region (right)Panels A-F represent each UN population region.", [["Panels A-F", "TEST", 147, 157], ["left", "ANATOMY_MODIFIER", 81, 85], ["right", "ANATOMY_MODIFIER", 141, 146]]], ["The plots on the left side show the population by age (blue line), those with only 1 condition (light green area) and those with multiple (two or more) conditions (dark green).", [["left", "ANATOMY_MODIFIER", 17, 21], ["population", "OBSERVATION", 36, 46], ["blue line", "OBSERVATION", 55, 64], ["multiple", "OBSERVATION_MODIFIER", 129, 137]]], ["The plots on the right show prevalence of one and multiple conditions by age. .", [["The plots", "TEST", 0, 9], ["right", "ANATOMY_MODIFIER", 17, 22], ["multiple", "OBSERVATION_MODIFIER", 50, 58], ["conditions", "OBSERVATION", 59, 69]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Proportion of population with underlying conditions relevant to COVID-19 disease by number of conditions, country and regionEach country is given, grouped by UN population regions.", [["COVID", "DISEASE", 64, 69], ["underlying conditions", "PROBLEM", 30, 51], ["COVID-19 disease", "PROBLEM", 64, 80], ["population", "OBSERVATION", 14, 24]]], ["Proportion of population with underlying conditions relevant to COVID-19 disease by number of conditions, country and region.", [["underlying conditions", "PROBLEM", 30, 51], ["COVID-19 disease", "PROBLEM", 64, 80], ["population", "OBSERVATION", 14, 24]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["Proportion of working age population (15-64 years) with at least one underlying condition relevant to COVID-19Countries shaded in darker green have a higher proportion of their working age population with at least one underlying condition relevant to COVID-19.", [["COVID-19", "CHEMICAL", 251, 259], ["COVID-19", "DNA", 251, 259], ["underlying condition", "PROBLEM", 69, 89], ["COVID", "TEST", 251, 256]]], ["Proportion of working age population (15-64 years) with at least one underlying condition relevant to COVID-19.", [["COVID-19", "CHEMICAL", 102, 110], ["COVID-19", "DNA", 102, 110], ["COVID", "TEST", 102, 107]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 403, 423], ["med", "ANATOMY", 99, 102], ["med", "ANATOMY", 307, 310]]], ["Ratio between observed and expected % of individuals with at least one condition by age from multimorbidity studies in Scotland and Southern ChinaFor the analysis of both males and females combined, the mean of all age-specific values of r was 0.92 (range 0.86 to 0.99) in Scotland and 0.92 (range (0.75 -1.15) in China.", [["multimorbidity studies", "TEST", 93, 115]]], ["For the main analysis we assumed 0.9 across all ages (central estimates) for males and females combined in all countries and varied this between 0.7 (low estimates) and 1.0 (high estimates).Figure 1.", [["the main analysis", "TEST", 4, 21], ["males", "PROBLEM", 77, 82]]], ["Ratio between observed and expected % of individuals with at least one condition by age from multimorbidity studies in Scotland and Southern China.", [["multimorbidity studies", "TEST", 93, 115]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["18.20064774 doi: medRxiv preprintFigure 2.", [["medRxiv preprintFigure", "TREATMENT", 17, 39]]], ["Multimorbidity fraction among those with at least one condition relevant for COVID-19 from cross-sectional studies in Scotland and Southern ChinaThe grey lines represent pooled estimates and 95% confidence intervals based on a 2 nd order polynomial model fitted to all data points.Figure 2.", [["ChinaThe grey lines", "CELL", 140, 159], ["Multimorbidity fraction", "PROBLEM", 0, 23], ["COVID", "TEST", 77, 82], ["a 2 nd order polynomial model", "TREATMENT", 225, 254], ["grey lines", "OBSERVATION", 149, 159]]], ["Multimorbidity fraction among those with at least one condition relevant for COVID-19 from cross-sectional studies in Scotland and Southern China.", [["Multimorbidity fraction", "PROBLEM", 0, 23], ["COVID", "TEST", 77, 82]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 236, 256], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted April 22, 2020. . https://doi.org/10.1101/2020.04.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 236, 256], ["med", "ANATOMY", 99, 102]]], ["High estimates of the number of individuals in millions (% of total population) at increased risk of severe COVID-19 illness by age, number of conditions, region and choice of age threshold", [["COVID", "DISEASE", 108, 113], ["illness", "DISEASE", 117, 124], ["severe COVID", "PROBLEM", 101, 113], ["severe", "OBSERVATION_MODIFIER", 101, 107]]]], "5ced283074c8934beadbdd609a4b7646b94afa79": [["COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial FibrillationTo the Editor, In the amidst of coronavirus disease 2019 (COVID-19) pandemic, a variety of extrapulmonary manifestations have been reported in literature.", [["Atrial", "ANATOMY", 65, 71], ["Takotsubo Cardiomyopathy", "DISEASE", 23, 47], ["Atrial Fibrillation", "DISEASE", 65, 84], ["coronavirus disease", "DISEASE", 116, 135], ["pandemic", "DISEASE", 152, 160], ["coronavirus", "ORGANISM", 116, 127], ["Takotsubo Cardiomyopathy", "PROBLEM", 23, 47], ["Atrial Fibrillation", "PROBLEM", 65, 84], ["coronavirus disease", "PROBLEM", 116, 135], ["COVID", "TEST", 142, 147], ["pandemic", "PROBLEM", 152, 160], ["extrapulmonary manifestations", "PROBLEM", 175, 204], ["Atrial", "ANATOMY", 65, 71], ["Fibrillation", "OBSERVATION", 72, 84], ["coronavirus disease", "OBSERVATION", 116, 135], ["variety", "OBSERVATION_MODIFIER", 164, 171], ["extrapulmonary", "ANATOMY", 175, 189], ["manifestations", "OBSERVATION", 190, 204]]], ["Cardiovascular manifestations can be early extrapulmonary COVID-19 manifestations, and can present as acute coronary syndrome, stress cardiomyopathy, myocardial injury, heart failure, arrhythmias, pericardial effusion, cardiac tamponade, thromboembolic complications, and cardiogenic shock [1] .COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial FibrillationA 67-year-old woman presented to the emergency department (ED) with a complaint of fever, chills, cough, malaise, and myalgias for 2 weeks.", [["Cardiovascular", "ANATOMY", 0, 14], ["coronary", "ANATOMY", 108, 116], ["myocardial", "ANATOMY", 150, 160], ["heart", "ANATOMY", 169, 174], ["pericardial", "ANATOMY", 197, 208], ["cardiac", "ANATOMY", 219, 226], ["Atrial", "ANATOMY", 360, 366], ["acute coronary syndrome", "DISEASE", 102, 125], ["stress cardiomyopathy", "DISEASE", 127, 148], ["myocardial injury", "DISEASE", 150, 167], ["heart failure", "DISEASE", 169, 182], ["arrhythmias", "DISEASE", 184, 195], ["pericardial effusion", "DISEASE", 197, 217], ["cardiac tamponade", "DISEASE", 219, 236], ["thromboembolic complications", "DISEASE", 238, 266], ["cardiogenic shock", "DISEASE", 272, 289], ["Takotsubo Cardiomyopathy", "DISEASE", 318, 342], ["Atrial FibrillationA", "DISEASE", 360, 380], ["fever", "DISEASE", 462, 467], ["chills", "DISEASE", 469, 475], ["cough", "DISEASE", 477, 482], ["myalgias", "DISEASE", 497, 505], ["myocardial", "MULTI-TISSUE_STRUCTURE", 150, 160], ["heart", "ORGAN", 169, 174], ["cardiac", "ORGAN", 219, 226], ["woman", "ORGANISM", 393, 398], ["woman", "SPECIES", 393, 398], ["Cardiovascular manifestations", "PROBLEM", 0, 29], ["early extrapulmonary COVID", "PROBLEM", 37, 63], ["acute coronary syndrome", "PROBLEM", 102, 125], ["stress cardiomyopathy", "PROBLEM", 127, 148], ["myocardial injury", "PROBLEM", 150, 167], ["heart failure", "PROBLEM", 169, 182], ["arrhythmias", "PROBLEM", 184, 195], ["pericardial effusion", "PROBLEM", 197, 217], ["cardiac tamponade", "PROBLEM", 219, 236], ["thromboembolic complications", "PROBLEM", 238, 266], ["cardiogenic shock", "PROBLEM", 272, 289], ["Takotsubo Cardiomyopathy", "PROBLEM", 318, 342], ["Atrial FibrillationA", "PROBLEM", 360, 380], ["fever", "PROBLEM", 462, 467], ["chills", "PROBLEM", 469, 475], ["cough", "PROBLEM", 477, 482], ["malaise", "PROBLEM", 484, 491], ["myalgias", "PROBLEM", 497, 505], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["coronary", "ANATOMY", 108, 116], ["syndrome", "OBSERVATION", 117, 125], ["myocardial", "ANATOMY", 150, 160], ["injury", "OBSERVATION", 161, 167], ["heart", "ANATOMY", 169, 174], ["failure", "OBSERVATION", 175, 182], ["arrhythmias", "OBSERVATION", 184, 195], ["pericardial", "ANATOMY", 197, 208], ["effusion", "OBSERVATION", 209, 217], ["cardiac", "ANATOMY", 219, 226], ["tamponade", "OBSERVATION", 227, 236], ["thromboembolic complications", "OBSERVATION", 238, 266], ["cardiogenic shock", "OBSERVATION", 272, 289], ["Atrial", "ANATOMY", 360, 366], ["fever", "OBSERVATION", 462, 467], ["chills", "OBSERVATION", 469, 475]]], ["She denied any diarrhea, constipation, sick contacts, recent travel, tobacco use, alcohol use, other illicit drug use, family history of cardiac disease, or prior cardiac disease.", [["cardiac", "ANATOMY", 137, 144], ["cardiac", "ANATOMY", 163, 170], ["diarrhea", "DISEASE", 15, 23], ["constipation", "DISEASE", 25, 37], ["alcohol", "CHEMICAL", 82, 89], ["cardiac disease", "DISEASE", 137, 152], ["cardiac disease", "DISEASE", 163, 178], ["alcohol", "CHEMICAL", 82, 89], ["tobacco", "ORGANISM", 69, 76], ["cardiac", "ORGAN", 137, 144], ["cardiac", "ORGAN", 163, 170], ["tobacco", "SPECIES", 69, 76], ["diarrhea", "PROBLEM", 15, 23], ["constipation", "PROBLEM", 25, 37], ["sick contacts", "PROBLEM", 39, 52], ["cardiac disease", "PROBLEM", 137, 152], ["prior cardiac disease", "PROBLEM", 157, 178], ["cardiac", "ANATOMY", 137, 144], ["disease", "OBSERVATION", 145, 152], ["cardiac", "ANATOMY", 163, 170], ["disease", "OBSERVATION", 171, 178]]], ["The patient's past medical history included hypertension, and type 2 diabetes mellitus.", [["hypertension", "DISEASE", 44, 56], ["type 2 diabetes mellitus", "DISEASE", 62, 86], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["hypertension", "PROBLEM", 44, 56], ["type 2 diabetes mellitus", "PROBLEM", 62, 86], ["hypertension", "OBSERVATION", 44, 56], ["diabetes mellitus", "OBSERVATION", 69, 86]]], ["Her medications included aspirin and a statin for CAD risk factor modifications and primary prevention.", [["aspirin", "CHEMICAL", 25, 32], ["statin", "CHEMICAL", 39, 45], ["CAD", "DISEASE", 50, 53], ["aspirin", "CHEMICAL", 25, 32], ["statin", "CHEMICAL", 39, 45], ["aspirin", "SIMPLE_CHEMICAL", 25, 32], ["Her medications", "TREATMENT", 0, 15], ["aspirin", "TREATMENT", 25, 32], ["a statin", "TREATMENT", 37, 45], ["CAD risk factor modifications", "PROBLEM", 50, 79], ["primary prevention", "TREATMENT", 84, 102]]], ["In ED her temperature was 98.5F\u00b0, blood pressure 133/64 mmHg, heart rate 114 beats per minute (BPM), respiratory rate 24 breaths/min, and blood oxygen saturation of 92% on ambient air.", [["blood", "ANATOMY", 34, 39], ["heart", "ANATOMY", 62, 67], ["respiratory", "ANATOMY", 101, 112], ["blood", "ANATOMY", 138, 143], ["oxygen", "CHEMICAL", 144, 150], ["oxygen", "CHEMICAL", 144, 150], ["blood", "ORGANISM_SUBSTANCE", 34, 39], ["heart", "ORGAN", 62, 67], ["blood", "ORGANISM_SUBSTANCE", 138, 143], ["oxygen", "SIMPLE_CHEMICAL", 144, 150], ["her temperature", "TEST", 6, 21], ["blood pressure", "TEST", 34, 48], ["heart rate", "TEST", 62, 72], ["BPM", "TEST", 95, 98], ["respiratory rate", "TEST", 101, 117], ["blood oxygen saturation", "TEST", 138, 161], ["heart", "ANATOMY", 62, 67]]], ["Physical examination revealed an anxious woman not in acute distress, and pulmonary exam was notable for bilateral coarse crackles most prominent in the lower lung fields.", [["pulmonary", "ANATOMY", 74, 83], ["lower lung", "ANATOMY", 153, 163], ["woman", "ORGANISM", 41, 46], ["pulmonary", "ORGAN", 74, 83], ["lung", "ORGAN", 159, 163], ["woman", "SPECIES", 41, 46], ["Physical examination", "TEST", 0, 20], ["acute distress", "PROBLEM", 54, 68], ["pulmonary exam", "TEST", 74, 88], ["bilateral coarse crackles", "PROBLEM", 105, 130], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["distress", "OBSERVATION", 60, 68], ["pulmonary", "ANATOMY", 74, 83], ["bilateral", "ANATOMY_MODIFIER", 105, 114], ["coarse", "OBSERVATION_MODIFIER", 115, 121], ["crackles", "OBSERVATION", 122, 130], ["prominent", "OBSERVATION_MODIFIER", 136, 145], ["lower", "ANATOMY_MODIFIER", 153, 158], ["lung", "ANATOMY", 159, 163], ["fields", "ANATOMY_MODIFIER", 164, 170]]], ["The differential diagnosis included community acquired pneumonia, COVID-19 pneumonia, acute coronary syndrome, Takotsubo cardiomyopathy, and myocarditis.", [["coronary", "ANATOMY", 92, 100], ["pneumonia", "DISEASE", 55, 64], ["pneumonia", "DISEASE", 75, 84], ["acute coronary syndrome", "DISEASE", 86, 109], ["Takotsubo cardiomyopathy", "DISEASE", 111, 135], ["myocarditis", "DISEASE", 141, 152], ["community acquired pneumonia", "PROBLEM", 36, 64], ["COVID", "TEST", 66, 71], ["pneumonia", "PROBLEM", 75, 84], ["acute coronary syndrome", "PROBLEM", 86, 109], ["Takotsubo cardiomyopathy", "PROBLEM", 111, 135], ["myocarditis", "PROBLEM", 141, 152], ["community acquired", "OBSERVATION_MODIFIER", 36, 54], ["pneumonia", "OBSERVATION", 55, 64], ["pneumonia", "OBSERVATION", 75, 84], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["coronary", "ANATOMY", 92, 100], ["syndrome", "OBSERVATION", 101, 109], ["Takotsubo cardiomyopathy", "OBSERVATION", 111, 135], ["myocarditis", "OBSERVATION", 141, 152]]], ["Chest x-ray at presentation demonstrated bibasilar mixed ground glass opacities.", [["Chest x-ray", "TEST", 0, 11], ["bibasilar mixed ground glass opacities", "PROBLEM", 41, 79], ["bibasilar", "ANATOMY_MODIFIER", 41, 50], ["mixed", "OBSERVATION_MODIFIER", 51, 56], ["ground glass opacities", "OBSERVATION", 57, 79]]], ["(Fig. 1 ) Initial electrocardiogram (EKG) showed normal sinus rhythm (NSR) with heart rate (HR) of 93 bpm, normal intervals, right bundle branch block (RBBB), and T-wave inversions in the inferolateral leads (Fig. 2a) .", [["sinus", "ANATOMY", 56, 61], ["heart", "ANATOMY", 80, 85], ["right bundle branch", "ANATOMY", 125, 144], ["heart", "ORGAN", 80, 85], ["Initial electrocardiogram", "TEST", 10, 35], ["EKG", "TEST", 37, 40], ["heart rate", "TEST", 80, 90], ["HR", "TEST", 92, 94], ["right bundle branch block", "PROBLEM", 125, 150], ["RBBB", "PROBLEM", 152, 156], ["T-wave inversions in the inferolateral leads", "PROBLEM", 163, 207], ["sinus rhythm", "ANATOMY", 56, 68], ["right", "ANATOMY_MODIFIER", 125, 130], ["bundle", "ANATOMY_MODIFIER", 131, 137], ["branch", "ANATOMY_MODIFIER", 138, 144], ["wave inversions", "OBSERVATION", 165, 180], ["inferolateral", "ANATOMY_MODIFIER", 188, 201]]], ["Pertinent laboratory results revealed leukocytosis of 18.87 K/uL, lymphopenia of 0.73 K/uL, elevated procalcitonin (PCT) of 82 ng/mL, high sensitivity C-reactive protein (hsCRP) of 222 mg/L, lactate dehydrogenase (LDH) of 442 U/L, ferritin of 591 ng/mL, D-dimer of 1,681 ng/mL, TSH 3.16 mIU/L, LDL 88.6 mg/dL, negative sputum and blood cultures.", [["sputum", "ANATOMY", 319, 325], ["blood cultures", "ANATOMY", 330, 344], ["leukocytosis", "DISEASE", 38, 50], ["lymphopenia", "DISEASE", 66, 77], ["lactate", "CHEMICAL", 191, 198], ["lactate", "CHEMICAL", 191, 198], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 101, 114], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 151, 169], ["hsCRP", "GENE_OR_GENE_PRODUCT", 171, 176], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 191, 212], ["LDH", "GENE_OR_GENE_PRODUCT", 214, 217], ["ferritin", "GENE_OR_GENE_PRODUCT", 231, 239], ["D-dimer", "GENE_OR_GENE_PRODUCT", 254, 261], ["LDL", "SIMPLE_CHEMICAL", 294, 297], ["sputum", "ORGANISM_SUBSTANCE", 319, 325], ["blood", "ORGANISM_SUBSTANCE", 330, 335], ["procalcitonin", "PROTEIN", 101, 114], ["PCT", "PROTEIN", 116, 119], ["high sensitivity C-reactive protein", "PROTEIN", 134, 169], ["hsCRP", "PROTEIN", 171, 176], ["lactate dehydrogenase", "PROTEIN", 191, 212], ["LDH", "PROTEIN", 214, 217], ["ferritin", "PROTEIN", 231, 239], ["LDL", "PROTEIN", 294, 297], ["leukocytosis", "PROBLEM", 38, 50], ["K", "TEST", 60, 61], ["uL", "TEST", 62, 64], ["lymphopenia", "PROBLEM", 66, 77], ["K/uL", "TEST", 86, 90], ["elevated procalcitonin", "PROBLEM", 92, 114], ["PCT", "TEST", 116, 119], ["high sensitivity C-reactive protein", "PROBLEM", 134, 169], ["hsCRP", "TEST", 171, 176], ["lactate dehydrogenase", "TEST", 191, 212], ["LDH", "TEST", 214, 217], ["U/L", "TEST", 226, 229], ["ferritin", "TEST", 231, 239], ["D-dimer", "TEST", 254, 261], ["TSH", "TEST", 278, 281], ["mIU", "TEST", 287, 290], ["LDL", "TEST", 294, 297], ["sputum", "TEST", 319, 325], ["blood cultures", "TEST", 330, 344], ["leukocytosis", "OBSERVATION", 38, 50], ["lymphopenia", "OBSERVATION", 66, 77]]], ["A nasopharyngeal swab for SARS CoV-2 reverse polymerase chain reaction (RT-PCR) returned positive.", [["nasopharyngeal swab", "ANATOMY", 2, 21], ["nasopharyngeal swab", "CANCER", 2, 21], ["SARS CoV", "SPECIES", 26, 34], ["A nasopharyngeal swab", "TEST", 0, 21], ["SARS CoV", "TEST", 26, 34], ["reverse polymerase chain reaction", "PROBLEM", 37, 70], ["RT-PCR", "TEST", 72, 78], ["nasopharyngeal", "ANATOMY", 2, 16]]], ["Three days following the initial presentation, the patient developed chest pain with EKG showing new-onset atrial fibrillation with a rapid ventricular response (RVR) and peak cardiac troponin T (cTnT) to 0.423 ng/mL (Fig. 2b ).", [["chest", "ANATOMY", 69, 74], ["atrial", "ANATOMY", 107, 113], ["ventricular", "ANATOMY", 140, 151], ["cardiac", "ANATOMY", 176, 183], ["chest pain", "DISEASE", 69, 79], ["atrial fibrillation", "DISEASE", 107, 126], ["patient", "ORGANISM", 51, 58], ["chest", "ORGANISM_SUBDIVISION", 69, 74], ["atrial", "MULTI-TISSUE_STRUCTURE", 107, 113], ["ventricular", "MULTI-TISSUE_STRUCTURE", 140, 151], ["troponin T", "GENE_OR_GENE_PRODUCT", 184, 194], ["cTnT", "GENE_OR_GENE_PRODUCT", 196, 200], ["troponin T", "PROTEIN", 184, 194], ["patient", "SPECIES", 51, 58], ["chest pain", "PROBLEM", 69, 79], ["EKG", "TEST", 85, 88], ["new-onset atrial fibrillation", "PROBLEM", 97, 126], ["a rapid ventricular response", "PROBLEM", 132, 160], ["RVR", "PROBLEM", 162, 165], ["peak cardiac troponin T", "TEST", 171, 194], ["TnT", "TEST", 197, 200], ["chest", "ANATOMY", 69, 74], ["atrial", "ANATOMY", 107, 113], ["fibrillation", "OBSERVATION", 114, 126], ["rapid ventricular response", "OBSERVATION", 134, 160]]], ["Transthoracic echocardiogram (TTE) demonstrated left ventricle ejection fraction (LVEF) of 30% with diffuse anterior wall and apical akinesia and apical ballooning.", [["left ventricle", "ANATOMY", 48, 62], ["anterior wall", "ANATOMY", 108, 121], ["apical", "ANATOMY", 126, 132], ["apical", "ANATOMY", 146, 152], ["akinesia", "DISEASE", 133, 141], ["ventricle", "MULTI-TISSUE_STRUCTURE", 53, 62], ["anterior wall", "MULTI-TISSUE_STRUCTURE", 108, 121], ["Transthoracic echocardiogram", "TEST", 0, 28], ["TTE", "TEST", 30, 33], ["left ventricle ejection fraction", "TEST", 48, 80], ["LVEF", "TEST", 82, 86], ["diffuse anterior wall and apical akinesia", "PROBLEM", 100, 141], ["apical ballooning", "PROBLEM", 146, 163], ["left ventricle", "ANATOMY", 48, 62], ["ejection fraction", "OBSERVATION", 63, 80], ["diffuse", "OBSERVATION_MODIFIER", 100, 107], ["anterior", "ANATOMY_MODIFIER", 108, 116], ["wall", "ANATOMY_MODIFIER", 117, 121], ["apical", "ANATOMY_MODIFIER", 126, 132], ["akinesia", "OBSERVATION", 133, 141], ["apical", "ANATOMY_MODIFIER", 146, 152], ["ballooning", "OBSERVATION", 153, 163]]], ["(Video 1) Initial therapy consisted of a five-day course of off-label hydroxychloroquine (400 mg QD) and azithromycin (400 mg QD), as well as supplemental oxygen via nasal cannula at 4L/minute for treatment of COVID-19 pneumonia with hypoxemia.", [["nasal", "ANATOMY", 166, 171], ["hydroxychloroquine", "CHEMICAL", 70, 88], ["azithromycin", "CHEMICAL", 105, 117], ["oxygen", "CHEMICAL", 155, 161], ["pneumonia", "DISEASE", 219, 228], ["hypoxemia", "DISEASE", 234, 243], ["hydroxychloroquine", "CHEMICAL", 70, 88], ["azithromycin", "CHEMICAL", 105, 117], ["oxygen", "CHEMICAL", 155, 161], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 70, 88], ["azithromycin", "SIMPLE_CHEMICAL", 105, 117], ["oxygen", "SIMPLE_CHEMICAL", 155, 161], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 166, 179], ["Initial therapy", "TREATMENT", 10, 25], ["label hydroxychloroquine", "TREATMENT", 64, 88], ["azithromycin", "TREATMENT", 105, 117], ["supplemental oxygen", "TREATMENT", 142, 161], ["nasal cannula", "TREATMENT", 166, 179], ["treatment", "TREATMENT", 197, 206], ["COVID", "TEST", 210, 215], ["pneumonia", "PROBLEM", 219, 228], ["hypoxemia", "PROBLEM", 234, 243], ["pneumonia", "OBSERVATION", 219, 228], ["hypoxemia", "OBSERVATION", 234, 243]]], ["The TTC was managed with dual antiplatelet treatment (DAPT) using aspirin and clopidogrel and high dose statin therapy.", [["DAPT", "CHEMICAL", 54, 58], ["aspirin", "CHEMICAL", 66, 73], ["clopidogrel", "CHEMICAL", 78, 89], ["statin", "CHEMICAL", 104, 110], ["aspirin", "CHEMICAL", 66, 73], ["clopidogrel", "CHEMICAL", 78, 89], ["TTC", "SIMPLE_CHEMICAL", 4, 7], ["DAPT", "SIMPLE_CHEMICAL", 54, 58], ["aspirin", "SIMPLE_CHEMICAL", 66, 73], ["clopidogrel", "SIMPLE_CHEMICAL", 78, 89], ["The TTC", "TEST", 0, 7], ["dual antiplatelet treatment", "TREATMENT", 25, 52], ["DAPT", "TREATMENT", 54, 58], ["aspirin", "TREATMENT", 66, 73], ["clopidogrel", "TREATMENT", 78, 89], ["high dose statin therapy", "TREATMENT", 94, 118]]], ["Atrial fibrillation was managed with amiodarone loading dose, and then 200 mg OD.", [["Atrial", "ANATOMY", 0, 6], ["Atrial fibrillation", "DISEASE", 0, 19], ["amiodarone", "CHEMICAL", 37, 47], ["amiodarone", "CHEMICAL", 37, 47], ["Atrial", "MULTI-TISSUE_STRUCTURE", 0, 6], ["amiodarone", "SIMPLE_CHEMICAL", 37, 47], ["Atrial fibrillation", "PROBLEM", 0, 19], ["amiodarone loading dose", "TREATMENT", 37, 60], ["fibrillation", "OBSERVATION", 7, 19]]], ["Due to the increased risk of thromboembolism from TTC, COVID-19, and AF, patient was started on rivaroxaban 20 mg PO QD.", [["thromboembolism", "DISEASE", 29, 44], ["TTC", "DISEASE", 50, 53], ["AF", "DISEASE", 69, 71], ["rivaroxaban", "CHEMICAL", 96, 107], ["rivaroxaban", "CHEMICAL", 96, 107], ["patient", "ORGANISM", 73, 80], ["rivaroxaban", "SIMPLE_CHEMICAL", 96, 107], ["patient", "SPECIES", 73, 80], ["thromboembolism", "PROBLEM", 29, 44], ["TTC", "TEST", 50, 53], ["COVID", "TEST", 55, 60], ["AF", "PROBLEM", 69, 71], ["rivaroxaban", "TREATMENT", 96, 107], ["increased", "OBSERVATION_MODIFIER", 11, 20], ["thromboembolism", "OBSERVATION", 29, 44]]], ["Her clinical symptoms, and oxygen requirement improved on the abovementioned regimen, and patient was subsequently discharged with home isolation precautions.COVID-19 Presenting as Takotsubo Cardiomyopathy Complicated with Atrial FibrillationStress cardiomyopathy/ Takotsubo cardiomyopathy (TTC) is a regional wall motion abnormality that can present as transient apical ballooning in the setting of emotional or physical stressors including infections [2, 3] .", [["Atrial", "ANATOMY", 223, 229], ["wall", "ANATOMY", 310, 314], ["apical", "ANATOMY", 364, 370], ["oxygen", "CHEMICAL", 27, 33], ["Takotsubo Cardiomyopathy", "DISEASE", 181, 205], ["Atrial FibrillationStress cardiomyopathy", "DISEASE", 223, 263], ["Takotsubo cardiomyopathy", "DISEASE", 265, 289], ["TTC", "DISEASE", 291, 294], ["infections", "DISEASE", 442, 452], ["oxygen", "CHEMICAL", 27, 33], ["oxygen", "SIMPLE_CHEMICAL", 27, 33], ["patient", "ORGANISM", 90, 97], ["patient", "SPECIES", 90, 97], ["Her clinical symptoms", "PROBLEM", 0, 21], ["oxygen requirement", "PROBLEM", 27, 45], ["the abovementioned regimen", "TREATMENT", 58, 84], ["home isolation precautions", "TREATMENT", 131, 157], ["Takotsubo Cardiomyopathy", "PROBLEM", 181, 205], ["Atrial FibrillationStress cardiomyopathy", "PROBLEM", 223, 263], ["Takotsubo cardiomyopathy", "PROBLEM", 265, 289], ["a regional wall motion abnormality", "PROBLEM", 299, 333], ["transient apical ballooning", "PROBLEM", 354, 381], ["emotional or physical stressors", "PROBLEM", 400, 431], ["infections", "PROBLEM", 442, 452], ["oxygen requirement", "OBSERVATION", 27, 45], ["Atrial", "ANATOMY", 223, 229], ["Takotsubo cardiomyopathy", "OBSERVATION", 265, 289], ["wall", "ANATOMY_MODIFIER", 310, 314], ["motion abnormality", "OBSERVATION", 315, 333], ["apical", "ANATOMY_MODIFIER", 364, 370], ["ballooning", "OBSERVATION", 371, 381]]], ["TTC is more prevalent in females with a mean age range of 62-76 years [2] .", [["TTC", "TEST", 0, 3], ["more prevalent", "OBSERVATION_MODIFIER", 7, 21]]], ["A diagnosis of TTC can be made if the patient meets all four Mayo clinic diagnostic criteria including 1) Transient regional left ventricular wall dysfunction; 2) ST elevation/T-wave inversions on EKG or elevated cTNT; 3) Absence of angiographic evidence of coronary obstruction; 4) Absence of myocarditis or pheochromocytoma [3] .", [["left ventricular wall", "ANATOMY", 125, 146], ["coronary", "ANATOMY", 258, 266], ["pheochromocytoma", "ANATOMY", 309, 325], ["TTC", "DISEASE", 15, 18], ["left ventricular wall dysfunction", "DISEASE", 125, 158], ["coronary obstruction", "DISEASE", 258, 278], ["myocarditis", "DISEASE", 294, 305], ["pheochromocytoma", "DISEASE", 309, 325], ["patient", "ORGANISM", 38, 45], ["ventricular wall", "MULTI-TISSUE_STRUCTURE", 130, 146], ["patient", "SPECIES", 38, 45], ["TTC", "PROBLEM", 15, 18], ["Transient regional left ventricular wall dysfunction", "PROBLEM", 106, 158], ["ST elevation/T-wave inversions", "PROBLEM", 163, 193], ["EKG", "TEST", 197, 200], ["elevated cTNT", "PROBLEM", 204, 217], ["coronary obstruction", "PROBLEM", 258, 278], ["myocarditis", "PROBLEM", 294, 305], ["pheochromocytoma", "PROBLEM", 309, 325], ["left ventricular", "ANATOMY", 125, 141], ["wall", "ANATOMY_MODIFIER", 142, 146], ["dysfunction", "OBSERVATION", 147, 158], ["coronary", "ANATOMY", 258, 266], ["obstruction", "OBSERVATION", 267, 278], ["myocarditis", "OBSERVATION", 294, 305], ["pheochromocytoma", "OBSERVATION", 309, 325]]], ["TTC can present with or without complications such as heart failure, cardiogenic shock, left ventricular outflow tract obstruction, arrhythmias, and thromboembolism [3] .", [["heart", "ANATOMY", 54, 59], ["left ventricular outflow tract", "ANATOMY", 88, 118], ["TTC", "DISEASE", 0, 3], ["heart failure", "DISEASE", 54, 67], ["cardiogenic shock", "DISEASE", 69, 86], ["left ventricular outflow tract obstruction", "DISEASE", 88, 130], ["arrhythmias", "DISEASE", 132, 143], ["thromboembolism", "DISEASE", 149, 164], ["TTC", "SIMPLE_CHEMICAL", 0, 3], ["heart", "ORGAN", 54, 59], ["ventricular", "MULTI-TISSUE_STRUCTURE", 93, 104], ["tract", "ORGANISM_SUBDIVISION", 113, 118], ["TTC", "TEST", 0, 3], ["complications", "PROBLEM", 32, 45], ["heart failure", "PROBLEM", 54, 67], ["cardiogenic shock", "PROBLEM", 69, 86], ["left ventricular outflow tract obstruction", "PROBLEM", 88, 130], ["arrhythmias", "PROBLEM", 132, 143], ["thromboembolism", "PROBLEM", 149, 164], ["heart", "ANATOMY", 54, 59], ["failure", "OBSERVATION", 60, 67], ["cardiogenic shock", "OBSERVATION", 69, 86], ["left ventricular", "ANATOMY", 88, 104], ["outflow tract", "ANATOMY", 105, 118], ["obstruction", "OBSERVATION", 119, 130], ["arrhythmias", "OBSERVATION", 132, 143], ["thromboembolism", "OBSERVATION", 149, 164]]], ["Arrhythmic complications of TTC, and COVID-19 can include atrial fibrillation, sinus node dysfunction, conductive tissue dysfunction, and ventricular tachyarrhythmias [1, 4] .", [["atrial", "ANATOMY", 58, 64], ["sinus node", "ANATOMY", 79, 89], ["tissue", "ANATOMY", 114, 120], ["ventricular", "ANATOMY", 138, 149], ["TTC", "DISEASE", 28, 31], ["COVID-19", "CHEMICAL", 37, 45], ["atrial fibrillation", "DISEASE", 58, 77], ["sinus node dysfunction", "DISEASE", 79, 101], ["conductive tissue dysfunction", "DISEASE", 103, 132], ["ventricular tachyarrhythmias", "DISEASE", 138, 166], ["COVID-19", "CHEMICAL", 37, 45], ["atrial", "MULTI-TISSUE_STRUCTURE", 58, 64], ["sinus node", "MULTI-TISSUE_STRUCTURE", 79, 89], ["tissue", "TISSUE", 114, 120], ["Arrhythmic complications of TTC", "PROBLEM", 0, 31], ["COVID", "TEST", 37, 42], ["atrial fibrillation", "PROBLEM", 58, 77], ["sinus node dysfunction", "PROBLEM", 79, 101], ["conductive tissue dysfunction", "PROBLEM", 103, 132], ["ventricular tachyarrhythmias", "PROBLEM", 138, 166], ["atrial", "ANATOMY", 58, 64], ["fibrillation", "OBSERVATION", 65, 77], ["sinus", "ANATOMY", 79, 84], ["node dysfunction", "OBSERVATION", 85, 101], ["conductive tissue dysfunction", "OBSERVATION", 103, 132], ["ventricular", "ANATOMY", 138, 149], ["tachyarrhythmias", "OBSERVATION", 150, 166]]], ["AF can be the first presentation of TTC and can be present in up to 4.7% of cases [4] .", [["AF", "DISEASE", 0, 2], ["TTC", "DISEASE", 36, 39], ["AF", "PROBLEM", 0, 2], ["TTC", "TEST", 36, 39]]], ["COVID-19 may cause arrhythmias via downregulation of ACE-2 and subsequent increased angiotensin-II type-1 receptor (AT-1R) pathway activation.", [["COVID-19", "CHEMICAL", 0, 8], ["arrhythmias", "DISEASE", 19, 30], ["angiotensin-II", "CHEMICAL", 84, 98], ["COVID-19", "CHEMICAL", 0, 8], ["COVID-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["ACE-2", "GENE_OR_GENE_PRODUCT", 53, 58], ["angiotensin-II type-1 receptor", "GENE_OR_GENE_PRODUCT", 84, 114], ["AT-1R", "GENE_OR_GENE_PRODUCT", 116, 121], ["ACE-2", "PROTEIN", 53, 58], ["angiotensin-II type-1 receptor", "PROTEIN", 84, 114], ["COVID", "TEST", 0, 5], ["arrhythmias", "PROBLEM", 19, 30], ["ACE", "TEST", 53, 56], ["subsequent increased angiotensin-II type", "PROBLEM", 63, 103], ["pathway activation", "PROBLEM", 123, 141], ["increased", "OBSERVATION_MODIFIER", 74, 83], ["angiotensin", "OBSERVATION", 84, 95]]], ["This increased AT-1R activation and associated cytokine storm induce oxidation ofIJC Heart & Vasculaturej o u r n a l h o m e p a g e : w w w . j o u r n a l s . e l s e v i e r . c o m / i j c -h e a r t -a n d -v a s c u l a t u r e Ca2+/calmodulin dependent protein kinase II (CAMK-II).", [["AT-1R", "GENE_OR_GENE_PRODUCT", 15, 20], ["Ca2+/calmodulin dependent protein kinase II", "GENE_OR_GENE_PRODUCT", 235, 278], ["CAMK-II", "GENE_OR_GENE_PRODUCT", 280, 287], ["cytokine", "PROTEIN", 47, 55], ["t u", "DNA", 227, 230], ["calmodulin dependent protein kinase II", "PROTEIN", 240, 278], ["CAMK-II", "PROTEIN", 280, 287], ["This increased AT", "PROBLEM", 0, 17], ["a g e", "TEST", 128, 133], ["u", "TEST", 148, 149], ["a l s", "TEST", 154, 159], ["e l s", "TEST", 162, 167], ["a t u", "TEST", 225, 230], ["Ca2+", "TEST", 235, 239], ["calmodulin dependent protein kinase II", "TEST", 240, 278], ["CAMK", "TEST", 280, 284], ["Heart", "ANATOMY", 85, 90]]], ["CAMK-II overly sensitizes cardiomyocytes to activating signals, which triggers inappropriate early cardiomyocyte depolarization leading to AF [5, 6] .IJC Heart & VasculatureOur patient presentation of apical wall motion abnormalities, troponemia, psychosocial and mechanical/inflammatory stress caused TTC with AF in the setting of confirmed COVID-19.", [["cardiomyocytes", "ANATOMY", 26, 40], ["cardiomyocyte", "ANATOMY", 99, 112], ["apical wall", "ANATOMY", 201, 212], ["CAMK-II", "CHEMICAL", 0, 7], ["AF", "DISEASE", 139, 141], ["troponemia", "DISEASE", 235, 245], ["TTC", "DISEASE", 302, 305], ["AF", "DISEASE", 311, 313], ["CAMK-II", "GENE_OR_GENE_PRODUCT", 0, 7], ["cardiomyocytes", "CELL", 26, 40], ["cardiomyocyte", "CELL", 99, 112], ["patient", "ORGANISM", 177, 184], ["apical wall", "MULTI-TISSUE_STRUCTURE", 201, 212], ["CAMK-II", "PROTEIN", 0, 7], ["cardiomyocytes", "CELL_TYPE", 26, 40], ["patient", "SPECIES", 177, 184], ["cardiomyocytes", "PROBLEM", 26, 40], ["activating signals", "PROBLEM", 44, 62], ["inappropriate early cardiomyocyte depolarization", "PROBLEM", 79, 127], ["AF", "PROBLEM", 139, 141], ["apical wall motion abnormalities", "PROBLEM", 201, 233], ["troponemia", "PROBLEM", 235, 245], ["mechanical/inflammatory stress", "PROBLEM", 264, 294], ["TTC", "PROBLEM", 302, 305], ["AF", "PROBLEM", 311, 313], ["COVID", "TEST", 342, 347], ["cardiomyocyte depolarization", "OBSERVATION", 99, 127], ["Heart", "ANATOMY", 154, 159], ["apical", "ANATOMY_MODIFIER", 201, 207], ["wall", "ANATOMY_MODIFIER", 208, 212], ["motion abnormalities", "OBSERVATION", 213, 233], ["inflammatory", "OBSERVATION_MODIFIER", 275, 287]]], ["TTC can often mimic ST-elevation myocardial infarction (STEMI), and coronary angiography should be performed to rule out coronary artery obstruction.", [["myocardial", "ANATOMY", 33, 43], ["coronary", "ANATOMY", 68, 76], ["coronary artery", "ANATOMY", 121, 136], ["TTC", "CHEMICAL", 0, 3], ["ST-elevation myocardial infarction", "DISEASE", 20, 54], ["STEMI", "DISEASE", 56, 61], ["coronary artery obstruction", "DISEASE", 121, 148], ["TTC", "SIMPLE_CHEMICAL", 0, 3], ["myocardial", "MULTI-TISSUE_STRUCTURE", 33, 43], ["coronary", "MULTI-TISSUE_STRUCTURE", 68, 76], ["coronary artery", "MULTI-TISSUE_STRUCTURE", 121, 136], ["TTC", "TEST", 0, 3], ["ST-elevation myocardial infarction", "PROBLEM", 20, 54], ["STEMI", "PROBLEM", 56, 61], ["coronary angiography", "TEST", 68, 88], ["coronary artery obstruction", "PROBLEM", 121, 148], ["myocardial", "ANATOMY", 33, 43], ["infarction", "OBSERVATION", 44, 54], ["coronary", "ANATOMY", 68, 76], ["coronary artery", "ANATOMY", 121, 136], ["obstruction", "OBSERVATION", 137, 148]]], ["However, normal coronary arteries do not preclude the diagnosis of TTC [2] .", [["coronary arteries", "ANATOMY", 16, 33], ["TTC", "DISEASE", 67, 70], ["coronary arteries", "MULTI-TISSUE_STRUCTURE", 16, 33], ["TTC", "PROBLEM", 67, 70], ["normal", "OBSERVATION", 9, 15], ["coronary arteries", "ANATOMY", 16, 33]]], ["In our case, angiography for STEMI and cardiac medical resonance imaging for myocarditis were not performed as per our patient preference, to avoid the risk of procedural transmission of COVID, and to lower potentially unnecessary testing.", [["cardiac", "ANATOMY", 39, 46], ["STEMI", "DISEASE", 29, 34], ["myocarditis", "DISEASE", 77, 88], ["COVID", "DISEASE", 187, 192], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["angiography", "TEST", 13, 24], ["STEMI", "PROBLEM", 29, 34], ["cardiac medical resonance imaging", "TEST", 39, 72], ["myocarditis", "PROBLEM", 77, 88], ["unnecessary testing", "TEST", 219, 238]]], ["AF can be treated by rhythm control, rate control or by ablation [7] .", [["AF", "DISEASE", 0, 2], ["AF", "PROBLEM", 0, 2], ["rhythm control", "TREATMENT", 21, 35], ["rate control", "TREATMENT", 37, 49]]], ["Our patient was treated with rhythm control, and mural thrombus was ruled out before the start of medications to prevent stroke.", [["mural thrombus", "ANATOMY", 49, 63], ["mural thrombus", "DISEASE", 49, 63], ["stroke", "DISEASE", 121, 127], ["patient", "ORGANISM", 4, 11], ["mural thrombus", "PATHOLOGICAL_FORMATION", 49, 63], ["patient", "SPECIES", 4, 11], ["rhythm control", "TREATMENT", 29, 43], ["mural thrombus", "PROBLEM", 49, 63], ["medications", "TREATMENT", 98, 109], ["stroke", "PROBLEM", 121, 127], ["mural", "OBSERVATION_MODIFIER", 49, 54], ["thrombus", "OBSERVATION", 55, 63], ["stroke", "OBSERVATION", 121, 127]]], ["Furthermore, patients are at increased risk of stroke from COVID-19-induced hypercoagulability, TTC induced blood stasis, and AF, which can all potentiate thromboembolism [6] [7] [8] .", [["blood", "ANATOMY", 108, 113], ["stroke", "DISEASE", 47, 53], ["COVID-19", "CHEMICAL", 59, 67], ["hypercoagulability", "DISEASE", 76, 94], ["TTC", "DISEASE", 96, 99], ["blood stasis", "DISEASE", 108, 120], ["AF", "DISEASE", 126, 128], ["thromboembolism", "DISEASE", 155, 170], ["COVID-19", "CHEMICAL", 59, 67], ["patients", "ORGANISM", 13, 21], ["COVID-19", "SIMPLE_CHEMICAL", 59, 67], ["TTC", "SIMPLE_CHEMICAL", 96, 99], ["blood", "ORGANISM_SUBSTANCE", 108, 113], ["patients", "SPECIES", 13, 21], ["stroke", "PROBLEM", 47, 53], ["COVID", "TEST", 59, 64], ["induced hypercoagulability", "PROBLEM", 68, 94], ["TTC induced blood stasis", "PROBLEM", 96, 120], ["AF", "PROBLEM", 126, 128], ["thromboembolism", "PROBLEM", 155, 170], ["stroke", "OBSERVATION", 47, 53], ["hypercoagulability", "OBSERVATION", 76, 94], ["blood stasis", "OBSERVATION", 108, 120]]], ["Our patient was initially started on enoxaparin and later changed to rivaroxaban, a direct oral anticoagulant (DOAC), to manage her increased risk of thrombosis.", [["oral", "ANATOMY", 91, 95], ["enoxaparin", "CHEMICAL", 37, 47], ["rivaroxaban", "CHEMICAL", 69, 80], ["DOAC", "CHEMICAL", 111, 115], ["thrombosis", "DISEASE", 150, 160], ["enoxaparin", "CHEMICAL", 37, 47], ["rivaroxaban", "CHEMICAL", 69, 80], ["patient", "ORGANISM", 4, 11], ["enoxaparin", "SIMPLE_CHEMICAL", 37, 47], ["rivaroxaban", "SIMPLE_CHEMICAL", 69, 80], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["anticoagulant", "SIMPLE_CHEMICAL", 96, 109], ["DOAC", "SIMPLE_CHEMICAL", 111, 115], ["patient", "SPECIES", 4, 11], ["enoxaparin", "TREATMENT", 37, 47], ["rivaroxaban", "TREATMENT", 69, 80], ["a direct oral anticoagulant (DOAC", "TREATMENT", 82, 115], ["thrombosis", "PROBLEM", 150, 160], ["thrombosis", "OBSERVATION", 150, 160]]], ["The patient was treated with hydroxychloroquine and azithromycin as per our hospital protocol, as it is the standard of care of all COVID-19 patients in our hospital.", [["hydroxychloroquine", "CHEMICAL", 29, 47], ["azithromycin", "CHEMICAL", 52, 64], ["hydroxychloroquine", "CHEMICAL", 29, 47], ["azithromycin", "CHEMICAL", 52, 64], ["patient", "ORGANISM", 4, 11], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 29, 47], ["azithromycin", "SIMPLE_CHEMICAL", 52, 64], ["patients", "ORGANISM", 141, 149], ["patient", "SPECIES", 4, 11], ["patients", "SPECIES", 141, 149], ["hydroxychloroquine", "TREATMENT", 29, 47], ["azithromycin", "TREATMENT", 52, 64]]], ["For TTC and AF, we continued the patient on an optimal medical regimen with DAPT, statin, amiodarone, and anticoagulation.", [["AF", "DISEASE", 12, 14], ["DAPT", "CHEMICAL", 76, 80], ["statin", "CHEMICAL", 82, 88], ["amiodarone", "CHEMICAL", 90, 100], ["DAPT", "CHEMICAL", 76, 80], ["statin", "CHEMICAL", 82, 88], ["amiodarone", "CHEMICAL", 90, 100], ["TTC", "SIMPLE_CHEMICAL", 4, 7], ["patient", "ORGANISM", 33, 40], ["DAPT", "SIMPLE_CHEMICAL", 76, 80], ["statin", "SIMPLE_CHEMICAL", 82, 88], ["amiodarone", "SIMPLE_CHEMICAL", 90, 100], ["patient", "SPECIES", 33, 40], ["TTC", "PROBLEM", 4, 7], ["AF", "PROBLEM", 12, 14], ["an optimal medical regimen", "TREATMENT", 44, 70], ["DAPT", "TREATMENT", 76, 80], ["statin", "TREATMENT", 82, 88], ["amiodarone", "TREATMENT", 90, 100], ["anticoagulation", "TREATMENT", 106, 121]]], ["Patient reported no notable interval complaints on tele follow up visit.", [["Patient", "SPECIES", 0, 7], ["notable interval complaints", "PROBLEM", 20, 47], ["no", "UNCERTAINTY", 17, 19], ["notable", "OBSERVATION_MODIFIER", 20, 27]]], ["Takotsubo cardiomyopathy with atrial fibrillation can be an early presentation of COVID-19 as an extrapulmonary manifestation, and diagnosis should be kept in mind, and optimal medical treatment should be started.", [["atrial", "ANATOMY", 30, 36], ["extrapulmonary", "ANATOMY", 97, 111], ["Takotsubo cardiomyopathy", "DISEASE", 0, 24], ["atrial fibrillation", "DISEASE", 30, 49], ["atrial", "MULTI-TISSUE_STRUCTURE", 30, 36], ["Takotsubo cardiomyopathy", "PROBLEM", 0, 24], ["atrial fibrillation", "PROBLEM", 30, 49], ["COVID", "TEST", 82, 87], ["an extrapulmonary manifestation", "PROBLEM", 94, 125], ["optimal medical treatment", "TREATMENT", 169, 194], ["cardiomyopathy", "OBSERVATION", 10, 24], ["atrial", "ANATOMY", 30, 36], ["fibrillation", "OBSERVATION", 37, 49], ["early", "OBSERVATION_MODIFIER", 60, 65], ["extrapulmonary", "ANATOMY", 97, 111], ["manifestation", "OBSERVATION", 112, 125]]]], "PMC6193705": [["IntroductionPre-weaning diarrhea (PWD) affecting suckling mink kits is a well-known syndrome in commercial mink production and farmers usually refer to this as \u201csticky kits\u201d, \u201cwet kits\u201d or \u201cgreasy kits\u201d.", [["diarrhea", "DISEASE", 24, 32], ["PWD", "DISEASE", 34, 37], ["mink", "ORGANISM", 58, 62], ["mink", "ORGANISM", 107, 111], ["mink", "SPECIES", 58, 62], ["mink", "SPECIES", 107, 111], ["mink", "SPECIES", 58, 62], ["mink", "SPECIES", 107, 111], ["diarrhea", "PROBLEM", 24, 32], ["known syndrome", "PROBLEM", 78, 92]]], ["In Denmark the syndrome was described more than 60 years ago [1] and normally affects kits from 1\u20134 weeks of age, in the suckling state of life [2\u20135].", [["the syndrome", "PROBLEM", 11, 23], ["syndrome", "OBSERVATION", 15, 23]]], ["It is characterized by diarrhea and a cutaneous exudation leading to a sticky appearance [2\u20135].", [["cutaneous", "ANATOMY", 38, 47], ["diarrhea", "DISEASE", 23, 31], ["diarrhea", "PROBLEM", 23, 31], ["a cutaneous exudation", "PROBLEM", 36, 57], ["a sticky appearance", "PROBLEM", 69, 88], ["diarrhea", "OBSERVATION", 23, 31], ["cutaneous", "OBSERVATION_MODIFIER", 38, 47], ["exudation", "OBSERVATION", 48, 57]]], ["Outbreaks of PWD occur on mink farms with variable severity between years and the morbidity may range from affecting a few litters up to more than 30% [6,7].", [["mink", "SPECIES", 26, 30], ["PWD", "PROBLEM", 13, 16]]], ["The mortality is usually 1\u20132 kits per litter and the impact of an outbreak may have serious economic consequences for the farmers due to treatments, losses of animals and experience of decreased welfare as well.", [["treatments", "TREATMENT", 137, 147], ["losses of animals", "PROBLEM", 149, 166], ["decreased", "OBSERVATION", 185, 194]]], ["Presently, it is generally accepted that the syndrome is multifactorial and infectious agents together with environmental and genetic risk factors have been suggested as causes [2,6,7\u20139].", [["the syndrome", "PROBLEM", 41, 53], ["infectious agents", "TREATMENT", 76, 93], ["environmental and genetic risk factors", "PROBLEM", 108, 146], ["syndrome", "OBSERVATION", 45, 53], ["infectious", "OBSERVATION", 76, 86]]], ["Associations between diarrhea in mink kits and different incriminated viruses and bacteria have been reported [10\u201318].", [["diarrhea", "DISEASE", 21, 29], ["mink", "ORGANISM", 33, 37], ["mink", "SPECIES", 33, 37], ["mink", "SPECIES", 33, 37], ["diarrhea in mink kits", "PROBLEM", 21, 42], ["different incriminated viruses", "PROBLEM", 47, 77], ["bacteria", "PROBLEM", 82, 90], ["diarrhea", "OBSERVATION", 21, 29], ["viruses", "OBSERVATION", 70, 77]]], ["Many of these microorganisms have been identified in both healthy and diarrheic mink kits, which leave their role in PWD unclear.", [["mink", "ORGANISM", 80, 84], ["mink", "SPECIES", 80, 84], ["diarrheic mink", "SPECIES", 70, 84], ["these microorganisms", "PROBLEM", 8, 28], ["microorganisms", "OBSERVATION", 14, 28], ["both healthy", "OBSERVATION_MODIFIER", 53, 65], ["diarrheic mink kits", "OBSERVATION", 70, 89]]], ["Generally, mink host many different viruses and studies have focused on astro-, calici-, rota- and coronaviruses in regard to the PWD syndrome [10\u201317].", [["astro-", "GENE_OR_GENE_PRODUCT", 72, 78], ["calici", "GENE_OR_GENE_PRODUCT", 80, 86], ["coronaviruses", "ORGANISM", 99, 112], ["mink", "SPECIES", 11, 15], ["studies", "TEST", 48, 55], ["astro-", "TEST", 72, 78], ["calici", "TEST", 80, 86], ["coronaviruses", "PROBLEM", 99, 112], ["the PWD syndrome", "PROBLEM", 126, 142], ["viruses", "OBSERVATION", 36, 43]]], ["Besides Escherichia coli (E. coli) Staphylococcus spp. have been incriminated in the PWD syndrome in mink [14,16,17\u201318].", [["Escherichia coli", "ORGANISM", 8, 24], ["E. coli", "ORGANISM", 26, 33], ["Staphylococcus spp", "ORGANISM", 35, 53], ["mink", "ORGANISM", 101, 105], ["Escherichia coli", "SPECIES", 8, 24], ["E. coli", "SPECIES", 26, 33], ["Staphylococcus spp", "SPECIES", 35, 53], ["Escherichia coli", "SPECIES", 8, 24], ["E. coli", "SPECIES", 26, 33], ["mink", "SPECIES", 101, 105], ["Escherichia coli (E. coli", "PROBLEM", 8, 33], ["Staphylococcus spp", "PROBLEM", 35, 53], ["the PWD syndrome", "PROBLEM", 81, 97], ["Escherichia coli", "OBSERVATION", 8, 24], ["E. coli", "OBSERVATION_MODIFIER", 26, 33], ["Staphylococcus spp", "OBSERVATION", 35, 53]]], ["Enteric colonization by S. delphini has besides in mink kits been reported in ferret kits with diarrhea and comparison to the \u201csticky kits\u201d syndrome was proposed [19].", [["diarrhea", "DISEASE", 95, 103], ["S. delphini", "ORGANISM", 24, 35], ["mink", "ORGANISM", 51, 55], ["ferret", "ORGANISM", 78, 84], ["S. delphini", "SPECIES", 24, 35], ["ferret", "SPECIES", 78, 84], ["S. delphini", "SPECIES", 24, 35], ["mink", "SPECIES", 51, 55], ["ferret", "SPECIES", 78, 84], ["Enteric colonization", "PROBLEM", 0, 20], ["diarrhea", "PROBLEM", 95, 103], ["syndrome", "PROBLEM", 140, 148], ["colonization", "OBSERVATION", 8, 20]]], ["S. delphini has also been isolated from different extra intestinal sites in mink including the urinary tract and skin [20\u201321], and a study showed that mustelids like mink are natural hosts of S. delphini group A [20].IntroductionStudying bacterial etiologic candidates for PWD indeed require knowledge about the normal intestinal microflora in mink at different ages.", [["intestinal sites", "ANATOMY", 56, 72], ["urinary tract", "ANATOMY", 95, 108], ["skin", "ANATOMY", 113, 117], ["intestinal microflora", "ANATOMY", 319, 340], ["S. delphini", "ORGANISM", 0, 11], ["intestinal sites", "MULTI-TISSUE_STRUCTURE", 56, 72], ["mink", "ORGANISM_SUBDIVISION", 76, 80], ["urinary tract", "ORGANISM_SUBDIVISION", 95, 108], ["skin", "ORGAN", 113, 117], ["mink", "ORGANISM", 166, 170], ["S. delphini", "ORGANISM", 192, 203], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 319, 340], ["mink", "ORGANISM", 344, 348], ["S. delphini", "SPECIES", 0, 11], ["mink", "SPECIES", 76, 80], ["mink", "SPECIES", 166, 170], ["S. delphini group", "SPECIES", 192, 209], ["S. delphini", "SPECIES", 0, 11], ["mink", "SPECIES", 76, 80], ["mink", "SPECIES", 166, 170], ["S. delphini", "SPECIES", 192, 203], ["mink", "SPECIES", 344, 348], ["different extra intestinal sites", "PROBLEM", 40, 72], ["a study", "TEST", 131, 138], ["mustelids", "PROBLEM", 151, 160], ["PWD", "PROBLEM", 273, 276], ["different", "OBSERVATION_MODIFIER", 40, 49], ["extra", "OBSERVATION_MODIFIER", 50, 55], ["intestinal sites", "OBSERVATION", 56, 72], ["urinary tract", "ANATOMY", 95, 108], ["skin", "ANATOMY", 113, 117], ["intestinal microflora", "ANATOMY", 319, 340]]], ["Research on the intestinal microflora in mink is sparse and mainly based on culture studies [22\u201324].", [["intestinal microflora", "ANATOMY", 16, 37], ["intestinal microflora", "MULTI-TISSUE_STRUCTURE", 16, 37], ["mink", "ORGANISM", 41, 45], ["mink", "SPECIES", 41, 45], ["culture studies", "TEST", 76, 91], ["intestinal microflora", "ANATOMY", 16, 37], ["sparse", "OBSERVATION_MODIFIER", 49, 55]]], ["Older conventional culture based studies showed that the total count of bacteria in colon of adult and juvenile mink is low compared to other species like ruminants or humans and consist of approximately equal counts of aerobic and anaerobic bacterial species which is different from other animal species, where 90% or more consist of anaerobic bacteria [22\u201323,25\u201326].", [["colon", "ANATOMY", 84, 89], ["colon", "ORGAN", 84, 89], ["mink", "ORGANISM", 112, 116], ["humans", "ORGANISM", 168, 174], ["mink", "SPECIES", 112, 116], ["ruminants", "SPECIES", 155, 164], ["humans", "SPECIES", 168, 174], ["mink", "SPECIES", 112, 116], ["humans", "SPECIES", 168, 174], ["Older conventional culture based studies", "TEST", 0, 40], ["the total count", "TEST", 53, 68], ["bacteria in colon of adult", "PROBLEM", 72, 98], ["juvenile mink", "PROBLEM", 103, 116], ["aerobic and anaerobic bacterial species", "PROBLEM", 220, 259], ["other animal species", "PROBLEM", 284, 304], ["anaerobic bacteria", "PROBLEM", 335, 353], ["bacteria", "OBSERVATION", 72, 80], ["colon", "ANATOMY", 84, 89], ["juvenile mink", "OBSERVATION", 103, 116], ["low", "OBSERVATION_MODIFIER", 120, 123], ["anaerobic bacterial species", "OBSERVATION", 232, 259]]], ["However, some intestinal bacteria are not cultivable which is a drawback when interpreting these results, and recent studies using next generation sequencing (NGS) have shown that the adult mink microbiota is dominated by Firmicutes class Clostridiales although large inter-individual differences were demonstrated [27\u201328].", [["intestinal", "ANATOMY", 14, 24], ["intestinal", "ORGAN", 14, 24], ["mink", "ORGANISM", 190, 194], ["mink", "SPECIES", 190, 194], ["mink", "SPECIES", 190, 194], ["some intestinal bacteria", "PROBLEM", 9, 33], ["recent studies", "TEST", 110, 124], ["next generation sequencing (NGS", "TEST", 131, 162], ["Firmicutes class Clostridiales", "PROBLEM", 222, 252], ["large inter-individual differences", "PROBLEM", 262, 296], ["intestinal", "ANATOMY", 14, 24], ["bacteria", "OBSERVATION", 25, 33], ["large", "OBSERVATION_MODIFIER", 262, 267], ["inter-individual", "OBSERVATION_MODIFIER", 268, 284]]], ["Adult mink also have a low amount of bacteroides compared to other species [23,26\u201329].", [["mink", "ORGANISM", 6, 10], ["mink", "SPECIES", 6, 10], ["mink", "SPECIES", 6, 10], ["a low amount of bacteroides", "PROBLEM", 21, 48], ["low amount", "OBSERVATION_MODIFIER", 23, 33], ["bacteroides", "OBSERVATION", 37, 48]]], ["Mink are characterized by having a simple intestinal tract with a rapid passage time (3\u20134 hours) which might be even shorter in suckling kits [23,30].", [["intestinal tract", "ANATOMY", 42, 58], ["intestinal tract", "ORGANISM_SUBDIVISION", 42, 58], ["a simple intestinal tract", "PROBLEM", 33, 58], ["simple", "OBSERVATION_MODIFIER", 35, 41], ["intestinal tract", "ANATOMY", 42, 58], ["rapid", "OBSERVATION_MODIFIER", 66, 71], ["passage", "OBSERVATION_MODIFIER", 72, 79]]], ["A study showed that the fecal aerobic microflora in healthy mink kits were dominated by hemolytic staphylococci, E.coli and enterococci [24].", [["hemolytic staphylococci", "DISEASE", 88, 111], ["mink", "ORGANISM", 60, 64], ["mink", "SPECIES", 60, 64], ["mink", "SPECIES", 60, 64], ["E.coli", "SPECIES", 113, 119], ["A study", "TEST", 0, 7], ["the fecal aerobic microflora in healthy mink kits", "PROBLEM", 20, 69], ["hemolytic staphylococci", "PROBLEM", 88, 111], ["E.coli", "PROBLEM", 113, 119], ["enterococci", "PROBLEM", 124, 135], ["fecal", "ANATOMY", 24, 29]]], ["The employment of HTS (High-throughput Sequencing) techniques with bioinformatics data analysis allow more complex infection biology issues to be studied [31] and has for example been applied in the study of the enteric disease complex NNPD (New Neonatal Porcine Diarrhea) [32].IntroductionIn the present study we performed NGS to determine the mink kit intestinal virome by identification of sequence reads using Basic Local Alignment Search Tool (BLASTx) [33].", [["intestinal", "ANATOMY", 354, 364], ["infection", "DISEASE", 115, 124], ["enteric disease", "DISEASE", 212, 227], ["NNPD", "DISEASE", 236, 240], ["Neonatal Porcine Diarrhea", "DISEASE", 246, 271], ["mink", "ORGANISM", 345, 349], ["intestinal", "ORGAN", 354, 364], ["Porcine", "SPECIES", 255, 262], ["mink", "SPECIES", 345, 349], ["HTS (High-throughput Sequencing)", "TREATMENT", 18, 50], ["bioinformatics data analysis", "TEST", 67, 95], ["more complex infection biology issues", "PROBLEM", 102, 139], ["the enteric disease complex", "PROBLEM", 208, 235], ["New Neonatal Porcine Diarrhea", "TREATMENT", 242, 271], ["NGS", "TEST", 324, 327], ["enteric", "ANATOMY", 212, 219], ["disease", "OBSERVATION", 220, 227]]], ["In addition, targeted 16S rRNA amplicon sequencing for determination of the composition of the gut bacterial microbiota in intestinal contents from mink kits with PWD and from healthy kits were carried out.", [["gut", "ANATOMY", 95, 98], ["intestinal", "ANATOMY", 123, 133], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["intestinal", "ORGAN", 123, 133], ["mink", "ORGANISM", 148, 152], ["mink", "SPECIES", 148, 152], ["mink", "SPECIES", 148, 152], ["targeted 16S rRNA amplicon sequencing", "TREATMENT", 13, 50], ["the gut bacterial microbiota", "PROBLEM", 91, 119], ["healthy kits", "TEST", 176, 188], ["gut", "ANATOMY", 95, 98], ["bacterial microbiota", "OBSERVATION", 99, 119], ["intestinal", "ANATOMY", 123, 133]]], ["It was our aim to characterize and compare the virome and bacterial microbiota in diarrheic and non-diarrheic mink kits to examine potential viral and bacterial involvement in the PWD syndrome in mink.", [["PWD syndrome", "DISEASE", 180, 192], ["mink", "ORGANISM", 110, 114], ["mink", "ORGANISM", 196, 200], ["mink", "SPECIES", 110, 114], ["mink", "SPECIES", 196, 200], ["mink", "SPECIES", 110, 114], ["mink", "SPECIES", 196, 200], ["the virome and bacterial microbiota", "PROBLEM", 43, 78], ["diarrheic", "PROBLEM", 82, 91], ["non-diarrheic mink kits", "PROBLEM", 96, 119], ["potential viral and bacterial involvement", "PROBLEM", 131, 172], ["the PWD syndrome", "PROBLEM", 176, 192], ["bacterial involvement", "OBSERVATION", 151, 172]]], ["Although NGS techniques have been used to examine the bacterial microbiota in adult mink, this is the first time NGS techniques are applied in the investigation of the etiology of PWD in mink.Sample collection ::: Material and methodsIn the pre-weaning period from May 11 to June 2, 2015 the investigation team visited 30 Danish commercial mink farms with either high or low frequency of PWD.", [["mink", "ORGANISM", 84, 88], ["mink", "ORGANISM", 187, 191], ["mink", "SPECIES", 84, 88], ["mink", "SPECIES", 84, 88], ["mink", "SPECIES", 187, 191], ["mink", "SPECIES", 340, 344], ["NGS techniques", "TREATMENT", 9, 23], ["NGS techniques", "TREATMENT", 113, 127], ["PWD", "PROBLEM", 180, 183], ["adult mink", "OBSERVATION_MODIFIER", 78, 88]]], ["From each farm 2\u20134 litters with and without clinical signs of PWD were conveniently sampled.", [["PWD", "PROBLEM", 62, 65]]], ["Clinical signs included cutaneous exudation, exudate covering the nails, red swollen anus, perineal soiling and dehydration (dry wrinkled skin).", [["cutaneous", "ANATOMY", 24, 33], ["exudate", "ANATOMY", 45, 52], ["nails", "ANATOMY", 66, 71], ["swollen anus", "ANATOMY", 77, 89], ["perineal", "ANATOMY", 91, 99], ["skin", "ANATOMY", 138, 142], ["perineal soiling", "DISEASE", 91, 107], ["dehydration", "DISEASE", 112, 123], ["nails", "ORGANISM_SUBDIVISION", 66, 71], ["anus", "ORGANISM_SUBDIVISION", 85, 89], ["skin", "ORGAN", 138, 142], ["Clinical signs", "TEST", 0, 14], ["cutaneous exudation", "PROBLEM", 24, 43], ["exudate", "PROBLEM", 45, 52], ["the nails", "PROBLEM", 62, 71], ["red swollen anus", "PROBLEM", 73, 89], ["perineal soiling", "PROBLEM", 91, 107], ["dehydration (dry wrinkled skin", "PROBLEM", 112, 142], ["cutaneous exudation", "OBSERVATION", 24, 43], ["exudate", "OBSERVATION", 45, 52], ["nails", "ANATOMY", 66, 71], ["red", "OBSERVATION_MODIFIER", 73, 76], ["swollen", "OBSERVATION_MODIFIER", 77, 84], ["anus", "ANATOMY", 85, 89], ["perineal", "ANATOMY", 91, 99], ["soiling", "OBSERVATION", 100, 107], ["dehydration", "OBSERVATION", 112, 123], ["dry", "OBSERVATION_MODIFIER", 125, 128], ["wrinkled", "OBSERVATION_MODIFIER", 129, 137], ["skin", "ANATOMY", 138, 142]]], ["From the litters, 2\u20133 mink kits were euthanized by injection of pentobarbital.", [["pentobarbital", "CHEMICAL", 64, 77], ["pentobarbital", "CHEMICAL", 64, 77], ["mink", "ORGANISM", 22, 26], ["pentobarbital", "SIMPLE_CHEMICAL", 64, 77], ["mink", "SPECIES", 22, 26], ["pentobarbital", "TREATMENT", 64, 77]]], ["The post-mortem examinations were conducted immediately after euthanization at the farm and the consistency and color of the intestinal contents in the aboral part of the gastrointestinal tract or at post mortem defecation was assessed.", [["intestinal", "ANATOMY", 125, 135], ["aboral part", "ANATOMY", 152, 163], ["gastrointestinal tract", "ANATOMY", 171, 193], ["intestinal", "ORGAN", 125, 135], ["aboral part", "MULTI-TISSUE_STRUCTURE", 152, 163], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 171, 193], ["The post-mortem examinations", "TEST", 0, 28], ["euthanization", "TREATMENT", 62, 75], ["intestinal", "ANATOMY", 125, 135], ["contents", "OBSERVATION", 136, 144], ["aboral", "ANATOMY_MODIFIER", 152, 158], ["gastrointestinal tract", "ANATOMY", 171, 193]]], ["The gut was evacuated in its whole length and the contents were squeezed out into a cryo tube and immediately placed in a cool box for maximum 6 hours and subsequently frozen at -20\u00b0C. The samples were collectively transported on dry ice to the National Veterinary Institute (SVA) Uppsala, Sweden, where they were stored at -80\u00b0C until preparation.", [["gut", "ANATOMY", 4, 7], ["samples", "ANATOMY", 189, 196], ["gut", "ORGANISM_SUBDIVISION", 4, 7], ["cryo tube", "TISSUE", 84, 93], ["a cryo tube", "TREATMENT", 82, 93], ["a cool box", "TREATMENT", 120, 130], ["gut", "ANATOMY", 4, 7], ["evacuated", "OBSERVATION", 12, 21], ["length", "OBSERVATION_MODIFIER", 35, 41], ["cryo tube", "OBSERVATION", 84, 93]]], ["The definition of litters with diarrhea and litters without diarrhea was based on consistency of the feces/caudal intestinal contents in combination with external clinical signs (S1 Fig and S1 Table).", [["feces", "ANATOMY", 101, 106], ["caudal intestinal", "ANATOMY", 107, 124], ["diarrhea", "DISEASE", 31, 39], ["diarrhea", "DISEASE", 60, 68], ["litters", "ORGANISM_SUBDIVISION", 18, 25], ["feces", "ORGANISM_SUBDIVISION", 101, 106], ["caudal intestinal", "MULTI-TISSUE_STRUCTURE", 107, 124], ["diarrhea", "PROBLEM", 31, 39], ["diarrhea", "PROBLEM", 60, 68], ["the feces/caudal intestinal contents", "PROBLEM", 97, 133], ["external clinical signs", "TEST", 154, 177], ["feces", "OBSERVATION", 101, 106], ["caudal", "ANATOMY_MODIFIER", 107, 113], ["intestinal", "ANATOMY", 114, 124], ["contents", "OBSERVATION", 125, 133]]], ["Some of the mink farmers had initiated antimicrobial feed medication of the whole herd in the nursing period, thus 18 females had received antimicrobials within one week of sampling, but none of the mink kits had received any medication.", [["mink", "ORGANISM", 12, 16], ["mink", "ORGANISM", 199, 203], ["mink", "SPECIES", 12, 16], ["mink", "SPECIES", 199, 203], ["antimicrobial feed medication", "TREATMENT", 39, 68], ["antimicrobials", "TREATMENT", 139, 153], ["the mink kits", "TEST", 195, 208], ["any medication", "TREATMENT", 222, 236]]], ["In total 7 litters were excluded from the study because the litters had received solid feed or the disease status was impossible to determine due to improper recordings, and two litters were excluded because they only contained one kit.", [["the study", "TEST", 38, 47], ["solid feed", "TREATMENT", 81, 91], ["the disease status", "PROBLEM", 95, 113]]], ["In total 39 diarrheic litters and 44 non-diarrheic litters were included in the study.", [["litters", "ANATOMY", 22, 29], ["44 non-diarrheic litters", "PROBLEM", 34, 58], ["the study", "TEST", 76, 85]]], ["The animals used in this project were solely euthanized for collection of their tissues/organs and thereby in accordance with the Danish Order regarding animal experimentation \u00a72, article1.", [["tissues", "ANATOMY", 80, 87], ["organs", "ANATOMY", 88, 94], ["tissues", "TISSUE", 80, 87], ["organs", "ORGAN", 88, 94], ["organs", "ANATOMY", 88, 94]]], ["Euthanasia was carried out humanely by injection of an overdose of pentobarbital by an authorized veterinarian and in accordance with the Danish Order regarding slaughter and euthanasia of animals.Sample preparation ::: Material and methodsAfter thawing, approximately 80\u03bcl of feces was mixed with 720 \u03bcl 1 x TURBO DNase Buffer (Thermo Fisher Scientific) and homogenized by vortexing for 30 sec.", [["feces", "ANATOMY", 277, 282], ["overdose", "DISEASE", 55, 63], ["pentobarbital", "CHEMICAL", 67, 80], ["pentobarbital", "CHEMICAL", 67, 80], ["pentobarbital", "SIMPLE_CHEMICAL", 67, 80], ["feces", "ORGANISM_SUBSTANCE", 277, 282], ["Euthanasia", "PROBLEM", 0, 10], ["pentobarbital", "TREATMENT", 67, 80]]], ["The suspensions were frozen once on dry ice before thawing and vortexed again.", [["The suspensions", "TREATMENT", 0, 15], ["dry ice", "TREATMENT", 36, 43], ["suspensions", "OBSERVATION_MODIFIER", 4, 15]]], ["Pools of feces from mink kits from the same litter were generated in the way that for litters with 3 samples 400 \u03bcl from each sample were pooled to a total amount of 1200 \u03bcl and from litters with only two samples 600 \u03bcl from each sample were pooled to a total amount of 1200 \u03bcl.", [["feces", "ANATOMY", 9, 14], ["sample", "ANATOMY", 126, 132], ["sample", "ANATOMY", 230, 236], ["feces", "ORGANISM_SUBSTANCE", 9, 14], ["mink", "ORGANISM", 20, 24], ["mink", "SPECIES", 20, 24], ["mink", "SPECIES", 20, 24], ["Pools of feces", "PROBLEM", 0, 14], ["mink kits", "TEST", 20, 29], ["feces", "OBSERVATION", 9, 14]]], ["The pooled samples were centrifuged at 12000 x g for 5 min at 4\u00b0C which gave approximately 250 \u03bcl pellet and 950 \u03bcl supernatant.", [["samples", "ANATOMY", 11, 18], ["supernatant", "ANATOMY", 116, 127], ["C", "SIMPLE_CHEMICAL", 64, 65]]], ["The supernatants were removed and stored at -80\u00b0C until used for extraction of viral RNA and the pellets were used for DNA extraction.DNA isolation ::: 16S rRNA amplicon sequencing ::: Material and methodsTotal DNA was extracted from the pellet with the PowerLyzer PowerSoil DNA Isolation Kit (MO BIO laboratories, QIAGEN) according to the manufacturer\u1ffds protocol with minor modifications.", [["supernatants", "ANATOMY", 4, 16], ["DNA", "CELLULAR_COMPONENT", 119, 122], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["DNA", "CELLULAR_COMPONENT", 211, 214], ["viral RNA", "RNA", 79, 88], ["extraction", "TREATMENT", 65, 75], ["viral RNA", "TREATMENT", 79, 88], ["the pellets", "TREATMENT", 93, 104], ["DNA extraction", "TREATMENT", 119, 133], ["DNA isolation", "TEST", 134, 147], ["methodsTotal DNA", "TREATMENT", 198, 214], ["the PowerLyzer PowerSoil", "TREATMENT", 250, 274], ["the manufacturer\u1ffds protocol", "TREATMENT", 336, 363], ["minor modifications", "TREATMENT", 369, 388], ["viral RNA", "OBSERVATION", 79, 88]]], ["Briefly, 250 \u03bcl pellet from the pooled samples was re-suspended in 750 \u03bcl Bead Solution and loaded into a Glass Bead Tube for homogenization.", [["samples", "ANATOMY", 39, 46], ["a Glass Bead Tube", "TREATMENT", 104, 121], ["Glass", "OBSERVATION", 106, 111], ["Bead Tube", "OBSERVATION", 112, 121]]], ["After adding the cell lysis solution (Solution C1) the samples were incubated for 10 min at 98\u00b0C. Homogenization was performed on a FastPrep-24 Sample Preparation System (MP Biomedicals) with the setting 6.5 m/s, for 2 times 60 sec.", [["cell", "ANATOMY", 17, 21], ["samples", "ANATOMY", 55, 62], ["cell", "CELL", 17, 21], ["the cell lysis solution", "TREATMENT", 13, 36], ["the samples", "TEST", 51, 62], ["a FastPrep", "TREATMENT", 130, 140], ["cell lysis", "OBSERVATION", 17, 27]]], ["After incubation and centrifugation with Solution C3, 700 \u03bcl of the supernatant was transferred to a clean Collection Tube.", [["supernatant", "ANATOMY", 68, 79], ["Solution C3", "TREATMENT", 41, 52], ["the supernatant", "TREATMENT", 64, 79], ["a clean Collection Tube", "TREATMENT", 99, 122], ["Tube", "OBSERVATION", 118, 122]]], ["DNA was eluted with 80 \u03bcl of the elution buffer heated to 65\u00b0C and allowed to work on the silica membrane for 2 min before centrifugation.", [["silica membrane", "ANATOMY", 90, 105], ["silica", "CHEMICAL", 90, 96], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["DNA", "TEST", 0, 3], ["the elution buffer", "TREATMENT", 29, 47], ["the silica membrane", "TREATMENT", 86, 105]]], ["The extracted DNA was stored at -20\u00b0C until continuing with the library preparation.16S library preparation ::: 16S rRNA amplicon sequencing ::: Material and methodsLibrary preparation for sequencing of the variable V3 and V4 regions of the 16S ribosomal RNA gene was done according to the protocol 16S Metagenomic Sequencing Library Preparation (Rev.B) recommended and applied for the Illumina MiSeq System (Illumina Inc, San Diego).", [["DNA", "CELLULAR_COMPONENT", 14, 17], ["16S", "GENE_OR_GENE_PRODUCT", 241, 244], ["ribosomal", "CELLULAR_COMPONENT", 245, 254], ["variable V3 and V4 regions", "DNA", 207, 233], ["16S ribosomal RNA gene", "DNA", 241, 263], ["The extracted DNA", "TEST", 0, 17], ["the library preparation", "TREATMENT", 60, 83], ["Material and methodsLibrary preparation", "TREATMENT", 145, 184], ["the variable V3 and V4 regions of the 16S ribosomal RNA gene", "PROBLEM", 203, 263], ["Metagenomic Sequencing Library Preparation (Rev.B)", "TREATMENT", 303, 353], ["the Illumina MiSeq System", "TREATMENT", 382, 407]]], ["The amplicon libraries were combined at equimolar concentrations, spiked with 5% PhiX control, denatured and loaded on a MiSeq flow cell and sequenced with a 600 cycles reagent kit v3 (Illumina Inc, San Diego) in paired-end sequencing runs.Virus enrichment and RNA extraction ::: Virome sequencing ::: Material and methodsThe supernatant from the pooled sample preparation was filtered through a Millex-HPF HV 0.45 \u03bcm filter (Merck Millipore) by use of a 2-ml syringe to remove bacterial and host cells.", [["cell", "ANATOMY", 132, 136], ["supernatant", "ANATOMY", 326, 337], ["sample", "ANATOMY", 354, 360], ["cells", "ANATOMY", 497, 502], ["Virus", "ORGANISM", 240, 245], ["host cells", "CELL", 492, 502], ["amplicon libraries", "DNA", 4, 22], ["MiSeq flow cell", "CELL_LINE", 121, 136], ["bacterial and host cells", "CELL_TYPE", 478, 502], ["The amplicon libraries", "TREATMENT", 0, 22], ["5% PhiX control", "TREATMENT", 78, 93], ["a MiSeq flow cell", "TREATMENT", 119, 136], ["a 600 cycles reagent kit v3 (Illumina Inc", "TREATMENT", 156, 197], ["Virus enrichment", "TREATMENT", 240, 256], ["RNA extraction", "TREATMENT", 261, 275], ["the pooled sample preparation", "TREATMENT", 343, 372], ["a Millex-HPF HV 0.45 \u03bcm filter (Merck Millipore", "TREATMENT", 394, 441], ["a 2-ml syringe", "TREATMENT", 453, 467], ["bacterial and host cells", "PROBLEM", 478, 502], ["RNA extraction", "OBSERVATION", 261, 275], ["host cells", "OBSERVATION", 492, 502]]], ["In total 180 \u03bcl of the filtrate was treated with 20 \u03bcl Turbo DNase (Ambion) and 2 \u03bcl RNase ONE Ribonuclease (Promega) at 37\u00b0C for 30 min to degrade nucleic acids not protected in viral capsids.", [["nucleic acids", "CHEMICAL", 148, 161], ["DNase", "GENE_OR_GENE_PRODUCT", 61, 66], ["nucleic acids", "SIMPLE_CHEMICAL", 148, 161], ["DNase", "PROTEIN", 61, 66], ["RNase", "PROTEIN", 85, 90], ["the filtrate", "TREATMENT", 19, 31], ["20 \u03bcl Turbo DNase (Ambion)", "TREATMENT", 49, 75], ["2 \u03bcl RNase ONE Ribonuclease (Promega)", "TREATMENT", 80, 117], ["nucleic acids", "TEST", 148, 161], ["viral capsids", "OBSERVATION", 179, 192]]], ["Nuclease digestion was stopped by adding three volumes (600 \u03bcl) of TRI Reagent LS (Sigma-Aldrich) to each sample and mixed for 5 min.", [["sample", "ANATOMY", 106, 112], ["TRI", "CHEMICAL", 67, 70], ["Nuclease", "GENE_OR_GENE_PRODUCT", 0, 8], ["Nuclease digestion", "PROBLEM", 0, 18], ["TRI Reagent LS", "TREATMENT", 67, 81]]], ["An equal amount of ethanol (99,5%) was added and mixed thoroughly before the mixture was transferred into a Zymo-Spin column placed in a collection tube (Direct-zol RNA MiniPrep Kit, Zymo Research).", [["ethanol", "CHEMICAL", 19, 26], ["ethanol", "CHEMICAL", 19, 26], ["ethanol", "SIMPLE_CHEMICAL", 19, 26], ["Zymo", "ORGANISM", 108, 112], ["tube", "TISSUE", 148, 152], ["a Zymo-Spin column", "TREATMENT", 106, 124], ["a collection tube", "TREATMENT", 135, 152], ["Direct-zol RNA", "TREATMENT", 154, 168], ["equal", "OBSERVATION_MODIFIER", 3, 8], ["amount", "OBSERVATION_MODIFIER", 9, 15], ["tube", "OBSERVATION", 148, 152]]], ["The columns were centrifuged at 16000 x g for 30 sec. after which they were washed two times with 400 \u03bcl of PreWash solution each time followed by 30 sec. of centrifugation.", [["PreWash", "CHEMICAL", 108, 115], ["PreWash", "SIMPLE_CHEMICAL", 108, 115], ["PreWash solution", "TREATMENT", 108, 124], ["centrifugation", "TREATMENT", 158, 172], ["columns", "OBSERVATION_MODIFIER", 4, 11], ["centrifugation", "OBSERVATION", 158, 172]]], ["Then 700 \u03bcl of RNA Wash Buffer was added to the columns followed by centrifugation for 2 min before they were transferred to RNase free Eppendorf tubes.", [["RNase", "GENE_OR_GENE_PRODUCT", 125, 130], ["RNase", "PROTEIN", 125, 130], ["RNA Wash Buffer", "TREATMENT", 15, 30], ["the columns", "TREATMENT", 44, 55], ["RNase free Eppendorf tubes", "TREATMENT", 125, 151], ["Eppendorf tubes", "OBSERVATION", 136, 151]]], ["RNA was eluted from the column matrix by adding 30 \u03bcl of DNase/RNase free water and centrifugation at 16,000 x g for 30 sec.Synthesis of double-stranded cDNA ::: Virome sequencing ::: Material and methodsThe concentration of RNA in the samples was measured with QUBIT RNA HS Kit in a Qubit 2.0 Flourometer (Invitrogen Thermo Fisher Scientific)).", [["samples", "ANATOMY", 236, 243], ["DNase", "GENE_OR_GENE_PRODUCT", 57, 62], ["RNase", "GENE_OR_GENE_PRODUCT", 63, 68], ["RNA", "RNA", 0, 3], ["DNase", "PROTEIN", 57, 62], ["RNase", "PROTEIN", 63, 68], ["double-stranded cDNA", "DNA", 137, 157], ["the column matrix", "TREATMENT", 20, 37], ["DNase/RNase free water", "TREATMENT", 57, 79], ["centrifugation", "TREATMENT", 84, 98], ["column", "ANATOMY", 24, 30], ["concentration", "OBSERVATION_MODIFIER", 208, 221], ["RNA", "OBSERVATION_MODIFIER", 225, 228]]], ["Using the SuperScript IV First-Strand Synthesis System (Invitrogen, Thermo Fisher Scientific) cDNA was synthesized with random hexamer on a Bio-Rad S1000 Thermal cycler according to the manufacturer\u2019s instructions.", [["SuperScript IV First-Strand Synthesis System (Invitrogen, Thermo Fisher Scientific) cDNA", "DNA", 10, 98], ["the SuperScript IV", "TREATMENT", 6, 24], ["Strand Synthesis System", "TREATMENT", 31, 54], ["random hexamer", "TREATMENT", 120, 134], ["a Bio-Rad S1000 Thermal cycler", "TREATMENT", 138, 168]]], ["RNase H was added to each well and incubated for 20 min at 37\u00b0C to destroy the template RNA.", [["RNase H", "GENE_OR_GENE_PRODUCT", 0, 7], ["RNase H", "PROTEIN", 0, 7], ["template RNA", "RNA", 79, 91], ["template RNA", "OBSERVATION", 79, 91]]], ["Ds-cDNA was synthesized by adding 0.5 \u03bcl of 3\u2019-5\u2019 exo- Klenow DNA polymerase (Klenow Fragment, New England BioLabs) and incubating for 60 min at 37\u00b0C followed by a 10-min enzyme inactivation step at 75\u00b0C. The concentration of ds-cDNA was measured with QUBIT dsDNA HS Kit (Invitrogen, Thermo Fisher Scientific) and normalized to 0.2 ng/\u03bcl for further library preparation.Library preparation and sequencing ::: Virome sequencing ::: Material and methodsLibraries with dual indexing for each sample were generated with Nextera XT DNA Library Prep Kit (Illumina Inc, San Diego) according to the manufacturer\u1ffds instructions with the minor modifications that half the volumes were used for all reagents in the tagmentation and amplification steps.", [["sample", "ANATOMY", 489, 495], ["DNA", "CELLULAR_COMPONENT", 62, 65], ["Ds", "DNA", 0, 2], ["cDNA", "DNA", 3, 7], ["Klenow DNA polymerase", "PROTEIN", 55, 76], ["ds-cDNA", "DNA", 226, 233], ["Ds", "TEST", 0, 2], ["Klenow DNA polymerase (Klenow Fragment", "TREATMENT", 55, 93], ["ds-cDNA", "TREATMENT", 226, 233], ["further library preparation", "TREATMENT", 342, 369], ["Library preparation", "TREATMENT", 370, 389], ["methodsLibraries", "TREATMENT", 444, 460], ["each sample", "TEST", 484, 495], ["Nextera XT DNA", "TREATMENT", 516, 530], ["Kit (Illumina Inc", "TREATMENT", 544, 561], ["the manufacturer\u1ffds instructions", "TREATMENT", 587, 618], ["the minor modifications", "TREATMENT", 624, 647], ["all reagents", "TREATMENT", 684, 696]]], ["The libraries were cleaned up with AMPure XP beads (Beckman Coulter) and the size distribution and the concentration of each library were estimated using a High Sensitivity DNA Chip in an Agilent 2100 Bioanalyzer Instrument (Agilent).", [["AMPure XP beads (Beckman Coulter", "TREATMENT", 35, 67], ["a High Sensitivity DNA Chip", "TREATMENT", 154, 181], ["an Agilent 2100 Bioanalyzer Instrument (Agilent)", "TREATMENT", 185, 233], ["size", "OBSERVATION_MODIFIER", 77, 81], ["distribution", "OBSERVATION_MODIFIER", 82, 94]]], ["The libraries were diluted in Resuspension Buffer (Illumina) to 2 nM and pooled.", [["The libraries", "TREATMENT", 0, 13], ["Resuspension Buffer (Illumina)", "TREATMENT", 30, 60]]], ["After denaturation with 0.2 M NaOH, the pool of libraries was diluted in Hybridization Buffer (Illumina) to 10pM and combined with 1% denatured PhiX Control before sequencing on the Illumina MiSeq platform with MiSeq 600 Cycles Reagent Kit v3.Bioinformatics and data analysis ::: Material and methodsMiSeq paired-end reads originating from RNA-preparations for virus detection of the pooled feces samples were acquired as described above.", [["feces samples", "ANATOMY", 391, 404], ["NaOH", "CHEMICAL", 30, 34], ["NaOH", "CHEMICAL", 30, 34], ["feces", "ORGANISM", 391, 396], ["PhiX", "PROTEIN", 144, 148], ["NaOH", "TREATMENT", 30, 34], ["the pool of libraries", "TREATMENT", 36, 57], ["Hybridization Buffer (Illumina)", "TREATMENT", 73, 104], ["1% denatured PhiX Control", "TREATMENT", 131, 156], ["the Illumina MiSeq platform", "TREATMENT", 178, 205], ["MiSeq", "TEST", 211, 216], ["RNA-preparations", "TREATMENT", 340, 356], ["virus detection", "TEST", 361, 376], ["the pooled feces samples", "TEST", 380, 404]]], ["The total number of pools generating sufficient data (a lower limit of 95 000 reads were employed) for further analysis were 30 and 31 for diarrheic and non-diarrheic pools, respectively.", [["diarrheic", "DISEASE", 139, 148], ["further analysis", "TEST", 103, 119], ["diarrheic", "PROBLEM", 139, 148], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The total number of reads taxonomically assigned to viruses from diarrheic and non-diarrheic pools were 1.50 and 0.90 million, respectively, after scaling against the total numbers of reads in each category as implemented in MEGAN6 [34].", [["diarrheic", "DISEASE", 65, 74], ["viruses", "PROBLEM", 52, 59], ["diarrheic", "PROBLEM", 65, 74], ["non-diarrheic pools", "PROBLEM", 79, 98]]], ["The sequence reads were then aligned to the ncbi nr database using the blastx algorithm as implemented in DIAMOND version 08.10 [35] with the e-value cutoff set to 10\u22125.", [["ncbi nr database", "DNA", 44, 60], ["the blastx algorithm", "TEST", 67, 87], ["the e-value cutoff", "TEST", 138, 156]]], ["The blast tables generated by DIAMOND were imported to MEGAN6 [34] for further analysis and taxonomic classification.", [["DIAMOND", "PROTEIN", 30, 37], ["further analysis", "TEST", 71, 87], ["taxonomic classification", "TEST", 92, 116]]], ["For analysis of the bacterial content of the pooled samples 16S rRNA amplicon sequencing was carried out.", [["analysis", "TEST", 4, 12], ["the bacterial content", "PROBLEM", 16, 37], ["the pooled samples 16S rRNA amplicon sequencing", "TEST", 41, 88]]], ["The V3 and V4 regions were amplified producing a 459 bp amplicon.", [["V3 and V4 regions", "DNA", 4, 21], ["459 bp amplicon", "DNA", 49, 64], ["a 459 bp amplicon", "TREATMENT", 47, 64], ["V3", "ANATOMY_MODIFIER", 4, 6], ["V4", "ANATOMY_MODIFIER", 11, 13], ["regions", "ANATOMY_MODIFIER", 14, 21]]], ["The MiSeq amplicon sequencing data were analyzed with the 16S amplicon data dedicated pipeline in the microbial genomics plugin module (version 2.5.1) of the CLC genomics workbench (version 10.1.1).", [["MiSeq amplicon", "DNA", 4, 18], ["The MiSeq amplicon sequencing data", "TEST", 0, 34], ["the 16S amplicon data", "TEST", 54, 75]]], ["The reads were trimmed based on quality parameters and samples with less than 40 000 reads were excluded.", [["quality parameters", "TEST", 32, 50], ["samples", "TEST", 55, 62]]], ["After this procedure 38 and 42 pools remained in the diarrheic and non-diarrheic groups, respectively, for further analysis.", [["diarrheic", "DISEASE", 53, 62], ["this procedure", "TREATMENT", 6, 20], ["further analysis", "TEST", 107, 123]]], ["The Paired end reads were merged and verified to be of identical length before operational taxonomical unit (OTU) clustering using the SILVA OTU 16S database v. 123 with 97% as required similarity for assignment [36].Microbiota ::: ResultsIn Fig 1 all the OTU-assigned 16S amplicons are grouped according to diarrheic/non-diarrheic status based on post-mortem examination.", [["Paired end reads", "DNA", 4, 20], ["SILVA OTU 16S", "DNA", 135, 148], ["16S amplicons", "DNA", 269, 282], ["16S amplicons", "TREATMENT", 269, 282], ["diarrheic", "PROBLEM", 308, 317], ["diarrheic status", "PROBLEM", 322, 338], ["post-mortem examination", "TEST", 348, 371]]], ["The bacterial populations are clearly different in the two groups.", [["The bacterial populations", "PROBLEM", 0, 25], ["bacterial", "OBSERVATION_MODIFIER", 4, 13], ["populations", "OBSERVATION", 14, 25], ["different", "OBSERVATION_MODIFIER", 38, 47]]], ["Generally firmicutes with bacillales and lactobacillales dominated in both groups with the most prevalent genera being enterococci (dark blue bottom), staphylococci (light blue bottom) and streptococci (dark blue top) (Note that in Fig 1 the aggregation of OTUs is on taxonomic genus level while the coloring is based on the phyla.", [["lactobacillales", "SIMPLE_CHEMICAL", 41, 56], ["bacillales and lactobacillales", "PROBLEM", 26, 56], ["enterococci", "PROBLEM", 119, 130], ["dark blue bottom", "PROBLEM", 132, 148], ["staphylococci", "PROBLEM", 151, 164], ["light blue bottom", "TEST", 166, 183], ["streptococci", "PROBLEM", 189, 201], ["firmicutes", "OBSERVATION", 10, 20], ["enterococci", "OBSERVATION", 119, 130], ["streptococci", "OBSERVATION", 189, 201]]], ["Different shades of the colors are used when genera of the same phylum appear next to each other in the bars.", [["shades", "OBSERVATION_MODIFIER", 10, 16], ["colors", "OBSERVATION_MODIFIER", 24, 30]]], ["However, for the reads coming from diarrheic pools, there were also a significant number of reads assigned to Clostridia (light blue top), Escherichia-Shigella (orange) and Enterobacter (red).Microbiota ::: ResultsA detailed view of the same data displaying individual pools is show in Fig 2.", [["Escherichia-Shigella", "ORGANISM", 139, 159], ["(orange)", "GENE_OR_GENE_PRODUCT", 160, 168], ["Enterobacter (red)", "GENE_OR_GENE_PRODUCT", 173, 191], ["Escherichia-Shigella", "SPECIES", 139, 159], ["diarrheic pools", "PROBLEM", 35, 50], ["Clostridia", "TEST", 110, 120], ["light blue top", "TEST", 122, 136], ["Escherichia", "TEST", 139, 150], ["Shigella", "PROBLEM", 151, 159], ["Enterobacter", "PROBLEM", 173, 185], ["Enterobacter", "OBSERVATION", 173, 185]]], ["In this figure the pools are grouped according to diarrheic and non-diarrheic.", [["diarrheic", "DISEASE", 50, 59], ["diarrheic", "PROBLEM", 50, 59], ["non-diarrheic", "PROBLEM", 64, 77]]], ["For some of the litters the female had been treated with amoxicillin and the corresponding pools have been indicated with a star (*).", [["amoxicillin", "CHEMICAL", 57, 68], ["amoxicillin", "CHEMICAL", 57, 68], ["female", "ORGANISM", 28, 34], ["amoxicillin", "SIMPLE_CHEMICAL", 57, 68], ["amoxicillin", "TREATMENT", 57, 68]]], ["It is seen that there is complete dominance by Bacillales and Lactobacillales among the non-diarrheic pools with more than 80% of the assigned amplicons.", [["Bacillales", "SIMPLE_CHEMICAL", 47, 57], ["Lactobacillales", "SIMPLE_CHEMICAL", 62, 77], ["Bacillales", "TREATMENT", 47, 57], ["Lactobacillales", "TREATMENT", 62, 77], ["the non-diarrheic pools", "PROBLEM", 84, 107], ["complete", "OBSERVATION_MODIFIER", 25, 33], ["dominance", "OBSERVATION", 34, 43]]], ["On the other hand, among the diarrheic pools there is a clear tendency for more significant contributions of Proteobacteria to the bacterial flora mainly constituting of Enterobacter, Escherichia-Shigella and Clostridia (not shown on this taxonomic level).", [["Escherichia-Shigella", "ORGANISM", 184, 204], ["Escherichia-Shigella", "SPECIES", 184, 204], ["the diarrheic pools", "PROBLEM", 25, 44], ["Proteobacteria", "PROBLEM", 109, 123], ["the bacterial flora", "PROBLEM", 127, 146], ["Enterobacter", "PROBLEM", 170, 182], ["Escherichia", "PROBLEM", 184, 195], ["Shigella", "PROBLEM", 196, 204], ["Clostridia", "PROBLEM", 209, 219], ["diarrheic pools", "OBSERVATION", 29, 44], ["bacterial flora", "OBSERVATION", 131, 146], ["Enterobacter", "OBSERVATION", 170, 182], ["Escherichia", "OBSERVATION_MODIFIER", 184, 195]]], ["Also a single diarrheic pool (no 82) with the bacterial population dominated by Pasteurella species is seen.", [["diarrheic", "DISEASE", 14, 23], ["Pasteurella species", "ORGANISM", 80, 99], ["a single diarrheic pool", "PROBLEM", 5, 28], ["the bacterial population", "PROBLEM", 42, 66], ["Pasteurella species", "PROBLEM", 80, 99], ["bacterial", "OBSERVATION_MODIFIER", 46, 55], ["population", "OBSERVATION", 56, 66], ["Pasteurella species", "OBSERVATION", 80, 99]]], ["From Fig 1 it is also clear that the enterococci increased in the diarrheic group accounting for 70% of the reads as compared to 50% in the non-diarrheic group.", [["diarrheic", "DISEASE", 66, 75], ["enterococci", "CANCER", 37, 48], ["the enterococci", "PROBLEM", 33, 48], ["enterococci", "OBSERVATION", 37, 48], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["diarrheic group", "OBSERVATION_MODIFIER", 66, 81]]], ["This increase was at the expense of staphylococci and streptococci that together accounted for almost 45% of the reads in the non-diarrheic group but only 17% in the diarrheic group (Fig 1).", [["staphylococci", "DISEASE", 36, 49], ["diarrheic", "DISEASE", 166, 175], ["staphylococci", "PROBLEM", 36, 49], ["streptococci", "PROBLEM", 54, 66], ["staphylococci", "OBSERVATION", 36, 49], ["streptococci", "OBSERVATION", 54, 66]]], ["From Fig 2, it can be seen that this general pattern emanates from a gradual appearance and dominance by Proteobacteria with increasing litter age (c.f.", [["Proteobacteria", "PROBLEM", 105, 119]]], ["The antibiotic treatment of the females does not seem to correlate with the composition of the microbiota in any way.Microbiota ::: ResultsIn Fig 3, the pools are ordered with respect to the litter age in days.", [["The antibiotic treatment", "TREATMENT", 0, 24]]], ["The younger litters are dominated by Bacillales while Lactobacillales increase and become dominating with age.", [["Lactobacillales", "SIMPLE_CHEMICAL", 54, 69]]], ["This is largely due to an increase of the enterococci and decrease of the staphylococci (c.f.", [["staphylococci", "DISEASE", 74, 87], ["the enterococci", "PROBLEM", 38, 53], ["the staphylococci", "PROBLEM", 70, 87], ["largely due to", "UNCERTAINTY", 8, 22], ["increase", "OBSERVATION_MODIFIER", 26, 34], ["enterococci", "OBSERVATION", 42, 53], ["decrease", "OBSERVATION_MODIFIER", 58, 66], ["staphylococci", "OBSERVATION", 74, 87]]], ["In addition, for the diarrheic pools, there is a tendency that Proteobacteria become more prominent with age (c.f.", [["diarrheic", "DISEASE", 21, 30], ["the diarrheic pools", "PROBLEM", 17, 36], ["a tendency that Proteobacteria", "PROBLEM", 47, 77], ["Proteobacteria", "OBSERVATION", 63, 77], ["more prominent", "OBSERVATION_MODIFIER", 85, 99]]], ["Fig 1).Microbiota ::: ResultsThe alpha diversity illustrates the species diversity at a habitat or a site; in our case a litter.", [["alpha", "GENE_OR_GENE_PRODUCT", 33, 38]]], ["The degree of species differentiation between habitats (i.e. between the different litters) is the beta-diversity [37].", [["species differentiation", "PROBLEM", 14, 37], ["degree", "OBSERVATION_MODIFIER", 4, 10], ["species differentiation", "OBSERVATION", 14, 37]]], ["The non-diarrheic samples are shown in blue while the diarrheic samples are shown in red.", [["samples", "ANATOMY", 18, 25], ["samples", "ANATOMY", 64, 71], ["non-diarrheic samples", "CANCER", 4, 25], ["The non-diarrheic samples", "TEST", 0, 25], ["blue", "PROBLEM", 39, 43], ["the diarrheic samples", "TEST", 50, 71], ["red", "OBSERVATION", 85, 88]]], ["Overall, the diversity appears to be similar.", [["diversity", "OBSERVATION", 13, 22], ["appears to be", "UNCERTAINTY", 23, 36], ["similar", "OBSERVATION_MODIFIER", 37, 44]]], ["A slight tendency for higher diversity in the diarrheic pools might be discernible (more red curves at the top of the graph).", [["diarrheic", "DISEASE", 46, 55], ["A slight tendency", "PROBLEM", 0, 17], ["higher diversity in the diarrheic pools", "PROBLEM", 22, 61], ["slight", "OBSERVATION_MODIFIER", 2, 8], ["tendency", "OBSERVATION_MODIFIER", 9, 17], ["higher", "OBSERVATION_MODIFIER", 22, 28], ["diversity", "OBSERVATION_MODIFIER", 29, 38], ["diarrheic pools", "OBSERVATION", 46, 61], ["might be", "UNCERTAINTY", 62, 70], ["discernible", "OBSERVATION_MODIFIER", 71, 82]]], ["The beta diversity is shown in Fig 5 in a three-dimensional principal component plot.", [["beta", "GENE_OR_GENE_PRODUCT", 4, 8], ["beta diversity", "OBSERVATION_MODIFIER", 4, 18]]], ["The non-diarrheic pools are shown in blue while the diarrheic pools are in red.", [["diarrheic", "DISEASE", 52, 61], ["The non-diarrheic pools", "PROBLEM", 0, 23], ["blue", "PROBLEM", 37, 41], ["the diarrheic pools", "PROBLEM", 48, 67], ["diarrheic pools", "OBSERVATION", 52, 67]]], ["The two groups do not form distinct clusters but have a clear tendency to separate mainly along the Pco1-axis.", [["Pco1", "GENE_OR_GENE_PRODUCT", 100, 104], ["Pco1", "PROTEIN", 100, 104], ["clear", "OBSERVATION", 56, 61]]], ["This is in accordance with the population results illustrated in Figs 1\u20133 that overall gives a clear picture that Proteobacteria becomes more predominant in diarrheic pools than the non-diarreic pools.Virome ::: ResultsThe 300 nt paired-end sequencing reads acquired were taxonomically categorized and analyzed in the diarrheic and non-diarrheic groups (see Material and methods for details).", [["Proteobacteria", "SIMPLE_CHEMICAL", 114, 128], ["Proteobacteria", "PROBLEM", 114, 128], ["diarrheic pools", "PROBLEM", 157, 172], ["predominant", "OBSERVATION_MODIFIER", 142, 153]]], ["In Fig 6 the viral content in terms of number of reads assigned to different virus groups are shown for diarrheic and non-diarrheic pools in terms of a heat map with reddish and bluish colors corresponding to many and few assigned reads, respectively.", [["diarrheic", "DISEASE", 104, 113], ["different virus groups", "TREATMENT", 67, 89], ["diarrheic", "PROBLEM", 104, 113], ["non-diarrheic pools", "PROBLEM", 118, 137], ["a heat map", "TREATMENT", 150, 160], ["reddish and bluish colors", "PROBLEM", 166, 191], ["viral content", "OBSERVATION", 13, 26], ["bluish colors", "OBSERVATION", 178, 191]]], ["In addition, viruses infecting bacteria have been excluded.", [["viruses infecting bacteria", "PROBLEM", 13, 39], ["viruses", "OBSERVATION_MODIFIER", 13, 20], ["infecting bacteria", "OBSERVATION", 21, 39]]], ["Vesiviruses, lagoviruses, sapoviruses and noroviruses all belong to the Caliciviridae family.", [["noroviruses", "DISEASE", 42, 53], ["Vesiviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["lagoviruses", "GENE_OR_GENE_PRODUCT", 13, 24], ["sapoviruses", "GENE_OR_GENE_PRODUCT", 26, 37], ["Caliciviridae", "GENE_OR_GENE_PRODUCT", 72, 85], ["Caliciviridae family", "PROTEIN", 72, 92], ["Vesiviruses", "TREATMENT", 0, 11], ["lagoviruses", "TREATMENT", 13, 24], ["sapoviruses", "TREATMENT", 26, 37], ["noroviruses", "PROBLEM", 42, 53]]], ["Caliciviruses and astroviruses were prevalent in both diarrheic and non-diarrheic pool samples and they were found in large amounts (Fig 6).", [["samples", "ANATOMY", 87, 94], ["astroviruses", "CANCER", 18, 30], ["Caliciviruses", "PROBLEM", 0, 13], ["astroviruses", "PROBLEM", 18, 30], ["astroviruses", "OBSERVATION", 18, 30], ["large", "OBSERVATION_MODIFIER", 118, 123], ["amounts", "OBSERVATION_MODIFIER", 124, 131]]], ["The number of reads assigned to caliciviruses was almost three times as many in the diarrheic group as in the non-diarrheic group of pools.", [["caliciviruses", "PROBLEM", 32, 45], ["caliciviruses", "OBSERVATION", 32, 45]]], ["Sapporo-like caliciviruses dominated and were almost ten times more abundant than Norwalk-like caliciviruses.", [["Sapporo-like caliciviruses", "ORGANISM", 0, 26], ["Norwalk-like caliciviruses", "ORGANISM", 82, 108], ["Sapporo-like caliciviruses", "PROBLEM", 0, 26], ["caliciviruses", "OBSERVATION", 13, 26], ["ten times", "OBSERVATION_MODIFIER", 53, 62], ["caliciviruses", "OBSERVATION", 95, 108]]], ["Furthermore, the sapoviruses were even more dominating in the diarrheic pools since the noroviruses actually were more prevalent in the non-diarrheic pools (Fig 6).", [["diarrheic", "DISEASE", 62, 71], ["sapoviruses", "GENE_OR_GENE_PRODUCT", 17, 28], ["noroviruses", "ORGANISM", 88, 99], ["the sapoviruses", "PROBLEM", 13, 28], ["the diarrheic pools", "PROBLEM", 58, 77], ["the noroviruses", "PROBLEM", 84, 99], ["noroviruses", "OBSERVATION", 88, 99]]], ["The amount of reads assigned to astroviruses was even more abundant than the caliciviruses but was more similar between the two groups with 10% more reads among the diarrheic pools.", [["diarrheic", "DISEASE", 165, 174], ["caliciviruses", "CANCER", 77, 90], ["astroviruses", "PROBLEM", 32, 44], ["the diarrheic pools", "PROBLEM", 161, 180], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["caliciviruses", "OBSERVATION", 77, 90]]], ["Astroviruses were of the mamastrovirus genus and almost exclusively of type 10 as usually found in mink.", [["mink", "ORGANISM", 99, 103], ["mink", "SPECIES", 99, 103], ["mink", "SPECIES", 99, 103], ["Astroviruses", "PROBLEM", 0, 12], ["the mamastrovirus genus", "TREATMENT", 21, 44]]], ["Kobuviruses and rotaviruses were quite common in the pools but usually occurred in relatively small quantities that overall did not differ much between diarrheic and non-diarrheic pools.", [["diarrheic", "DISEASE", 152, 161], ["Kobuviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["rotaviruses", "ORGANISM", 16, 27], ["Kobuviruses", "TREATMENT", 0, 11], ["rotaviruses", "TREATMENT", 16, 27], ["rotaviruses", "OBSERVATION", 16, 27]]], ["Other viruses occurred sporadically and in small quantities.DiscussionThe application of HTS technologies to characterize the virome in diarrheic and healthy mink kits showed that mink kits host many different viruses in their gut some of which also have been found in adult mink and ferrets [38\u201339].", [["gut", "ANATOMY", 227, 230], ["diarrheic", "DISEASE", 136, 145], ["mink", "ORGANISM", 158, 162], ["mink kits", "ORGANISM", 180, 189], ["gut", "ORGANISM_SUBDIVISION", 227, 230], ["mink", "ORGANISM", 275, 279], ["ferrets", "ORGANISM", 284, 291], ["mink", "SPECIES", 158, 162], ["mink", "SPECIES", 180, 184], ["mink", "SPECIES", 275, 279], ["ferrets", "SPECIES", 284, 291], ["mink", "SPECIES", 158, 162], ["mink", "SPECIES", 180, 184], ["mink", "SPECIES", 275, 279], ["Other viruses", "PROBLEM", 0, 13], ["HTS technologies", "TREATMENT", 89, 105], ["the virome in diarrheic and healthy mink kits", "PROBLEM", 122, 167], ["viruses", "OBSERVATION", 6, 13], ["small quantities", "OBSERVATION_MODIFIER", 43, 59], ["viruses", "OBSERVATION", 210, 217]]], ["The most prevalent eukaryotic viruses were caliciviruses (Norovirus and Sapovirus) and astroviruses.", [["caliciviruses", "GENE_OR_GENE_PRODUCT", 43, 56], ["Sapovirus", "CANCER", 72, 81], ["astroviruses", "CANCER", 87, 99], ["caliciviruses", "PROBLEM", 43, 56], ["Norovirus", "PROBLEM", 58, 67], ["Sapovirus", "PROBLEM", 72, 81], ["astroviruses", "PROBLEM", 87, 99], ["most prevalent", "OBSERVATION_MODIFIER", 4, 18], ["viruses", "OBSERVATION", 30, 37]]], ["As expected from several previous studies caliciviruses and astroviruses were prevalent in both diarrheic and non-diarrheic samples [10\u201312,14].", [["samples", "ANATOMY", 124, 131], ["diarrheic", "DISEASE", 96, 105], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 42, 55], ["astroviruses", "CANCER", 60, 72], ["several previous studies caliciviruses", "PROBLEM", 17, 55], ["astroviruses", "PROBLEM", 60, 72]]], ["Kobuvirus and rotavirus were also detected but with smaller number of reads.", [["Kobuvirus", "CHEMICAL", 0, 9], ["Kobuvirus", "GENE_OR_GENE_PRODUCT", 0, 9], ["rotavirus", "ORGANISM", 14, 23], ["rotavirus", "SPECIES", 14, 23], ["Kobuvirus", "TREATMENT", 0, 9], ["rotavirus", "PROBLEM", 14, 23], ["rotavirus", "OBSERVATION", 14, 23]]], ["Calicivirus was found in higher amounts in pools from mink kits with diarrhea compared to non-diarrheic mink kits which is consistent with an earlier study which found calicivirus to be associated with PWD [10].", [["diarrhea", "DISEASE", 69, 77], ["calicivirus", "DISEASE", 168, 179], ["mink", "ORGANISM", 54, 58], ["mink", "ORGANISM", 104, 108], ["calicivirus", "ORGANISM", 168, 179], ["mink", "SPECIES", 104, 108], ["Calicivirus", "SPECIES", 0, 11], ["mink", "SPECIES", 54, 58], ["mink", "SPECIES", 104, 108], ["Calicivirus", "PROBLEM", 0, 11], ["diarrhea", "PROBLEM", 69, 77], ["non-diarrheic mink kits", "PROBLEM", 90, 113], ["an earlier study", "TEST", 139, 155], ["calicivirus", "PROBLEM", 168, 179], ["higher", "OBSERVATION_MODIFIER", 25, 31], ["amounts", "OBSERVATION_MODIFIER", 32, 39], ["pools", "OBSERVATION_MODIFIER", 43, 48], ["mink kits", "OBSERVATION", 54, 63], ["consistent with", "UNCERTAINTY", 123, 138], ["calicivirus", "OBSERVATION", 168, 179]]], ["Furthermore, Sapporo-like viruses (SLV, Sapovirus) dominated in the pools supporting the results from a previous study where mink enteric calicivirus (MEC) was characterized as being close related to SLV viruses in other animal species [13].", [["MEC", "ANATOMY", 151, 154], ["enteric calicivirus", "DISEASE", 130, 149], ["Sapporo-like viruses", "ORGANISM", 13, 33], ["SLV", "ORGANISM", 35, 38], ["mink enteric calicivirus", "ORGANISM", 125, 149], ["MEC", "CANCER", 151, 154], ["SLV viruses", "ORGANISM", 200, 211], ["mink enteric calicivirus", "SPECIES", 125, 149], ["SLV", "SPECIES", 35, 38], ["mink enteric calicivirus", "SPECIES", 125, 149], ["SLV", "SPECIES", 200, 203], ["Sapporo-like viruses", "PROBLEM", 13, 33], ["Sapovirus", "PROBLEM", 40, 49], ["a previous study", "TEST", 102, 118], ["mink enteric calicivirus", "PROBLEM", 125, 149], ["SLV viruses", "PROBLEM", 200, 211], ["viruses", "OBSERVATION", 26, 33], ["Sapovirus", "OBSERVATION", 40, 49]]], ["However, caliciviruses were also found in considerable amounts in pools from healthy kits which corresponds to results from previous work [10,14].", [["caliciviruses", "PROBLEM", 9, 22], ["caliciviruses", "OBSERVATION", 9, 22], ["considerable", "OBSERVATION_MODIFIER", 42, 54], ["amounts", "OBSERVATION_MODIFIER", 55, 62]]], ["The number of reads assigned to astrovirus was not significantly different between diarrheic and non-diarrheic pools.", [["astrovirus", "DISEASE", 32, 42], ["diarrheic", "DISEASE", 83, 92], ["astrovirus", "ORGANISM", 32, 42], ["astrovirus", "PROBLEM", 32, 42], ["diarrheic and non-diarrheic pools", "PROBLEM", 83, 116]]], ["This contrasts the discovery, that astrovirus was found to be significantly associated with PWD both on farm and kit level [10].", [["astrovirus", "ORGANISM", 35, 45], ["astrovirus", "PROBLEM", 35, 45], ["PWD", "PROBLEM", 92, 95]]], ["This discrepancy might be explained by the complexity of multifactorial diseases where incubation period, infective dose, immune competence and co-infections with other pathogens might influence the outbreak of the syndrome.", [["co-infections", "DISEASE", 144, 157], ["multifactorial diseases", "PROBLEM", 57, 80], ["infective dose", "TREATMENT", 106, 120], ["immune competence", "PROBLEM", 122, 139], ["co-infections", "PROBLEM", 144, 157], ["other pathogens", "PROBLEM", 163, 178], ["the syndrome", "PROBLEM", 211, 223], ["multifactorial", "OBSERVATION_MODIFIER", 57, 71], ["diseases", "OBSERVATION", 72, 80]]], ["There might also be strains with different pathogenic potential since a huge diversity of astroviruses has been found in other species, including human [40\u201342].", [["astroviruses", "DISEASE", 90, 102], ["astroviruses", "CANCER", 90, 102], ["human", "ORGANISM", 146, 151], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["strains", "PROBLEM", 20, 27], ["a huge diversity of astroviruses", "PROBLEM", 70, 102], ["huge", "OBSERVATION_MODIFIER", 72, 76], ["diversity", "OBSERVATION", 77, 86], ["astroviruses", "OBSERVATION", 90, 102]]], ["We might also have expected a difference if non-diarrheic pools had solely been sampled from farms without PWD at all, but in fact, that was not the situation with the present material from 2015 where most of the included farms experienced problems with PWD to some extent.", [["non-diarrheic pools", "PROBLEM", 44, 63], ["PWD", "PROBLEM", 107, 110], ["some extent", "OBSERVATION_MODIFIER", 261, 272]]], ["Astrovirus have been found in adult healthy mink and ferrets [38\u201339] as well as in a wide range of animal species primary affecting young individuals where they appear to have acquired host-specificity [43\u201344].", [["Astrovirus", "CHEMICAL", 0, 10], ["Astrovirus", "GENE_OR_GENE_PRODUCT", 0, 10], ["mink", "ORGANISM", 44, 48], ["ferrets", "ORGANISM", 53, 60], ["mink", "SPECIES", 44, 48], ["ferrets", "SPECIES", 53, 60], ["mink", "SPECIES", 44, 48], ["Astrovirus", "PROBLEM", 0, 10]]], ["In humans e.g., astrovirus symptoms of infection range from unapparent or very mild signs of diarrhea to less commonly vomiting, fever and even mortality in children, elderly and immune compromised people [45\u201347].", [["astrovirus symptoms", "DISEASE", 16, 35], ["infection", "DISEASE", 39, 48], ["diarrhea", "DISEASE", 93, 101], ["vomiting", "DISEASE", 119, 127], ["fever", "DISEASE", 129, 134], ["humans", "ORGANISM", 3, 9], ["astrovirus", "ORGANISM", 16, 26], ["children", "ORGANISM", 157, 165], ["people", "ORGANISM", 198, 204], ["humans", "SPECIES", 3, 9], ["children", "SPECIES", 157, 165], ["people", "SPECIES", 198, 204], ["humans", "SPECIES", 3, 9], ["astrovirus symptoms", "PROBLEM", 16, 35], ["infection range", "PROBLEM", 39, 54], ["very mild signs of diarrhea", "PROBLEM", 74, 101], ["vomiting", "PROBLEM", 119, 127], ["fever", "PROBLEM", 129, 134], ["infection", "OBSERVATION", 39, 48], ["very", "OBSERVATION_MODIFIER", 74, 78], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["diarrhea", "OBSERVATION", 93, 101], ["less commonly", "OBSERVATION_MODIFIER", 105, 118]]], ["Thus, based on a general behavior of astrovirus, it is not unlikely that mink kits can host astrovirus without expressing obvious signs of diarrhea.DiscussionOur study groups were suckling mink kits which had not been introduced to solid feed, and therefore their composition of gut bacteria was expected to be not so diverse and to differ from adult minks since the development of the bacterial microbiota is dependent on age and type of feeding [23,25].", [["astrovirus", "DISEASE", 37, 47], ["astrovirus", "DISEASE", 92, 102], ["diarrhea", "DISEASE", 139, 147], ["astrovirus", "ORGANISM", 37, 47], ["mink", "ORGANISM", 73, 77], ["astrovirus", "ORGANISM", 92, 102], ["mink", "ORGANISM", 189, 193], ["gut", "ORGANISM_SUBDIVISION", 279, 282], ["mink", "SPECIES", 73, 77], ["mink", "SPECIES", 189, 193], ["mink", "SPECIES", 73, 77], ["mink", "SPECIES", 189, 193], ["astrovirus", "PROBLEM", 37, 47], ["mink kits can host astrovirus", "PROBLEM", 73, 102], ["diarrhea", "PROBLEM", 139, 147], ["gut bacteria", "PROBLEM", 279, 291], ["the bacterial microbiota", "PROBLEM", 382, 406], ["astrovirus", "OBSERVATION", 37, 47], ["not unlikely", "UNCERTAINTY", 55, 67], ["diarrhea", "OBSERVATION", 139, 147], ["bacterial microbiota", "OBSERVATION", 386, 406]]], ["Our results showed that the major groups of bacteria in both healthy and diseased animals were enterococci and staphylococci which differ from the composition in adult mink where Clostridia, Fusobacteria and Gammaproteobacteria dominate [27\u201329,48].", [["mink", "ORGANISM", 168, 172], ["mink", "SPECIES", 168, 172], ["mink", "SPECIES", 168, 172], ["bacteria", "PROBLEM", 44, 52], ["enterococci", "PROBLEM", 95, 106], ["staphylococci", "PROBLEM", 111, 124], ["Clostridia", "PROBLEM", 179, 189], ["Fusobacteria", "PROBLEM", 191, 203], ["Gammaproteobacteria", "TEST", 208, 227], ["bacteria", "OBSERVATION", 44, 52], ["diseased", "OBSERVATION_MODIFIER", 73, 81]]], ["Large differences between the pools were seen and seem to correlate with litter age (Figs 2 and 3).", [["Large differences between the pools", "PROBLEM", 0, 35]]], ["This is consistent with results from another study which noted large inter-individual variation of the bacterial flora of adult mink [27].", [["mink", "SPECIES", 128, 132], ["mink", "SPECIES", 128, 132], ["another study", "TEST", 37, 50], ["large inter-individual variation", "PROBLEM", 63, 95], ["the bacterial flora", "PROBLEM", 99, 118], ["consistent with", "UNCERTAINTY", 8, 23], ["large", "OBSERVATION_MODIFIER", 63, 68], ["inter-individual", "OBSERVATION_MODIFIER", 69, 85], ["variation", "OBSERVATION_MODIFIER", 86, 95], ["bacterial flora", "OBSERVATION", 103, 118]]], ["The present study showed that Bacillales (staphylococci) were dominating in the youngest mink kits and were gradually outnumbered by Lactobacillales (enterococci) (Fig 3) which is supported by a previous culture based study [24].", [["Bacillales", "CHEMICAL", 30, 40], ["Bacillales", "GENE_OR_GENE_PRODUCT", 30, 40], ["mink", "ORGANISM", 89, 93], ["Lactobacillales", "SIMPLE_CHEMICAL", 133, 148], ["mink", "SPECIES", 89, 93], ["mink", "SPECIES", 89, 93], ["The present study", "TEST", 0, 17], ["Bacillales (staphylococci", "PROBLEM", 30, 55], ["enterococci", "PROBLEM", 150, 161], ["a previous culture based study", "TEST", 193, 223], ["staphylococci", "OBSERVATION", 42, 55], ["youngest mink kits", "OBSERVATION", 80, 98]]], ["The Staphylococcus group was decreased in the diarrheic pools compared to the non-diarrheic pools which indicates that this group of bacteria is not likely involved in the etiology of PWD syndrome but supports previous findings that staphylococci (Staphylococcus delphini) are natural inhabitants in mink [20,23\u201324].", [["diarrheic", "DISEASE", 46, 55], ["PWD syndrome", "DISEASE", 184, 196], ["staphylococci", "DISEASE", 233, 246], ["Staphylococcus delphini", "DISEASE", 248, 271], ["Staphylococcus group", "ORGANISM", 4, 24], ["staphylococci", "ORGANISM", 233, 246], ["Staphylococcus delphini", "ORGANISM", 248, 271], ["mink", "ORGANISM", 300, 304], ["Staphylococcus group", "SPECIES", 4, 24], ["Staphylococcus delphini", "SPECIES", 248, 271], ["Staphylococcus delphini", "SPECIES", 248, 271], ["mink", "SPECIES", 300, 304], ["The Staphylococcus group", "PROBLEM", 0, 24], ["the diarrheic pools", "PROBLEM", 42, 61], ["the non-diarrheic pools", "PROBLEM", 74, 97], ["bacteria", "PROBLEM", 133, 141], ["PWD syndrome", "PROBLEM", 184, 196], ["staphylococci", "PROBLEM", 233, 246], ["Staphylococcus delphini", "PROBLEM", 248, 271], ["Staphylococcus", "OBSERVATION", 4, 18], ["decreased", "OBSERVATION_MODIFIER", 29, 38], ["diarrheic pools", "OBSERVATION", 46, 61], ["not likely", "UNCERTAINTY", 145, 155]]], ["In diarrheic pools, we found a clear tendency for more contributions to the bacterial flora of Enterobacter, Escherichia-Shigella and Clostridia, which emerged at the expense of not only staphylococci but also streptococci.", [["Enterobacter", "CHEMICAL", 95, 107], ["Enterobacter", "SIMPLE_CHEMICAL", 95, 107], ["Escherichia-Shigella", "ORGANISM", 109, 129], ["Escherichia-Shigella", "SPECIES", 109, 129], ["diarrheic pools", "PROBLEM", 3, 18], ["a clear tendency", "PROBLEM", 29, 45], ["the bacterial flora", "PROBLEM", 72, 91], ["Enterobacter", "PROBLEM", 95, 107], ["Escherichia", "PROBLEM", 109, 120], ["Shigella", "PROBLEM", 121, 129], ["Clostridia", "PROBLEM", 134, 144], ["staphylococci", "PROBLEM", 187, 200], ["streptococci", "PROBLEM", 210, 222], ["Enterobacter", "OBSERVATION", 95, 107], ["staphylococci", "OBSERVATION", 187, 200], ["streptococci", "OBSERVATION", 210, 222]]], ["E.coli has been studied in both healthy and diarrheic mink kits but it has not been possible to identify certain types of E.coli involved in the pre-weaning diarrhea syndrome [14,18].", [["diarrhea", "DISEASE", 157, 165], ["mink", "ORGANISM", 54, 58], ["E.coli", "GENE_OR_GENE_PRODUCT", 122, 128], ["mink", "SPECIES", 54, 58], ["E.coli", "SPECIES", 0, 6], ["diarrheic mink", "SPECIES", 44, 58], ["E.coli", "SPECIES", 122, 128], ["E.coli", "PROBLEM", 0, 6], ["E.coli", "PROBLEM", 122, 128], ["the pre-weaning diarrhea syndrome", "PROBLEM", 141, 174], ["E.coli", "OBSERVATION", 122, 128]]], ["The pronounced increase in the number of reads assigned to enterococci in the diarrheic group raises questions about their pathogenic potential, and in e.g. suckling rats, piglets and kittens enterococci have been associated with diarrhea [49\u201353].", [["diarrheic", "DISEASE", 78, 87], ["diarrhea", "DISEASE", 230, 238], ["suckling rats", "ORGANISM", 157, 170], ["piglets", "ORGANISM", 172, 179], ["kittens", "ORGANISM", 184, 191], ["enterococci", "ORGANISM", 192, 203], ["rats", "SPECIES", 166, 170], ["piglets", "SPECIES", 172, 179], ["The pronounced increase", "PROBLEM", 0, 23], ["enterococci", "PROBLEM", 59, 70], ["kittens enterococci", "PROBLEM", 184, 203], ["diarrhea", "PROBLEM", 230, 238], ["pronounced", "OBSERVATION_MODIFIER", 4, 14], ["increase", "OBSERVATION_MODIFIER", 15, 23], ["enterococci", "OBSERVATION", 59, 70]]], ["Interestingly, the combination of increased proportion of enterococci and E.coli that we found in the diarrheic group also has been demonstrated in piglets with New Neonatal Porcine Diarrhea (NNPD) [32,52,54], suggesting some similarities in pathology between mink kits and piglets with diarrhea in the suckling period.", [["diarrheic", "DISEASE", 102, 111], ["Neonatal Porcine Diarrhea", "DISEASE", 165, 190], ["NNPD", "DISEASE", 192, 196], ["diarrhea", "DISEASE", 287, 295], ["enterococci", "CANCER", 58, 69], ["E.coli", "GENE_OR_GENE_PRODUCT", 74, 80], ["piglets", "ORGANISM", 148, 155], ["mink", "ORGANISM", 260, 264], ["piglets", "ORGANISM", 274, 281], ["piglets", "SPECIES", 148, 155], ["Porcine", "SPECIES", 174, 181], ["mink", "SPECIES", 260, 264], ["piglets", "SPECIES", 274, 281], ["E.coli", "SPECIES", 74, 80], ["mink", "SPECIES", 260, 264], ["enterococci", "PROBLEM", 58, 69], ["E.coli", "PROBLEM", 74, 80], ["New Neonatal Porcine Diarrhea", "PROBLEM", 161, 190], ["diarrhea", "PROBLEM", 287, 295], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["proportion", "OBSERVATION_MODIFIER", 44, 54], ["enterococci", "OBSERVATION", 58, 69], ["E.coli", "OBSERVATION", 74, 80], ["diarrheic", "OBSERVATION", 102, 111], ["piglets", "OBSERVATION_MODIFIER", 148, 155], ["New", "OBSERVATION_MODIFIER", 161, 164], ["Neonatal", "OBSERVATION_MODIFIER", 165, 173], ["Porcine Diarrhea", "OBSERVATION", 174, 190], ["pathology", "OBSERVATION", 242, 251]]], ["Clostridia and Escherichia-Shigella are major components of the adult bacterial microbiota [27,29], and based on these findings PWD in mink kits may be interpreted as a general result of less tolerance of too early colonization by specific bacteria groups.", [["Clostridia", "CHEMICAL", 0, 10], ["Escherichia-Shigella", "ORGANISM", 15, 35], ["mink", "ORGANISM", 135, 139], ["Escherichia-Shigella", "SPECIES", 15, 35], ["mink", "SPECIES", 135, 139], ["mink", "SPECIES", 135, 139], ["Clostridia", "PROBLEM", 0, 10], ["Escherichia", "PROBLEM", 15, 26], ["Shigella", "PROBLEM", 27, 35], ["the adult bacterial microbiota", "PROBLEM", 60, 90], ["too early colonization", "PROBLEM", 205, 227], ["Escherichia", "OBSERVATION", 15, 26], ["Shigella", "OBSERVATION_MODIFIER", 27, 35], ["adult", "OBSERVATION_MODIFIER", 64, 69], ["bacterial microbiota", "OBSERVATION", 70, 90]]], ["Material for this study was collected from commercial mink farms with severe on-going outbreaks of PWD and therefore it was impossible to control and avoid antimicrobial treatment of the females in all the sampled litters.", [["mink", "SPECIES", 54, 58], ["this study", "TEST", 13, 23], ["PWD", "TREATMENT", 99, 102], ["antimicrobial treatment", "TREATMENT", 156, 179], ["severe", "OBSERVATION_MODIFIER", 70, 76]]], ["However, none of the sampled mink kits were treated and from Fig 2, this does not seem to influence the composition of the mink kit microbiota and the overall results.DiscussionIn the present study, we did not see a clear tendency that the diversity of the bacterial community is strongly influenced (Fig 5) but the relative amounts of different bacteria were affected.", [["community", "ANATOMY", 267, 276], ["mink", "ORGANISM", 29, 33], ["mink", "ORGANISM", 123, 127], ["mink", "SPECIES", 123, 127], ["mink", "SPECIES", 29, 33], ["mink", "SPECIES", 123, 127], ["the sampled mink kits", "TEST", 17, 38], ["different bacteria", "PROBLEM", 336, 354], ["bacterial", "OBSERVATION_MODIFIER", 257, 266], ["amounts", "OBSERVATION_MODIFIER", 325, 332], ["different", "OBSERVATION_MODIFIER", 336, 345], ["bacteria", "OBSERVATION", 346, 354]]], ["Similarily, the viruses detected overall appeared both in diarrheic and non-diarrheic pools but the amounts differed significantly in particular for sapoviruses.", [["diarrheic", "DISEASE", 58, 67], ["the viruses", "PROBLEM", 12, 23], ["diarrheic", "PROBLEM", 58, 67], ["non-diarrheic pools", "PROBLEM", 72, 91], ["sapoviruses", "PROBLEM", 149, 160], ["viruses", "OBSERVATION", 16, 23], ["both", "OBSERVATION_MODIFIER", 50, 54], ["diarrheic", "OBSERVATION", 58, 67]]], ["In conclusion, this study has, with application of NGS methods, provided information about the bacterial and viral community in healthy and diarrheic mink kits.", [["community", "ANATOMY", 115, 124], ["mink", "ORGANISM", 150, 154], ["mink", "SPECIES", 150, 154], ["diarrheic mink", "SPECIES", 140, 154], ["this study", "TEST", 15, 25], ["NGS methods", "TREATMENT", 51, 62], ["diarrheic mink", "OBSERVATION", 140, 154]]], ["Thus, our data support a model where there is no single etiological agent but there is a balance in the microbiota that is perturbed in the diarrheic animals where both caliciviruses and astroviruses increase and simultaneously enterococci, Enterobacter and Clostridia become more prevalent at the expense of staphylococci and streptococci.", [["diarrheic", "DISEASE", 140, 149], ["Enterobacter", "CHEMICAL", 241, 253], ["staphylococci", "DISEASE", 309, 322], ["staphylococci", "CANCER", 309, 322], ["single etiological agent", "PROBLEM", 49, 73], ["a balance in the microbiota", "PROBLEM", 87, 114], ["the diarrheic animals", "PROBLEM", 136, 157], ["both caliciviruses", "PROBLEM", 164, 182], ["astroviruses", "PROBLEM", 187, 199], ["simultaneously enterococci", "PROBLEM", 213, 239], ["Enterobacter", "PROBLEM", 241, 253], ["Clostridia", "PROBLEM", 258, 268], ["staphylococci", "PROBLEM", 309, 322], ["streptococci", "PROBLEM", 327, 339], ["no", "UNCERTAINTY", 46, 48], ["balance", "OBSERVATION", 89, 96], ["caliciviruses", "OBSERVATION", 169, 182], ["astroviruses", "OBSERVATION_MODIFIER", 187, 199], ["increase", "OBSERVATION_MODIFIER", 200, 208], ["staphylococci", "OBSERVATION", 309, 322], ["streptococci", "OBSERVATION", 327, 339]]], ["Possibly, there could be certain variants of caliciviruses and astroviruses that are more pathogenic and play a leading role in this scenario which is currently under investigation.", [["caliciviruses", "GENE_OR_GENE_PRODUCT", 45, 58], ["astroviruses", "GENE_OR_GENE_PRODUCT", 63, 75], ["caliciviruses", "PROBLEM", 45, 58], ["astroviruses", "PROBLEM", 63, 75], ["could be", "UNCERTAINTY", 16, 24], ["caliciviruses", "OBSERVATION", 45, 58], ["astroviruses", "OBSERVATION", 63, 75]]], ["Further investigation with more specific methods is needed to clarify the interplay between certain agents and the host in the pre-weaning diarrhea syndrome of mink.", [["diarrhea", "DISEASE", 139, 147], ["mink", "ORGANISM", 160, 164], ["mink", "SPECIES", 160, 164], ["Further investigation", "TEST", 0, 21], ["certain agents", "TREATMENT", 92, 106], ["the pre-weaning diarrhea syndrome", "PROBLEM", 123, 156]]]], "a9e0af55087fc53b4038bfc3d98d74dc1f668308": [["We did a case-control study in five Hong Kong hospitals, with 241 non-infected and 13 infected staff with documented exposures to 11 index patients with severe acute respiratory syndrome (SARS) during patient care.", [["acute respiratory syndrome", "DISEASE", 160, 186], ["SARS", "DISEASE", 188, 192], ["patients", "ORGANISM", 139, 147], ["patient", "ORGANISM", 201, 208], ["patients", "SPECIES", 139, 147], ["patient", "SPECIES", 201, 208], ["severe acute respiratory syndrome", "PROBLEM", 153, 186], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory syndrome", "OBSERVATION", 166, 186]]], ["All participants were surveyed about use of mask, gloves, gowns, and hand-washing, as recommended under droplets and contact precautions when caring for index patients with SARS.", [["hand", "ANATOMY", 69, 73], ["SARS", "DISEASE", 173, 177], ["patients", "ORGANISM", 159, 167], ["participants", "SPECIES", 4, 16], ["patients", "SPECIES", 159, 167], ["mask", "TREATMENT", 44, 48], ["gloves", "TREATMENT", 50, 56], ["gowns", "TREATMENT", 58, 63], ["hand-washing", "TREATMENT", 69, 81], ["contact precautions", "TREATMENT", 117, 136], ["SARS", "PROBLEM", 173, 177], ["hand", "ANATOMY", 69, 73]]], ["69 staff who reported use of all four measures were not infected, whereas all infected staff had omitted at least one measure (p=0\u00b70224).", [["all four measures", "TREATMENT", 29, 46], ["infected", "OBSERVATION", 56, 64]]], ["Fewer staff who wore masks (p=0\u00b70001), gowns (p=0\u00b7006), and washed their hands (p=0\u00b7047) became infected compared with those who didn't, but stepwise logistic regression was significant only for masks (p=0\u00b7011).", [["infected", "PROBLEM", 96, 104], ["hands", "ANATOMY", 73, 78], ["infected", "OBSERVATION", 96, 104]]], ["Practice of droplets precaution and contact precaution is adequate in significantly reducing the risk of infection after exposures to patients with SARS.", [["infection", "DISEASE", 105, 114], ["SARS", "DISEASE", 148, 152], ["patients", "ORGANISM", 134, 142], ["patients", "SPECIES", 134, 142], ["Practice of droplets precaution", "TREATMENT", 0, 31], ["contact precaution", "TREATMENT", 36, 54], ["infection", "PROBLEM", 105, 114], ["SARS", "PROBLEM", 148, 152], ["infection", "OBSERVATION", 105, 114]]], ["The protective role of the mask suggests that in hospitals, infection is transmitted by droplets.", [["infection", "DISEASE", 60, 69], ["the mask", "TREATMENT", 23, 31], ["infection", "PROBLEM", 60, 69], ["infection", "OBSERVATION", 60, 69]]], ["On March 12, 2003, WHO issued a worldwide alert for severe acute respiratory syndrome (SARS).", [["acute respiratory syndrome", "DISEASE", 59, 85], ["SARS", "DISEASE", 87, 91], ["severe acute respiratory syndrome", "PROBLEM", 52, 85], ["acute", "OBSERVATION_MODIFIER", 59, 64], ["respiratory syndrome", "OBSERVATION", 65, 85]]], ["1 The hospital authority, which oversees all public hospitals in Hong Kong, had requested cases to be reported centrally since early February, in response to media reports of pneumonia outbreaks in Guangdong Province, People's Republic of China.", [["pneumonia", "DISEASE", 175, 184], ["pneumonia", "PROBLEM", 175, 184], ["pneumonia", "OBSERVATION", 175, 184]]], ["2 At that time, droplets precautions 3 and rigorous universal precautions 3 or standard precautions 3 were recommended for the care of patients with SARS.", [["SARS", "DISEASE", 149, 153], ["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143], ["droplets precautions", "TREATMENT", 16, 36], ["rigorous universal precautions", "TREATMENT", 43, 73], ["standard precautions", "TREATMENT", 79, 99], ["SARS", "PROBLEM", 149, 153]]], ["Here we report findings of a case-control study assessing the effectiveness of droplets precautions for prevention of nosocomial transmission.", [["a case-control study", "TEST", 27, 47], ["droplets precautions", "TREATMENT", 79, 99], ["nosocomial transmission", "PROBLEM", 118, 141], ["nosocomial", "OBSERVATION", 118, 128]]]], "PMC7211414": [["On the hundredth day since days since the WHO was notified of the first cases of \u201cpneumonia with unknown cause\u201d in China, the COVID-19 pandemic, caused by SARS-CoV-2, has spread throughout the world to 195 countries with over 1.5 million cases and more than 85 000 deaths [1].", [["pneumonia", "DISEASE", 82, 91], ["SARS-CoV-2", "CHEMICAL", 155, 165], ["deaths", "DISEASE", 265, 271], ["SARS-CoV-2", "ORGANISM", 155, 165], ["SARS-CoV", "SPECIES", 155, 163], ["\u201cpneumonia", "PROBLEM", 81, 91], ["the COVID", "TEST", 122, 131], ["SARS", "PROBLEM", 155, 159], ["pneumonia", "OBSERVATION", 82, 91]]], ["In early January, when we had just learned that a newly discovered disease was spreading in faraway China, only a few thought it would soon be coming to Croatia.", [["a newly discovered disease", "PROBLEM", 48, 74], ["disease", "OBSERVATION", 67, 74]]], ["Nevertheless, by February, when the epidemic was rapidly spreading in northern Italy, it was already quite likely that it would not bypass Croatia, and on 25 February 2020 the first case of COVID-19 was registered in our country [2].", [["COVID", "TEST", 190, 195]]]], "PMC7261357": [["IntroductionSARS-CoV-2, the virus that causes COVID-19, represents a once-in-a-lifetime global threat.", [["COVID-19", "CHEMICAL", 46, 54], ["IntroductionSARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 22], ["IntroductionSARS", "TEST", 0, 16], ["the virus", "PROBLEM", 24, 33], ["COVID", "TEST", 46, 51]]], ["In a matter of four months, the virus has spread from Wuhan, China to nearly 95% of all countries in the world.", [["the virus", "PROBLEM", 28, 37]]], ["As of mid April, there have been over 2,000,000 confirmed cases with more than 134,000 deaths worldwide.1 This exponential growth is partially explained by its transmission during the pre-symptomatic or mildly symptomatic phases of illness.2", [["deaths", "DISEASE", 87, 93], ["illness", "DISEASE", 232, 239], ["the pre-symptomatic or mildly symptomatic phases of illness", "PROBLEM", 180, 239], ["growth", "OBSERVATION_MODIFIER", 123, 129], ["mildly", "OBSERVATION_MODIFIER", 203, 209], ["symptomatic", "OBSERVATION_MODIFIER", 210, 221]]]], "PMC7297588": [["According to 2017 figures from the World Health Organization (WHO), each year around 1.3 million people die in road accidents worldwide, and between 20 and 50 million suffer non-fatal injuries that cause disabilities [17].", [["accidents", "DISEASE", 116, 125], ["injuries", "DISEASE", 184, 192], ["people", "ORGANISM", 97, 103], ["people", "SPECIES", 97, 103]]], ["According to data from the National Institute of Public Health (INSP), Mexico ranks seventh in the world and third in the Latin American region in terms of road deaths, with 22 deaths of young people between 15 and 29 years of age per day [9].IntroductionRoad specialists and road safety experts report that behind every vehicle accident the human factor is involved in 90% [6].", [["deaths", "DISEASE", 161, 167], ["deaths", "DISEASE", 177, 183], ["people", "ORGANISM", 193, 199], ["human", "ORGANISM", 342, 347], ["human factor", "PROTEIN", 342, 354], ["people", "SPECIES", 193, 199], ["human", "SPECIES", 342, 347], ["human", "SPECIES", 342, 347]]], ["So for several years, car manufacturers have implemented technologies such as ADAS which assist the driver in the driving process.", [["car manufacturers", "TREATMENT", 22, 39]]], ["ADAS goal is to increase automobile safety and road safety in general using Human-Machine Interfaces (HMI).", [["Human", "ORGANISM", 76, 81], ["Human", "SPECIES", 76, 81]]], ["These systems use multiple sensors (radar, lidar, camera, GPS, etc.) to identify the environment with which the vehicle interacts.IntroductionWhen driving a vehicle the driver depends on rear-view mirrors and body movements to observe other vehicles approaching, however, this practice represents risks due to the generation of areas where vision is partially or completely occluded, these areas are called \u201cblind spots\u201d.", [["body", "ANATOMY", 209, 213], ["body", "ORGANISM_SUBDIVISION", 209, 213], ["the generation of areas where vision", "PROBLEM", 310, 346], ["blind spots", "PROBLEM", 408, 419], ["occluded", "OBSERVATION", 374, 382]]], ["Due to the large number of accidents caused by this situation, BSW systems have been developed which provide the driver with information about the vehicles around him to avoid possible collisions.IntroductionThis document is organized as follows.", [["accidents", "DISEASE", 27, 36], ["BSW systems", "PROBLEM", 63, 74], ["large", "OBSERVATION_MODIFIER", 11, 16], ["number", "OBSERVATION_MODIFIER", 17, 23]]], ["Section 3 presents the different techniques and technologies implemented in the proposed BSW system, such as the neural models, the applied transformations and the visualization platform used.", [["neural", "ANATOMY", 113, 119], ["the visualization platform", "TEST", 160, 186], ["neural models", "ANATOMY", 113, 126]]], ["Typically there are two basic approaches to obtain and processing information: range-based and vision-based.Related WorkWorks such as presented in [14, 16, 22, 23] describe range-based systems that implement ultrasonic or radar devices mounted around the vehicle to estimate the distance of approaching objects, subsequently alert the driver by means of indicators on the side mirrors.Related WorkVision-based systems aim to obtain information from the environment using cameras and then perform image analysis for obstacles detection while driving.", [["radar devices", "TREATMENT", 222, 235], ["image analysis", "TEST", 496, 510], ["obstacles detection", "TEST", 515, 534]]], ["Most BSW systems employ classic image processing techniques for their development.", [["BSW systems", "CELL_LINE", 5, 16]]], ["Such as [3, 13, 18, 19, 23] histogram of oriented gradients (HOG), filters for edge detection, entropy, optical flow, Gabor\u2019s filter, among others are used to extract useful information and techniques such as clustering and vector support machines [13, 18] to classify where vehicles are.", [["edge detection", "TEST", 79, 93], ["Gabor\u2019s filter", "TREATMENT", 118, 132], ["vector support machines", "TREATMENT", 224, 247]]], ["In [11] the concept of depth estimation is implemented to determine whether a vehicle is near or far from the driver\u2019s vehicle, they make use of features such as texture and blur in the image, and techniques such as principal component analysis (PCA) and discrete cosine transformation.Related WorkIn recent years, neural models have been implemented for the classification and detection of objects in images due to good performance obtained.", [["neural", "ANATOMY", 315, 321], ["depth estimation", "TEST", 23, 39], ["blur in the image", "TEST", 174, 191], ["principal component analysis", "TEST", 216, 244], ["discrete cosine transformation", "PROBLEM", 255, 285], ["objects in images", "TEST", 391, 408], ["discrete", "OBSERVATION_MODIFIER", 255, 263], ["cosine transformation", "OBSERVATION", 264, 285]]], ["In [15, 21] fully connected neural networks (FCN) are used for vehicle detection in blind spot areas, in addition to techniques such as HOG, heat mapping and threshold levels for pre-processing of images.Related WorkOther types of BSW systems have been developed with more complex neural models; such is the case of [26] where first the objects are located by classic image segmentation, then the candidates are classified with a Convolutional Neural Network (CNN) and the vehicle is tracked using optical flow analysis.", [["neural networks", "ANATOMY", 28, 43], ["neural", "ANATOMY", 281, 287], ["neural networks", "MULTI-TISSUE_STRUCTURE", 28, 43], ["FCN", "PROTEIN", 45, 48], ["vehicle detection", "TEST", 63, 80], ["blind spot areas", "PROBLEM", 84, 100], ["HOG, heat mapping", "TEST", 136, 153], ["threshold levels", "TEST", 158, 174], ["pre-processing of images", "TEST", 179, 203], ["BSW systems", "PROBLEM", 231, 242], ["optical flow analysis", "TEST", 498, 519], ["more", "OBSERVATION_MODIFIER", 268, 272], ["complex", "OBSERVATION_MODIFIER", 273, 280], ["neural models", "OBSERVATION", 281, 294]]], ["On the other hand in [27] blind spot vehicles are treated as a classification problem in which a CNN takes full responsibility for classifying whether or not a vehicle exists in the predetermined area.Related WorkLastly, in [19] a BSW system is developed implementing multi-object tracking (MOT) from a fusion of sensors, including cameras, LIDAR, among others; in addition, techniques such as decision by Markov models and reinforcement learning for information processing are applied.Car Detection ::: Proposed MethodFor car detection in the images, two very popular neural architectures were tested: YOLOv3 and Detectron2.Car Detection ::: Proposed MethodYOLOv3 [20] is a neural model for object detection that processes approximately 30 images per second in COCO test-set obtaining an average precision of 33% and consists of 53 convolutional layers (Darknet 53).", [["neural", "ANATOMY", 569, 575], ["neural", "ANATOMY", 675, 681], ["YOLOv3", "GENE_OR_GENE_PRODUCT", 603, 609], ["YOLOv3", "PROTEIN", 603, 609], ["Detectron2", "PROTEIN", 614, 624], ["blind spot vehicles", "PROBLEM", 26, 45], ["a fusion of sensors", "TREATMENT", 301, 320], ["car detection in the images", "TEST", 523, 550], ["Detectron2", "TREATMENT", 614, 624], ["object detection", "TEST", 692, 708], ["COCO test", "TEST", 762, 771]]], ["This model has several advantages over systems based on classifiers and sliding window, for example, it examines the entire image at the time of inference so that predictions have information about the overall context of the image.", [["sliding window", "TEST", 72, 86], ["several", "OBSERVATION_MODIFIER", 15, 22], ["advantages", "OBSERVATION_MODIFIER", 23, 33]]], ["In addition, it develops the predictions with a single evaluation of the image which makes it a very fast network.Car Detection ::: Proposed MethodDetectron2 is a neural model developed by Facebook AI Research that implements SOTA object detection algorithms.", [["neural", "ANATOMY", 163, 169], ["MethodDetectron2", "DNA", 141, 157], ["a single evaluation of the image", "TEST", 46, 78], ["neural model", "OBSERVATION", 163, 175]]], ["The average precision of this model is 39.8% obtained in COCO test-set.Depth Estimation ::: Proposed MethodConsidering that car detecting in images does not give us clear information about the distance they are, which is fundamental for the understanding of a scene, a single-image depth estimation (SIDE) has been implemented to know the distance in the Z-axis (deep).", [["this model", "TEST", 25, 35], ["COCO test", "TEST", 57, 66], ["a single-image depth estimation", "TEST", 267, 298], ["deep", "ANATOMY_MODIFIER", 363, 367]]], ["Different neuronal models were considered.", [["neuronal", "ANATOMY", 10, 18], ["neuronal", "CELL", 10, 18]]]], "PMC7153315": [["Potential biological weapons and warfare agentsBiological weapons are refers to those which contain replicating infectious and lethal forms of life including bacteria, viruses, fungi, protozoa, prions, or poisonous chemical toxins produced by living organisms (Rogers et al., 1999).", [["warfare agents", "TREATMENT", 33, 47], ["bacteria", "PROBLEM", 158, 166], ["viruses", "PROBLEM", 168, 175], ["fungi", "PROBLEM", 177, 182], ["protozoa", "PROBLEM", 184, 192], ["prions", "PROBLEM", 194, 200], ["poisonous chemical toxins", "PROBLEM", 205, 230], ["infectious", "OBSERVATION", 112, 122]]], ["Biological warfare agents (BWAs) as bioweapons have been widely used in wars because of their easy availability, low production costs, easy transportation and dispersal, and nondetection by basic security systems.", [["BWAs", "SIMPLE_CHEMICAL", 27, 31]]], ["Biowarfare agents are responsible for the spread of human diseases associated with high morbidity and mortality rates.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["Biowarfare agents", "TREATMENT", 0, 17], ["human diseases", "PROBLEM", 52, 66], ["high morbidity", "PROBLEM", 83, 97], ["mortality rates", "TEST", 102, 117]]], ["Further, these agents can multiply in the host organism and get transmitted to others individuals, causing erratic consequences, which lead to mass geographical spread.", [["erratic consequences", "PROBLEM", 107, 127], ["mass geographical spread", "PROBLEM", 143, 167]]], ["Due to low production costs and easy cultivation, any developed or under developed country can afford their manufacturing and maintenance.", [["low production costs", "PROBLEM", 7, 27], ["easy cultivation", "TREATMENT", 32, 48], ["low production", "OBSERVATION_MODIFIER", 7, 21]]], ["These are available in liquid as well as in dry forms with extensive storage life.", [["extensive storage life", "TREATMENT", 59, 81]]], ["People who have not previously encountered these biowarfare agents usually do not have any natural immunity in their body against these agents, thus are highly prone to infections.", [["body", "ANATOMY", 117, 121], ["infections", "DISEASE", 169, 179], ["People", "ORGANISM", 0, 6], ["body", "ORGANISM_SUBDIVISION", 117, 121], ["People", "SPECIES", 0, 6], ["these agents", "TREATMENT", 130, 142], ["infections", "PROBLEM", 169, 179]]], ["Moreover, in comparison to common human diseases, the etiological agents causing these deadly diseases have highly hostile animal reservoirs (called zoonotic in nature) and are difficult to diagnose and cure.", [["human diseases", "DISEASE", 34, 48], ["human", "ORGANISM", 34, 39], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 34, 39], ["common human diseases", "PROBLEM", 27, 48], ["these deadly diseases", "PROBLEM", 81, 102], ["diseases", "OBSERVATION", 40, 48], ["hostile", "OBSERVATION_MODIFIER", 115, 122], ["reservoirs", "OBSERVATION_MODIFIER", 130, 140]]], ["The nature, properties, and lethal effects caused by many zoonotic biological agents that have been used for biowarfare purposes over the years and have led to serious epidemiological outbreaks, are summarized in Table 1.Potential biological weapons and warfare agentsThe utilization of these BWAs in previous bioterror incidences leading to adverse consequences has been well documented in various review articles (Jansen et al., 2014; Madad, 2014; Krishan et al., 2017).", [["warfare agents", "TREATMENT", 254, 268], ["previous bioterror incidences", "PROBLEM", 301, 330], ["adverse consequences", "PROBLEM", 342, 362]]], ["Following the historical pattern of biological terror attacks and disease outbreaks, it can be concluded that biotechnology has accidently unleashed a new threat to mankind in the form of virulent bioweapons to inflict mass causalities and devastation (Lesser et al., 1999).", [["biological terror attacks", "PROBLEM", 36, 61], ["disease outbreaks", "PROBLEM", 66, 83], ["inflict mass causalities", "PROBLEM", 211, 235], ["devastation", "PROBLEM", 240, 251], ["mass", "OBSERVATION", 219, 223]]], ["So, highly efficient and cost-effective medical countermeasures based on ethnic specificity of the biological agent need to be developed with the purpose of bio-preparedness and biosecurity (Horn, 2003; Jansen et al., 2014; Pal et al., 2016).", [["cost-effective medical countermeasures", "TREATMENT", 25, 63], ["the biological agent", "TREATMENT", 95, 115]]], ["Associated risks with human pathogens must be evaluated on the basis of rate of mortality, availability of treatment and prophylactic measures, need for hospitalization, public perception, and epidemiological spread (Rotz et al., 2002).A brief history of biological warfareAny documentation related to history of biological warfare is difficult to extract from the literature since all the allegations are based solely on eye-witness accounts and circumstantial evidence after the event.", [["eye", "ANATOMY", 422, 425], ["human", "ORGANISM", 22, 27], ["eye", "ORGAN", 422, 425], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human pathogens", "PROBLEM", 22, 37], ["treatment", "TREATMENT", 107, 116], ["prophylactic measures", "TREATMENT", 121, 142], ["hospitalization", "TREATMENT", 153, 168], ["biological warfare", "PROBLEM", 313, 331], ["the event", "PROBLEM", 477, 486]]], ["In 1155 AD, at a battle in Tortona, Italy, Barbarossa broadened the scope of biological warfare by using the dead bodies of soldiers as well as animals to pollute wells.", [["AD", "DISEASE", 8, 10]]], ["During war with the French in 18th century, British forces under the direction of Sir Jettray Ahmest gave blankets that had been used by smallpox and yellow fever victims to the native Americans in order to spread disease (Frischknecht, 2003).", [["fever", "DISEASE", 157, 162], ["blankets", "TREATMENT", 106, 114], ["smallpox and yellow fever victims", "PROBLEM", 137, 170]]], ["During the US civil war, in 1863 AD, General Johnson used dead bodies of sheep and pigs to pollute drinking water at Videsburg, Mississippi.", [["AD", "DISEASE", 33, 35], ["sheep", "ORGANISM", 73, 78], ["pigs", "ORGANISM", 83, 87], ["sheep", "SPECIES", 73, 78], ["pigs", "SPECIES", 83, 87], ["sheep", "SPECIES", 73, 78], ["pigs", "SPECIES", 83, 87]]], ["During World War I, in 1915, the first allegation was made against the Germans that they had attempted to employ the biological agents of Cholera against Italy and Plague against Britain.", [["Cholera", "DISEASE", 138, 145]]], ["Later, in 1916, they were accused of using Anthrax at Bucharest, Romania (Metcalfe, 2002).", [["Anthrax", "DISEASE", 43, 50]]], ["The first incidence of biological warfare was documented during World War I when millions of deaths were recorded due to pandemic outbreak of The 1918 Spanish Influenza virus (H1N1) that triggered naturally.", [["deaths", "DISEASE", 93, 99], ["Influenza virus", "DISEASE", 159, 174], ["H1N1", "DISEASE", 176, 180], ["Influenza virus", "ORGANISM", 159, 174], ["Influenza virus (H1N1", "SPECIES", 159, 180], ["1918 Spanish Influenza virus", "SPECIES", 146, 174], ["deaths", "PROBLEM", 93, 99], ["pandemic outbreak", "PROBLEM", 121, 138], ["Spanish Influenza virus", "PROBLEM", 151, 174], ["H1N1", "PROBLEM", 176, 180]]], ["This was the most striking example of indirect offense where a disease causing biological agent was used to deteriorate combat capabilities of enemy forces at the war front.", [["a disease", "PROBLEM", 61, 70], ["biological agent", "TREATMENT", 79, 95]]], ["This perhaps led to the establishment of the concept of biowarfare agents and bioterrorism.", [["biowarfare agents", "TREATMENT", 56, 73], ["bioterrorism", "PROBLEM", 78, 90]]], ["In the last few decades, several incidences of bioterrorism/biological warfare were recorded (Ainscough, 2002).A brief history of biological warfareThe history of biological warfare programs in the United States and Former Soviet Union (FSU) is extensively documented in the literature.", [["bioterrorism", "PROBLEM", 47, 59]]], ["As a rapidly evolving super power, the FSU initiated its biological warfare program during the mid-1960s to 1970s, when they started showing interest in genetics and genetic manipulations of potential human pathogens.", [["human", "ORGANISM", 201, 206], ["human", "SPECIES", 201, 206], ["human", "SPECIES", 201, 206], ["potential human pathogens", "PROBLEM", 191, 216]]], ["Extensive research was carried out to weaponize the developed agents to powder or aerosol formulations for direct loading into munitions such as spray tanks and cluster bombs.", [["agents to powder", "TREATMENT", 62, 78], ["aerosol formulations", "TREATMENT", 82, 102], ["direct loading into munitions", "TREATMENT", 107, 136]]], ["The first genetically engineered vaccine tolerant pathogen Francisella tularensis, causing tularemia, was established under the \u201cEnzyme\u201d program during the 1950s to 1960s, which modernized the concept of biological warfare.", [["Francisella tularensis", "DISEASE", 59, 81], ["tularemia", "DISEASE", 91, 100], ["Francisella tularensis", "ORGANISM", 59, 81], ["Francisella tularensis", "SPECIES", 59, 81], ["Francisella tularensis", "SPECIES", 59, 81], ["tularemia", "PROBLEM", 91, 100], ["tularemia", "OBSERVATION", 91, 100]]], ["Until 1992, they had a repository of 52 highly contagious strains that could overcome all the barriers of immune systems and current medical treatments.", [["immune systems", "TREATMENT", 106, 120], ["current medical treatments", "TREATMENT", 125, 151]]], ["Anthrax strain 836, Pasechnik\u2019s superplague strain, glanders strain, myelin toxin forming Yersinia pestis, tularemia (Schu S-4), and viruses like Ebola, Marburg and influenza are only a few to name them.", [["Yersinia pestis", "DISEASE", 90, 105], ["tularemia", "DISEASE", 107, 116], ["Schu S-4", "CHEMICAL", 118, 126], ["Ebola, Marburg", "DISEASE", 146, 160], ["influenza", "DISEASE", 165, 174], ["Anthrax strain 836", "ORGANISM", 0, 18], ["Pasechnik\u2019s superplague strain", "ORGANISM", 20, 50], ["glanders strain", "ORGANISM", 52, 67], ["myelin toxin", "ORGANISM", 69, 81], ["Yersinia pestis", "ORGANISM", 90, 105], ["Schu S-4", "ORGANISM", 118, 126], ["Ebola", "ORGANISM", 146, 151], ["Marburg", "ORGANISM", 153, 160], ["Yersinia pestis", "SPECIES", 90, 105], ["Ebola", "SPECIES", 146, 151], ["Pasechnik\u2019s superplague strain", "SPECIES", 20, 50], ["Yersinia pestis", "SPECIES", 90, 105], ["Anthrax strain", "PROBLEM", 0, 14], ["Pasechnik", "TREATMENT", 20, 29], ["superplague strain", "PROBLEM", 32, 50], ["glanders strain", "PROBLEM", 52, 67], ["myelin toxin", "PROBLEM", 69, 81], ["Yersinia pestis", "PROBLEM", 90, 105], ["tularemia", "PROBLEM", 107, 116], ["Schu S", "TEST", 118, 124], ["viruses", "PROBLEM", 133, 140], ["influenza", "PROBLEM", 165, 174], ["tularemia", "OBSERVATION", 107, 116], ["Ebola", "OBSERVATION", 146, 151]]], ["They also tried their hands at the production of chimeric viruses by introducing genetic elements from Venezuelan equine encephalitis (VEEV), Ebola (EBOV), and Marburg (MARV) into native smallpox virus (Ainscough, 2002).A brief history of biological warfareIn 1997, Russian scientists published a research paper in the journal Vaccines where they suggested a method of introducing Bacillus cereus genes into B. anthracis for making it resistant to Russian anthrax vaccine.", [["Venezuelan equine encephalitis", "DISEASE", 103, 133], ["VEEV", "DISEASE", 135, 139], ["Ebola (EBOV), and Marburg (MARV) into native smallpox", "DISEASE", 142, 195], ["anthrax", "DISEASE", 456, 463], ["Venezuelan equine encephalitis", "ORGANISM", 103, 133], ["VEEV", "ORGANISM", 135, 139], ["Ebola (EBOV", "ORGANISM", 142, 153], ["Marburg (MARV", "ORGANISM", 160, 173], ["native smallpox virus", "ORGANISM", 180, 201], ["Bacillus cereus", "ORGANISM", 381, 396], ["B. anthracis", "ORGANISM", 408, 420], ["Bacillus cereus genes", "DNA", 381, 402], ["Venezuelan equine encephalitis", "SPECIES", 103, 133], ["Ebola", "SPECIES", 142, 147], ["Bacillus cereus", "SPECIES", 381, 396], ["B. anthracis", "SPECIES", 408, 420], ["Venezuelan equine encephalitis", "SPECIES", 103, 133], ["VEEV", "SPECIES", 135, 139], ["EBOV", "SPECIES", 149, 153], ["MARV", "SPECIES", 169, 173], ["native smallpox virus", "SPECIES", 180, 201], ["Bacillus cereus", "SPECIES", 381, 396], ["B. anthracis", "SPECIES", 408, 420], ["chimeric viruses", "PROBLEM", 49, 65], ["Venezuelan equine encephalitis", "PROBLEM", 103, 133], ["Ebola", "PROBLEM", 142, 147], ["native smallpox virus", "PROBLEM", 180, 201], ["the journal Vaccines", "TREATMENT", 315, 335], ["a method of introducing Bacillus cereus genes", "TREATMENT", 357, 402], ["Russian anthrax vaccine", "TREATMENT", 448, 471], ["smallpox virus", "OBSERVATION", 187, 201]]], ["Introduction of antibiotic resistant genes in pathogenic strains can significantly enhance lethality of disease by reducing treatment options (Athamna et al., 2004).", [["antibiotic resistant genes", "DNA", 16, 42], ["antibiotic resistant genes", "TREATMENT", 16, 42], ["pathogenic strains", "PROBLEM", 46, 64], ["lethality of disease", "PROBLEM", 91, 111], ["reducing treatment options", "TREATMENT", 115, 141]]], ["Similarly, the prophylactic effects can be circumvented by suppression of the immune system through the expression of immune modifier genes using viral vectors, e.g., expression of mouse interlukin-4 in recombinant Ectromelia virus suppresses immune functions of the host and overcomes genetic resistance to mouse pox.", [["immune system", "ANATOMY", 78, 91], ["immune system", "ANATOMICAL_SYSTEM", 78, 91], ["mouse", "ORGANISM", 181, 186], ["interlukin-4", "GENE_OR_GENE_PRODUCT", 187, 199], ["recombinant", "ORGANISM", 203, 214], ["Ectromelia virus", "ORGANISM", 215, 231], ["mouse", "ORGANISM", 308, 313], ["immune modifier genes", "DNA", 118, 139], ["mouse interlukin-4", "DNA", 181, 199], ["mouse", "SPECIES", 181, 186], ["mouse", "SPECIES", 308, 313], ["mouse", "SPECIES", 181, 186], ["Ectromelia virus", "SPECIES", 215, 231], ["mouse", "SPECIES", 308, 313], ["the prophylactic effects", "TREATMENT", 11, 35], ["the immune system", "TREATMENT", 74, 91], ["immune modifier genes", "TREATMENT", 118, 139], ["viral vectors", "TREATMENT", 146, 159], ["mouse interlukin", "TREATMENT", 181, 197], ["recombinant Ectromelia virus suppresses", "TREATMENT", 203, 242], ["mouse pox", "TREATMENT", 308, 317], ["Ectromelia virus", "OBSERVATION", 215, 231]]], ["In 1998, a DNA sequence based investigation on the preserved samples of 11 victims revealed simultaneous occurrence of 4 distinct virulent variants of B. anthracis, showing the continuation of a biological warfare program, which was reportedly denied from time to time by FSU.", [["samples", "ANATOMY", 61, 68], ["B. anthracis", "DISEASE", 151, 163], ["DNA", "CELLULAR_COMPONENT", 11, 14], ["B. anthracis", "ORGANISM", 151, 163], ["B. anthracis", "SPECIES", 151, 163], ["B. anthracis", "SPECIES", 151, 163], ["a DNA sequence", "TEST", 9, 23], ["4 distinct virulent variants of B. anthracis", "PROBLEM", 119, 163], ["4 distinct", "OBSERVATION_MODIFIER", 119, 129], ["virulent variants", "OBSERVATION", 130, 147]]], ["Surprisingly, genetic manipulation procedures were adopted to enhance resistance of the existing etiological agents to high temperature and the available range of therapeutic antibiotics and prophylactic measures, and to make novel immune-suppressive agents that could be easily weaponized when needed.", [["genetic manipulation procedures", "TREATMENT", 14, 45], ["high temperature", "PROBLEM", 119, 135], ["therapeutic antibiotics", "TREATMENT", 163, 186], ["prophylactic measures", "TREATMENT", 191, 212], ["novel immune-suppressive agents", "TREATMENT", 226, 257]]], ["Later, a lower level bench scientist in Pasechnik\u2019s lab, referred by the code name \u201cTemple Fortune,\u201d also defected to the United Kingdom, 3 years after the defection of Dr. Pasechnik, where he replicated his previous account of a biowarfare program and then disclosed it to the British government.", [["a biowarfare program", "TREATMENT", 228, 248]]], ["In 1999, Alibek\u2019s article on \u201cBiohazard\u201d narrated his first-hand experience as a member of the FSU program and emphasized the extensive research and development of genetically manipulated biological warfare agents, large scale production facilities, weaponization of BW agents, defensive measures, and future BW goals of the Russian Government (Alibek, 2008).", [["large scale production facilities", "TREATMENT", 215, 248], ["BW agents", "TREATMENT", 267, 276], ["defensive measures", "TREATMENT", 278, 296]]], ["But many intelligent analysts suspected the execution of a biowarfare program in a very secretive mode and its substitution in the Russian military doctrine.A brief history of biological warfareEarlier, in 1997, the Office of the Secretary of Defence, United States, also released a special report on Proliferation: Threats and Responses indicating then circulating trends in biological warfare capabilities (Cohen, 1997).", [["a biowarfare program", "TREATMENT", 57, 77], ["a very secretive mode", "TREATMENT", 81, 102]]], ["There is also a thriller novel written by Richard Preston in 1998 titled The Cobra Event, which describes fictional bioterror attacks on the United States in 1997, where a genetically engineered virus designated as \u201cCobra\u201d was used to spread a \u201cDesigner Disease called Brain Pox,\u201d which symptomatically resembles smallpox, Lesch-Nyhan syndrome, and the common cold (O\u2019Toole, 1999).", [["smallpox", "DISEASE", 313, 321], ["Lesch-Nyhan syndrome", "DISEASE", 323, 343], ["a genetically engineered virus", "PROBLEM", 170, 200], ["Brain Pox", "PROBLEM", 269, 278], ["Nyhan syndrome", "PROBLEM", 329, 343], ["Brain", "ANATOMY", 269, 274], ["Nyhan syndrome", "OBSERVATION", 329, 343]]], ["Soon after the September 11 terror attacks on the World Trade Centre and the Pentagon in 2001, anthrax-laced letters were sent to national legislators of the United States, which resulted in the spread of terror among civilians and triggered the adoption of prophylactic measures by communities on a mass scale.", [["anthrax", "DISEASE", 95, 102], ["prophylactic measures", "TREATMENT", 258, 279], ["a mass scale", "TREATMENT", 298, 310]]], ["The US military has repeatedly discussed the possible use of biotechnology for upgrading offensive warfare potential by developing material degrading microbes to destroy biofuels, construction materials, and stealth paints.", [["stealth paints", "OBSERVATION", 208, 222]]], ["The first evidence emerged in 1998, when J. Campbell at the Naval Research Laboratory in Washington DC described the possible application of genetically modified fungi to destroy military paints in 72 h.", [["DC", "ANATOMY", 100, 102], ["Washington DC", "CELL_LINE", 89, 102], ["genetically modified fungi", "TREATMENT", 141, 167]]], ["The second evidence came to light in 1990, when the United States started conducting field trials on pathogenic Pleospora papaveracea strains against the drug producing crop, opium poppy.", [["opium poppy", "CHEMICAL", 175, 186], ["Pleospora papaveracea", "ORGANISM", 112, 133], ["Pleospora papaveracea", "SPECIES", 112, 133], ["Pleospora papaveracea", "SPECIES", 112, 133], ["pathogenic Pleospora papaveracea strains", "TREATMENT", 101, 141], ["opium poppy", "TREATMENT", 175, 186], ["opium poppy", "OBSERVATION", 175, 186]]], ["Potential risks were successively tested by evaluating crop destruction in 2001 in Tashkant, Uzbekistan.", [["Potential risks", "PROBLEM", 0, 15], ["crop destruction", "PROBLEM", 55, 71]]], ["Similarly, pathogenic Fusarium oxysporum strains were developed in the United States to destroy coca plants with field test scheduled to be held in Columbia, 2001.", [["Fusarium oxysporum", "DISEASE", 22, 40], ["Fusarium oxysporum", "ORGANISM", 22, 40], ["strains", "ORGANISM", 41, 48], ["Fusarium oxysporum", "SPECIES", 22, 40], ["Fusarium oxysporum strains", "SPECIES", 22, 48], ["pathogenic Fusarium oxysporum strains", "PROBLEM", 11, 48], ["field test", "TEST", 113, 123], ["pathogenic", "OBSERVATION_MODIFIER", 11, 21], ["Fusarium", "OBSERVATION_MODIFIER", 22, 30], ["oxysporum strains", "OBSERVATION", 31, 48]]], ["However, worldwide protest against field trials on pathogenic destruction of drug producing (cocaine, benzoylecgonine, ecgonine) cash crops produced strong public opposition leading to termination of the project.", [["cocaine", "CHEMICAL", 93, 100], ["benzoylecgonine", "CHEMICAL", 102, 117], ["ecgonine", "CHEMICAL", 119, 127], ["cocaine", "CHEMICAL", 93, 100], ["benzoylecgonine", "CHEMICAL", 102, 117], ["ecgonine", "CHEMICAL", 119, 127], ["cocaine", "SIMPLE_CHEMICAL", 93, 100], ["benzoylecgonine", "SIMPLE_CHEMICAL", 102, 117], ["ecgonine", "SIMPLE_CHEMICAL", 119, 127], ["pathogenic destruction", "PROBLEM", 51, 73], ["benzoylecgonine", "TREATMENT", 102, 117]]], ["The third evidence came from the use of psychoactive substances (sleeping gas- BZ) as biological weapons in the Moscow hostage crisis in 2002, which caused death of more than 170 people.", [["sleeping gas- BZ", "CHEMICAL", 65, 81], ["death", "DISEASE", 156, 161], ["people", "ORGANISM", 179, 185], ["people", "SPECIES", 179, 185], ["psychoactive substances", "TREATMENT", 40, 63]]], ["The US Marine Corps also investigated the military usefulness of benzodiazepines and alpha-2 adrenoreceptor agonists as potential weapons.", [["benzodiazepines", "CHEMICAL", 65, 80], ["benzodiazepines", "CHEMICAL", 65, 80], ["benzodiazepines", "SIMPLE_CHEMICAL", 65, 80], ["alpha-2 adrenoreceptor", "GENE_OR_GENE_PRODUCT", 85, 107], ["benzodiazepines", "TREATMENT", 65, 80], ["alpha-2 adrenoreceptor agonists", "TREATMENT", 85, 116]]], ["Other BTWC signature states have developed potential biowarfare agents through extensive research and development, but as far as their delivery is concerned, it is still in its infancy as compared to weaponization of biowarfare agents by FSU (Van Aken and Hammond, 2003).Binary biological weapons ::: Emergence of next generation biological weaponsRussian scientists were masters of binary biological weapons technique, which was used to enhance virulence of several human pathogens causing anthrax, dysentery, and plague.", [["anthrax", "DISEASE", 491, 498], ["dysentery", "DISEASE", 500, 509], ["plague", "DISEASE", 515, 521], ["human", "ORGANISM", 467, 472], ["human", "SPECIES", 467, 472], ["human", "SPECIES", 467, 472], ["biowarfare agents", "TREATMENT", 53, 70], ["biowarfare agents", "TREATMENT", 217, 234], ["several human pathogens", "PROBLEM", 459, 482], ["anthrax", "PROBLEM", 491, 498], ["dysentery", "PROBLEM", 500, 509], ["dysentery", "OBSERVATION", 500, 509]]], ["It includes a dual component system consisting of a pathogenic host strain and virulence genes bearing plasmids, which could be individually propagated at a large scale.", [["plasmids", "ANATOMY", 103, 111], ["virulence genes", "DNA", 79, 94], ["plasmids", "DNA", 103, 111], ["a dual component system", "PROBLEM", 12, 35], ["a pathogenic host strain", "PROBLEM", 50, 74], ["virulence genes bearing plasmids", "PROBLEM", 79, 111], ["dual component", "OBSERVATION_MODIFIER", 14, 28], ["pathogenic host strain", "OBSERVATION", 52, 74], ["bearing plasmids", "OBSERVATION", 95, 111]]], ["Just before their deployment into a bioweapon, these components would have been mixed together and subsequent biotransformation would have taken place within the munition acting as a bioreactor.Designer genes ::: Emergence of next generation biological weaponsThe decoding and availability of whole genome sequence data has provided ample opportunity to biotechnologists for designing and reconstruction of virulent genes, which introduces desired virulence characteristics in the existing repertoire of pathogenic microorganisms.", [["Designer genes", "DNA", 194, 208], ["virulent genes", "DNA", 407, 421], ["a bioweapon", "TREATMENT", 34, 45], ["a bioreactor", "TREATMENT", 181, 193], ["whole genome sequence data", "TEST", 293, 319], ["reconstruction", "TREATMENT", 389, 403], ["virulent genes", "PROBLEM", 407, 421], ["pathogenic microorganisms", "PROBLEM", 504, 529], ["virulent genes", "OBSERVATION", 407, 421]]], ["Advanced synthetic biology techniques and genetic engineering techniques have led to the feasible construction of designer genes, which can further be used for the creation of genetically modified human pathogens.Designer diseases ::: Emergence of next generation biological weaponsRecent breakthroughs in molecular and cellular biology have equipped biologists to develop designer diseases by creating designer pathogens as etiological agents to achieve desired symptoms of progress of a hypothetical disease.", [["cellular", "ANATOMY", 320, 328], ["human", "ORGANISM", 197, 202], ["cellular", "CELL", 320, 328], ["designer genes", "DNA", 114, 128], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["genetic engineering techniques", "TREATMENT", 42, 72], ["genetically modified human pathogens", "PROBLEM", 176, 212], ["designer diseases", "PROBLEM", 373, 390], ["desired symptoms", "PROBLEM", 455, 471], ["a hypothetical disease", "PROBLEM", 487, 509], ["hypothetical disease", "OBSERVATION", 489, 509]]], ["Their potential targets include somatic or germ cells of the body, in which tissue destruction is induced through apoptosis, enhanced cell proliferation causing cancerous effects on important tissue or organ systems, or through immunosuppressive effects, which are difficult to reverse, e.g., \u201cBrain Pox\u201d disease\u2014the fictional disease described in the novel The Cobra Event, written by R. Preston.Gene therapy based bioweapons ::: Emergence of next generation biological weaponsGene therapy based treatment changes genetic composition of a patient through programmed repairing or replacement of faulty genes, and has huge potential in treating diseases causing high mortality in human populations.", [["somatic", "ANATOMY", 32, 39], ["germ cells", "ANATOMY", 43, 53], ["body", "ANATOMY", 61, 65], ["tissue", "ANATOMY", 76, 82], ["cell", "ANATOMY", 134, 138], ["cancerous", "ANATOMY", 161, 170], ["tissue", "ANATOMY", 192, 198], ["organ systems", "ANATOMY", 202, 215], ["tissue destruction", "DISEASE", 76, 94], ["somatic", "CELL", 32, 39], ["germ cells", "CELL", 43, 53], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["tissue", "TISSUE", 76, 82], ["cell", "CELL", 134, 138], ["cancerous", "CANCER", 161, 170], ["tissue", "TISSUE", 192, 198], ["organ", "ORGAN", 202, 207], ["patient", "ORGANISM", 540, 547], ["human", "ORGANISM", 679, 684], ["somatic or germ cells", "CELL_TYPE", 32, 53], ["faulty genes", "DNA", 595, 607], ["patient", "SPECIES", 540, 547], ["human", "SPECIES", 679, 684], ["human", "SPECIES", 679, 684], ["somatic or germ cells of the body", "PROBLEM", 32, 65], ["tissue destruction", "PROBLEM", 76, 94], ["apoptosis", "PROBLEM", 114, 123], ["enhanced cell proliferation", "PROBLEM", 125, 152], ["cancerous effects", "PROBLEM", 161, 178], ["organ systems", "PROBLEM", 202, 215], ["the fictional disease", "PROBLEM", 313, 334], ["Gene therapy", "TREATMENT", 397, 409], ["Gene therapy", "TREATMENT", 478, 490], ["treatment changes", "TREATMENT", 497, 514], ["genetic composition", "TREATMENT", 515, 534], ["a patient through programmed repairing", "TREATMENT", 538, 576], ["replacement of faulty genes", "TREATMENT", 580, 607], ["treating diseases", "PROBLEM", 635, 652], ["high mortality in human populations", "PROBLEM", 661, 696], ["germ cells", "OBSERVATION", 43, 53], ["body", "ANATOMY", 61, 65], ["tissue", "ANATOMY", 76, 82], ["destruction", "OBSERVATION", 83, 94], ["enhanced", "OBSERVATION_MODIFIER", 125, 133], ["cell proliferation", "OBSERVATION", 134, 152], ["Brain", "ANATOMY", 294, 299], ["fictional disease", "OBSERVATION", 317, 334]]], ["It can be accomplished in germ cells or somatic cells of the body based upon severity of the disease and to prevent its inheritance by future generations.", [["germ cells", "ANATOMY", 26, 36], ["somatic cells", "ANATOMY", 40, 53], ["body", "ANATOMY", 61, 65], ["germ cells", "CELL", 26, 36], ["somatic cells", "CELL", 40, 53], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["germ cells", "CELL_TYPE", 26, 36], ["somatic cells", "CELL_TYPE", 40, 53], ["germ cells", "PROBLEM", 26, 36], ["somatic cells", "PROBLEM", 40, 53], ["the disease", "PROBLEM", 89, 100], ["germ cells", "OBSERVATION", 26, 36], ["somatic cells", "OBSERVATION", 40, 53], ["body", "ANATOMY_MODIFIER", 61, 65], ["disease", "OBSERVATION", 93, 100]]], ["It has been successfully tested in animal models, e.g., the vaccinia virus has been used as a vector to insert genes in mammalian cells, but the technology is still in its infancy as it is totally unethical to enroll human volunteers for introducing and predicting genetic effects of gene therapies.", [["cells", "ANATOMY", 130, 135], ["vaccinia virus", "ORGANISM", 60, 74], ["mammalian cells", "CELL", 120, 135], ["human", "ORGANISM", 217, 222], ["volunteers", "ORGANISM", 223, 233], ["mammalian cells", "CELL_TYPE", 120, 135], ["human", "SPECIES", 217, 222], ["vaccinia virus", "SPECIES", 60, 74], ["human", "SPECIES", 217, 222], ["the vaccinia virus", "TREATMENT", 56, 74], ["a vector", "TREATMENT", 92, 100], ["genes in mammalian cells", "TREATMENT", 111, 135], ["gene therapies", "TREATMENT", 284, 298], ["mammalian cells", "OBSERVATION", 120, 135]]], ["Retroviruses can be utilized as delivery vehicles as they can easily integrate themselves into the human genome and can overcome all barriers of the natural defense system of the human body.Host swapping diseases ::: Emergence of next generation biological weaponsIn the case of zoonotic diseases, where a pathogenic virus has a natural animal reservoir to reside and multiply with little or no effect observed in the carrier species, e.g., chimpanzee for HIV, fruit bats and monkeys for Ebola and Marburg, pigs for swine flu, etc., they can be readily transmitted to the humans through carrier animal species that are in close contact with the human population.", [["body", "ANATOMY", 185, 189], ["zoonotic diseases", "DISEASE", 279, 296], ["Ebola and Marburg", "DISEASE", 488, 505], ["swine flu", "DISEASE", 516, 525], ["Retroviruses", "ORGANISM", 0, 12], ["human", "ORGANISM", 99, 104], ["human", "ORGANISM", 179, 184], ["body", "ORGANISM_SUBDIVISION", 185, 189], ["chimpanzee", "ORGANISM", 441, 451], ["HIV", "ORGANISM", 456, 459], ["fruit bats", "ORGANISM", 461, 471], ["monkeys", "ORGANISM", 476, 483], ["Ebola", "ORGANISM", 488, 493], ["Marburg", "ORGANISM", 498, 505], ["pigs", "ORGANISM", 507, 511], ["swine flu", "ORGANISM", 516, 525], ["humans", "ORGANISM", 572, 578], ["human", "ORGANISM", 645, 650], ["human genome", "DNA", 99, 111], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 179, 184], ["chimpanzee", "SPECIES", 441, 451], ["HIV", "SPECIES", 456, 459], ["monkeys", "SPECIES", 476, 483], ["Ebola", "SPECIES", 488, 493], ["pigs", "SPECIES", 507, 511], ["swine flu", "SPECIES", 516, 525], ["humans", "SPECIES", 572, 578], ["human", "SPECIES", 645, 650], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 179, 184], ["HIV", "SPECIES", 456, 459], ["swine flu", "SPECIES", 516, 525], ["humans", "SPECIES", 572, 578], ["human", "SPECIES", 645, 650], ["Retroviruses", "TREATMENT", 0, 12], ["delivery vehicles", "TREATMENT", 32, 49], ["zoonotic diseases", "PROBLEM", 279, 296], ["a pathogenic virus", "PROBLEM", 304, 322], ["a natural animal reservoir", "TREATMENT", 327, 353], ["the carrier species", "PROBLEM", 414, 433], ["HIV", "PROBLEM", 456, 459], ["Ebola", "PROBLEM", 488, 493], ["swine flu", "PROBLEM", 516, 525], ["human genome", "OBSERVATION", 99, 111], ["natural defense", "OBSERVATION", 149, 164], ["human body", "ANATOMY_MODIFIER", 179, 189], ["zoonotic", "OBSERVATION_MODIFIER", 279, 287], ["diseases", "OBSERVATION", 288, 296]]], ["Further, animal viruses may be genetically modified to utilize preferential human codons, thereby eliminating the chance of codon biasing, and such generated humanized viral agents would have serious implications in future biowarfare programs.Stealth viruses ::: Emergence of next generation biological weaponsThese consist of cryptic viral agents bearing potential human oncogenes that can be illicitly or secretly transferred to human genomes.", [["human", "ORGANISM", 76, 81], ["human", "ORGANISM", 366, 371], ["human", "ORGANISM", 431, 436], ["human oncogenes", "DNA", 366, 381], ["human genomes", "DNA", 431, 444], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 366, 371], ["human", "SPECIES", 431, 436], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 366, 371], ["human", "SPECIES", 431, 436], ["animal viruses", "PROBLEM", 9, 23], ["preferential human codons", "TREATMENT", 63, 88], ["codon biasing", "TREATMENT", 124, 137], ["humanized viral agents", "TREATMENT", 158, 180], ["biowarfare programs", "TREATMENT", 223, 242], ["cryptic viral agents", "TREATMENT", 327, 347], ["human oncogenes", "TREATMENT", 366, 381], ["viruses", "OBSERVATION", 16, 23], ["cryptic viral", "OBSERVATION", 327, 340]]], ["Usually, they remain dormant for many years but exposure to a single natural stimulus can activate oncogenic determinants present on the stealth viruses and could cause vast destruction in the human population.", [["human", "ORGANISM", 193, 198], ["human", "SPECIES", 193, 198], ["human", "SPECIES", 193, 198], ["a single natural stimulus", "TREATMENT", 60, 85], ["the stealth viruses", "PROBLEM", 133, 152], ["vast destruction in the human population", "PROBLEM", 169, 209], ["dormant", "OBSERVATION", 21, 28], ["vast", "OBSERVATION_MODIFIER", 169, 173], ["destruction", "OBSERVATION", 174, 185]]], ["For example, human herpes virus can cause oral and genital lesions after induction.", [["oral", "ANATOMY", 42, 46], ["genital lesions", "ANATOMY", 51, 66], ["herpes virus", "DISEASE", 19, 31], ["oral and genital lesions", "DISEASE", 42, 66], ["human", "ORGANISM", 13, 18], ["herpes virus", "ORGANISM", 19, 31], ["oral", "ORGANISM_SUBDIVISION", 42, 46], ["genital lesions", "PATHOLOGICAL_FORMATION", 51, 66], ["human", "SPECIES", 13, 18], ["herpes virus", "SPECIES", 19, 31], ["human herpes virus", "SPECIES", 13, 31], ["human herpes virus", "PROBLEM", 13, 31], ["oral and genital lesions", "PROBLEM", 42, 66], ["genital", "ANATOMY", 51, 58], ["lesions", "OBSERVATION", 59, 66]]], ["Similarly, people who have contracted chicken pox previously present a natural reservoir of varicella virus that sometimes rejuvenates in the form of herpes zoster virus causing shingles disease in some people.Synthesis of bacteriophage \u03c6X174 ::: Synthetic biology assisted whole genome synthesis of bacterial clones and bacteriophagesThe first artificial bacteriophage, \u03c6X174, was constructed to understand the structure and functions of viral genomes infecting important bacterial strains of human relevance.", [["clones", "ANATOMY", 310, 316], ["varicella virus", "DISEASE", 92, 107], ["herpes zoster", "DISEASE", 150, 163], ["shingles disease", "DISEASE", 178, 194], ["people", "ORGANISM", 11, 17], ["chicken", "ORGANISM", 38, 45], ["pox", "ORGANISM", 46, 49], ["varicella virus", "ORGANISM", 92, 107], ["herpes zoster virus", "ORGANISM", 150, 169], ["people", "ORGANISM", 203, 209], ["bacterial clones", "CELL", 300, 316], ["\u03c6X174", "CELL", 371, 376], ["human", "ORGANISM", 494, 499], ["bacterial clones", "CELL_LINE", 300, 316], ["\u03c6X174", "DNA", 371, 376], ["viral genomes", "DNA", 439, 452], ["people", "SPECIES", 11, 17], ["chicken pox", "SPECIES", 38, 49], ["herpes zoster virus", "SPECIES", 150, 169], ["people", "SPECIES", 203, 209], ["human", "SPECIES", 494, 499], ["chicken pox", "SPECIES", 38, 49], ["varicella virus", "SPECIES", 92, 107], ["herpes zoster virus", "SPECIES", 150, 169], ["human", "SPECIES", 494, 499], ["contracted chicken pox", "PROBLEM", 27, 49], ["varicella virus", "PROBLEM", 92, 107], ["herpes zoster virus", "PROBLEM", 150, 169], ["shingles disease", "PROBLEM", 178, 194], ["bacterial clones", "PROBLEM", 300, 316], ["bacteriophages", "TREATMENT", 321, 335], ["The first artificial bacteriophage", "TREATMENT", 335, 369], ["viral genomes", "PROBLEM", 439, 452], ["varicella virus", "OBSERVATION", 92, 107], ["herpes zoster virus", "OBSERVATION", 150, 169], ["bacterial clones", "OBSERVATION", 300, 316], ["viral genomes", "OBSERVATION", 439, 452]]], ["Smith and coworkers in 2003 described synthesis of 5386 bp genome of \u03c6X174 by stitching together synthetic DNA fragments using polymerase cycle assembly techniques.", [["DNA", "CELLULAR_COMPONENT", 107, 110], ["5386 bp genome", "DNA", 51, 65], ["\u03c6X174", "DNA", 69, 74], ["synthetic DNA fragments", "DNA", 97, 120], ["synthetic DNA fragments", "PROBLEM", 97, 120], ["polymerase cycle", "TREATMENT", 127, 143]]], ["Researchers at the Institute for Biological Energy Alternatives (IBEA) at Rockville, Maryland, wanted to use this technology for construction of artificial bacterial chromosomes consisting of a few million base pairs of DNA.", [["chromosomes", "ANATOMY", 166, 177], ["DNA", "CELLULAR_COMPONENT", 220, 223], ["artificial bacterial chromosomes", "DNA", 145, 177], ["this technology", "TREATMENT", 109, 124], ["artificial bacterial chromosomes", "TREATMENT", 145, 177], ["DNA", "PROBLEM", 220, 223]]], ["Artificial bacterial chromosomes with important genes may be used to generate synthetic microbial factories to produce biofuels such as hydrogen and to cut down carbon emissions from coal degasification units (Smith et al., 2003).Synthesis bacteriophage T7 genome by refactoring process ::: Synthetic biology assisted whole genome synthesis of bacterial clones and bacteriophagesChan and colleagues used refactoring methods to redesign T7 bacteriophage genome (39,937 bp) with the aim to study its important gene functions (Chan et al., 2005).", [["chromosomes", "ANATOMY", 21, 32], ["clones", "ANATOMY", 354, 360], ["hydrogen", "CHEMICAL", 136, 144], ["hydrogen", "CHEMICAL", 136, 144], ["carbon", "CHEMICAL", 161, 167], ["coal", "CHEMICAL", 183, 187], ["hydrogen", "SIMPLE_CHEMICAL", 136, 144], ["bacterial clones", "CELL", 344, 360], ["Artificial bacterial chromosomes", "DNA", 0, 32], ["bacteriophage T7 genome", "DNA", 240, 263], ["bacterial clones", "CELL_LINE", 344, 360], ["T7 bacteriophage genome", "DNA", 436, 459], ["39,937 bp", "DNA", 461, 470], ["Artificial bacterial chromosomes", "PROBLEM", 0, 32], ["hydrogen", "TREATMENT", 136, 144], ["Synthesis bacteriophage", "TREATMENT", 230, 253], ["bacterial clones", "PROBLEM", 344, 360], ["bacteriophages", "TREATMENT", 365, 379], ["redesign T7 bacteriophage genome", "TREATMENT", 427, 459], ["bp", "TEST", 468, 470], ["bacterial chromosomes", "OBSERVATION", 11, 32], ["T7 genome", "OBSERVATION", 254, 263], ["bacterial clones", "OBSERVATION", 344, 360]]], ["They generated three chimeric bacteriophages, namely \u03b1-WT, WT-\u03b2-WT, and \u03b1-\u03b2-WT by removing overlapping genetic segments and replacing a 11,515 bp stretch of wild type (WT) genome with 12,179 bp synthetic \u03b1- and \u03b2-cassettes using recombination supporting E. coli BL21.", [["\u03b1-WT", "ORGANISM", 53, 57], ["WT-\u03b2-WT", "ORGANISM", 59, 66], ["\u03b1-\u03b2-WT", "ORGANISM", 72, 78], ["\u03b1-", "GENE_OR_GENE_PRODUCT", 204, 206], ["E. coli", "ORGANISM", 254, 261], ["BL21", "GENE_OR_GENE_PRODUCT", 262, 266], ["\u03b1-WT", "PROTEIN", 53, 57], ["WT", "PROTEIN", 59, 61], ["\u03b2-WT", "PROTEIN", 62, 66], ["\u03b1-\u03b2-WT", "PROTEIN", 72, 78], ["11,515 bp stretch", "DNA", 136, 153], ["wild type (WT) genome", "DNA", 157, 178], ["12,179 bp synthetic \u03b1- and \u03b2-cassettes", "DNA", 184, 222], ["E. coli BL21", "SPECIES", 254, 266], ["E. coli", "SPECIES", 254, 261], ["WT", "TEST", 55, 57], ["WT", "TEST", 59, 61], ["WT", "TEST", 64, 66], ["a 11,515 bp stretch", "TREATMENT", 134, 153], ["bp synthetic", "TEST", 191, 203], ["E. coli BL21", "PROBLEM", 254, 266], ["coli BL21", "OBSERVATION", 257, 266]]], ["Overlapping segments conserved but not needed for viral replication can be removed/replaced while maintaining its viability.", [["Overlapping segments conserved", "PROBLEM", 0, 30], ["viral replication", "TREATMENT", 50, 67]]], ["This study revealed the potential of dwarfed genome to perform all replicative and functional activities and paved the way to the development of the first synthetic bacterial clone, as described below.Synthesis of M. genitalium and M. mycoides clones using minimal genome content ::: Synthetic biology assisted whole genome synthesis of bacterial clones and bacteriophagesUsing systematic mutagenesis approach, researchers at The Institute for Genome Research (TIGR), Rockville, Maryland, identified 265\u2013350 genes of urethritis causing Mycoplasma genitalium, essential for maintaining cell viability and supporting cell replication.", [["clone", "ANATOMY", 175, 180], ["clones", "ANATOMY", 347, 353], ["cell", "ANATOMY", 585, 589], ["cell", "ANATOMY", 615, 619], ["urethritis", "DISEASE", 517, 527], ["Mycoplasma genitalium", "DISEASE", 536, 557], ["clone", "CELL", 175, 180], ["M. genitalium", "ORGANISM", 214, 227], ["M. mycoides clones", "CELL", 232, 250], ["bacterial clones", "CELL", 337, 353], ["\u2013350", "GENE_OR_GENE_PRODUCT", 503, 507], ["Mycoplasma genitalium", "ORGANISM", 536, 557], ["cell", "CELL", 585, 589], ["cell", "CELL", 615, 619], ["dwarfed genome", "DNA", 37, 51], ["bacterial clones", "CELL_LINE", 337, 353], ["M. genitalium", "SPECIES", 214, 227], ["M. mycoides", "SPECIES", 232, 243], ["Mycoplasma genitalium", "SPECIES", 536, 557], ["M. genitalium", "SPECIES", 214, 227], ["M. mycoides", "SPECIES", 232, 243], ["Mycoplasma genitalium", "SPECIES", 536, 557], ["This study", "TEST", 0, 10], ["dwarfed genome", "PROBLEM", 37, 51], ["all replicative", "TREATMENT", 63, 78], ["the first synthetic bacterial clone", "PROBLEM", 145, 180], ["Synthesis of M. genitalium", "PROBLEM", 201, 227], ["M. mycoides clones", "PROBLEM", 232, 250], ["bacterial clones", "PROBLEM", 337, 353], ["bacteriophages", "TREATMENT", 358, 372], ["systematic mutagenesis approach", "TREATMENT", 378, 409], ["urethritis", "PROBLEM", 517, 527], ["Mycoplasma genitalium", "PROBLEM", 536, 557], ["cell viability", "TREATMENT", 585, 599], ["supporting cell replication", "TREATMENT", 604, 631], ["bacterial clone", "OBSERVATION", 165, 180], ["bacterial clones", "OBSERVATION", 337, 353], ["urethritis", "OBSERVATION", 517, 527], ["Mycoplasma genitalium", "OBSERVATION", 536, 557], ["cell viability", "OBSERVATION", 585, 599], ["cell replication", "OBSERVATION", 615, 631]]], ["It was the first attempt to construct a synthetic bacterial clone using artificial assembled genetic constructs and it was initiated in 1999.", [["synthetic bacterial clone", "CELL_LINE", 40, 65], ["a synthetic bacterial clone", "TREATMENT", 38, 65], ["artificial assembled genetic constructs", "TREATMENT", 72, 111]]], ["Results of the study were published in Science, indicating minimal genome content required for DNA replication and repair, gene expression, cellular transport, and metabolism and energy generation in a living prokaryotic cell.", [["cellular", "ANATOMY", 140, 148], ["cell", "ANATOMY", 221, 225], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cellular", "CELL", 140, 148], ["cell", "CELL", 221, 225], ["living prokaryotic cell", "CELL_TYPE", 202, 225], ["the study", "TEST", 11, 20], ["minimal genome content", "PROBLEM", 59, 81], ["DNA replication", "TREATMENT", 95, 110], ["repair", "TREATMENT", 115, 121], ["cellular transport", "TEST", 140, 158], ["minimal", "OBSERVATION_MODIFIER", 59, 66], ["genome content", "OBSERVATION", 67, 81], ["prokaryotic cell", "OBSERVATION", 209, 225]]], ["This study further led to the successful synthesis of the first dwarfed (582,970 bp) genome of M. genitalium (Gibson et al., 2008).", [["M. genitalium", "ORGANISM", 95, 108], ["dwarfed (582,970 bp) genome", "DNA", 64, 91], ["M. genitalium", "SPECIES", 95, 108], ["M. genitalium", "SPECIES", 95, 108], ["This study", "TEST", 0, 10]]], ["Preliminary investigations on the genomic transplants in M. laboratorium and M. capricolum have revealed the possibility of development of synthetic species using artificially constructed bacterial genomes.", [["M. laboratorium", "ORGANISM", 57, 72], ["M. capricolum", "ORGANISM", 77, 90], ["M. laboratorium", "SPECIES", 57, 72], ["M. capricolum", "SPECIES", 77, 90], ["M. laboratorium", "SPECIES", 57, 72], ["M. capricolum", "SPECIES", 77, 90], ["Preliminary investigations", "TEST", 0, 26], ["the genomic transplants", "TREATMENT", 30, 53], ["M. capricolum", "TEST", 77, 90], ["synthetic species", "PROBLEM", 139, 156], ["artificially constructed bacterial genomes", "PROBLEM", 163, 205], ["synthetic species", "OBSERVATION", 139, 156], ["bacterial genomes", "OBSERVATION", 188, 205]]], ["The slow growing M. genitalium was replaced with more prolific strain M. mycoides to synthesize the first synthetic bacterial cell, named M. mycoides JCV-1-syn1.0, which was successfully booted to life in 2010 (Gibson et al., 2010; Sleator, 2010; Glass, 2012).", [["cell", "ANATOMY", 126, 130], ["M. genitalium", "ORGANISM", 17, 30], ["M. mycoides", "ORGANISM", 70, 81], ["bacterial cell", "CELL", 116, 130], ["M. mycoides", "ORGANISM", 138, 149], ["JCV", "ORGANISM", 150, 153], ["M. genitalium", "SPECIES", 17, 30], ["M. mycoides", "SPECIES", 70, 81], ["M. mycoides", "SPECIES", 138, 149], ["M. genitalium", "SPECIES", 17, 30], ["M. mycoides", "SPECIES", 70, 81], ["M. mycoides", "SPECIES", 138, 149], ["The slow growing M. genitalium", "PROBLEM", 0, 30], ["more prolific strain M. mycoides", "PROBLEM", 49, 81], ["JCV", "TEST", 150, 153], ["slow", "OBSERVATION_MODIFIER", 4, 8], ["growing", "OBSERVATION_MODIFIER", 9, 16], ["genitalium", "OBSERVATION", 20, 30], ["bacterial cell", "OBSERVATION", 116, 130]]], ["Work is still under progress to construct an entirely new designer strain, called M. genitalium syn2.0, containing minimum set of essential genes required for life, to study the potential of synthetic agents in bioremediation and biomedicine.Synthesis of the 1918 Spanish flu virus ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesThe historical influenza pandemic, causing death of more than 50 million persons worldwide during 1918\u201319, remained undiscovered until 1995.", [["influenza pandemic", "DISEASE", 380, 398], ["death", "DISEASE", 408, 413], ["M. genitalium", "ORGANISM", 82, 95], ["syn2.0", "ORGANISM", 96, 102], ["flu virus", "ORGANISM", 272, 281], ["chimeric viruses", "ORGANISM", 349, 365], ["M. genitalium", "SPECIES", 82, 95], ["Spanish flu virus", "SPECIES", 264, 281], ["persons", "SPECIES", 438, 445], ["M. genitalium", "SPECIES", 82, 95], ["Spanish flu virus", "SPECIES", 264, 281], ["synthetic agents", "TREATMENT", 191, 207], ["chimeric viruses", "PROBLEM", 349, 365], ["The historical influenza pandemic", "PROBLEM", 365, 398], ["chimeric viruses", "OBSERVATION", 349, 365]]], ["Taubenberger and coworkers, in 1997, initiated efforts to recover viral RNA segments from lung tissue autopsy samples of a 21 year soldier and frozen tissue of an Inuit women buried in the permafrost, both were among the 1918 pandemic victims (Taubenberger et al., 1997).", [["lung tissue autopsy samples", "ANATOMY", 90, 117], ["tissue", "ANATOMY", 150, 156], ["pandemic", "DISEASE", 226, 234], ["lung tissue", "TISSUE", 90, 101], ["tissue", "TISSUE", 150, 156], ["women", "ORGANISM", 169, 174], ["women", "SPECIES", 169, 174], ["lung", "ANATOMY", 90, 94], ["frozen tissue", "OBSERVATION_MODIFIER", 143, 156]]], ["They reconstructed the genomes of the 1918 \u201cSpanish Flu\u201d virus from eight viral RNA segments using the techniques of gene sequencing and RT-PCR and, later, the authors successfully assembled artificial virus responsible for the Spanish Flu pandemic.", [["Flu", "CHEMICAL", 236, 239], ["Flu\u201d virus", "ORGANISM", 52, 62], ["viral RNA segments", "DNA", 74, 92], ["Spanish Flu\u201d virus", "SPECIES", 44, 62], ["gene sequencing", "TEST", 117, 132], ["RT-PCR", "TEST", 137, 143], ["artificial virus", "PROBLEM", 191, 207]]], ["Out of a total of eight genes, hemeagglutinin (HA), neuraminidase (NA), and polymerase B1 (PB1) were considered important virulent factors contributing to the severity of the disease.", [["hemeagglutinin", "GENE_OR_GENE_PRODUCT", 31, 45], ["HA", "GENE_OR_GENE_PRODUCT", 47, 49], ["neuraminidase (NA)", "GENE_OR_GENE_PRODUCT", 52, 70], ["polymerase B1", "GENE_OR_GENE_PRODUCT", 76, 89], ["PB1", "GENE_OR_GENE_PRODUCT", 91, 94], ["hemeagglutinin", "PROTEIN", 31, 45], ["HA", "PROTEIN", 47, 49], ["neuraminidase", "PROTEIN", 52, 65], ["NA", "PROTEIN", 67, 69], ["polymerase B1", "PROTEIN", 76, 89], ["PB1", "PROTEIN", 91, 94], ["hemeagglutinin (HA", "TREATMENT", 31, 49], ["neuraminidase (NA)", "TEST", 52, 70], ["polymerase B1 (PB1", "TEST", 76, 94], ["virulent factors", "PROBLEM", 122, 138], ["the disease", "PROBLEM", 171, 182], ["disease", "OBSERVATION", 175, 182]]], ["Sixteen different variants were reported for HA antigens, mainly aglycoproteins in nature that help in attachment of virus to the host cell, while nine subtypes of NA, antigenic glycoproteins, were reported in humans and animals, with N1 and N2 linked to epidemics in man and others, specifically, for ducks and chickens.", [["cell", "ANATOMY", 135, 139], ["NA", "CHEMICAL", 164, 166], ["HA antigens", "GENE_OR_GENE_PRODUCT", 45, 56], ["aglycoproteins", "GENE_OR_GENE_PRODUCT", 65, 79], ["host cell", "CELL", 130, 139], ["NA", "MULTI-TISSUE_STRUCTURE", 164, 166], ["humans", "ORGANISM", 210, 216], ["man", "ORGANISM", 268, 271], ["ducks", "ORGANISM", 302, 307], ["chickens", "ORGANISM", 312, 320], ["HA antigens", "PROTEIN", 45, 56], ["aglycoproteins", "PROTEIN", 65, 79], ["antigenic glycoproteins", "PROTEIN", 168, 191], ["humans", "SPECIES", 210, 216], ["man", "SPECIES", 268, 271], ["ducks", "SPECIES", 302, 307], ["chickens", "SPECIES", 312, 320], ["humans", "SPECIES", 210, 216], ["ducks", "SPECIES", 302, 307], ["chickens", "SPECIES", 312, 320], ["Sixteen different variants", "PROBLEM", 0, 26], ["HA antigens", "PROBLEM", 45, 56], ["virus", "PROBLEM", 117, 122], ["NA, antigenic glycoproteins", "PROBLEM", 164, 191], ["host cell", "OBSERVATION", 130, 139]]], ["HA type-5 (HA5) and NA type-1 (N1) are important components of viral capsids required for assembly of infectious viral particles.", [["HA type-5", "CHEMICAL", 0, 9], ["HA type-5", "GENE_OR_GENE_PRODUCT", 0, 9], ["HA5", "GENE_OR_GENE_PRODUCT", 11, 14], ["NA type-1", "GENE_OR_GENE_PRODUCT", 20, 29], ["N1", "CANCER", 31, 33], ["HA type-5 (HA5)", "PROBLEM", 0, 15], ["NA type-1 (N1)", "PROBLEM", 20, 34], ["viral capsids", "TREATMENT", 63, 76], ["infectious viral particles", "PROBLEM", 102, 128], ["viral capsids", "OBSERVATION", 63, 76], ["infectious", "OBSERVATION_MODIFIER", 102, 112], ["viral particles", "OBSERVATION", 113, 128]]], ["Neuraminidase activity is important to release replicated viruses from the infected host cell.", [["cell", "ANATOMY", 89, 93], ["Neuraminidase", "GENE_OR_GENE_PRODUCT", 0, 13], ["host cell", "CELL", 84, 93], ["infected host cell", "CELL_TYPE", 75, 93], ["Neuraminidase activity", "PROBLEM", 0, 22], ["infected", "OBSERVATION_MODIFIER", 75, 83], ["host cell", "OBSERVATION", 84, 93]]], ["The Spanish Flu virus probably originated in birds, and evolved to cause the 1918 epidemic.Synthesis of poliovirus ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesIn 2002, Cello and coworkers artificially constructed poliovirus using cDNA driven synthesis of viral RNA genome in absence of its natural template and then, using a mixture of biologicals, the resulting RNA genomes were subsequently enveloped to generate artificial poliovirus (Cello et al., 2002).", [["Flu", "CHEMICAL", 12, 15], ["Spanish Flu virus", "ORGANISM", 4, 21], ["birds", "ORGANISM", 45, 50], ["poliovirus", "ORGANISM", 104, 114], ["chimeric viruses", "ORGANISM", 182, 198], ["poliovirus", "ORGANISM", 252, 262], ["viral RNA genome", "DNA", 294, 310], ["RNA genomes", "DNA", 402, 413], ["Spanish Flu virus", "SPECIES", 4, 21], ["poliovirus", "SPECIES", 252, 262], ["The Spanish Flu virus", "PROBLEM", 0, 21], ["chimeric viruses", "PROBLEM", 182, 198], ["poliovirus", "PROBLEM", 252, 262], ["cDNA driven synthesis", "TREATMENT", 269, 290], ["viral RNA genome", "PROBLEM", 294, 310], ["a mixture of biologicals", "TREATMENT", 362, 386], ["the resulting RNA genomes", "PROBLEM", 388, 413], ["Flu virus", "OBSERVATION", 12, 21], ["poliovirus", "OBSERVATION", 104, 114], ["chimeric viruses", "OBSERVATION", 182, 198], ["viral RNA genome", "OBSERVATION", 294, 310], ["RNA genomes", "OBSERVATION", 402, 413]]], ["Synthetic virology approach was followed to investigate the functional features of the viral genome and the underlying mechanism of pathogenicity associated with its important virulence factors.", [["viral genome", "DNA", 87, 99], ["virulence factors", "PROTEIN", 176, 193], ["Synthetic virology approach", "TREATMENT", 0, 27], ["the viral genome", "PROBLEM", 83, 99], ["pathogenicity", "PROBLEM", 132, 145], ["viral genome", "OBSERVATION", 87, 99], ["pathogenicity", "OBSERVATION", 132, 145]]], ["Twenty-five mutations were introduced intentionally in the synthetic cDNA construct that served as genetic markers to assess properties of viral genome architecture and associated functional genetic loci.", [["synthetic cDNA construct", "DNA", 59, 83], ["functional genetic loci", "DNA", 180, 203], ["genetic markers", "TEST", 99, 114], ["viral genome architecture", "PROBLEM", 139, 164], ["viral genome architecture", "OBSERVATION", 139, 164], ["functional genetic loci", "OBSERVATION", 180, 203]]], ["Subsequently, artificial viruses were tested for infection using HeLa cell lines and CD155tg mice models and confirmed as infectious.", [["HeLa cell lines", "ANATOMY", 65, 80], ["infection", "DISEASE", 49, 58], ["HeLa cell lines", "CELL", 65, 80], ["CD155tg", "CELL", 85, 92], ["mice", "ORGANISM", 93, 97], ["HeLa cell lines", "CELL_LINE", 65, 80], ["mice", "SPECIES", 93, 97], ["mice", "SPECIES", 93, 97], ["artificial viruses", "PROBLEM", 14, 32], ["infection", "PROBLEM", 49, 58], ["HeLa cell lines", "TREATMENT", 65, 80], ["CD155tg mice models", "TREATMENT", 85, 104], ["infectious", "PROBLEM", 122, 132], ["artificial viruses", "OBSERVATION", 14, 32], ["HeLa cell lines", "OBSERVATION", 65, 80], ["infectious", "OBSERVATION", 122, 132]]], ["However, the rate of infection was considerably lesser than the wild type strain.", [["infection", "DISEASE", 21, 30], ["infection", "PROBLEM", 21, 30], ["the wild type strain", "PROBLEM", 60, 80], ["infection", "OBSERVATION", 21, 30], ["lesser", "OBSERVATION_MODIFIER", 48, 54], ["type strain", "OBSERVATION", 69, 80]]], ["Chemical synthesis of this first lytic animal RNA virus confirmed the accuracy of the deduced viral genome sequence and assigned oncological features to defined loci in the viral genome.Synthesis of human endogenous retrovirus ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesHuman endogenous retrovirus (HER) includes a class of degenerate human retroviruses including Human Mouse Mammary Tumor Virus-like 2 provirus (HML-2) of the Human Endogenous Retrovirus K provirus (HERV-K (HML-2)).", [["human", "ORGANISM", 199, 204], ["retrovirus", "ORGANISM", 216, 226], ["chimeric viruses", "ORGANISM", 294, 310], ["Human", "ORGANISM", 310, 315], ["endogenous retrovirus", "ORGANISM", 316, 337], ["HER", "GENE_OR_GENE_PRODUCT", 339, 342], ["human", "ORGANISM", 375, 380], ["retroviruses", "ORGANISM", 381, 393], ["Human", "ORGANISM", 404, 409], ["Mouse Mammary Tumor Virus-like 2 provirus", "ORGANISM", 410, 451], ["HML-2", "CELL", 453, 458], ["Human", "ORGANISM", 467, 472], ["Retrovirus K provirus", "ORGANISM", 484, 505], ["HERV-K", "GENE_OR_GENE_PRODUCT", 507, 513], ["HML-2", "GENE_OR_GENE_PRODUCT", 515, 520], ["viral genome sequence", "DNA", 94, 115], ["viral genome", "DNA", 173, 185], ["HER", "PROTEIN", 339, 342], ["HML", "DNA", 515, 518], ["human", "SPECIES", 199, 204], ["Human", "SPECIES", 310, 315], ["human", "SPECIES", 375, 380], ["Human", "SPECIES", 404, 409], ["Mouse", "SPECIES", 410, 415], ["Human", "SPECIES", 467, 472], ["human", "SPECIES", 199, 204], ["Human", "SPECIES", 310, 315], ["human", "SPECIES", 375, 380], ["Human Endogenous Retrovirus K provirus", "SPECIES", 467, 505], ["this first lytic animal RNA virus", "PROBLEM", 22, 55], ["the deduced viral genome sequence", "TEST", 82, 115], ["chimeric viruses", "PROBLEM", 294, 310], ["Human endogenous retrovirus", "PROBLEM", 310, 337], ["degenerate human retroviruses", "PROBLEM", 364, 393], ["Human Mouse Mammary Tumor Virus", "PROBLEM", 404, 435], ["the Human Endogenous Retrovirus K provirus", "PROBLEM", 463, 505], ["HERV-K (HML", "TREATMENT", 507, 518], ["viral genome", "OBSERVATION", 173, 185], ["endogenous retrovirus", "OBSERVATION", 205, 226], ["chimeric viruses", "OBSERVATION", 294, 310], ["endogenous retrovirus", "OBSERVATION", 316, 337], ["degenerate human retroviruses", "OBSERVATION", 364, 393], ["Mammary", "ANATOMY", 416, 423], ["Tumor Virus", "OBSERVATION", 424, 435]]], ["Synthetic consensus sequence and site-directed mutagenesis were used to generate infectious proviral particles of (HERV-K (HML-2) called \u201cPhoenix\u201d (Dewannieux et al., 2006).", [["consensus sequence", "DNA", 10, 28], ["Synthetic consensus sequence", "TEST", 0, 28], ["directed mutagenesis", "TREATMENT", 38, 58], ["HERV", "TEST", 115, 119]]], ["Another proviral clone HERV-KCON, a close relative of progenetor HERV-K (HML-2) variant that infested human genome few million years ago and inherited since then with the human genome in a Mendelian fashion, was generated using whole genome synthesis (Lee and Bieniasz, 2007).", [["HERV-KCON", "GENE_OR_GENE_PRODUCT", 23, 32], ["HERV-K", "GENE_OR_GENE_PRODUCT", 65, 71], ["HML-2", "GENE_OR_GENE_PRODUCT", 73, 78], ["human", "ORGANISM", 102, 107], ["human", "ORGANISM", 171, 176], ["HERV", "DNA", 23, 27], ["KCON", "DNA", 28, 32], ["progenetor HERV-K (HML-2) variant", "DNA", 54, 87], ["human genome", "DNA", 102, 114], ["human genome", "DNA", 171, 183], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 171, 176], ["few", "OBSERVATION_MODIFIER", 115, 118]]], ["Thorough investigations were carried out in human cell lines, namely HEK293T, HeLa, SH-SY5Y, Baby Hamster Kidney BHK21, Feline G355.5, and Murine WOP cell lines.", [["cell lines", "ANATOMY", 50, 60], ["HEK293T", "ANATOMY", 69, 76], ["HeLa", "ANATOMY", 78, 82], ["SH-SY5Y", "ANATOMY", 84, 91], ["Kidney BHK21", "ANATOMY", 106, 118], ["WOP cell lines", "ANATOMY", 146, 160], ["human", "ORGANISM", 44, 49], ["cell lines", "CELL", 50, 60], ["HEK293T", "CELL", 69, 76], ["HeLa", "CELL", 78, 82], ["SH-SY5Y", "CELL", 84, 91], ["Baby Hamster Kidney BHK21", "CELL", 93, 118], ["Feline G355.5", "CELL", 120, 133], ["Murine", "ORGANISM", 139, 145], ["WOP cell lines", "CELL", 146, 160], ["human cell lines", "CELL_LINE", 44, 60], ["HEK293T", "CELL_LINE", 69, 76], ["HeLa", "CELL_LINE", 78, 82], ["SH-SY5Y", "CELL_LINE", 84, 91], ["Baby Hamster Kidney BHK21", "CELL_LINE", 93, 118], ["Feline G355.5", "CELL_LINE", 120, 133], ["Murine WOP cell lines", "CELL_LINE", 139, 160], ["human", "SPECIES", 44, 49], ["Murine", "SPECIES", 139, 145], ["human", "SPECIES", 44, 49], ["Thorough investigations", "TEST", 0, 23], ["Kidney", "ANATOMY", 106, 112], ["cell lines", "OBSERVATION", 150, 160]]], ["Out of these, no infection was reported in the case of HeLa and WOP cell lines by Phoenix.", [["HeLa", "ANATOMY", 55, 59], ["WOP cell lines", "ANATOMY", 64, 78], ["infection", "DISEASE", 17, 26], ["HeLa", "CELL", 55, 59], ["WOP cell lines", "CELL", 64, 78], ["Phoenix", "CELL", 82, 89], ["HeLa", "CELL_LINE", 55, 59], ["WOP cell lines", "CELL_LINE", 64, 78], ["infection", "PROBLEM", 17, 26], ["HeLa and WOP cell lines", "TREATMENT", 55, 78], ["no", "UNCERTAINTY", 14, 16], ["infection", "OBSERVATION", 17, 26], ["cell lines", "OBSERVATION", 68, 78]]], ["Ancestors of these proviral strains may be much less infectious, but these studies may provide valuable information related to ancient proviral genomic repertoires that have contributed immensely to human evolution and physiology.Synthesis of HIVcpz ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesViruses causing zoonotic infections, such as human immunodeficiency virus (HIV-1) and simian immunodeficiency virus (SIVcpz) have natural reservoirs in wild chimpanzees such as Pan Troglodytes troglodytes.", [["zoonotic infections", "DISEASE", 349, 368], ["human immunodeficiency virus (HIV-1) and simian immunodeficiency virus", "DISEASE", 378, 448], ["human", "ORGANISM", 199, 204], ["HIVcpz", "SIMPLE_CHEMICAL", 243, 249], ["chimeric viruses", "ORGANISM", 317, 333], ["human immunodeficiency virus", "ORGANISM", 378, 406], ["HIV-1", "ORGANISM", 408, 413], ["simian immunodeficiency virus", "ORGANISM", 419, 448], ["chimpanzees", "ORGANISM", 490, 501], ["Pan Troglodytes troglodytes", "ORGANISM", 510, 537], ["HIVcpz", "PROTEIN", 243, 249], ["human", "SPECIES", 199, 204], ["human immunodeficiency virus", "SPECIES", 378, 406], ["HIV-1", "SPECIES", 408, 413], ["simian immunodeficiency virus", "SPECIES", 419, 448], ["Troglodytes troglodytes", "SPECIES", 514, 537], ["human", "SPECIES", 199, 204], ["human immunodeficiency virus", "SPECIES", 378, 406], ["HIV-1", "SPECIES", 408, 413], ["simian immunodeficiency virus", "SPECIES", 419, 448], ["Pan Troglodytes troglodytes", "SPECIES", 510, 537], ["these proviral strains", "PROBLEM", 13, 35], ["these studies", "TEST", 69, 82], ["ancient proviral genomic repertoires", "PROBLEM", 127, 163], ["chimeric viruses", "PROBLEM", 317, 333], ["Viruses", "PROBLEM", 333, 340], ["zoonotic infections", "PROBLEM", 349, 368], ["human immunodeficiency virus", "PROBLEM", 378, 406], ["HIV", "TEST", 408, 411], ["simian immunodeficiency virus", "PROBLEM", 419, 448], ["natural reservoirs", "TREATMENT", 463, 481], ["wild chimpanzees", "PROBLEM", 485, 501], ["Pan Troglodytes troglodytes", "PROBLEM", 510, 537], ["proviral strains", "OBSERVATION", 19, 35], ["may be", "UNCERTAINTY", 36, 42], ["much less", "OBSERVATION_MODIFIER", 43, 52], ["chimeric viruses", "OBSERVATION", 317, 333], ["zoonotic", "OBSERVATION_MODIFIER", 349, 357], ["infections", "OBSERVATION", 358, 368], ["reservoirs", "OBSERVATION_MODIFIER", 471, 481]]], ["A research group isolated viral nucleic acid strings from fecal samples from wild Pan Troglodytes troglodytes.", [["fecal samples", "ANATOMY", 58, 71], ["nucleic acid", "CHEMICAL", 32, 44], ["fecal samples", "ORGANISM_SUBSTANCE", 58, 71], ["Pan Troglodytes troglodytes", "ORGANISM", 82, 109], ["Pan Troglodytes troglodytes", "SPECIES", 82, 109], ["Pan Troglodytes troglodytes", "SPECIES", 82, 109], ["A research group isolated viral nucleic acid strings", "PROBLEM", 0, 52], ["fecal samples", "TEST", 58, 71], ["viral nucleic acid strings", "OBSERVATION", 26, 52]]], ["They derived a consensus viral sequence that was synthesized artificially and used to produce infectious molecular clones of SIVcpz (Keele et al., 2006; Takehisa et al., 2007).", [["consensus viral sequence", "DNA", 15, 39], ["a consensus viral sequence", "TEST", 13, 39]]], ["Synthesis of in vitro particles might facilitate investigation of important viral elements that determine cross species transmission of these retroviral elements and mechanism of host adaptive responses to viral infections.Synthesis of SARS-like coronavirus ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesFrom 2002 to 2003, an unknown infectious agent infected 8427 persons in China, of whom 813 died due to unknown cause and lack of appropriate treatment measures.", [["viral infections", "DISEASE", 206, 222], ["SARS", "DISEASE", 236, 240], ["retroviral", "ORGANISM", 142, 152], ["SARS-like coronavirus", "ORGANISM", 236, 257], ["persons", "ORGANISM", 402, 409], ["viral elements", "DNA", 76, 90], ["retroviral elements", "DNA", 142, 161], ["persons", "SPECIES", 402, 409], ["Synthesis of in vitro particles", "TREATMENT", 0, 31], ["important viral elements", "PROBLEM", 66, 90], ["these retroviral elements", "TREATMENT", 136, 161], ["viral infections", "PROBLEM", 206, 222], ["SARS", "PROBLEM", 236, 240], ["chimeric viruses", "PROBLEM", 325, 341], ["appropriate treatment measures", "TREATMENT", 470, 500], ["viral elements", "OBSERVATION", 76, 90], ["retroviral elements", "OBSERVATION", 142, 161], ["viral infections", "OBSERVATION", 206, 222], ["SARS", "OBSERVATION", 236, 240], ["infectious", "OBSERVATION_MODIFIER", 371, 381]]], ["The causal agent was soon identified as a new species of coronavirus named \u201csevere acute respiratory syndrome virus coronavirus (SARS-CoV)\u201d by the World Health Organization.", [["coronavirus", "DISEASE", 57, 68], ["acute respiratory syndrome virus coronavirus", "DISEASE", 83, 127], ["SARS-CoV)\u201d", "DISEASE", 129, 139], ["coronavirus", "ORGANISM", 57, 68], ["\u201csevere acute respiratory syndrome virus coronavirus", "ORGANISM", 75, 127], ["SARS-CoV", "ORGANISM", 129, 137], ["coronavirus", "SPECIES", 57, 68], ["virus coronavirus", "SPECIES", 110, 127], ["coronavirus named \u201csevere acute respiratory syndrome virus coronavirus", "SPECIES", 57, 127], ["SARS-CoV", "SPECIES", 129, 137], ["a new species", "PROBLEM", 40, 53], ["coronavirus", "PROBLEM", 57, 68], ["severe acute respiratory syndrome virus coronavirus", "PROBLEM", 76, 127], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["respiratory syndrome", "OBSERVATION", 89, 109], ["virus coronavirus", "OBSERVATION", 110, 127]]], ["SARS-CoV disappeared in July 2003, as rapidly as it had emerged in 2002.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8], ["CoV", "OBSERVATION_MODIFIER", 5, 8]]], ["Bats are natural reservoirs of SARS-CoV and none of the human in vitro culture systems supports viral replication.", [["SARS", "DISEASE", 31, 35], ["Bats", "CELL", 0, 4], ["SARS-CoV", "ORGANISM", 31, 39], ["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["SARS-CoV", "SPECIES", 31, 39], ["human", "SPECIES", 56, 61], ["SARS", "PROBLEM", 31, 35], ["CoV", "PROBLEM", 36, 39], ["the human in vitro culture systems", "TEST", 52, 86], ["viral replication", "TREATMENT", 96, 113], ["natural", "OBSERVATION_MODIFIER", 9, 16], ["reservoirs", "OBSERVATION_MODIFIER", 17, 27], ["viral replication", "OBSERVATION", 96, 113]]], ["The possibility of human adaptation of bat SARS-CoV was studied using synthetic SARS-CoV viral cDNA.", [["SARS", "DISEASE", 43, 47], ["human", "ORGANISM", 19, 24], ["bat SARS-CoV", "ORGANISM", 39, 51], ["SARS-CoV", "ORGANISM", 80, 88], ["SARS-CoV viral cDNA", "DNA", 80, 99], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 80, 88], ["bat SARS", "PROBLEM", 39, 47], ["synthetic SARS", "PROBLEM", 70, 84], ["CoV viral cDNA", "TREATMENT", 85, 99]]], ["Authors created artificial clones by exchanging the receptor binding domain (RBD) with that of human SARS-CoV capable of infecting VeroE6 cell, DBT-hACE2, DBT-cACE2 (murine cell lines), HAE human cell lines, and BALB/c mice.", [["clones", "ANATOMY", 27, 33], ["VeroE6 cell", "ANATOMY", 131, 142], ["cell lines", "ANATOMY", 173, 183], ["cell lines", "ANATOMY", 196, 206], ["DBT", "CHEMICAL", 144, 147], ["DBT", "CHEMICAL", 155, 158], ["HAE", "DISEASE", 186, 189], ["clones", "CELL", 27, 33], ["human", "ORGANISM", 95, 100], ["SARS-CoV", "ORGANISM", 101, 109], ["VeroE6 cell", "CELL", 131, 142], ["DBT-hACE2", "CELL", 144, 153], ["DBT-cACE2", "CELL", 155, 164], ["murine", "ORGANISM", 166, 172], ["cell lines", "CELL", 173, 183], ["HAE", "CELL", 186, 189], ["human", "ORGANISM", 190, 195], ["cell lines", "CELL", 196, 206], ["BALB/c mice", "ORGANISM", 212, 223], ["receptor binding domain", "PROTEIN", 52, 75], ["RBD", "PROTEIN", 77, 80], ["VeroE6 cell", "CELL_LINE", 131, 142], ["DBT-hACE2, DBT-cACE2", "CELL_LINE", 144, 164], ["murine cell lines", "CELL_LINE", 166, 183], ["HAE human cell lines", "CELL_LINE", 186, 206], ["human", "SPECIES", 95, 100], ["murine", "SPECIES", 166, 172], ["human", "SPECIES", 190, 195], ["mice", "SPECIES", 219, 223], ["human SARS-CoV", "SPECIES", 95, 109], ["human", "SPECIES", 190, 195], ["mice", "SPECIES", 219, 223], ["artificial clones", "TREATMENT", 16, 33], ["the receptor binding domain", "TREATMENT", 48, 75], ["human SARS", "TEST", 95, 105], ["infecting VeroE6 cell", "PROBLEM", 121, 142], ["DBT", "TEST", 144, 147], ["hACE2", "TEST", 148, 153], ["DBT", "TEST", 155, 158], ["cACE2 (murine cell lines", "TREATMENT", 159, 183], ["HAE human cell lines", "TREATMENT", 186, 206], ["BALB/c mice", "TREATMENT", 212, 223], ["artificial clones", "OBSERVATION", 16, 33], ["VeroE6 cell", "OBSERVATION", 131, 142], ["cell lines", "OBSERVATION", 173, 183], ["cell lines", "OBSERVATION", 196, 206]]], ["This was the example of the largest retroviral genome (approx.", [["retroviral", "ORGANISM", 36, 46], ["retroviral genome", "DNA", 36, 53], ["largest", "OBSERVATION_MODIFIER", 28, 35], ["retroviral genome", "OBSERVATION", 36, 53]]], ["30 kb) capable of replicating and infecting human cells.", [["cells", "ANATOMY", 50, 55], ["human", "ORGANISM", 44, 49], ["cells", "CELL", 50, 55], ["human cells", "CELL_TYPE", 44, 55], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49], ["infecting human cells", "PROBLEM", 34, 55], ["infecting human cells", "OBSERVATION", 34, 55]]], ["It is suspected that SARS-CoV may re-emerge again, and might be even more deadly than the previous form, due to the possibility of cross species transmission of virulent characters to existing repertoire of coronavirus infecting other mammals like civets (Li et al., 2005; Becker et al., 2008).Synthesis of SARS-like coronavirus ::: Synthetic biology assisted whole genome synthesis of native or chimeric virusesThe authors also fear that replication of the acquired knowledge related to virulent genetic loci and assembly of designer pathogens is possible and might be utilized by bioweaponeers for construction of more deadly viruses and designer pathogens that confer efficient transmission among humans.Mechanism for dsRNA viral genome packaging ::: In vitro packaging of viral genomesIn \u03c612 viruses containing dsRNA genome, the ssRNA acts as a substrate for the packaging motor protein, i.e., P4 ATPase.", [["SARS", "DISEASE", 21, 25], ["SARS", "DISEASE", 307, 311], ["SARS-CoV", "ORGANISM", 21, 29], ["coronavirus", "ORGANISM", 207, 218], ["SARS-like coronavirus", "ORGANISM", 307, 328], ["chimeric viruses", "ORGANISM", 396, 412], ["humans", "ORGANISM", 700, 706], ["viral genomesIn \u03c612 viruses", "ORGANISM", 776, 803], ["P4 ATPase", "GENE_OR_GENE_PRODUCT", 898, 907], ["dsRNA genome", "DNA", 815, 827], ["ssRNA", "DNA", 833, 838], ["packaging motor protein", "PROTEIN", 867, 890], ["P4 ATPase", "PROTEIN", 898, 907], ["humans", "SPECIES", 700, 706], ["SARS-CoV", "SPECIES", 21, 29], ["humans", "SPECIES", 700, 706], ["SARS", "PROBLEM", 21, 25], ["cross species transmission of virulent characters", "PROBLEM", 131, 180], ["SARS", "PROBLEM", 307, 311], ["chimeric viruses", "PROBLEM", 396, 412], ["virulent genetic loci", "PROBLEM", 488, 509], ["designer pathogens", "PROBLEM", 526, 544], ["more deadly viruses", "PROBLEM", 616, 635], ["designer pathogens", "PROBLEM", 640, 658], ["viral genomesIn \u03c612 viruses", "TREATMENT", 776, 803], ["dsRNA genome", "TREATMENT", 815, 827], ["the ssRNA acts", "TREATMENT", 829, 843], ["the packaging motor protein", "TEST", 863, 890], ["coronavirus", "OBSERVATION", 207, 218], ["SARS", "OBSERVATION", 307, 311], ["chimeric viruses", "OBSERVATION", 396, 412], ["viral genomesIn", "OBSERVATION", 776, 791]]], ["Inside the capsid, the positive-sense strand of the virus genome is packaged and replicated to form dsRNA.", [["positive-sense strand", "DNA", 23, 44], ["virus genome", "DNA", 52, 64], ["the virus genome", "TREATMENT", 48, 64], ["dsRNA", "PROBLEM", 100, 105], ["capsid", "ANATOMY", 11, 17], ["virus genome", "OBSERVATION", 52, 64], ["dsRNA", "OBSERVATION", 100, 105]]], ["P4 ATPase comprises a hexameric multifunctional unit (lined with a helix \u03b16 and loops L1 and L2) that plays an important role in procapsid assembly and ssRNA packaging.", [["P4 ATPase", "GENE_OR_GENE_PRODUCT", 0, 9], ["\u03b16", "GENE_OR_GENE_PRODUCT", 73, 75], ["procapsid", "GENE_OR_GENE_PRODUCT", 129, 138], ["P4 ATPase", "PROTEIN", 0, 9], ["hexameric multifunctional unit", "PROTEIN", 22, 52], ["helix \u03b16", "PROTEIN", 67, 75], ["L1", "PROTEIN", 86, 88], ["L2", "PROTEIN", 93, 95], ["a hexameric multifunctional unit", "TREATMENT", 20, 52], ["a helix \u03b16 and loops L1 and L2", "TREATMENT", 65, 95], ["procapsid assembly", "TREATMENT", 129, 147], ["ssRNA packaging", "TREATMENT", 152, 167], ["loops", "ANATOMY_MODIFIER", 80, 85], ["L1", "ANATOMY", 86, 88], ["L2", "ANATOMY", 93, 95]]], ["During infection, it acts as a passive channel for the extrusion of newly synthesized mRNA molecules from the virus.", [["infection", "DISEASE", 7, 16], ["mRNA molecules", "PROTEIN", 86, 100], ["infection", "PROBLEM", 7, 16], ["a passive channel", "TREATMENT", 29, 46], ["newly synthesized mRNA molecules", "PROBLEM", 68, 100], ["the virus", "PROBLEM", 106, 115], ["infection", "OBSERVATION", 7, 16]]], ["The genome of \u03c612 encloses three segmented dsRNAs, each comprising a positive strand sequentially recognized by the procapsid, which undergoes conformational changes to accommodate all the RNA segments.", [["procapsid", "GENE_OR_GENE_PRODUCT", 116, 125], ["\u03c612", "DNA", 14, 17], ["dsRNAs", "DNA", 43, 49], ["procapsid", "PROTEIN", 116, 125], ["RNA segments", "RNA", 189, 201], ["a positive strand", "PROBLEM", 67, 84], ["dsRNAs", "OBSERVATION", 43, 49]]], ["The loops L1 and L2 are vital for RNA binding and translocation.", [["L1", "DNA", 10, 12], ["L2", "DNA", 17, 19], ["RNA binding", "PROBLEM", 34, 45], ["loops", "ANATOMY_MODIFIER", 4, 9], ["L1", "ANATOMY", 10, 12], ["L2", "ANATOMY_MODIFIER", 17, 19], ["RNA binding", "OBSERVATION", 34, 45]]], ["The phosphate-binding P-loop upon ATP hydrolysis changes its confirmation from \u201cdown\u201d to \u201cup\u201d form, accompanied by similar transition of \u03b16 and loop L2 from \u201cup\u201d to \u201cdown\u201d position, signifying the driving force for RNA translocation.", [["phosphate", "CHEMICAL", 4, 13], ["ATP", "CHEMICAL", 34, 37], ["phosphate", "CHEMICAL", 4, 13], ["ATP", "CHEMICAL", 34, 37], ["phosphate", "SIMPLE_CHEMICAL", 4, 13], ["ATP", "SIMPLE_CHEMICAL", 34, 37], ["\u03b16", "GENE_OR_GENE_PRODUCT", 137, 139], ["phosphate-binding P-loop", "PROTEIN", 4, 28], ["\u03b16", "PROTEIN", 137, 139], ["loop L2", "PROTEIN", 144, 151], ["The phosphate-binding P-loop upon ATP hydrolysis changes", "TREATMENT", 0, 56], ["its confirmation", "TEST", 57, 73], ["RNA translocation", "PROBLEM", 215, 232], ["similar", "OBSERVATION_MODIFIER", 115, 122], ["transition", "OBSERVATION", 123, 133], ["L2", "ANATOMY_MODIFIER", 149, 151]]], ["The arginine finger of hexameric ATPase motors plays an important role in sequential ATP hydrolysis, inducing conformational changes that direct the trans arginine finger to active center of ATPase (neighboring subunit), thus triggering the successive ATP hydrolysis.Mechanism of linear motor assisted viral genome packaging ::: Mechanism for dsDNA viral genome packaging ::: In vitro packaging of viral genomesAn electrostatic interactions based mechanism has been proposed for viral genome packaging in bacteriophage T4.", [["arginine", "CHEMICAL", 4, 12], ["ATP", "CHEMICAL", 85, 88], ["arginine", "CHEMICAL", 155, 163], ["ATP", "CHEMICAL", 252, 255], ["arginine", "CHEMICAL", 4, 12], ["ATP", "CHEMICAL", 85, 88], ["arginine", "CHEMICAL", 155, 163], ["ATP", "CHEMICAL", 252, 255], ["ATPase", "GENE_OR_GENE_PRODUCT", 33, 39], ["ATP", "SIMPLE_CHEMICAL", 85, 88], ["ATPase", "GENE_OR_GENE_PRODUCT", 191, 197], ["ATP", "SIMPLE_CHEMICAL", 252, 255], ["dsDNA", "CELLULAR_COMPONENT", 343, 348], ["bacteriophage T4", "ORGANISM", 505, 521], ["hexameric ATPase motors", "PROTEIN", 23, 46], ["trans arginine finger", "PROTEIN", 149, 170], ["ATPase", "PROTEIN", 191, 197], ["neighboring subunit", "PROTEIN", 199, 218], ["dsDNA viral genome", "DNA", 343, 361], ["viral genomes", "DNA", 398, 411], ["bacteriophage T4", "SPECIES", 505, 521], ["sequential ATP hydrolysis", "TREATMENT", 74, 99], ["conformational changes", "PROBLEM", 110, 132], ["the successive ATP hydrolysis", "TREATMENT", 237, 266], ["viral genomes", "PROBLEM", 398, 411], ["An electrostatic interactions", "PROBLEM", 411, 440], ["viral genome packaging", "TREATMENT", 479, 501], ["ATP hydrolysis", "OBSERVATION", 252, 266], ["linear", "OBSERVATION_MODIFIER", 280, 286], ["viral genomes", "OBSERVATION", 398, 411], ["electrostatic interactions", "OBSERVATION", 414, 440], ["bacteriophage T4", "OBSERVATION", 505, 521]]], ["The packaging motor protein has two domains, i.e., N-terminal ATPase domain and C-terminal nuclease domain, which are linked together by small amino acids to provide the flexibility to the motor to ensure packaging.", [["amino acids", "CHEMICAL", 143, 154], ["C", "CHEMICAL", 80, 81], ["amino acids", "CHEMICAL", 143, 154], ["ATPase", "GENE_OR_GENE_PRODUCT", 62, 68], ["amino acids", "AMINO_ACID", 143, 154], ["packaging motor protein", "PROTEIN", 4, 27], ["N-terminal ATPase domain", "PROTEIN", 51, 75], ["C-terminal nuclease domain", "PROTEIN", 80, 106], ["The packaging motor protein", "TEST", 0, 27], ["N-terminal ATPase domain", "TEST", 51, 75], ["C-terminal nuclease domain", "PROBLEM", 80, 106], ["small amino acids", "TREATMENT", 137, 154], ["packaging", "TREATMENT", 205, 214], ["motor protein", "OBSERVATION", 14, 27]]], ["ATP hydrolysis is triggered upon dsDNA binding to C-terminal domain (gp17 subunit) and thereby positioning the cis \u201carginine\u201d finger of N-terminal domain into the ATPase active center that further results in subsequent conformation changes.", [["ATP", "CHEMICAL", 0, 3], ["arginine", "CHEMICAL", 116, 124], ["ATP", "CHEMICAL", 0, 3], ["C", "CHEMICAL", 50, 51], ["arginine", "CHEMICAL", 116, 124], ["N", "CHEMICAL", 136, 137], ["ATP", "SIMPLE_CHEMICAL", 0, 3], ["dsDNA", "CELLULAR_COMPONENT", 33, 38], ["gp17 subunit", "GENE_OR_GENE_PRODUCT", 69, 81], ["ATPase", "GENE_OR_GENE_PRODUCT", 163, 169], ["C-terminal domain", "PROTEIN", 50, 67], ["gp17 subunit", "PROTEIN", 69, 81], ["N-terminal domain", "PROTEIN", 136, 153], ["ATPase active center", "PROTEIN", 163, 183], ["ATP hydrolysis", "PROBLEM", 0, 14], ["subsequent conformation changes", "PROBLEM", 208, 239]]], ["These changes align opposite charges of both N- and C-terminal domains that pull C-terminal domain towards N-terminal domain by the action of electrostatic forces, leading to packaging two base pairs of dsDNA (Sun et al., 2010).Mechanism of rotary motor assisted viral genome packaging ::: Mechanism for dsDNA viral genome packaging ::: In vitro packaging of viral genomesThe main component of DNA packaging machine is portal protein gp10 (dodecameric) of \u03c629 having a central \u03b1-helical channel lined with negative charges for easy passage of DNA.", [["N", "CHEMICAL", 45, 46], ["C", "CHEMICAL", 52, 53], ["C", "CHEMICAL", 81, 82], ["N", "CHEMICAL", 107, 108], ["dsDNA", "CELLULAR_COMPONENT", 203, 208], ["dsDNA", "CELLULAR_COMPONENT", 304, 309], ["DNA", "CELLULAR_COMPONENT", 394, 397], ["gp10", "GENE_OR_GENE_PRODUCT", 434, 438], ["DNA", "CELLULAR_COMPONENT", 543, 546], ["N- and C-terminal domains", "PROTEIN", 45, 70], ["pull C-terminal domain", "PROTEIN", 76, 98], ["N-terminal domain", "PROTEIN", 107, 124], ["dsDNA viral genome", "DNA", 304, 322], ["viral genomes", "DNA", 359, 372], ["portal protein", "PROTEIN", 419, 433], ["gp10", "PROTEIN", 434, 438], ["dodecameric", "PROTEIN", 440, 451], ["\u03c629", "PROTEIN", 456, 459], ["central \u03b1-helical channel", "PROTEIN", 469, 494], ["C-terminal domains", "PROBLEM", 52, 70], ["pull C-terminal domain", "PROBLEM", 76, 98], ["electrostatic forces", "PROBLEM", 142, 162], ["viral genomes", "PROBLEM", 359, 372], ["DNA packaging machine", "TREATMENT", 394, 415], ["a central \u03b1-helical channel lined", "TREATMENT", 467, 500], ["easy passage of DNA", "PROBLEM", 527, 546], ["electrostatic forces", "OBSERVATION", 142, 162], ["viral genomes", "OBSERVATION", 359, 372], ["main", "OBSERVATION_MODIFIER", 376, 380], ["component", "OBSERVATION_MODIFIER", 381, 390], ["DNA packaging", "OBSERVATION", 394, 407], ["portal", "ANATOMY", 419, 425], ["protein gp10", "OBSERVATION", 426, 438], ["negative charges", "OBSERVATION", 506, 522]]], ["It also comprises a wider end inside the capsid and a narrower end protruding from the capsid; and energy from ATP hydrolysis is used for rotating the portal in order to drive the DNA into the procapsid (Hugel et al., 2007).Examples of in vitro packaged viral genomes ::: In vitro packaging of viral genomesAdeno-associated virus (AAV) are nonenveloped icosahedral parvoviruses containing ssDNA with intact inverted terminal repeats (ITR), resulting in the formation of important secondary structures in viral genome.", [["ATP", "CHEMICAL", 111, 114], ["ATP", "CHEMICAL", 111, 114], ["ATP", "SIMPLE_CHEMICAL", 111, 114], ["DNA", "CELLULAR_COMPONENT", 180, 183], ["viral genomes", "ORGANISM", 294, 307], ["Adeno-associated virus", "ORGANISM", 307, 329], ["AAV", "ORGANISM", 331, 334], ["ssDNA", "CELLULAR_COMPONENT", 389, 394], ["terminal repeats", "CELLULAR_COMPONENT", 416, 432], ["viral genomes", "DNA", 254, 267], ["viral genomes", "DNA", 294, 307], ["inverted terminal repeats", "DNA", 407, 432], ["ITR", "DNA", 434, 437], ["viral genome", "DNA", 504, 516], ["Adeno-associated virus", "SPECIES", 307, 329], ["AAV", "SPECIES", 331, 334], ["a narrower end protruding", "PROBLEM", 52, 77], ["ATP hydrolysis", "TREATMENT", 111, 125], ["viral genomesAdeno-associated virus (AAV)", "PROBLEM", 294, 335], ["nonenveloped icosahedral parvoviruses containing ssDNA", "PROBLEM", 340, 394], ["intact inverted terminal repeats", "PROBLEM", 400, 432], ["wider", "OBSERVATION_MODIFIER", 20, 25], ["end", "OBSERVATION_MODIFIER", 26, 29], ["capsid", "OBSERVATION_MODIFIER", 41, 47], ["narrower", "OBSERVATION_MODIFIER", 54, 62], ["end", "OBSERVATION_MODIFIER", 63, 66], ["protruding", "OBSERVATION_MODIFIER", 67, 77], ["capsid", "OBSERVATION_MODIFIER", 87, 93], ["ATP hydrolysis", "OBSERVATION", 111, 125], ["portal", "ANATOMY", 151, 157], ["viral genomes", "OBSERVATION", 254, 267], ["viral genomes", "OBSERVATION", 294, 307], ["icosahedral parvoviruses", "OBSERVATION", 353, 377], ["ssDNA", "OBSERVATION_MODIFIER", 389, 394], ["secondary structures", "OBSERVATION", 480, 500], ["viral genome", "OBSERVATION", 504, 516]]], ["Further, co-infection with helper virus (like adenovirus or herpes simplex virus, HSV) assists its replication with host cell polymerase (Ni et al., 1994).", [["cell", "ANATOMY", 121, 125], ["co-infection", "DISEASE", 9, 21], ["herpes simplex virus", "DISEASE", 60, 80], ["helper virus", "ORGANISM", 27, 39], ["like adenovirus", "ORGANISM", 41, 56], ["herpes simplex virus", "ORGANISM", 60, 80], ["HSV", "ORGANISM", 82, 85], ["host cell", "CELL", 116, 125], ["host cell polymerase", "PROTEIN", 116, 136], ["herpes simplex virus", "SPECIES", 60, 80], ["helper virus", "SPECIES", 27, 39], ["herpes simplex virus", "SPECIES", 60, 80], ["HSV", "SPECIES", 82, 85], ["co-infection", "PROBLEM", 9, 21], ["helper virus", "PROBLEM", 27, 39], ["adenovirus", "PROBLEM", 46, 56], ["herpes simplex virus", "PROBLEM", 60, 80], ["HSV", "PROBLEM", 82, 85], ["host cell polymerase", "TREATMENT", 116, 136], ["co-infection", "OBSERVATION", 9, 21], ["host cell", "OBSERVATION_MODIFIER", 116, 125]]], ["An in vitro course of action for the packaging of AAV was studied by Zhou and Muzyczka (1998).", [["AAV", "ORGANISM", 50, 53], ["the packaging of AAV", "TREATMENT", 33, 53], ["AAV", "OBSERVATION", 50, 53]]], ["Synthesis of an infectious AAV particle was done by using its replicative-form of DNA as a substrate, AAV Rep, and capsid proteins in order to transfer recombinant gene to mammalian cells.", [["cells", "ANATOMY", 182, 187], ["AAV", "ORGANISM", 27, 30], ["DNA", "CELLULAR_COMPONENT", 82, 85], ["AAV", "ORGANISM", 102, 105], ["Rep", "GENE_OR_GENE_PRODUCT", 106, 109], ["mammalian cells", "CELL", 172, 187], ["AAV Rep", "PROTEIN", 102, 109], ["capsid proteins", "PROTEIN", 115, 130], ["recombinant gene", "DNA", 152, 168], ["mammalian cells", "CELL_TYPE", 172, 187], ["an infectious AAV particle", "PROBLEM", 13, 39], ["DNA", "PROBLEM", 82, 85], ["AAV Rep", "TREATMENT", 102, 109], ["capsid proteins", "TREATMENT", 115, 130], ["infectious", "OBSERVATION", 16, 26], ["mammalian cells", "OBSERVATION", 172, 187]]], ["Two types of products formed, both were heat-resistant, indicating an appropriate ratio of protein-to-DNA.", [["DNA", "CELLULAR_COMPONENT", 102, 105], ["products", "TREATMENT", 13, 21]]], ["In addition, products also share structural resemblance of mature AAV particles.", [["AAV", "ORGANISM", 66, 69], ["mature AAV particles", "OBSERVATION", 59, 79]]], ["An efficiently synthesized particle enclosing intact terminal repeats always shows chloroform, DNase I, and heat-resistance, pertaining to an authentic AAV particle.", [["chloroform", "CHEMICAL", 83, 93], ["chloroform", "CHEMICAL", 83, 93], ["chloroform", "SIMPLE_CHEMICAL", 83, 93], ["DNase I", "GENE_OR_GENE_PRODUCT", 95, 102], ["AAV", "ORGANISM", 152, 155], ["DNase I", "PROTEIN", 95, 102], ["An efficiently synthesized particle", "TREATMENT", 0, 35], ["particle", "OBSERVATION_MODIFIER", 27, 35], ["chloroform", "OBSERVATION", 83, 93], ["resistance", "OBSERVATION", 113, 123], ["AAV particle", "OBSERVATION", 152, 164]]], ["Resistance is known to be a vital property for packaging purposes.", [["packaging purposes", "TREATMENT", 47, 65]]], ["However, nonpathogenic and persistent nature, in combination with its broad range of infection, as reported by Wright and coworkers, marked this virus as an imperative nominee for a therapeutic gene transfer vector (Wright et al., 2003).Examples of in vitro packaged viral genomes ::: In vitro packaging of viral genomesAn in vitro study was conducted by Cashion et al. (2005) to investigate the application of gene therapy for treatment of neurological diseases by using human polyoma virus JCV derived virus-like particles (VLP).", [["neurological", "ANATOMY", 441, 453], ["infection", "DISEASE", 85, 94], ["neurological diseases", "DISEASE", 441, 462], ["human", "ORGANISM", 472, 477], ["polyoma virus JCV derived virus-like particles", "ORGANISM", 478, 524], ["VLP", "ORGANISM", 526, 529], ["viral genomes", "DNA", 267, 280], ["viral genomes", "DNA", 307, 320], ["human", "SPECIES", 472, 477], ["polyoma virus JCV", "SPECIES", 478, 495], ["human polyoma virus", "SPECIES", 472, 491], ["nonpathogenic", "PROBLEM", 9, 22], ["infection", "PROBLEM", 85, 94], ["this virus", "PROBLEM", 140, 150], ["viral genomes", "PROBLEM", 307, 320], ["An in vitro study", "TEST", 320, 337], ["gene therapy", "TREATMENT", 411, 423], ["treatment", "TREATMENT", 428, 437], ["neurological diseases", "PROBLEM", 441, 462], ["human polyoma virus JCV derived virus", "TREATMENT", 472, 509], ["nonpathogenic", "OBSERVATION_MODIFIER", 9, 22], ["persistent", "OBSERVATION_MODIFIER", 27, 37], ["nature", "OBSERVATION_MODIFIER", 38, 44], ["broad", "OBSERVATION_MODIFIER", 70, 75], ["infection", "OBSERVATION", 85, 94], ["viral genomes", "OBSERVATION", 267, 280], ["viral genomes", "OBSERVATION", 307, 320]]], ["Here, VLP act as a delivery vector for the central nervous system (CNS) because JCV preferentially infects both oligodendrocytes and astrocytes.", [["central nervous system", "ANATOMY", 43, 65], ["CNS", "ANATOMY", 67, 70], ["oligodendrocytes", "ANATOMY", 112, 128], ["astrocytes", "ANATOMY", 133, 143], ["VLP", "GENE_OR_GENE_PRODUCT", 6, 9], ["central nervous system", "ANATOMICAL_SYSTEM", 43, 65], ["CNS", "ANATOMICAL_SYSTEM", 67, 70], ["JCV", "ORGANISM", 80, 83], ["oligodendrocytes", "CELL", 112, 128], ["astrocytes", "CELL", 133, 143], ["oligodendrocytes", "CELL_TYPE", 112, 128], ["astrocytes", "CELL_TYPE", 133, 143], ["JCV", "SPECIES", 80, 83], ["a delivery vector", "TREATMENT", 17, 34], ["JCV", "PROBLEM", 80, 83], ["central nervous", "ANATOMY", 43, 58], ["astrocytes", "ANATOMY", 133, 143]]], ["The construction of JCV-derived recombinant VP1 in insect cells and respective packaging strategies for purified VP1 and plasmid DNA were optimized.", [["cells", "ANATOMY", 58, 63], ["JCV", "ORGANISM", 20, 23], ["VP1", "GENE_OR_GENE_PRODUCT", 44, 47], ["insect cells", "CELL", 51, 63], ["VP1", "GENE_OR_GENE_PRODUCT", 113, 116], ["DNA", "CELLULAR_COMPONENT", 129, 132], ["recombinant VP1", "PROTEIN", 32, 47], ["insect cells", "CELL_TYPE", 51, 63], ["purified VP1 and plasmid DNA", "DNA", 104, 132], ["JCV-derived recombinant VP1 in insect cells", "TREATMENT", 20, 63], ["respective packaging strategies", "TREATMENT", 68, 99], ["purified VP1 and plasmid DNA", "TREATMENT", 104, 132]]], ["In order to illustrate tropism and species specificity of VP1-VLP containing plasmid DNA expressing EGFP in vitro, transduction of VP1-VLP was done in human and rodent brain-derived and nonbrain derived cells.", [["brain", "ANATOMY", 168, 173], ["nonbrain derived cells", "ANATOMY", 186, 208], ["VP1-VLP", "ORGANISM", 58, 65], ["plasmid DNA", "CELLULAR_COMPONENT", 77, 88], ["EGFP", "GENE_OR_GENE_PRODUCT", 100, 104], ["VP1-VLP", "GENE_OR_GENE_PRODUCT", 131, 138], ["human", "ORGANISM", 151, 156], ["brain-derived", "CELL", 168, 181], ["nonbrain derived cells", "CELL", 186, 208], ["VP1", "PROTEIN", 58, 61], ["plasmid DNA", "DNA", 77, 88], ["EGFP", "DNA", 100, 104], ["VP1", "PROTEIN", 131, 134], ["human and rodent brain-derived and nonbrain derived cells", "CELL_TYPE", 151, 208], ["human", "SPECIES", 151, 156], ["rodent", "SPECIES", 161, 167], ["human", "SPECIES", 151, 156], ["tropism", "PROBLEM", 23, 30], ["VP1-VLP", "TREATMENT", 58, 65], ["plasmid DNA", "TREATMENT", 77, 88], ["VP1-VLP", "TEST", 131, 138], ["brain", "ANATOMY", 168, 173]]], ["Significant transduction was observed in human prostate cell line (PC-3); thus, assigning VP1-VLP as an efficient and selective delivery system for therapeutic genes to target specific cells in the brain (Cashion et al., 2005).Examples of in vitro packaged viral genomes ::: In vitro packaging of viral genomesTechniques of synthetic biology foster current challenges in agriculture and industry, biological defense, environmental, and medical sciences and provide important breakthroughs in improving global scenarios of human and animal health.", [["prostate cell line", "ANATOMY", 47, 65], ["PC-3", "ANATOMY", 67, 71], ["cells", "ANATOMY", 185, 190], ["brain", "ANATOMY", 198, 203], ["human", "ORGANISM", 41, 46], ["prostate cell line", "CELL", 47, 65], ["PC-3", "CELL", 67, 71], ["VP1", "ORGANISM", 90, 93], ["cells", "CELL", 185, 190], ["brain", "ORGAN", 198, 203], ["human", "ORGANISM", 522, 527], ["human prostate cell line", "CELL_LINE", 41, 65], ["PC-3", "CELL_LINE", 67, 71], ["VP1", "PROTEIN", 90, 93], ["therapeutic genes", "DNA", 148, 165], ["viral genomes", "DNA", 257, 270], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 522, 527], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 522, 527], ["Significant transduction", "PROBLEM", 0, 24], ["human prostate cell line", "TREATMENT", 41, 65], ["PC", "TEST", 67, 69], ["VP1", "TEST", 90, 93], ["selective delivery system", "TREATMENT", 118, 143], ["viral genomes", "TREATMENT", 297, 310], ["prostate", "ANATOMY", 47, 55], ["cell line", "OBSERVATION", 56, 65], ["brain", "ANATOMY", 198, 203], ["viral genomes", "OBSERVATION", 257, 270], ["viral genomes", "OBSERVATION", 297, 310]]], ["It is, however, difficult to rule out the possibility of replicating existing knowledge domains of synthetic biology for unlawful activities and spreading economic and physiological distress at a global scale among vulnerable human populations.Microbiological culturing ::: Biowarfare agent detection: Methods and challengesMicrobiological culturing is the conventional method used for the isolation and identification of biological agents such as bacteria, fungi, and viruses.", [["human", "ORGANISM", 226, 231], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 226, 231], ["unlawful activities", "PROBLEM", 121, 140], ["spreading economic and physiological distress", "PROBLEM", 145, 190], ["Microbiological culturing", "TEST", 244, 269], ["Microbiological culturing", "TEST", 324, 349], ["the conventional method", "TREATMENT", 353, 376], ["the isolation", "TREATMENT", 386, 399], ["biological agents", "TREATMENT", 422, 439], ["bacteria", "PROBLEM", 448, 456], ["fungi", "PROBLEM", 458, 463], ["viruses", "PROBLEM", 469, 476]]], ["Microbes have the ability to propagate in selective culture media, which allow only the targeted microorganism to grow.", [["selective culture media", "TEST", 42, 65], ["the targeted microorganism", "PROBLEM", 84, 110]]], ["Selective culturing offers an additional benefit of long term viability and enrichment of the concerned microbe for further characterization.", [["Selective culturing", "TEST", 0, 19], ["long term viability", "PROBLEM", 52, 71], ["further characterization", "TEST", 116, 140], ["long term viability", "OBSERVATION_MODIFIER", 52, 71]]], ["Various tests have been employed for the morphological identification and biochemical characterization of a particular biological agent.", [["Various tests", "TEST", 0, 13], ["the morphological identification", "TEST", 37, 69], ["biochemical characterization", "TEST", 74, 102]]], ["Microbiological culturing is highly reliable and specific, but is laborious and time consuming, which limits its efficacy (Pal et al., 2016).Flow cytometry ::: Biowarfare agent detection: Methods and challengesFlow cytometry involves scattering of laser light and emission of fluorescence by excitation of dyes linked with bacterial cells.", [["cells", "ANATOMY", 333, 338], ["cells", "CELL", 333, 338], ["bacterial cells", "CELL_TYPE", 323, 338], ["Microbiological culturing", "TEST", 0, 25], ["Flow cytometry", "TEST", 210, 224], ["laser light", "TEST", 248, 259], ["dyes", "TREATMENT", 306, 310], ["bacterial cells", "PROBLEM", 323, 338], ["bacterial cells", "OBSERVATION", 323, 338]]], ["Cell size and cell count in the case of liquid suspension are estimated by laser light scattering.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 14, 18], ["Cell", "CELL", 0, 4], ["cell", "CELL", 14, 18], ["Cell size", "TEST", 0, 9], ["cell count", "TEST", 14, 24], ["liquid suspension", "TREATMENT", 40, 57], ["size", "OBSERVATION_MODIFIER", 5, 9], ["cell count", "OBSERVATION", 14, 24], ["liquid suspension", "OBSERVATION", 40, 57]]], ["Monoclonal antibodies that are fluorescently labeled can also be used for detection of various pathogens.", [["Monoclonal antibodies", "PROTEIN", 0, 21], ["Monoclonal antibodies", "TEST", 0, 21], ["various pathogens", "PROBLEM", 87, 104]]], ["Biowarfare agents such as B. anthracis, B. melitensis, botulinum toxin, F. tularensis, and Y. pestis can be easily identified using flow cytometry techniques (McBride et al., 2003; Hindson et al., 2005).Cellular fatty acid based profiling ::: Biowarfare agent detection: Methods and challengesIn 1963, two separate reports, by Abel and coworkers and Kaneda, described bacterial identification methods based on cellular fatty acid profiling.", [["cellular", "ANATOMY", 410, 418], ["fatty acid", "CHEMICAL", 212, 222], ["fatty acid", "CHEMICAL", 419, 429], ["fatty acid", "CHEMICAL", 212, 222], ["fatty acid", "CHEMICAL", 419, 429], ["B. anthracis", "ORGANISM", 26, 38], ["B. melitensis", "ORGANISM", 40, 53], ["botulinum toxin", "ORGANISM", 55, 70], ["F. tularensis", "ORGANISM", 72, 85], ["Y. pestis", "ORGANISM", 91, 100], ["Cellular fatty acid", "SIMPLE_CHEMICAL", 203, 222], ["cellular", "CELL", 410, 418], ["fatty acid", "SIMPLE_CHEMICAL", 419, 429], ["B. anthracis", "SPECIES", 26, 38], ["B. melitensis", "SPECIES", 40, 53], ["botulinum toxin", "SPECIES", 55, 70], ["F. tularensis", "SPECIES", 72, 85], ["Y. pestis", "SPECIES", 91, 100], ["B. anthracis", "SPECIES", 26, 38], ["B. melitensis", "SPECIES", 40, 53], ["F. tularensis", "SPECIES", 72, 85], ["Y. pestis", "SPECIES", 91, 100], ["Biowarfare agents", "TREATMENT", 0, 17], ["B. melitensis", "PROBLEM", 40, 53], ["botulinum toxin", "PROBLEM", 55, 70], ["bacterial identification methods", "PROBLEM", 368, 400], ["cellular fatty acid profiling", "PROBLEM", 410, 439], ["fatty acid", "OBSERVATION", 212, 222], ["fatty acid", "OBSERVATION", 419, 429]]], ["Bacterial strains can be easily distinguished in terms of variability of their fatty acids structures and profiles.", [["fatty acids", "CHEMICAL", 79, 90], ["fatty acids", "AMINO_ACID", 79, 90], ["Bacterial strains", "PROBLEM", 0, 17], ["strains", "OBSERVATION", 10, 17], ["fatty acids", "OBSERVATION", 79, 90]]], ["Firstly, conversion of cellular fatty acids to fatty acid methyl esters takes place, followed by analysis by gas liquid chromatography.", [["cellular", "ANATOMY", 23, 31], ["fatty acids", "CHEMICAL", 32, 43], ["fatty acid methyl esters", "CHEMICAL", 47, 71], ["fatty acids", "CHEMICAL", 32, 43], ["fatty acid methyl esters", "CHEMICAL", 47, 71], ["cellular", "CELL", 23, 31], ["fatty acids", "SIMPLE_CHEMICAL", 32, 43], ["fatty acid methyl esters", "SIMPLE_CHEMICAL", 47, 71], ["cellular fatty acids", "TREATMENT", 23, 43], ["fatty acid methyl esters", "TREATMENT", 47, 71], ["gas liquid chromatography", "TEST", 109, 134], ["fatty acids", "OBSERVATION", 32, 43]]], ["GC chromatograms generate important fatty acid fingerprints that have been successfully employed for identification and characterization of various biological agents, viz.", [["fatty acid", "CHEMICAL", 36, 46], ["fatty acid", "SIMPLE_CHEMICAL", 36, 46], ["GC chromatograms", "TEST", 0, 16], ["important fatty acid fingerprints", "PROBLEM", 26, 59], ["various biological agents", "TREATMENT", 140, 165]]], ["B. anthracis, B. mallei, Brucella, B. pseudomallei, F. tularensis, and Y. pestis (Abel and Peterson, 1963; Kaneda, 1963; Pal et al., 2016).PCR based detection ::: Biowarfare agent detection: Methods and challengesMolecular biology techniques offer specific and rapid identification of biowarfare agents, as compared to conventional microbiological techniques.", [["Y. pestis", "DISEASE", 71, 80], ["B. anthracis", "ORGANISM", 0, 12], ["B. mallei", "ORGANISM", 14, 23], ["Brucella,", "ORGANISM", 25, 34], ["B. pseudomallei", "ORGANISM", 35, 50], ["F. tularensis", "ORGANISM", 52, 65], ["Y. pestis", "ORGANISM", 71, 80], ["B. anthracis", "SPECIES", 0, 12], ["B. mallei", "SPECIES", 14, 23], ["B. pseudomallei", "SPECIES", 35, 50], ["F. tularensis", "SPECIES", 52, 65], ["Y. pestis", "SPECIES", 71, 80], ["B. anthracis", "SPECIES", 0, 12], ["B. mallei", "SPECIES", 14, 23], ["B. pseudomallei", "SPECIES", 35, 50], ["F. tularensis", "SPECIES", 52, 65], ["Y. pestis (Abel and Peterson, 1963; Kaneda, 1963; Pal et al., 2016", "SPECIES", 71, 137], ["Brucella", "PROBLEM", 25, 33], ["PCR", "TEST", 139, 142], ["biowarfare agents", "TREATMENT", 285, 302], ["tularensis", "OBSERVATION", 55, 65]]], ["Polymerase chain reaction (PCR) based assays identify an organism on the basis of presence of specific DNA sequence(s) in the organism.", [["DNA", "CELLULAR_COMPONENT", 103, 106], ["DNA sequence", "DNA", 103, 115], ["Polymerase chain reaction", "PROBLEM", 0, 25], ["PCR) based assays", "TEST", 27, 44], ["an organism", "PROBLEM", 54, 65], ["specific DNA sequence", "TEST", 94, 115]]], ["Quantitative real-time PCR (Q-PCR) based on specific and nonspecific detection is also used for amplification and simultaneous detection of targets.", [["Quantitative real-time PCR", "TEST", 0, 26], ["nonspecific detection", "TEST", 57, 78], ["simultaneous detection", "TEST", 114, 136]]], ["PCR-based identification has been reported in the case of various biowarfare agents such as arenaviruses, B. anthracis, C. burnetii, filoviruses, F. tularensis, and Y. pestis.", [["Y. pestis", "DISEASE", 165, 174], ["arenaviruses", "ORGANISM", 92, 104], ["B. anthracis", "ORGANISM", 106, 118], ["C. burnetii", "ORGANISM", 120, 131], ["filoviruses", "GENE_OR_GENE_PRODUCT", 133, 144], ["F. tularensis", "ORGANISM", 146, 159], ["Y. pestis", "ORGANISM", 165, 174], ["B. anthracis", "SPECIES", 106, 118], ["C. burnetii", "SPECIES", 120, 131], ["F. tularensis", "SPECIES", 146, 159], ["Y. pestis", "SPECIES", 165, 174], ["B. anthracis", "SPECIES", 106, 118], ["C. burnetii", "SPECIES", 120, 131], ["F. tularensis", "SPECIES", 146, 159], ["Y. pestis", "SPECIES", 165, 174], ["PCR", "TEST", 0, 3], ["various biowarfare agents", "TREATMENT", 58, 83], ["arenaviruses", "TREATMENT", 92, 104], ["C. burnetii", "PROBLEM", 120, 131], ["filoviruses", "PROBLEM", 133, 144], ["pestis", "OBSERVATION", 168, 174]]], ["Recombinase polymerase amplification (RPA), an alternative form of DNA amplification technique, has been used to scan the presence of double stranded DNA templates for homologous sequences.", [["Recombinase polymerase", "GENE_OR_GENE_PRODUCT", 0, 22], ["DNA", "CELLULAR_COMPONENT", 67, 70], ["DNA", "CELLULAR_COMPONENT", 150, 153], ["Recombinase polymerase", "PROTEIN", 0, 22], ["double stranded DNA templates", "DNA", 134, 163], ["homologous sequences", "DNA", 168, 188], ["DNA amplification technique", "TREATMENT", 67, 94], ["double stranded DNA templates", "TREATMENT", 134, 163], ["homologous sequences", "TREATMENT", 168, 188]]], ["RPA is rapid and highly sensitive technique, as it can detect even a single copy of the target in < 20 min.", [["RPA", "GENE_OR_GENE_PRODUCT", 0, 3], ["RPA", "PROTEIN", 0, 3], ["rapid", "OBSERVATION_MODIFIER", 7, 12], ["highly sensitive", "OBSERVATION_MODIFIER", 17, 33]]], ["RPA assays and reverse transcriptase RPA (RT-RPA) assays have been successfully used for detection of BWAs such as B. anthracis, Brucella sp., Ebola virus, F. tularensis, Marburg virus, Rift Valley fever virus, Sudan virus, variola virus, and Y. pestis.", [["Ebola virus", "DISEASE", 143, 154], ["Rift Valley fever", "DISEASE", 186, 203], ["variola virus", "DISEASE", 224, 237], ["Y. pestis", "DISEASE", 243, 252], ["BWAs", "GENE_OR_GENE_PRODUCT", 102, 106], ["B. anthracis", "ORGANISM", 115, 127], ["Brucella sp.", "ORGANISM", 129, 141], ["Ebola virus", "ORGANISM", 143, 154], ["F. tularensis", "ORGANISM", 156, 169], ["Marburg virus", "ORGANISM", 171, 184], ["Rift Valley fever virus", "ORGANISM", 186, 209], ["Sudan virus", "ORGANISM", 211, 222], ["variola virus", "ORGANISM", 224, 237], ["Y. pestis", "ORGANISM", 243, 252], ["RPA", "PROTEIN", 0, 3], ["reverse transcriptase", "PROTEIN", 15, 36], ["RPA", "PROTEIN", 45, 48], ["B. anthracis", "SPECIES", 115, 127], ["Brucella sp.", "SPECIES", 129, 141], ["Ebola virus", "SPECIES", 143, 154], ["F. tularensis", "SPECIES", 156, 169], ["Marburg virus", "SPECIES", 171, 184], ["Rift Valley fever virus", "SPECIES", 186, 209], ["Sudan virus", "SPECIES", 211, 222], ["variola virus", "SPECIES", 224, 237], ["Y. pestis", "SPECIES", 243, 252], ["B. anthracis", "SPECIES", 115, 127], ["Brucella sp.", "SPECIES", 129, 141], ["Ebola virus", "SPECIES", 143, 154], ["F. tularensis", "SPECIES", 156, 169], ["Marburg virus", "SPECIES", 171, 184], ["Rift Valley fever virus", "SPECIES", 186, 209], ["Sudan virus", "SPECIES", 211, 222], ["variola virus", "SPECIES", 224, 237], ["Y. pestis", "SPECIES", 243, 252], ["RPA assays", "TEST", 0, 10], ["reverse transcriptase RPA", "TREATMENT", 15, 40], ["BWAs", "PROBLEM", 102, 106], ["B. anthracis", "PROBLEM", 115, 127], ["Brucella sp.", "PROBLEM", 129, 141], ["Ebola virus", "PROBLEM", 143, 154], ["Marburg virus", "PROBLEM", 171, 184], ["Rift Valley fever virus", "PROBLEM", 186, 209], ["Sudan virus", "PROBLEM", 211, 222], ["variola virus", "PROBLEM", 224, 237], ["variola virus", "OBSERVATION", 224, 237], ["pestis", "OBSERVATION", 246, 252]]], ["RT-PCR has also been used for the detection of chimeric viruses such as Zika virus, yellow fever virus, Ebola virus, and Mengla virus (Alfson et al., 2017; Kum et al., 2018; Yang et al., 2019).", [["yellow fever", "DISEASE", 84, 96], ["Ebola virus", "DISEASE", 104, 115], ["Zika virus", "ORGANISM", 72, 82], ["yellow fever virus", "ORGANISM", 84, 102], ["Ebola virus", "ORGANISM", 104, 115], ["Mengla virus", "ORGANISM", 121, 133], ["Zika virus", "SPECIES", 72, 82], ["yellow fever virus", "SPECIES", 84, 102], ["Ebola virus", "SPECIES", 104, 115], ["Mengla virus", "SPECIES", 121, 133], ["Zika virus", "SPECIES", 72, 82], ["yellow fever virus", "SPECIES", 84, 102], ["Ebola virus", "SPECIES", 104, 115], ["Mengla virus", "SPECIES", 121, 133], ["RT-PCR", "TEST", 0, 6], ["chimeric viruses", "PROBLEM", 47, 63], ["Zika virus", "PROBLEM", 72, 82], ["yellow fever virus", "PROBLEM", 84, 102], ["Ebola virus", "PROBLEM", 104, 115], ["Mengla virus", "PROBLEM", 121, 133], ["chimeric viruses", "OBSERVATION", 47, 63]]], ["Disadvantages of nucleic acid based detection techniques include their inability to detect proteins such as toxins (Janse et al., 2010; Trombley et al., 2010; De Bruin et al., 2011).Immunological methods ::: Biowarfare agent detection: Methods and challengesImmunoassays based on antigen-antibody interactions have been widely exploited for identification of potential biowarfare agents.", [["nucleic acid", "CHEMICAL", 17, 29], ["nucleic acid", "SIMPLE_CHEMICAL", 17, 29], ["nucleic acid", "TREATMENT", 17, 29], ["challengesImmunoassays", "TEST", 248, 270], ["antigen", "TEST", 280, 287], ["potential biowarfare agents", "TREATMENT", 359, 386]]], ["Antibodies bind to specific antigens present on the surface of the cell and form a colored or detectable complex, which ultimately marks the presence/detection of a bioagent in the sample.", [["surface", "ANATOMY", 52, 59], ["cell", "ANATOMY", 67, 71], ["sample", "ANATOMY", 181, 187], ["surface", "CELLULAR_COMPONENT", 52, 59], ["cell", "CELL", 67, 71], ["antigens", "PROTEIN", 28, 36], ["colored or detectable complex", "PROTEIN", 83, 112], ["Antibodies bind", "PROBLEM", 0, 15], ["specific antigens", "TEST", 19, 36], ["cell", "ANATOMY", 67, 71], ["detectable", "OBSERVATION_MODIFIER", 94, 104], ["complex", "OBSERVATION_MODIFIER", 105, 112]]], ["Enzyme linked immunosorbant assay (ELISA) has been mainly used for quantitative detection of antigen following the basic principle of immunoassays.", [["Enzyme linked immunosorbant assay", "TEST", 0, 33], ["ELISA", "TEST", 35, 40], ["antigen", "PROBLEM", 93, 100], ["immunoassays", "TEST", 134, 146]]], ["ELISA has been widely used for diagnosis of several diseases and simultaneous screening of large number of samples.", [["samples", "ANATOMY", 107, 114], ["samples", "CANCER", 107, 114], ["several diseases", "PROBLEM", 44, 60], ["simultaneous screening", "TEST", 65, 87], ["several", "OBSERVATION_MODIFIER", 44, 51], ["diseases", "OBSERVATION", 52, 60], ["large", "OBSERVATION_MODIFIER", 91, 96]]], ["To date, ELISAs have been successfully employed for the detection of biowarfare agents such as B. anthracis, B. pseudomallei, B. mallei, Brucella abortus, Ebola virus, F. tularensis, Marburg virus, toxins, and Y. pestis.", [["Ebola virus", "DISEASE", 155, 166], ["Y. pestis", "DISEASE", 210, 219], ["B. anthracis", "ORGANISM", 95, 107], ["B. pseudomallei", "ORGANISM", 109, 124], ["B. mallei", "ORGANISM", 126, 135], ["Brucella abortus", "ORGANISM", 137, 153], ["Ebola virus", "ORGANISM", 155, 166], ["F. tularensis", "ORGANISM", 168, 181], ["Marburg virus", "ORGANISM", 183, 196], ["Y. pestis", "ORGANISM", 210, 219], ["B. anthracis", "SPECIES", 95, 107], ["B. pseudomallei", "SPECIES", 109, 124], ["B. mallei", "SPECIES", 126, 135], ["Brucella abortus", "SPECIES", 137, 153], ["Ebola virus", "SPECIES", 155, 166], ["F. tularensis", "SPECIES", 168, 181], ["Marburg virus", "SPECIES", 183, 196], ["Y. pestis", "SPECIES", 210, 219], ["B. anthracis", "SPECIES", 95, 107], ["B. pseudomallei", "SPECIES", 109, 124], ["B. mallei", "SPECIES", 126, 135], ["Brucella abortus", "SPECIES", 137, 153], ["Ebola virus", "SPECIES", 155, 166], ["F. tularensis", "SPECIES", 168, 181], ["Marburg virus", "SPECIES", 183, 196], ["Y. pestis", "SPECIES", 210, 219], ["ELISAs", "TEST", 9, 15], ["biowarfare agents", "TREATMENT", 69, 86], ["B. anthracis", "PROBLEM", 95, 107], ["B. pseudomallei", "PROBLEM", 109, 124], ["B. mallei", "PROBLEM", 126, 135], ["Brucella abortus", "PROBLEM", 137, 153], ["Ebola virus", "PROBLEM", 155, 166], ["Marburg virus", "PROBLEM", 183, 196], ["toxins", "PROBLEM", 198, 204], ["pestis", "OBSERVATION", 213, 219]]], ["Besides these, fluorescent microscopy has also been used for biowarfare agent detection, where a fluorescent labeled antibody attached to antigenic receptors present on the surface of the microbial cells aids in its detection.", [["surface", "ANATOMY", 173, 180], ["cells", "ANATOMY", 198, 203], ["surface", "CELLULAR_COMPONENT", 173, 180], ["microbial cells", "CELL", 188, 203], ["fluorescent labeled antibody", "PROTEIN", 97, 125], ["antigenic receptors", "PROTEIN", 138, 157], ["microbial cells", "CELL_TYPE", 188, 203], ["fluorescent microscopy", "TEST", 15, 37], ["biowarfare agent detection", "TREATMENT", 61, 87], ["a fluorescent labeled antibody", "TREATMENT", 95, 125], ["antigenic receptors", "TEST", 138, 157], ["microbial cells", "OBSERVATION", 188, 203]]], ["Immuno-histochemical based methods have also enabled detection of some viruses such as Alphaviruses and Chikanguniya viruses (Wang et al., 2008).", [["Chikanguniya viruses", "ORGANISM", 104, 124], ["some viruses", "PROBLEM", 66, 78], ["Alphaviruses", "PROBLEM", 87, 99], ["Chikanguniya viruses", "PROBLEM", 104, 124], ["viruses", "OBSERVATION", 71, 78]]], ["Other immunoassay, namely, hand-held immuno-chromatographic assays (HHIAs), are also used for detection of biowarfare agents such as B. anthracis, B. abortus, B. pseudomallei, botulinum, F. tularensis, smallpox virus, Ricin toxin, variola virus, and Y. pestis.", [["Y. pestis", "DISEASE", 250, 259], ["B. anthracis", "ORGANISM", 133, 145], ["B. abortus", "ORGANISM", 147, 157], ["B. pseudomallei", "ORGANISM", 159, 174], ["botulinum,", "ORGANISM", 176, 186], ["F. tularensis", "ORGANISM", 187, 200], ["smallpox virus", "ORGANISM", 202, 216], ["Ricin toxin", "ORGANISM", 218, 229], ["variola virus", "ORGANISM", 231, 244], ["Y. pestis", "ORGANISM", 250, 259], ["B. anthracis", "SPECIES", 133, 145], ["B. abortus", "SPECIES", 147, 157], ["B. pseudomallei", "SPECIES", 159, 174], ["botulinum", "SPECIES", 176, 185], ["F. tularensis", "SPECIES", 187, 200], ["smallpox virus", "SPECIES", 202, 216], ["variola virus", "SPECIES", 231, 244], ["Y. pestis", "SPECIES", 250, 259], ["B. anthracis", "SPECIES", 133, 145], ["B. abortus", "SPECIES", 147, 157], ["B. pseudomallei", "SPECIES", 159, 174], ["F. tularensis", "SPECIES", 187, 200], ["smallpox virus", "SPECIES", 202, 216], ["variola virus", "SPECIES", 231, 244], ["Y. pestis", "SPECIES", 250, 259], ["Other immunoassay", "TEST", 0, 17], ["chromatographic assays", "TEST", 44, 66], ["biowarfare agents", "TREATMENT", 107, 124], ["pseudomallei", "PROBLEM", 162, 174], ["botulinum", "PROBLEM", 176, 185], ["smallpox virus", "PROBLEM", 202, 216], ["Ricin toxin", "TREATMENT", 218, 229], ["variola virus", "PROBLEM", 231, 244], ["variola virus", "OBSERVATION", 231, 244]]], ["HHIAs are cost-effective, simple, rapid, and are performed on nitrocellulose or nylon membranes and are based on lateral flow immunoassays.", [["nylon membranes", "ANATOMY", 80, 95], ["nitrocellulose", "CHEMICAL", 62, 76], ["HHIAs", "SIMPLE_CHEMICAL", 0, 5], ["membranes", "CELLULAR_COMPONENT", 86, 95], ["nitrocellulose or nylon membranes", "TREATMENT", 62, 95], ["lateral flow immunoassays", "TEST", 113, 138], ["nylon membranes", "OBSERVATION", 80, 95]]], ["Even having several advantages, these assays are less sensitive and specific as compared to other immunological methods (Gomes-Solecki et al., 2005; Wang et al., 2009; Ghosh and Goel, 2012; Sharma et al., 2013; Pal et al., 2016).Next generation sequencing ::: Biowarfare agent detection: Methods and challengesDNA sequencing techniques have been used for the unambiguous identification of biological warfare agents.", [["these assays", "TEST", 32, 44], ["Methods and challengesDNA sequencing techniques", "TREATMENT", 288, 335], ["biological warfare agents", "TREATMENT", 389, 414]]], ["Next-generation sequencing (NGS) technologies have radically changed the traditional ways of DNA sequencing, and thus, have opened new vistas in the field of identification of bacterial and viral bio-threats from clinical and environmental samples.", [["DNA", "CELLULAR_COMPONENT", 93, 96], ["DNA sequencing", "TEST", 93, 107], ["bacterial and viral bio-threats", "PROBLEM", 176, 207], ["bacterial", "OBSERVATION_MODIFIER", 176, 185]]], ["NGS involves simultaneous sequencing of multiple DNA fragments for determination of the desired sequence.", [["DNA", "CELLULAR_COMPONENT", 49, 52], ["multiple DNA fragments", "DNA", 40, 62], ["NGS", "TEST", 0, 3], ["multiple DNA fragments", "PROBLEM", 40, 62], ["multiple", "OBSERVATION_MODIFIER", 40, 48], ["DNA fragments", "OBSERVATION", 49, 62]]], ["In recent years, NGS technologies have gained much importance and validation as an effective biodefense strategy due to their highly specific and rapid detection capabilities.", [["NGS technologies", "TEST", 17, 33]]], ["NGS techniques have been applied for B. anthracis detection in air and soil samples.", [["samples", "ANATOMY", 76, 83], ["B. anthracis", "ORGANISM", 37, 49], ["air", "TISSUE", 63, 66], ["soil samples", "ORGANISM_SUBSTANCE", 71, 83], ["B. anthracis", "SPECIES", 37, 49], ["B. anthracis", "SPECIES", 37, 49], ["NGS techniques", "TREATMENT", 0, 14], ["B. anthracis detection in air and soil samples", "TEST", 37, 83], ["air", "OBSERVATION", 63, 66]]], ["Strain-specific polymorphism has also been identified by NGS in the case of B. anthracis and Y. pestis.", [["Y. pestis", "DISEASE", 93, 102], ["B. anthracis", "ORGANISM", 76, 88], ["Y. pestis", "ORGANISM", 93, 102], ["B. anthracis", "SPECIES", 76, 88], ["Y. pestis", "SPECIES", 93, 102], ["B. anthracis", "SPECIES", 76, 88], ["Y. pestis", "SPECIES", 93, 102], ["Strain-specific polymorphism", "PROBLEM", 0, 28], ["pestis", "OBSERVATION", 96, 102]]], ["F. tularensis was detected in human abscess samples of unknown etiology by next generation direct DNA sequencing technique.", [["abscess samples", "ANATOMY", 36, 51], ["abscess", "DISEASE", 36, 43], ["F. tularensis", "ORGANISM", 0, 13], ["human", "ORGANISM", 30, 35], ["abscess samples", "CANCER", 36, 51], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["F. tularensis", "SPECIES", 0, 13], ["human", "SPECIES", 30, 35], ["F. tularensis", "SPECIES", 0, 13], ["human", "SPECIES", 30, 35], ["F. tularensis", "PROBLEM", 0, 13], ["human abscess samples", "PROBLEM", 30, 51], ["tularensis", "OBSERVATION", 3, 13], ["abscess", "OBSERVATION", 36, 43]]], ["NGS technologies have been extensively used in medical diagnostics, mainly for the identification of novel infectious biological agents for which diagnostics and therapeutics are currently unavailable (Cummings et al., 2010; Kuroda et al., 2012; Lefterova et al., 2015).Bio-sensors ::: Biowarfare agent detection: Methods and challengesBio-sensors are analytical devices that generate response in the form of an electrical signal by interacting with the analyte in a biological component (biological warfare agent).", [["NGS technologies", "TEST", 0, 16], ["analytical devices", "TREATMENT", 352, 370], ["biological warfare agent", "TREATMENT", 489, 513]]], ["The biological response produced is then converted to a detectable form by the transducer, which marks the presence of any biowarfare agent in the sample.", [["sample", "ANATOMY", 147, 153], ["the transducer", "TEST", 75, 89], ["any biowarfare agent", "TREATMENT", 119, 139]]], ["Biosensors offer significant advantages in terms of high specificity and selectivity in comparison to conventional detection techniques.", [["Biosensors", "TREATMENT", 0, 10], ["conventional detection techniques", "TEST", 102, 135]]], ["Thus, these are being widely used for biological detection.", [["biological detection", "TEST", 38, 58]]], ["Bio-sensors have been categorized into different types according to the type of transducer and bioreceptor used.Bio-sensors ::: Biowarfare agent detection: Methods and challengesNanomaterials have also been used for the development of highly efficient and specific electrochemical bio-sensors for easy detection of biowarfare agents.", [["Nanomaterials", "SIMPLE_CHEMICAL", 178, 191], ["biowarfare agents", "SIMPLE_CHEMICAL", 315, 332], ["bioreceptor", "TREATMENT", 95, 106], ["Methods and challengesNanomaterials", "TREATMENT", 156, 191], ["biowarfare agents", "TREATMENT", 315, 332]]], ["A highly specific electrochemical immuno-biosensor consisting of bismuth nanoparticles (BiNPs) has been developed for anthrax PA toxin detection in a particular sample (Sharma et al., 2015).", [["bismuth nanoparticles", "CHEMICAL", 65, 86], ["BiNPs", "CHEMICAL", 88, 93], ["bismuth", "CHEMICAL", 65, 72], ["bismuth nanoparticles", "SIMPLE_CHEMICAL", 65, 86], ["BiNPs", "SIMPLE_CHEMICAL", 88, 93], ["PA", "GENE_OR_GENE_PRODUCT", 126, 128], ["bismuth nanoparticles (BiNPs", "TREATMENT", 65, 93], ["anthrax PA toxin detection", "TEST", 118, 144]]], ["Another electrochemical immunosensor, consisting of gold and palladium bimetallic nanoparticles, has been developed for detection of B. anthracis with the 1 pg/mL detection limit (Sharma et al., 2016).", [["palladium", "CHEMICAL", 61, 70], ["palladium", "CHEMICAL", 61, 70], ["gold", "SIMPLE_CHEMICAL", 52, 56], ["palladium bimetallic nanoparticles", "SIMPLE_CHEMICAL", 61, 95], ["B. anthracis", "ORGANISM", 133, 145], ["B. anthracis", "SPECIES", 133, 145], ["B. anthracis", "SPECIES", 133, 145], ["Another electrochemical immunosensor", "TEST", 0, 36], ["gold and palladium bimetallic nanoparticles", "TREATMENT", 52, 95], ["B. anthracis", "PROBLEM", 133, 145]]], ["B. anthracis was also identified using electrochemical genosensor loaded with gold nanoparticles by detecting its PCR amplicons with detection limit of 1.0 pM (Das et al., 2015).", [["gold nanoparticles", "CHEMICAL", 78, 96], ["B. anthracis", "ORGANISM", 0, 12], ["gold nanoparticles", "SIMPLE_CHEMICAL", 78, 96], ["PCR amplicons", "DNA", 114, 127], ["B. anthracis", "SPECIES", 0, 12], ["B. anthracis", "SPECIES", 0, 12], ["B. anthracis", "PROBLEM", 0, 12], ["gold nanoparticles", "TREATMENT", 78, 96]]], ["Botulinum neurotoxin type-E was also identified by an electrochemical immunosensor assembled with gold nanoparticles and graphene transducer (Narayanan et al., 2015).", [["Botulinum neurotoxin type-E", "CHEMICAL", 0, 27], ["gold nanoparticles", "CHEMICAL", 98, 116], ["graphene", "CHEMICAL", 121, 129], ["Botulinum neurotoxin", "ORGANISM", 0, 20], ["type-E", "GENE_OR_GENE_PRODUCT", 21, 27], ["gold nanoparticles", "SIMPLE_CHEMICAL", 98, 116], ["an electrochemical immunosensor", "TREATMENT", 51, 82], ["gold nanoparticles and graphene transducer", "TREATMENT", 98, 140]]], ["Wu and coworkers reported the identification of B. melitensis using an impedometric immunosensor loaded with gold nanoparticles and carbon electrodes (Wu et al., 2013).Bio-sensors ::: Biowarfare agent detection: Methods and challengesSurface plasmon resonance (SPR) technique has also been used for label-free detection of various biological agents.", [["gold nanoparticles", "CHEMICAL", 109, 127], ["carbon", "CHEMICAL", 132, 138], ["B. melitensis", "ORGANISM", 48, 61], ["gold nanoparticles", "SIMPLE_CHEMICAL", 109, 127], ["B. melitensis", "SPECIES", 48, 61], ["B. melitensis", "SPECIES", 48, 61], ["B. melitensis", "PROBLEM", 48, 61], ["an impedometric immunosensor loaded with gold nanoparticles and carbon electrodes", "TREATMENT", 68, 149], ["Surface plasmon resonance (SPR) technique", "TREATMENT", 234, 275], ["various biological agents", "TREATMENT", 323, 348], ["carbon electrodes", "OBSERVATION", 132, 149]]], ["Label free detection offers significant advantages over other methods, which require secondary labeled reagents for the detection purposes.", [["secondary labeled reagents", "TREATMENT", 85, 111], ["the detection purposes", "TEST", 116, 138]]], ["Using SPR technique, rapid and specific detection of bioagents has been reported, such as of B. anthracis, botulinum neurotoxin, Brucella, Staphylococcus enterotoxin A (SEA) and B (SEB), and Y. pestis.", [["Y. pestis", "DISEASE", 191, 200], ["B. anthracis", "ORGANISM", 93, 105], ["botulinum neurotoxin", "ORGANISM", 107, 127], ["Brucella", "ORGANISM", 129, 137], ["Staphylococcus enterotoxin A", "ORGANISM", 139, 167], ["SEA", "GENE_OR_GENE_PRODUCT", 169, 172], ["B", "GENE_OR_GENE_PRODUCT", 178, 179], ["SEB", "GENE_OR_GENE_PRODUCT", 181, 184], ["Y. pestis", "ORGANISM", 191, 200], ["SEA", "PROTEIN", 169, 172], ["SEB", "PROTEIN", 181, 184], ["B. anthracis", "SPECIES", 93, 105], ["botulinum neurotoxin", "SPECIES", 107, 127], ["Staphylococcus enterotoxin", "SPECIES", 139, 165], ["Y. pestis", "SPECIES", 191, 200], ["B. anthracis", "SPECIES", 93, 105], ["Staphylococcus enterotoxin A", "SPECIES", 139, 167], ["Y. pestis", "SPECIES", 191, 200], ["SPR technique", "TREATMENT", 6, 19], ["bioagents", "TREATMENT", 53, 62], ["B. anthracis", "PROBLEM", 93, 105], ["botulinum neurotoxin", "TEST", 107, 127], ["Brucella", "PROBLEM", 129, 137], ["Staphylococcus enterotoxin", "PROBLEM", 139, 165], ["pestis", "OBSERVATION", 194, 200]]], ["However, piezoelectric bio-sensors using quartz crystal microbalances (QCM) have been considered as better alternatives to SPR, hence have also been extensively used for biological agent detection.", [["quartz crystal microbalances", "CHEMICAL", 41, 69], ["quartz", "CHEMICAL", 41, 47], ["quartz crystal microbalances (QCM", "TREATMENT", 41, 74], ["biological agent detection", "TREATMENT", 170, 196]]], ["A piezoelectric immunosensor with detection limit of 5 \u00d7 106 cells has been developed for detection of F. tularensis.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["F. tularensis", "ORGANISM", 103, 116], ["F. tularensis", "SPECIES", 103, 116], ["F. tularensis", "SPECIES", 103, 116], ["A piezoelectric immunosensor", "TEST", 0, 28], ["F. tularensis", "PROBLEM", 103, 116], ["tularensis", "OBSERVATION", 106, 116]]], ["An immunosensor assembled with QCM detection has been developed for detection of staphylococcal enterotoxin A in milk samples (Salmain et al., 2012; Ghosh et al., 2013).Biophysical detector systems ::: Biowarfare agent detection: Methods and challengesGenerally, biological detectors only detect the presence of any biowarfare agent in a particular environment without identifying the nature and type of that bioagent.", [["milk samples", "ANATOMY", 113, 125], ["staphylococcal enterotoxin A", "SIMPLE_CHEMICAL", 81, 109], ["milk samples", "ORGANISM_SUBSTANCE", 113, 125], ["staphylococcal enterotoxin A", "PROTEIN", 81, 109], ["staphylococcal enterotoxin A", "SPECIES", 81, 109], ["An immunosensor", "TEST", 0, 15], ["QCM detection", "TEST", 31, 44], ["staphylococcal enterotoxin", "PROBLEM", 81, 107]]], ["For sample collection, various types of samplers/collectors are being used, such as cyclone samplers, viable particle size samplers, and virtual impactors.", [["sample", "ANATOMY", 4, 10], ["sample collection", "PROBLEM", 4, 21], ["samplers/collectors", "TREATMENT", 40, 59], ["cyclone samplers", "TREATMENT", 84, 100], ["size", "OBSERVATION_MODIFIER", 118, 122]]], ["Whereas for detection/identification purposes, different types of detectors, such as fluorescence-based detectors and particle size-based detectors, are being used.", [["detection/identification purposes", "TEST", 12, 45], ["particle", "OBSERVATION_MODIFIER", 118, 126], ["size", "OBSERVATION_MODIFIER", 127, 131]]], ["Nowadays, biological detectors are also widely used for various biological agent detection (Pal et al., 2016).Synthesis of chimeric LLOV-(EBOV/MARV/RESTV) ::: Chimeric or designer viruses as candidates to study disease pathogenesis ::: Protection against next generation biological agents: Methods and challengesA filovirus called Lloviu virus (LLOV) was discovered for the first time in Spain, causing high mortality (Negredo et al., 2011).", [["LLOV", "GENE_OR_GENE_PRODUCT", 132, 136], ["EBOV", "ORGANISM", 138, 142], ["MARV", "ORGANISM", 143, 147], ["challengesA filovirus", "ORGANISM", 302, 323], ["Lloviu virus", "ORGANISM", 331, 343], ["LLOV", "ORGANISM", 345, 349], ["chimeric LLOV", "PROTEIN", 123, 136], ["RESTV", "PROTEIN", 148, 153], ["Lloviu virus", "SPECIES", 331, 343], ["MARV", "SPECIES", 143, 147], ["Lloviu virus", "SPECIES", 331, 343], ["LLOV", "SPECIES", 345, 349], ["Chimeric or designer viruses", "PROBLEM", 159, 187], ["Protection", "TREATMENT", 236, 246], ["Methods and challengesA filovirus", "TREATMENT", 290, 323]]], ["Recently, LLOV emerged in Northeast Hungary, causing increased mortality in Miniopterus schrei bersii bats (Kemenesi et al., 2018).", [["Miniopterus schrei bersii", "ORGANISM", 76, 101], ["Miniopterus schrei bersii", "SPECIES", 76, 101], ["Miniopterus schrei bersii bats", "SPECIES", 76, 106], ["increased mortality", "PROBLEM", 53, 72], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["mortality", "OBSERVATION_MODIFIER", 63, 72]]], ["Manhart et al. (2018) obtained partial genome sequence of Lloviu virus (LLOV) with no known pathogenicity showing it a close relative of EBOV.", [["EBOV", "DISEASE", 137, 141], ["Lloviu virus", "ORGANISM", 58, 70], ["LLOV", "CANCER", 72, 76], ["EBOV", "ORGANISM", 137, 141], ["Lloviu virus", "SPECIES", 58, 70], ["Lloviu virus", "SPECIES", 58, 70], ["LLOV", "SPECIES", 72, 76], ["EBOV", "SPECIES", 137, 141], ["Lloviu virus", "PROBLEM", 58, 70], ["known pathogenicity", "PROBLEM", 86, 105], ["no known", "UNCERTAINTY", 83, 91], ["pathogenicity", "OBSERVATION", 92, 105], ["EBOV", "OBSERVATION", 137, 141]]], ["Both share the same replication strategy, as LLOV polymerase also binds to 3\u2032 terminal nucleotides for recognition of promoter region.", [["nucleotides", "CHEMICAL", 87, 98], ["LLOV polymerase", "GENE_OR_GENE_PRODUCT", 45, 60], ["LLOV polymerase", "PROTEIN", 45, 60], ["promoter region", "DNA", 118, 133], ["LLOV polymerase", "PROBLEM", 45, 60], ["terminal nucleotides", "TREATMENT", 78, 98], ["recognition of promoter region", "TREATMENT", 103, 133]]], ["Authors also reported that human cells support replication and transcription of LLOV.", [["cells", "ANATOMY", 33, 38], ["human", "ORGANISM", 27, 32], ["cells", "CELL", 33, 38], ["LLOV", "GENE_OR_GENE_PRODUCT", 80, 84], ["human cells", "CELL_TYPE", 27, 38], ["LLOV", "PROTEIN", 80, 84], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["human cells support replication", "TREATMENT", 27, 58], ["transcription of LLOV", "TREATMENT", 63, 84]]], ["Chimeric LLOV mini-genome using EBOV, MARV, and RESTV (Reston virus) leader and trailer regions was constructed to study sequence of events that occur during transcription and replication of infected human BRT7/5, HEK293T cells.", [["BRT7/5", "ANATOMY", 206, 212], ["HEK293T cells", "ANATOMY", 214, 227], ["LLOV", "GENE_OR_GENE_PRODUCT", 9, 13], ["EBOV", "ORGANISM", 32, 36], ["MARV", "ORGANISM", 38, 42], ["RESTV (Reston virus", "ORGANISM", 48, 67], ["human", "ORGANISM", 200, 205], ["BRT7/5", "CELL", 206, 212], ["HEK293T cells", "CELL", 214, 227], ["Chimeric LLOV mini-genome", "DNA", 0, 25], ["EBOV, MARV, and RESTV (Reston virus) leader and trailer regions", "DNA", 32, 95], ["infected human BRT7/5, HEK293T cells", "CELL_LINE", 191, 227], ["human", "SPECIES", 200, 205], ["LLOV", "SPECIES", 9, 13], ["EBOV", "SPECIES", 32, 36], ["MARV", "SPECIES", 38, 42], ["Reston virus", "SPECIES", 55, 67], ["human", "SPECIES", 200, 205], ["EBOV", "PROBLEM", 32, 36], ["MARV", "PROBLEM", 38, 42], ["RESTV (Reston virus)", "TREATMENT", 48, 68], ["infected human BRT7", "TEST", 191, 210], ["infected", "OBSERVATION", 191, 199]]], ["Thus, mini-genome strategy proved to be significant enough to rescue infectious LLOV clones and for characterization of novel mini-genome filovirus (Manhart et al., 2018).Synthesis of chimeric MLAV-(EBOV/MARV) ::: Chimeric or designer viruses as candidates to study disease pathogenesis ::: Protection against next generation biological agents: Methods and challengesYang and coworkers reported the characterization of another phylogenetically distinct relative, named M\u04d7ngl\u1e9a virus (MLAV), from Rousettus bats in China, which has 32%\u201354% genome sequence identity with known filoviruses.", [["LLOV clones", "CELL", 80, 91], ["mini-genome filovirus", "ORGANISM", 126, 147], ["MLAV", "GENE_OR_GENE_PRODUCT", 193, 197], ["EBOV", "ORGANISM", 199, 203], ["MARV", "ORGANISM", 204, 208], ["M\u04d7ngl\u1e9a virus", "ORGANISM", 469, 481], ["MLAV", "ORGANISM", 483, 487], ["Rousettus bats", "ORGANISM", 495, 509], ["filoviruses", "PATHOLOGICAL_FORMATION", 574, 585], ["infectious LLOV clones", "CELL_LINE", 69, 91], ["chimeric MLAV", "PROTEIN", 184, 197], ["MARV", "SPECIES", 204, 208], ["M\u04d7ngl\u1e9a virus", "SPECIES", 469, 481], ["MLAV", "SPECIES", 483, 487], ["Rousettus bats", "SPECIES", 495, 509], ["infectious LLOV clones", "PROBLEM", 69, 91], ["novel mini-genome filovirus", "PROBLEM", 120, 147], ["Chimeric or designer viruses", "PROBLEM", 214, 242], ["Protection", "TREATMENT", 291, 301], ["Methods", "TREATMENT", 345, 352], ["known filoviruses", "PROBLEM", 568, 585], ["China", "ANATOMY", 513, 518], ["filoviruses", "OBSERVATION", 574, 585]]], ["As per pairwise sequence comparison (PASC), analysis of genome designates MLAV as a new genus, i.e., Dianlovirus (family: filoviridae).", [["MLAV", "GENE_OR_GENE_PRODUCT", 74, 78], ["filoviridae", "CANCER", 122, 133], ["MLAV", "DNA", 74, 78]]], ["Chimeric MLAV mini-genomes with EBOV or MARV leader and trailer sequences were constructed to study replication-competence and interspecies spillover transmission by transducing cell lines derived from bats, dogs, hamsters, humans, and monkeys.", [["cell lines", "ANATOMY", 178, 188], ["MLAV", "GENE_OR_GENE_PRODUCT", 9, 13], ["EBOV", "ORGANISM", 32, 36], ["MARV", "ORGANISM", 40, 44], ["cell lines", "CELL", 178, 188], ["bats", "ORGANISM", 202, 206], ["dogs", "ORGANISM", 208, 212], ["hamsters", "ORGANISM", 214, 222], ["humans", "ORGANISM", 224, 230], ["monkeys", "ORGANISM", 236, 243], ["Chimeric MLAV mini-genomes", "DNA", 0, 26], ["EBOV or MARV leader and trailer sequences", "DNA", 32, 73], ["transducing cell lines", "CELL_LINE", 166, 188], ["dogs", "SPECIES", 208, 212], ["hamsters", "SPECIES", 214, 222], ["humans", "SPECIES", 224, 230], ["monkeys", "SPECIES", 236, 243], ["EBOV", "SPECIES", 32, 36], ["MARV", "SPECIES", 40, 44], ["hamsters", "SPECIES", 214, 222], ["humans", "SPECIES", 224, 230], ["Chimeric MLAV mini-genomes", "TREATMENT", 0, 26], ["EBOV", "PROBLEM", 32, 36], ["MARV leader", "TREATMENT", 40, 51], ["trailer sequences", "TEST", 56, 73], ["study replication", "TEST", 94, 111], ["transducing cell lines", "TREATMENT", 166, 188], ["cell lines", "OBSERVATION", 178, 188]]], ["However, the assessment of risks involved in interspecies transmission needs to be evaluated in vivo to study pathogenesis of MLAV (Yang et al., 2019).Chimeric Zika virus ::: Chimeric viruses as important vaccines candidates ::: Protection against next generation biological agents: Methods and challengesZika virus (ZIKV) is a single-stranded RNA flavivirus transmitted by Aedes spp. mosquitoes and is associated with various congenital neurological complications.", [["neurological", "ANATOMY", 438, 450], ["congenital neurological complications", "DISEASE", 427, 464], ["Chimeric Zika virus", "ORGANISM", 151, 170], ["Zika virus", "ORGANISM", 305, 315], ["ZIKV", "GENE_OR_GENE_PRODUCT", 317, 321], ["Aedes spp", "ORGANISM", 374, 383], ["mosquitoes", "ORGANISM", 385, 395], ["Zika virus", "SPECIES", 305, 315], ["MLAV", "SPECIES", 126, 130], ["Zika virus", "SPECIES", 160, 170], ["Zika virus", "SPECIES", 305, 315], ["ZIKV", "SPECIES", 317, 321], ["Aedes spp", "SPECIES", 374, 383], ["the assessment", "TEST", 9, 23], ["Chimeric viruses", "PROBLEM", 175, 191], ["Protection", "TREATMENT", 229, 239], ["next generation biological agents", "TREATMENT", 248, 281], ["Methods", "TREATMENT", 283, 290], ["Zika virus", "PROBLEM", 305, 315], ["a single-stranded RNA flavivirus", "PROBLEM", 326, 358], ["various congenital neurological complications", "PROBLEM", 419, 464], ["Zika virus", "OBSERVATION", 160, 170], ["viruses", "OBSERVATION", 184, 191]]], ["The 10.8 kb genome of ZIKV encodes a single polyprotein that, upon action of host and viral proteases, forms three structural proteins (C, PrM, and E) and seven nonstructural proteins (NS1\u20135 NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Ye et al., 2016).", [["ZIKV", "GENE_OR_GENE_PRODUCT", 22, 26], ["C", "GENE_OR_GENE_PRODUCT", 136, 137], ["PrM", "GENE_OR_GENE_PRODUCT", 139, 142], ["NS1\u20135 NS2A", "GENE_OR_GENE_PRODUCT", 185, 195], ["NS2B", "GENE_OR_GENE_PRODUCT", 197, 201], ["NS3", "GENE_OR_GENE_PRODUCT", 203, 206], ["NS4A", "GENE_OR_GENE_PRODUCT", 208, 212], ["NS4B", "GENE_OR_GENE_PRODUCT", 214, 218], ["10.8 kb genome", "DNA", 4, 18], ["ZIKV", "DNA", 22, 26], ["viral proteases", "PROTEIN", 86, 101], ["structural proteins", "PROTEIN", 115, 134], ["C", "PROTEIN", 136, 137], ["PrM", "PROTEIN", 139, 142], ["E", "PROTEIN", 148, 149], ["nonstructural proteins", "PROTEIN", 161, 183], ["NS1\u20135", "PROTEIN", 185, 190], ["NS2A", "PROTEIN", 191, 195], ["NS2B", "PROTEIN", 197, 201], ["NS3", "PROTEIN", 203, 206], ["NS4A", "PROTEIN", 208, 212], ["NS4B", "PROTEIN", 214, 218], ["NS5", "PROTEIN", 224, 227], ["ZIKV", "SPECIES", 22, 26], ["ZIKV", "PROBLEM", 22, 26], ["a single polyprotein", "PROBLEM", 35, 55], ["viral proteases", "TEST", 86, 101], ["PrM", "TEST", 139, 142], ["seven nonstructural proteins", "TEST", 155, 183], ["NS2A", "TREATMENT", 191, 195], ["NS2B", "TREATMENT", 197, 201], ["NS3", "TREATMENT", 203, 206], ["NS4A", "TREATMENT", 208, 212], ["NS4B", "TREATMENT", 214, 218], ["NS5", "TREATMENT", 224, 227], ["10.8 kb", "OBSERVATION_MODIFIER", 4, 11]]], ["Numerous approaches are being employed to develop live attenuated virus (Shan et al., 2017), inactivated whole virus (Sumathy et al., 2017), subunit DNA/RNA vaccines (Pardi et al., 2017; To et al., 2018), virus like particles (Espinosa et al., 2018; Salvo et al., 2018), over virus vectored (Xu et al., 2018), and chimeric ZIKV (Kum et al., 2018; Li et al., 2018) vaccines pertaining to several benefits including economical and long-term immunity.", [["DNA", "CELLULAR_COMPONENT", 149, 152], ["ZIKV", "SPECIES", 323, 327], ["live attenuated virus", "PROBLEM", 50, 71], ["subunit DNA/RNA vaccines", "TREATMENT", 141, 165], ["virus like particles", "PROBLEM", 205, 225], ["vaccines", "TREATMENT", 364, 372], ["economical and long-term immunity", "TREATMENT", 414, 447]]], ["Recently, a ZIKV vaccine candidate based on JEV, a licensed live attenuated SA14-14.2 flavivirus vaccine as a backbone was reported (Li et al., 2018).Chimeric Zika virus ::: Chimeric viruses as important vaccines candidates ::: Protection against next generation biological agents: Methods and challenges", [["SA14", "CHEMICAL", 76, 80], ["JEV", "ORGANISM", 44, 47], ["SA14-14.2 flavivirus", "ORGANISM", 76, 96], ["Chimeric Zika virus", "ORGANISM", 150, 169], ["ZIKV", "SPECIES", 12, 16], ["JEV", "SPECIES", 44, 47], ["Zika virus", "SPECIES", 159, 169], ["a ZIKV vaccine", "TREATMENT", 10, 24], ["flavivirus vaccine", "TREATMENT", 86, 104], ["Chimeric viruses", "PROBLEM", 174, 190], ["Protection", "TREATMENT", 228, 238], ["Methods", "TREATMENT", 282, 289], ["Zika virus", "OBSERVATION", 159, 169], ["viruses", "OBSERVATION", 183, 190]]]]}